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ABSTRACT 
 
This thesis begins with an introduction to inflammation and current anti-
inflammatory drugs in general, and the new small molecule somatotaxins developed 
by Fox and colleagues in particular. Chapter 1 describes the evidence used to 
propose the existence of structurally similar C-terminal lactam peptides that could 
potentially provide a novel anti-inflammatory pathway in vitro. 
Chapter 2 describes the synthesis of some C-terminal lactam peptides using solution 
phase peptide synthesis. Both linear and block syntheses were used. This chapter 
also describes some of the problems encountered using peptide coupling agents and 
our attempts to overcome them. 
Chapter 3 describes our investigations into thioacids for the block synthesis of 
peptides. The use of isoleucine in model peptides for the quantification of 
epimerization at the C-terminal amino-acid is also illustrated, and a series of NMR 
experiments were performed to allow us to differentiate between the relative 
stereoisomers of isoleucine residues in compounds.  
Chapter 4 describes the use of these 1H NMR experiments to predict the relative 
stereochemistry of a C-terminal isoleucine residue in the natural product, azolemycin 
A. The first total synthesis of azolemycins A and B, and a number of analogues, is 
then described.  
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CHAPTER 1: INFLAMMATION 
Inflammation is a natural, non-specific, immune response to infection or tissue 
injury, leading to characteristic physical symptoms, namely localised heat, swelling, 
redness and pain.1 Inflammation is generally considered to be beneficial, as it 
protects an organism against sustained damage and infection. 
1.1 THE INFLAMMATORY PROCESS 
The innate immune system has an important role in inducing the acute inflammatory 
response.2 When physical damage to tissue occurs, dead and dying cells release or 
expose cell-derived molecules known as damage-associated molecular patterns 
(DAMPs).3 These are located in both intra- and extracellular spaces including plasma 
membranes, mitochondria and other intracellular molecules, and the extracellular 
matrix.4 In contrast, pathogen-associated molecular patterns (PAMPs) and non –
pathogenic microbe-associated molecular patterns (MAMPs) are not derived within 
the body, but are instead a diverse group of evolutionarily conserved molecules 
expressed by a range of pathogens, including nucleic acids, surface proteins and 
carbohydrates (Figure 1).5, 6 
Both PAMPs and DAMPs are recognised by pattern-recognition receptors (PRRs) 
expressed by a number of cells including macrophages, dendritic cells, and cells not 
directly involved with inflammation such as epithelial and endothelial cells and 
fibroblasts.7 These PRRs include toll-like receptors (TLRs), NOD-like receptors 
(NLRs), C-type lectin receptors (CLRs) and RIG-I-like receptors (RLRs) and are 
located in both the transmembrane and cytoplasmic regions of the cells. Upon 
binding PAMPs and DAMPs, PRRs signal the presence of damage or infection and 
induce a pro-inflammatory response and, if pathogens are present, an antimicrobial 
response.8 This generally results in the upregulation of the transcription of genes 
encoding pro-inflammatory cytokines, chemokines, type 1 interferons (IFNs) and 
many other  proteins.7  
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Figure 1: Mechanisms for the induction of inflammation (reproduced from Mills, K. H. G., Nature Reviews 
Immunology, 2011)6 
The induction of inflammation elicits the production of a diverse range of 
inflammatory mediators. These lead to the three broad, overlapping phases of 
inflammation: a vascular response, a cellular response and a chemical response.  
The vascular response is initiated by a variety of inflammatory mediators. These are 
released by the degranulation of mast cells and include vasoactive amines, such as 
histamine and serotonin, and vasoactive peptides including kinin, thrombin and 
plasmin.9 These molecules induce localised vasodilation and an increase in vascular 
permeability. This is designed to allow rapid influx of anti-inflammatory cells to the 
area, as well as the dilution of any toxic pathogenic products and the drainage of 
fluid out of the vessels. It is also this that causes the physical symptoms of swelling 
and redness, as blood rushes to the area and fluid collects, causing oedema.  
The cellular response is predominately involved in the recruitment and activation of 
leukocytes to the site of trauma. Leukocytes, often called white blood cells, are 
normally present in the blood and, following an inflammatory trigger, they must be 
diverted to the source of infection or damage, which is usually outside of a blood 
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vessel. There are a number of chemical mediators that are involved in the initial 
recruitment and directing of the leukocytes (Figure 2). Activation of the endothelial 
cells by cytokines such as IL-1β and TNF-α causes the expression of adhesion 
molecules, leading to leukocytes binding loosely to the blood vessel walls.10 The 
selectin family of molecules is then responsible for rolling the leukocytes along the 
walls. Once rolling, chemokines activate integrin molecules on the leukocytes, and 
the cells are activated to bind more firmly to the endothelial cells.11 Following 
binding, the leukocytes then migrate across the endothelium into the affected tissue. 
This is mediated by a number of molecules found on the endothelial cell borders, 
including platelet endothelial cell adhesion molecule-1 (PECAM-1, or CD31) and 
vascular cell adhesion molecule-1 (VCAM-1).12 These help to bind the leukocytes as 
they squeeze between the endothelial cells into the extracellular space.  
Figure 2: Recruitment and activation of leukocytes(reproduced from Kunkel E. J. et al, Nature Reviews 
Immunology, 2003)13  
Once outside of the blood vessel, chemotactic molecules produced by neutrophils at 
the site of infection or injury form a chemical gradient that guides the leukocytes to 
the area. There is a diverse array of chemotactic mediators linked to inflammation 
including: 
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• C5 fragments, produced by cleavage of the C5-glycoprotein at the site of 
infection14  
• N-formyl peptides, from the processing of bacterial proteins15  
• Leukotriene B4 from the metabolism of arachidonic acid 
• Cytokines, including TNF-α, IL-8 and MCP-1.16 
Once outside the blood vessel and at the site of infection, leukocyte differentiation is 
triggered. Neutrophils are the first leukocytes to gather, recognize and engulf 
pathogens at the site of infection. They are activated by a number of cytokines and 
chemokines, and this leads to molecular changes that extend the lives of the cell 
allowing them to effectively tackle infection. As well as releasing further pro-
inflammatory chemokines, they also release a number of proteases and reactive 
oxygen species (ROS) in order to kill phagocytosed cells. 17 Once they have engulfed 
and destroyed pathogens, apoptosis is induced. Apoptotic cells release further signals 
that attract macrophages, which engulf them. This prevents the toxic cell contents 
being released during necrosis.18, 19 
At the site of infection, monocytes differentiate into either mature macrophages or 
immature dendritic cells.20 Macrophages are the main source of cytokines and 
growth factors that affect the local cell environment and induce tissue repair at the 
site of injury. 21 In addition, as previously mentioned, macrophages are involved in 
the phagocytosis of apoptotic neutrophils. It appears that the ingestion of dead 
neutrophils may trigger the egress of macrophages from the site of inflammation to 
the local lymph system, where they are removed.19  
In addition to the vascular and cellular responses to inflammation, there is also a 
concurrent chemical response. A huge array of different chemical mediators is 
released during the acute phase of inflammation. In addition to those already 
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mentioned (vasoactive amines and amides, and kinins) there are a number of other 
notable groups of mediators. 
1.2 THE COMPLEMENT SYSTEM 
This is a collection of more than 30 soluble or membrane proteins that make up part 
of the innate immune system; that is, it does not adapt to new threats, but can be 
recruited by the adaptive immune system.22 The complement system is widely 
distributed throughout the blood plasma, and is activated locally to help trigger anti-
bacterial and anti-inflammatory responses.23 
1.2.1 ARACHIDONIC ACID METABOLITES 
Archidonic acid is a 20-carbon unsaturated fatty acid derived from the phospholipid 
bilayer. It is metabolised by a variety of enzymes, namely cyclooxygenases (COX 
enzymes) and lipoxygenases, to give a range of prostaglandin and leukotriene 
products that are intimately involved in the propagation of an inflammatory response 
(Figure 3).24 
Figure 3: The metabolism of arachidonic acid to prostaglandins and other derivatives24 
Prostaglandins are products of the COX enzymes, and their production is linked to 
sensitisation of pain receptors, vasodilation, increased vascular permeability, 
chemotaxis, and platelet aggregation.25 Leukotrienes are produced by 5-lipoxygenase 
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and act on vasodilation and constriction, chemotaxis of neutrophils and vascular 
permeability.  
1.2.2 CYTOKINES 
Cytokines are small proteins (8 - 40kDa) that are expressed by nearly every cell.26 
Depending on their source, they can regulate both pro- and anti-inflammatory 
responses. Broadly, there are three main groups of cytokines: Interleukins, TNF and 
chemokines.  
Interleukins and TNF are produced mainly by mast cells, endothelial cells and  
macrophages at the site of infection.27 The major interleukins associated with 
inflammation are IL-1 and IL-6. IL-1 is involved in prostaglandin synthesis, growth 
and differentiation of T and B cells and growth of fibroblasts,28 while IL-6 is linked 
to macrophage and B cell differentiation and antibody formation, and  both  IL-1 and 
IL-6 are also linked to the induction of acute phase proteins.29  TNF primarily acts on 
endothelial cells, leading to leukocyte accumulation and adhesion, increased vascular 
permeability and endothelial cell hypertrophy.30 Both IL-1 and TNF also stimulate 
chemotactic factors, as well as acting on target organs e.g. acting on the brain to 
cause fever, and the bone marrow to promote leukocyte production. 31 
1.2.3 CHEMOKINES 
Chemokines are a range of small proteins involved in regulating the traffic of various 
cells to different tissues. They are intimately involved in the process of 
inflammation, as they are released at the site of injury or infection and direct 
leukocytes and other macrophages to the area, leading to the physical response that is 
known as inflammation.32 They act by binding to specific 7-transmembrane G-
protein coupled receptors (GPCRs) located on the surface of target cells.33 These 
receptors all contain a conserved disulphide bridge between cysteine residues in the 
first two extracellular loops, which is essential to maintain the structure of the 
receptor for ligand binding.32, 34  
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There are at least 46 known chemokines, all small peptides, generally with four 
characteristic conserved cysteine residues.35 The relative position of the first two 
cysteine residues is used to group the chemokines into families. There are two major 
chemokine groups, CC and CXC, and two minor groups, CX3C and C, in which C 
denotes a cysteine residue, and X a non-cysteine amino acid.36 Of the two major 
groups, CC chemokines act to induce monocyte proliferation, while CXC 
chemokines are chemoattractants for neutrophils.37, 38   
As chemokines are separated into families, so are the receptors according to their 
particular chemokine preference. There are at least 7 described as CXCR, 11 as 
CCR, and 1 each of either XCR or CX3CR respectively.39 Within each family of 
receptors, each receptor can bind to several chemokines, and each chemokine can 
bind to several receptors, though this promiscuity cannot cross the family 
boundaries.40  
1.3 RESOLUTION OF INFLAMMATION 
If the inflammatory stimulus is successfully removed, the initial acute phase is 
actively terminated and the emphasis moves to removing dead cells and repairing 
damaged tissue, in a process known as the resolution phase. At this stage, normally a 
few hours after the start of an inflammatory event, a switch from prostaglandins and 
leukotrienes to lipoxins is instigated, neutrophil recruitment stops and apoptosis of 
leukocytes begins. If the inflammatory stimuli persist, or the normal mechanism for 
inflammation resolution is disrupted, chronic inflammation can occur. This results in 
the constant renewal and degradation of the tissue, and is associated with ongoing 
pain, swelling and loss of function. Infiltration by neutrophils and macrophages is 
primarily connected to acute inflammation, while chronic inflammation tends to 
involve the influx of plasma cells and T-cells.1 Persistent, inappropriate 
inflammation has been linked to a variety of diseases, including HIV, 
atherosclerosis, asthma and rheumatoid arthritis.41-45  
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1.4 CURRENT ANTI-INFLAMMATORY DRUGS 
Inflammation is a highly complex process, and as such is difficult to treat. Anti-
inflammatory drugs tend to act by blocking early pro-inflammatory pathways, 
preventing the physiological effects of swelling and pain.  
Historically, treatments for inflammation are broadly split between two groups of 
molecules-non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. 
NSAIDs, a class of drug that includes aspirin, ibuprofen and naproxen amongst 
others, are commonly used to treat pain and inflammation from arthritis, headaches, 
and a variety of musculoskeletal problems. They act on the cyclooxygenase (COX) 
enzymes in the body. Normally, these enzymes catalyse the oxidation of arachidonic 
acid to give prostaglandin-H2, the precursor to the pro-inflammatory agents 
prostaglandins and thromboxane.46 Aspirin irreversibly binds COX enzymes, while 
other NSAIDs such as ibuprofen, bind reversibly.47  
There are two main classes of COX enzymes, COX-1, COX-2, and traditional 
NSAIDs such as aspirin are non-selective. COX-1 is widespread in the body, and 
amongst other things is responsible for the production of gastro-protectional 
prostaglandins. Inhibition of COX-1 by NSAIDs can therefore be detrimental, 
leading to gastric ulcers and renal toxicity.48 COX-2, in contrast, is an inducible 
enzyme, and is produced in response to endotoxins, mitogens and cytokines in cells 
responsible for the production of inflammatory prostaglandins.49 However, the 
development of a COX-2 specific anti-inflammatory has been hampered by the 
potential side-effects. Vioxx, a COX-2 inhibitor produced by Merck, was withdrawn 
from used in 2004 after studies linked it to an increased risk of cardiovascular 
events.50  
Corticosteroids refers to both mineralocorticoids, which are steroid hormones linked 
to regulating salt levels,51 and glucocorticoids.  Glucocorticoids consist of both 
naturally occurring hormones and synthetic analogues, and are used to treat a range 
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of inflammatory disorders, most commonly as the first line of treatment for asthma.52 
They act by binding to the glucocorticoid receptor, which is present in most tissues.53  
When stimulated by the endogenous ligand cortisol (Figure 4), the receptor directly 
inhibits a variety of anti-inflammatory pathways through the production of anti-
inflammatory molecules such as MAPK phosphatase I and by blocking the 
transcription of inflammatory molecules such as prostaglandins and calcium kinase 
II.54  
A range of synthetic glucocorticoids have been developed that exhibit greater 
potency than the endogenous ligand, cortisone. An inhaled steroid preparation is 
manufactured by GlaxoSmithKline under the brand name Advair (Figure 4), and is a 
mixture of a glucocorticoid (fluticasone propionate) administered with a 
bronchodilator (salmeterol xinafoate).55 It was the sixth best selling prescription drug 
in the United States of 2013, with sales of over $3.7 billion.56 However, there have 
been concerns that long term use may exacerbate asthma-related deaths, though this 
is likely to be due to the salmeterol component rather than the steroid.57  
Figure 4: The structures of cortisol and Advair58 
Potential side effects associated with glucocorticoid drugs include localised atrophy 
of the skin and muscles, delayed wound healing, increased risk of infection and a 
number of endocrine, gastrointestinal and cardiovascular disorders.59 Limiting the 
dose and length of treatment are generally recommended for these reasons. In 
addition, a minority of inflammatory diseases commonly treated with steroids appear 
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to be resistant to their effects. Other diseases related to inflammation, including 
cystic fibrosis, chronic obstructive pulmonary disease and interstitial fibrosis, seem 
to be almost completely resistant to treatment by steroids. 60   
Drugs that inhibit cell migration molecules, including chemokines, are very 
attractive pharmaceutically. To begin with, cell migration molecules target G-protein 
coupled receptors (GPCRs). GPCRs tend to be readily inhibited by small organic 
molecules, which in turn tend to be orally available. In addition, chemoattractant 
molecules are abundant, suggesting they must be prominent in precisely directing 
leukocyte traffic, and indeed inhibition of chemoattractants has been shown to be 
highly effective against a range of anti-inflammatory agents in a range of models. 61-
63
 
1.5 SPECIFIC CHEMOKINE INHIBITORS 
Inhibition of chemokines is considered to be a promising method to interfere with 
cellular recruitment, and hence induce anti-inflammatory effects.64  Upregulation of  
chemokine receptors and their ligands has been associated with a number of 
inflammatory diseases, including  rheumatoid arthritis,65 angiogenesis,66 transplant 
rejection,67 and HIV/AIDS.68 
Attempts to treat these diseases using specific chemokine receptor inhibitors have 
met with mixed success. Both CCR5 and CXCR4 receptors can act as co-receptors 
for entry of HIV-1 strains into cells, and therefore inhibition of either could provide 
promising new classes of antiviral treatments for HIV infection.69 A number of 
CCR5 antagonists for the treatment of HIV/AIDS have been developed (Figure 5), 
including maraviroc (Pfizer),70 vicriviroc (Schering-Plough and Merck),71 and 
aplaviroc (GlaxoSmithKline).72  
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Figure 5: CCR5 antagonists 
Studies of aplaviroc were discontinued due to concerns about heptotoxicity,73 and 
Merck announced it would not seek federal approval for vicriviroc after it failed to 
show superior results compared to the optimised regimes in Phase III trials.74 
However, maraviroc was approved by the European Commission for the treatment of 
HIV in 2007,75 and has performed well in Phase I and II trials.76  
Several CXCR4 antagonists have been developed to date (Figure 6). Plerixafor 
reached Phase I trials and AMD11070 reached Phase II trials for the treatment of  T-
tropic HIV, but both were discontinued.77 However, CXCR4 antagonists are also 
known  to mobilize a variety of leukocytes, most notably hematopoietic stem cells.78 
This has led to the a number of CXCR4 antagonists being developed for other 
purposes including enhancement of current chemotherapy treatments, and, in the 
case of plerixafor, the treatment of non-Hodgkin's lymphoma (NHL) or multiple 
myeloma (MM).  
Figure 6: CXCR4 inhibitors79 
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CCR9 is primarily expressed on T cells migrating within the digestive system, and is 
present in high concentrations in the intestinal mucosa.80 It has one known ligand, 
CCL25, which is also highly expressed in the intestine and thymus.81 Overexpression 
of both CCR9 and CCL25 has been linked to the incidence of inflammatory bowel 
diseases, particularly Crohn's disease.82, 83 GSK-1605786 (CCX-272; Traficet-EN; 
vercirnon; Figure 7) is a small molecule CCR9 antagonist being developed by 
GlaxoSmithKline, under license from ChemoCentryx, for the treatment of IBDs, 
including Crohn's disease and celiac disease.84 It has shown promising results in the 
treatment of Crohn's disease, entering Phase III clinical trials in 2013.85 
Figure 7: CCR9 antagonist 
The complex nature of chemokine receptors and their multiple ligands, including the 
high level of redundancy, mean that targeting a specific receptor for a particular 
disease can be difficult. Animal models, including gene-deficient mice, are often 
used to mimic diseases, but often drugs that are effective in animal models show no 
activity in human trials. This has been particularly obvious in the antagonism of 
single chemokine receptors for the treatment of rheumatoid arthritis that showed 
promise in animal trials that did not translate to human treatment.86-88 
The level of redundancy between chemokines and their receptors means that drugs 
must be targeted to cell migration molecules carefully. Too great a selectivity and it 
is likely the drug might be ineffective, as a number of chemokines may promote pro-
inflammatory molecules in parallel by signalling through a number of different 
receptors. Equally, as the full complexity of chemokine receptors is not yet 
understood, too broad a selectivity and the drug risks unknown 
immunocompromising side effects.63, 89  
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1.6 BROAD SPECTRUM CHEMOKINE INHIBITORS 
In 1991, Grainger et al. published the discovery of "Peptide 3", an amino-acid 
sequence isolated from monocyte chemoattractant protein-1 (MCP-1), which was 
shown to inhibit a wide range of chemokines in vitro.90 MCP-1, also known as 
CCL2, is a member of the CC chemokine subgroup, and is a 13kDa protein 
expressed either constitutively or after induction by a number of pro-inflammatory 
triggers.91 MCP-1 attracts and activates monocytes by binding to a number of 
GPCRs, including CCR2,92 CCR11,93 and the Duffy antigen receptor for chemokines 
(DARC). This last is unusual in that it binds a range of chemokines from both the 
CC and CXC subgroups.94 Peptide 3 corresponded to the amino-acids 51-62 of 
MCP-1 (EICADPKQKWVQ, single letter amino-acid code), and inhibited leucocyte 
migration induced by MCP-1, MIP-1α, RANTES, IL-8 and stromal cell-derived 
factor-1 α (SDF- α) at the 2-10 µM range.  However, it did not inhibit the migration 
of leukocytes induced by non-chemokine chemoattractants, including tumour growth 
factor beta-1 (TGF-β1) and N-formylmethionine leucyl-phenylalanine (fMLP). As 
such Peptide 3 was the first synthesised pan-chemokine inhibitor, but was unsuitable 
for in vitro studies due to poor solubility, short plasma halflife and susceptibility to 
enzymatic degradation.  
In an attempt to combat this, a cyclic peptide, NR58-3.14.3, was synthesised using 
the unnatural D-amino acid equivalents (Figure 8). This afforded a BSCI with a 
backbone unaffected by proteolytic digestion, and vastly improved potency of 
around 1000 times that of Peptide 3.15 NR58-3.14.3 was shown to be a promising 
anti-inflammatory agent in neuroprotection studies against ischemia-reperfusion 
injury in rats,95 and in the treatment of endometriosis in mice.95, 96 However, oral 
bioavailability was extremely poor and it had a plasma half-life of less than half an 
hour.97  
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Figure 8: Peptide 3 (single letter amino acid code) and the retroinverse analogue, NR58-3.14.3. The shaded 
circles represent the carbons of the D-amino-acids, and the C and N terminals are marked. The peptide was 
oxidatively cyclised between the two terminal cysteine residues98  
Structural-activity relationship analysis was performed on the original peptide 3 
sequence, dividing it first into two hexapeptides, EICADP and KQKWVQ.99 Both of 
these inhibited leukocyte migration, but only the C-terminal fragment retained the 
potency of the parent protein. This was further divided into two tripeptides, KQK 
and WVQ. WVQ inhibited all chemokines tested (MCP-1, MIP-1α, RANTES, IL8 
and SDF-1α) with roughly equal potency to peptide 3. In contrast, the KQK 
tripeptide which also showed good MCP-1 inhibition in vitro, but displayed no broad 
spectrum chemokine inhibition and was not pursued further. Further abbreviation of 
the WVQ tripeptide destroyed the activity. Substitution studies identified a lipophilic 
tail group (tryptophan, tyrosine or phenylalanine) and a glutamine head group as key 
elements for retention of activity (Table 1). 99 The middle amino-acid could be any 
small aliphatic amino acid without impeding activity, though the glycine analogue 
(WGQ) was most active.   
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Peptide ED50 vs. MCP-1 (µM) 
EICADPKQKWVQ 8 ± 3 
EICADP 50 ± 17 
KQKWVQ 6 ± 3 
KQK 12 ± 4 
WVQ 4 ± 2 
Table 1: The concentration of peptide 3 fragments required to reduce leukocyte migration by 50 % (ED50). 
Migration of THP1 cells was induced with 25 ng/mL MCP-1 in the presence of a various concentrations of the 
peptides. The ED50 value is the mean ± sem of three separate measurements99 
From this WxQ motif, a variety of non-peptide, low molecular weight acylglutamine 
and acylamino-glutarimides derivatives were synthesised. The most promising of 
these, NR58.4 (Figure 9), was effective in blocking leukocytes in LPS induced 
inflammation in addition to inhibiting chemokine-mediated chemotaxis with good 
potency, showing an ED50 of 5-15 nM in vitro (against MCP-1 induced migration of 
THP1 cells), and 0.3 mg kg-1 in vivo (against LPS-induced TNF-α migration in 
mice).99 Despite being around four times as potent as peptide 3 in this model of 
inflammation, NR58.4 was inactive in models of chronic inflammation in which 
NR58-3.14.3 was known to be effective. This lack of potency was primarily due to 
the rapid enzymatic metabolism of the aminoglutarimide ring in vivo, eventually 
affording the biologically inactive glutamate derivate (Figure 9).101 
Figure 9: The probable metabolic fate of NR58.4100 
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In order to circumvent this, the 6-deoxo analogue of NR58.4 analogue, (Figure 10), 
was investigated as, despite displaying considerably lower BSCI activity (~100nM 
compared to 5 nM for NR58.4),99 it was almost completely stable in serum. A range 
of 5 and 7-membered lactam analogues were synthesised in an attempt to improve 
the activity while retaining the stability, with a variety of alkyl chains. It had been 
previously noted that the (R) enantiomer of NR58.4 was at least 50 times less active 
than the (S) enantiomer, and this stereo-preference was found to be generally true for 
the lactam analogues.100  
Figure 10: Lactam analogues of NR58.4, showing ED50 values for MCP-1 induced leukocyte migration in 
vitro100 
The most active of these, a seven-membered lactam with an unsaturated 16-carbon 
tailgroup (Figure 10), had comparable BSCI activity to NR58.4 both in vivo and in 
vitro, but was significantly more stable in serum. However, the potency was not 
mirrored when it was administered orally, falling to an ED50 of 1mg/kg.100  Further 
experimentation showed that including a quaternary substituent on the 2’ position 
improved BSCI activity both in vitro and in vivo, with saturated chains giving more 
potent compounds than unsaturated. A series of increasingly truncated adamantane 
substituted compounds (Figure 11) had improved BSCI activity to the long chain 
compound when administered both orally and subcutaneously in the endotoxemia 
model of inflammation. In the case of the bulkier compounds, this did not translate 
into good pharmacokinetic profiles following single dose administration in rats. 
Investigations into the metabolic fate of these compounds showed both were rapidly 
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hydroxylated, presumably by cytochrome P450 enzymes in the liver. In contrast, the 
simple tert-butyl substituted lactam (Figure 11) showed a promising combination of 
activity, pharmacokinetic parameters and potency.102 A similar compound to this, 
named FX125L, was chosen as the lead compound. FX125L started Phase 2 clinical 
trials, showing promise in the treatment of allergic asthma and other diseases related 
to inflammation.103 Importantly, throughout the development of FX125L, no obvious 
unfavourable toxicological effects were noted.100 Regulatory preclinical studies with 
FX125L suggested a very good safety profile and wide therapeutic range.104 It was 
acquired by Boehringer Ingelheim for an undisclosed sum in July 2012.105  
Figure 11: Subcutaneous and oral ED50 values for inhibition of LPS induced TNF-α model of inflammation in 
vivo102   
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1.6.1 NATURALLY OCCURRING LACTAMS 
Naturally occurring 6- or 7-membered lactams are not common, but there exist a few 
which have been biosynthesised and offer potent biochemical effects. Bengamides 
and cilitamides (Figure 12) are both currently being investigated as potential sources 
of new drug candidates.106, 107 
Figure 12: The structure of Bengamide E and three ciliatamides. Both molecules have well defined 
stereochemistry which affects their biological activity 
Gramicidin S is a cyclic decapeptide composed of two identical dimers, Val-Orn-
Leu-D-Phe-Pro.108 The reaction sequence of gramicidin S synthetase consists of 16 
steps, starting with a phenylalanine racemase (gramicidin S synthestase 1, GS1), 
followed by activation of the amino-acids by aminoacyl transferase and thioester 
formation.109 These activated units are linked together by a series of transpeptidation 
and transthiolation reactions.108 It was noted that in some circumstances side-
reactions can occur, leading to early termination of the peptide chain.110 The 
ornithine linked thioester intermediate is particulary unstable and, especially in the 
absence of L-leucine, this can form a C-terminal lactam tetrapeptide, D-Phe-Pro-Val-
cyclo-Orn (Figure 13).110, 111 
Figure 13: The possible early termination reaction at gramicidin S synthetase 2 (a condensing multi-enzyme) to 
give a C-terminal lactam peptide110 
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As well as occurring as a by-product from the natural gramicidin S synthase, this 
reaction can occur during solid phase synthesis. When synthesising the pentapeptide 
substrate analogue of gramicidin, Boc-D-Phe-Val-Pro-Orn-Leu-S-linker-TG, Bu et 
al. reported that, in the absence of the leucine residue, the cleaved C-terminal lactam 
peptide Boc-D-Phe-Val-Pro-cyclo-Orn was formed.112 It seems likely that the δ-NH2 
of the deblocked ornithine cleaves the thioester to form the cyclised lactam. 
1.6.2 MODE OF ACTION OF BSCIS 
During the early stages of BSCI development, the mechanism by which the 
molecules inhibited chemokine migration was unclear. Biotinylated peptide 3 was 
found to bind to cells that expressed no chemokine receptors with the same affinity 
as to those in which chemokine receptors were expressed at over one million copies 
per cell. In addition, the binding of chemokines to receptors was found to be 
unaffected by the presence of peptide 3 and its derivatives.113 Early structure-activity 
relationship studies showed that any modification to the molecules had the same 
effect against all chemokines tested. The possibility of BSCIs binding to the 
chemokine ligands themselves was also ruled out. Taken together, these facts 
suggested that the BSCIs were binding to a single, extracellular target,113 showing a 
correlation between binding affinity at this site and potency of chemokine inhibition. 
These BSCI molecules do not block early cell signalling events linked to leukocyte 
migration, such as calcium mobilisation, nor the chemokine induced down-
regulation of chemokine receptors, and it seems likely that BSCIs target a compenent 
of the intracellular signalling pathway related only to chemokine migration.113  
Following extensive receptor screening, it was shown that both peptide and the 
current aminolactam BSCIs bind to the type 2 somatostatin receptor (sstr2), an 
extracellular GPCR.114, 115 For this reason, they are now known as somatotaxins 
(somatostatin-mediated chemotaxis inhibitors).114 
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1.7 SOMATOSTATIN 
Somatostatin is an endogenous regulatory peptide that is widely distributed 
throughout the central nervous system (CNS), the endocrine system, and the 
gastrointestinal tract.116 It was first identified as a cyclic 14 amino-acid peptide 
(SST-14) in hypothalamic extracts that inhibited the secretion of growth hormone in 
1973 (Figure 14).117 In 1980, a second bioactive form of somatostatin was isolated, 
as an NH2-terminally extended, 28 amino-acid (SST-28) peptide. 
Both SST-14 and SST-28 are generated by the post-translational processing of a 
larger, 116 amino-acid, residue named pre-prosomatostatin.118 Somatostatin is 
released from cells in the central and peripheral nervous system,119 in the GI tract,120 
and from certain immune cells121 in response to a range of chemical and molecular 
signals including hormones, cytokines and nutrients.116  
Figure 14: The primary structures of SST-14 and SST-28122 
While initially noted for inhibition of growth hormone, somatostatin is now linked to 
the inhibition of a number of other hormones including thyrotropin and insulin, as 
well as neuro-enterohormones such as dopamine and exocrine secretions, and acts as 
a pan-inhibitory agent for all gastrointestinal hormones.122, 123 Somatostatin can act 
as a neurotransmitter in the central nervous system, while in the peripheral nervous 
system it acts to downregulate neurogenic components of inflammation.124, 125 In 
addition, somatostatin also has anti-proliferative effects in both normal dividing 
cells, as well as in abnormal tumours. These effects include both cytotoxic and 
cytostatic actions, and are mediated either directly by somatostatin receptors on the 
cell surface, or indirectly by somatostatin receptor on non-tumour cells. Binding of 
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somatostatin to these receptors leads to inhibition of the secretion of hormones and 
growth factors linked to tumour growth, as well as the inhibition of angiogenesis and 
mediation of immune cell function.116, 126-129 Both SST-14 and SST-28 have 
extremely short half-lives (less than 3 minutes), so somatostatin producing cells and 
synaptic somatostatin stores are usually found near the target cells.130  
Somatostatin exerts these, and other, physiological effects by binding to seven 
transmembrane domain (7TM) GPCRs found on the target cell surface. Five 
subtypes of somatostatin receptor, sstr1-5, have been identified.131, 132 These can be 
grouped into two subclasses based on ligand affinity and amino-acid identity, with 
sstr2,3 and sstr5 in one class, and sstr1 and sstr4 in the other. All five receptors bind 
SST-14 with a similar potency, but sstr5 binds with a greater affinity to SST-28, and 
appears to be SST-28 selective.133  
1.7.1 SOMATOSTATIN RECEPTORS 
The somatostatin receptors are each encoded by separate genes on different 
chromosomes.134  The gene encoding for sstr2 contains an intron allowing the 
possibility of two isoforms, which differ in length of the cytoplasmic C-terminal.135 
sstr2A , the longer isoform, is the most common and the only one expressed in 
humans, while sstr2B is the minor form.136 Somatostatin receptors are expressed by a 
wide range of cells in varying concentrations, including those in the brain, pancreas, 
GI tract, liver and spleen.136-138 In addition, sstr2 and sstr3 are known to be expressed 
by certain cells of the immune system including macrophages and T- and B- cells.116 
When activated by ligand binding, somatostatin receptors induce cellular responses 
by G-protein mediated messenger systems. These key second-messenger effects 
include the inhibition of adenylyl cyclase, activation of phosphotyrosine phospatase 
(PTP) and adjustment of mitogen-activated protein kinase (MAPK).116 In addition, 
they activate several types of voltage channels in a subtype-specific fashion, 
including the stimulation of K+
 
channels (sstr3, sstr4, sstr5), activation of Ca2+ 
channels (sstr1, sstr2) and activation of an Na+/H+ exchanger (sstr1).139, 
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140Somatostatin receptors are known to be expressed on the surface of a number of 
tumours types, most commonly neuroendocrine tumours,141 but also breast,142 
liver,143 lung144 and ovarian tumours145 amongst others. Generally, tumour cells 
express more than one sstr subtype, with sstr2 the most commonly expressed 
subtype. Subtypes 3 and 5 are also frequently expressed, but sstr4 is uncommon.146  
Due to the complex range of physiological effects elicited by the binding of 
somatostatin and associated ligands, it is difficult to tell whether each separate 
response is linked to only one sstr subtype, or is the result of  multiple receptors 
working in concert.116 However, some subtype selectivity has been identified. sstr3 is 
known to elicit cytotoxic effects,147 and sstr5  appears to be unique among the sstr 
group in regulating insulin production.148, 149sstr2 appears to be expressly involved in 
the inhibition of gastric acid secretion and immune responses. 150-153 Sstr2 is also 
expressed on the surface of a wide range of human and rat tumour cell lines, 
apparently in much greater quantities than other sstrs.154, 155 
1.7.2 SOMATOSTATIN ANALOGUES 
Somatostatin itself is unsuitable for clinical use due to rapid blood clearance and 
post-infusion hypersecretion of hormones,156 and a number of analogues have been 
synthesised to overcome these problems. Based on the supposition that the sequence 
Phe7-Trp-Lys-Thr10 was the essential pharmacophore fragment of somatostatin,157, 158 
the first analogue licensed for clinical use, octreotide, was reported in 1982 (Figure 
15).159  
Figure 15: The structure of octreotide160 
D-Phe-Cys-Phe
D-Trp
Lys
(Thr-ol)-Cys-Val
Octreotide
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In monkeys, octreotide inhibited the release of growth hormone fortyfive times more 
powerfully than somatostatin, inhibits glucagon release eleven times more 
powerfully and insulin 1.3 times more powerfully.161 Octreotide also showed far 
superior half-life, and showed no rebound hypersecretion compared to 
somatostatin.162 However, unlike SST-14, octreotide was found to bind primarily to 
sstr2, with lesser activity at the sstr3 and sstr5 subgroups.163, 164 Octreotide (trade 
name Sandostatin®)165 is approved for the treatment of a number of hormone 
secreting tumours, including growth hormone producing tumours and 
neuroendocrine tumours.166, 167 Side effects associated with octreotide include 
cramps, diarrhoea, nausea and diabetic glucose tolerance.168 In tests on sstr2-/- and 
sstr2
+/+
 mice, binding of octreotide to sstr2 was also shown to exhibit potent anti-
inflammatory and anti-nociceptive activity.169 
The development of somatostatin analogues and identification of their binding sites 
has provided a substantial amount of information about sstr subtypes and their 
modes of action. A number of somatostatin receptor subtype-specific analogues have 
been developed in an attempt to exploit possible subtype-specific physiological 
effects. These include  BIM-23745 and BIM-23926 (sstr1 specific), BIM-23197 and 
BIM-23120 (sstr2 specific), L-796778 (sstr3 specific) and BIM-23268 and BIM-
23206 (sstr5 specific), which were synthesised in an attempt to  isolate the subtype 
associated with maximum anti-proliferation effects.170 However, all but the sstr3 
subtype showed some anti-proliferative activity, and, as sstr3 is known to 
hetereodimerise with other sstr subtypes, 171  it seems likely that the activation of all 
the sstr subtypes may be required to obtain maximal anti-proliferative effect.  
TT-232 (Figure 16) binds predominately to sstr4, with some activity at sstr1. This 
compound had significant anti-inflammatory activity in a number of models both in 
vivo and in vitro,124, 138 as well as showing anti-proliferative effects on tumour cells. 
172, 173
 Attempts to further probe sub-type selective responses using sstr knock-out 
mice have not clarified the situation. Sstr2 has been convincingly linked to pituitary 
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GH secretion, but mice with a deficiency of sstr2 develop normally both in utero and 
up to 15 months with the exception of a few minor side-effects, namely high levels 
of basal gastric acid and an absence of GH-induced feedback suppression of GH.174  
Attempts to optimise the pharmacological response by developing multireceptor 
binding analogues have produced a number of peptide and non-peptide analogues of 
SST-14. KE-108 has a high affinity for all five sstr subtypes,175 while SOM-230 
binds with high affinity to sstr1-3 and sstr5 (Figure 16).176 Despite being designed to 
mimic natural SST-14 binding and activity, both KE-108 and SOM-230 exhibit 
distinct signalling pathways to the natural ligand. In sstr2 expressing cells, 
somatostatin was found to inhibit cAMP production, stimulated intracellular calcium 
and increased ERK phosphorylation.177  Like somatostatin, both KE-108 and SOM-
230 acted as full agonists for inhibition of adenylyl cyclase, but antagonised 
somatostatins effects on intracellular calcium and ERK phosphorylation. This 
implies that both KE-108 and SOM-230 exhibit functional selectivity (vide infra) 
different signalling pathways at sstr2.177 
Figure 16: The structures of TT-232, KE-108 and SOM-230173, 178 
1.7.3 INFLAMMATION AND SSTR2 
Though somatostatin is classically linked to hormone inhibition, it has been linked to 
inflammation for a number of years. Somatostatin is known to exhibit anti-
proliferative effects on T lymphocytes and granulocytes,179 as well as displaying 
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inhibitory activities on human natural killer cells, 180 and the release of inflammatory 
mediators such as TNF-α, IL-1β, and IL-6  cells IFN-γ.136, 181-183 Somatostatin 
binding sites were first identified on human monocytes and lymphocytes in 1981,184 
and since then they have been identified on a variety of immune and haemopoietic 
cells.185 Radio-labelling and fluorescent studies have shown the presence of sstrs on 
B and T lymphocytes from a variety of sites around the body, as well as thymocytes 
and human leukaemic cells.181, 186-188 In addition, somatostatin is expressed by a 
range of inflammatory and immune cells including lymphocytes, macrophages, 
synovial, cells and thymocytes. 189,152, 190 
Sstr2 has been identified as the most common sstr subtype expressed by 
inflammatory cells,136, 191 and as such has been studied extensively as a target for 
novel anti-inflammatory therapies. Both octreotide and a related compound, 
pasireotide, were shown to exhibit anti-inflammatory actions mediated primarily by 
the sstr2 subtype.169 It should be noted however, that sstr2 is not the only sstr 
associated with anti-inflammatory activity. TT-232 is a cyclopenta-ring somatostatin 
analogue identified as a potent anti-inflammatory with no associated endocrine 
effects and binds exclusively to sstr4, with some sstr1 activity.124, 192 138  
The essential sequence for binding of sstr2 has been investigated using MK-678 
(c[N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe]), a somatostatin agonist that binds to potently 
to sstr2, but not to sstr1 or sstr3.193, 194 A series of sstr1 and sstr2 chimeras were tested 
to find the specific regions needed for MK-678 binding and this identified the 
residues Phe294-Asp295-Phe296-Val297 in trans-membrane region 7 as the essential 
region for sstr2 binding. 
Work by Kaupmann et al. showed that a phenylalanine residue in the trans-
membrane VII helice and an asparagine residue in trans-membrane VI were 
necessary for the binding of octreotide to human sstr2, interacting with the Phe-Phe-
Trp-Lys-Thr-Phe (amino-acids 6 to 11) sequence of SST-14 (Figure 17).195  
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Figure 17:The structure of sstr2 (taken from Reisine et al.)196 
1.7.4. FUNCTIONAL SELECTIVITY 
Functional selectivity posits that, rather than each sstr subtype educing a single 
discrete set of effects on agonist binding, instead different agonists may elicit 
different responses from the same receptor.197 ‘Traditional’ receptor theory states 
that an agonist is a drug that activates a receptor, and this can either be a full agonist 
(maximally stimulate all effects linked to the receptor), a partial agonist (limited 
receptor response), a neutral antagonist (preventing activation of a receptor without 
eliciting a response) or an inverse agonist (reduce constitutive signalling).198, 199 
Therefore it would be expected that a full agonist would activate all signalling 
pathways to the same extent as the endogenous ligand. Equally, this theory suggests 
that a ligand that antagonizes one signal associated with a receptor should also 
antagonize all other signals effected by the receptor to the same extent.199 However, 
this cannot explain how agonists such as KE 108 and SOM 230 are able to act as 
both agonists and antagonists for different somatostatin agonist pathways at sstr2. 
The concept of functional selectivity was first described for nuclear receptors, but 
has also be described for a number of GPCRs.200, 201  
Following the identification of sstr2 as the binding site for the somatotaxin FX125L, 
a number of molecules analogous to both somatostatin and the early BSCIs were 
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synthesised to probe the relationship between ‘classical’ somatostatin activities e.g. 
growth hormone inhibition, and ‘non-classical’ BSCI activity, i.e. anti-inflammatory 
activity, at the sstr2 subtype receptor.202 
1.7.5 SOMATOTAXINS AND SSTR2 
As the Phe-Trp-Lys residues of SST-14 have found to be essential for bioactivity, it 
is not suprising that a large number of small molecule sstr2 ligands have been 
developed, based the KWF motif. In particular, Merck has developed a wide range of 
structurally related compounds that have been shown to be potent sstr2 agonists that 
inhibit growth hormone release in vitro (Figure 18).203-205  
Figure 18: The KWF sequence, and the related sstr2 ligand, L-054, 522203 
The KWF motif overlaps with the tripeptide sequence WxQ from which the current 
families of somatotaxins are derived. The presence of the lysine preceding the WxQ 
is therefore potentially significant in explaining the binding of BSCIs to sstr2.99 The 
functional selectivity displayed by sstr2 when these two structurally related families 
of compounds bind (growth hormone inhibition for KWF and anti-inflammatory 
activity for the somatotaxins) implied it should be possible to manipulate the 
physiological response (tip it more towards one effect than another) by synthesising 
a range of hybrid somatostatin/somatotaxin analogues. A variety of KWFQ, KWF, 
WF, WFQ and FQ analogues were synthesised to identify the critical motifs 
responsible for both sstr2 binding and somatotaxin activity (Figure 19).202   
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Figure 19: The structures of one of the KWF mimics (left) and one of the lactam containing KWFQ mimics 
(right) 
Unsurprisingly, the KWF and KWFQ mimics showed the highest sstr2 binding 
activities, judged by displacement of fluorescently labelled somatostatin (KWF = 
97%, KWFQ = 98%; % inhibition of labelled SST14 at sstr2 at 1 nm concentration). 
More interestingly, both of these sets of compounds also showed very high inhibition 
of neutrophil migration  in vitro, with some of the KWF mimics up to 100-fold more 
potent than the KWFQ mimics (KWF = 95%, KWFQ = 115%, % inhibition of 
neutrophil migration at 1 nm concentration). This was surprising, as these results 
showed that the WxQ or lactam motifs are not necessary for BSCI activity. 
For these larger compounds, there appeared to be a correlation between the binding 
activity of the ligands at sstr2 (and hence the level of displacement of SST14), and 
the inhibition of neutrophil migration. However, the current small molecule 
somatotaxins produce a potent anti-inflammatory effect, with extremely low levels 
of somatostatin displacement (Figure 20).  
Figure 20: % somatostatin inhibition and leukocyte migration inhibition  
The bulkier alkyl chain substituents appeared to compete more strongly with SST14 
but this did not necessarily correspond with improved BSCI activity. This implies 
that BSCI activity is not, in fact, linked to the ability of the ligand to displace sstr2 
bound SST-14.   
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As the endogenous ligand for sstr2, SST-14 would be expected to have the maximum 
binding activity However, though SST-14 is known to have anti-inflammatory 
properties it only exerted a maximum of 50 % inhibition of leukocyte migration.202 
The fact that the small molecule somatotaxins are able to exert an extremely potent 
anti-inflammatory effect without displacing SST-14 implies that they bind to a 
region of the receptor not inhabited by somatostatin. In addition to the orthosteric 
binding site, which binds the endogenous ligand, GPCRs are known to exhibit 
allosteric binding sites. These are topographically distinct binding sites, and have the 
potential to modulate or produce distinct physiological effects compared to the 
orthosteric site.206-208 It seems likely that the somatotaxins bind to an allosteric site of 
sstr2 close to the orthosteric site. This would explain why the smallest somatotaxins 
are able to bind without blocking somatostatin, while the bulkier somatotaxins both 
exert an allosteric effect and compete with somatostatin (Figure 21). 
 
Figure 21: Model of binding of ligands to sstr2 via proposed orthosteric and allosteric binding sites  
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It seems likely that binding to the orthosteric site of sstr2 has the potential for some 
anti-inflammatory activity, as shown by the KWF and KWFQ mimics, while binding 
to the allosteric site provides the maximal BSCI activity.  
As a natural sstr2 mediated anti-inflammatory mechanism exists that is not 
maximally induced by SST-14, it seems likely that a non-somatostatin endogenous 
ligand must exist for this allosteric site that takes advantage of this. The fact that the 
small molecules somatotaxins, including FX125L, are amino-acid derived, extremely 
potent BSCIs and very well tolerated in vivo implies that they could be structurally 
related to these endogenous ligands.  
Ornithine is not one of the proteinogenic amino-acids, as it is generally considered to 
be unsuitable for incorporation into stable peptides.209 Ornithine rapidly cyclises in 
peptides and activated esters, resulting in lactam formation and scission of the 
amide/ester bond, even in extremely mild conditions.210-212 Instead metabolism of 
arginine by arginase enzymes and L-arginine:glycine amidinotransferase is the main 
source of ornithine in the body.213, 214 Interestingly, inflammation and infection leads 
to increased levels of arginine and hence elevated levels of ornithine.215-217 
Normally, ornithine is then metabolised further to polyamines and proline but 
potentially, excess ornithine could lead to greater ornithine incorporation into  
peptide precursors. 
We propose that these endogenous ligands could be C-terminal lactam peptides, 
equivalent to the synthesised somatotaxins, formed during inflammatory episodes by 
cleavage of precursor peptide at lysine residues or at arginine residues with 
additional guanidine hydrolysis to create ornithine. This would provide a novel anti-
inflammatory pathway in vivo. Equally, these CTLPs, if formed transiently and in 
low concentrations, may act as natural ‘negative feedback’ regulators via this 
allosteric, non-classical, sstr2-mediated pathway. No conclusive evidence has yet 
been found for their existence, let alone the mechanism for an anti-inflammatory 
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response, but there is accumulating circumstantial evidence for their production 
within the body.  
1.8 MECHANISMS OF ENDOGENOUS CTLP FORMATION 
There are a number of mechanisms by which endogenous C-terminal lactam peptides 
could be synthesised from peptidyl lysine or arginine. Thrombin cleaves peptides 
including preprosomatostatin, fibrinogen and secretin at lysine residues with high 
specificity.218  These could potentially form C-terminal 7-membered lactam peptides 
as a minor product during periods of peptidase enzyme activity, such as an 
inflammatory episode. The fact they have not been isolated is not necessarily proof 
of their non-existence, as it is likely they would occur in only very small amounts. 
E. coli lysyl-tRNA synthase is known to edit ornithine by converting it into ornithine 
lactam by a pre-transfer mechanism, and it seems likely that this also occurs in the 
human body.219 Due to the instability of ornithine in growing peptide chains, 
naturally occurring ornithine-containing peptides are rare, but a number have been 
identified in bacterium, primarily ornithine lipids extracted from both gram-negative 
and gram-positive bacteria (Figure 22). 
Figure 22: α-N-(3-Hydroxyhexadecanoyl)ornithine, a lyso-ornithine lipid produced by OlsB from S. meliloti 
strain 1021220 
While ornithine lipids are quite widespread in bacteria,221 only one ornithine 
containing peptide has been isolated from multicellular organism. This tripeptide, α-
N-[α-N-(β-alanyl)-L-ornithyl]-L-ornithine, was isolated from the brackish-water 
bivalve Corbicula japonica but as yet little is known about its physiological role.222 
In patients with the metabolic disorders, hyperornithinemia-hyperammonemia-
homocytrullinemia (HHH) syndrome and gyrate atrophy of the choroid and 
retina,223-225  unnaturally high levels of ornithine accumulate in the body. A 
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significant proportion of this is excreted in the urine as the ornithine lactam, 
apparently by spontaneous cyclisation of the free ornithine in the body.226, 227 
Significantly, low concentrations of the ornithine-lactam (average concentration 
0.364 µM) are also known to be present in the plasma of healthy humans.228 This 
suggests that there is an equilibrium between the open-chain and lactam forms of 
ornithine in the plasma. 
In higher organisms, inteins could also provide a mechanism for the cleavage of 
peptides and formation of CTLPs. These are self-extracting peptide stretches that 
catalyse their own excision from a protein strand. This requires a specific amino acid 
sequence and involves an N-S/ N-O transfer from the oxygen of a serine or the 
sulphur of a cysteine residue binding to the N-extein, to effectively provide an 
activated ester or thioester.229, 230 This is followed by trans-esterification and ring 
closure to produce the excised intein (Figure 23).230 This mechanism is analogous to 
that observed in the early termination reaction of Gramicidin synthase.110 
Figure 23: The hypothetical route to provide C-terminal 6-membered lactam peptides 
1.9 DIRTY CHICKEN HYPOTHESIS 
We posit that, in healthy individuals, a very small proportion of arginine or lysine-
containing peptides may be converted to the equivalent CTLPs by one of the 
mechanisms proposed above, with production upregulated during times of 
inflammatory stress. 
It has long been known that there is a link between heightened levels of 
inflammation and restricted growth. In 1963, Coates et al. described how chickens 
grew faster when kept in germfree conditions than those kept in the usual 
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environment.231 First proposed by Solomons et al. in 1993, the ‘Dirty Chicken 
Hypothesis’ is based on this observation that chickens raised in unhygienic, 
overcrowded conditions tend to be smaller than those reared in similar conditions but 
given antibiotics which tend to grow to normal size.232 Controlled studies showed 
that chicks reared in dirty conditions, as well as being smaller, showed high levels of 
interleukin 1, a protein that plays a major role in immune responses. This was not 
observed in either chicks raised in clean conditions, or those raised in dirty 
conditions but given antibiotics.233 This analogy is used to explain the reason that 
children that grow up in squalid, impoverished conditions tend to be shorter than 
their wealthier counterparts, even if adequately fed. It is believed that constant 
exposure to infectious conditions causes a state of constant low-level inflammation, 
which in turn affects growth, believed to be caused by diversion of nutrients towards 
fighting infections, and poor uptake on nutrients due to inflammation of the gut.234 
It would be expected that, unlike the small molecule anti-inflammatory lactams (e.g. 
tert-butyl substituted seven membered lactam, Figure 11), CTLPs could be larger 
and act as inhibitors of somatostatin binding to sstr2 (cf. Figure 21). In healthy 
individuals, where CTLPs are present as part of the natural immune system, 
somatostatin binding is inhibited and normal growth via the production of GH is 
observed. In individuals with chronic inflammation and an exhausted pool of CTLP 
precursor proteins, CTLP levels will be low, resulting in little inhibition of 
somatostatin binding to sstr2 and a resulting inhibition of GH production, and hence 
restricted growth. 
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1.10 RESEARCH AIMS AT START OF PROJECT 
The primary aim of this part of the thesis was the synthesis of a range of peptidyl 
CTLPs that could be tested for their somatotaxin activity. A secondary aim was to 
use these compounds to provide more information about the endogenous CTLPs we 
postulate may be formed in vivo. 
Initially, the synthesis of ten CTLPs was planned (Figure 24). These fell into three 
basic groups: 
1) 15 atom tailgroups: Three compounds, a di-, tri- and tetrapeptide, were 
synthesised with varying lengths of alkyl tail group (C11, C8 and C5 
respectively) to give compounds with a similar structure, but different 
polarities, to assess how this would affect sstr2 binding and somatotaxin 
activity. 
2) Acetylated CTLPs: Three compounds were synthesised, a di-, tri and tetra-
peptide, with an N-terminal acyl group to assess how peptide length might 
affect binding and somatotaxin activity. 
3) Boc-protected CTLPs: The Boc-protected di-, tri-, tetra- and pentapeptides 
were synthesised both as potential novel somatotaxins or as tools for further 
investigation of the sstr2 mediated anti-inflammatory mechanism. 
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CHAPTER 2: C-TERMINAL LACTAM PEPTIDES 
 
2.1 LINEAR PEPTIDE SYNTHESIS 
Figure 24: The 10 CTLPs proposed for synthesis 
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The first nine compounds (2.01 - 2.09, Figure 24) were synthesised using C to N 
linear solution phase peptide synthesis. L-Alanine was chosen as a simple example 
and because of the ability of even short peptide stretches to form regular secondary 
protein structures, with tetraalanine calculated to form α-helices in some solvents, 
and we hoped to see how this affected sstr2 binding and somatotaxin activity.1, 2 As 
the (S)-3-amino-2-piperidones are very water soluble, it was decided to use δ-N-
benzyloxycarbonyl-L-ornithine methyl ester hydrochloride, 2.12, as a more lipophilic 
headgroup throughout the synthesis. This was then deprotected and spontaneously 
ring closed to provide the desired lactam products. The synthesis started with  
ornithine being selectively protected using a copper (II) chelate, leaving only the δ-
nitrogen free to react with the benzyl chloroformate (Scheme 1).3, 4 The copper was 
then sequestered using EDTA to afford the δ-N-benzyloxycarbonyl-L-ornithine as 
the acid, which was readily converted to the methyl ester hydrochloride 2.12 using 
methanolic HCl. 
Scheme 1: The route to the selectively mono-protected ornithine 2.12 using a copper (II) chelate 
A combination of α-N-terminal Boc protection and a C-terminal methyl ester were 
chosen as compatible protecting groups, as N-tert-butoxy-L-alanine (Boc-L-alanine) 
is cheap and readily available, and the Boc group could be deblocked easily using 
methanolic HCl without affecting other functional groups. 
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The peptide chains were built using successive rounds of peptide coupling using 
Boc-L-alanine, HATU and triethylamine (Scheme 2). O-(7-Aza-benzotriazol-1-yl)-
N, N, N’, N’-tetramethyluronium hexafluorophosphate (HATU) is one of large 
number of commercially available peptide coupling agents based on 1-
hydroxybenzotriazole (HOBt). It consists of a guanidinium salt of a 1-hydroxy-7-
azabenzotriazole (HOAt), and is considered to be superior to HOBt in terms of 
reduction of racemisation and rate of reaction.5-8 The carboxylic acid of the first 
amino-acid reacts rapidly with the guanidinium functionality of HATU to form an 
activated ester. This is rapidly intercepted by the HOAt moiety to give a second ester 
with the elimination of tetramethylurea (TMU).9 The coupling is completed with the 
nucleophilic substitution by a free amine to give the coupled product. 
The peptide couplings performed between Boc-L-alanine and the growing peptide 
generally proceeded with very high conversions but the TMU by-product initially 
proved difficult to remove. A literature search showed that it was possible to exploit 
the comparative solubility of TMU in water and toluene.10 Concentration of the 
crude reaction mixture, followed by dissolution of the residue in toluene and several 
aqueous washes (pH 2 buffer, saturated carbonate solution, water) followed by 
concentration in vacuo and a toluene azeotrope generally gave the coupled product in 
very high yields and purity, without the need for column chromatography or further 
drying. Boc-deprotection was achieved easily using methanolic HCl. Each 
deprotected peptide underwent three further reactions: a reaction with acetic 
anhydride to give the capped peptide (e.g. 2.15, Scheme 2), reaction with the 
relevant acyl chloride to give a 15 atom tail group (e.g. 2.16, Scheme 2) or a further 
peptide coupling with Boc-l-alanine (e.g. 2.17, Scheme 2). 
Once the final tail group was added, compounds were hydrogenated over palladium 
to deprotect the γ-NH2, leading to spontaneous ring closure and loss of the methyl 
ester to give the desired series of CTLPs. 
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Scheme 2: The linear synthesis of the first nine CTLPs 
Using this method, the first nine CTLPs were synthesised in sufficient quantities for 
full characterisation and further testing. However, though the yields for the peptide 
coupling and acylation reactions were generally good, the overall yields were often 
poor. In addition, with the exception of the four simplest dipeptides, all needed 
purification by reverse phase HPLC in order to remove residual inorganics and 
impurities from the coupling steps and final hydrogenation. With the addition of 
longer tailgroups and more amino-acids the compounds became less easy to 
manipulate and purify. The tri-alanine tetrapeptides (2.22 - 2.24) were much less 
soluble than the di- and tripeptides, to the extent that they were insoluble in the 
toluene used in the removal of TMU and had to be stirred vigorously as a suspension 
in toluene and water at high temperatures and filtered to remove both the TMU and 
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the triethylamine hydrochloride salt. The tetra-alanine pentapeptide was so insoluble 
as to form a gelatinous solid in both DCM and MeOH, preventing complete reaction. 
In addition, even the relatively soluble small compounds were unexpectedly difficult 
to hydrogenate at the final step, requiring at least 2 days under a constant pressure of 
hydrogen rather than hours observed in comparable reactions within the research 
group. It seems likely that the peptides were complexing to the catalyst, preventing 
complete reaction of the substrate and leading to reduced yields (5 - 76%). 
 
2.2 BLOCK SYNTHESIS OF PENTAPEPTIDES USING ETHYL 
HYDROXIMINO-2-CYANOACETATE 
The linear peptide coupling method used to produce the first 9 CTLPs suffered from 
a variety of disadvantages, and it was obvious that in order to obtain the 6-membered 
lactam with a tetrapeptide tail, a different route will have to be attempted. Initially, 
we planned to build up the tetra-alanyl chain using convergent block synthesis of a 
pair of dipeptides (Scheme 3).  
Scheme 3: Proposed synthesis of the tetraalanyl CTLP, 2.10 
As the final hydrogenation and ring closure step was problematic, it was hoped to 
bypass this by performing a coupling directly between the lactam headgroup and the 
tetrapeptide chain. Finally, a different peptide coupling reagent was sought, as the 
tetramethyl urea (TMU) by-product from HATU became increasingly difficult to 
remove as the peptide chain length increased. 
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A peptide coupling method proposed by Pu et al. provided a viable route to the 
pentapeptide.11 The reaction was performed in aqueous EtOH, which led to greatly 
improved solubility of both the intermediates and the products. EDCI was used as 
the coupling agent, with the advantage of producing readily water-soluble by-
products. Rather than using the benzotriazole HOBt as a racemisation suppression 
agent, it was decided to use ethyl hydroximino-2-cyanoacetate (Oxyma, Figure 25). 
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This coupling agent works in a similar way to the benzotriazole based HOBt and 
HOAt coupling agents with improved suppression of epimerization, but does not 
have the same risk of explosion, and hence is cheaper and easier to obtain.13 The 
reported decrease in racemization in reactions using Oxyma is likely to be due to the 
nucleophilic, yet stable, oxime anion, reducing the rate of 5-(4H)-oxazolone 
formation (Figure 25).14 
Figure 25: Resonance forms of deprotonated Oxyma14 
However, unlike linear C to N peptide synthesis, where epimerisation is largely 
avoided by using urethane protected amino-acids (Scheme 2), block peptide 
couplings risk epimerisation of the C-terminal amino-acid during the coupling 
reactions. 
As a starting point to test racemisation with this method, we synthesised both N-tert-
butoxy-L-alanyl-L-alanine, 2.27, and N-tert-butoxy-L-alanyl-D-alanine, 2.30 (Scheme 
4).  
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Scheme 4: The synthesis of two diastereomers of Boc-L-alanylalanine 
Unfortunately, there were no discernible differences between these two 
diastereomers by 1H NMR spectroscopy.15 At this point it was noted that the harsh 
conditions used for the formation of the benzyl ester 2.25 appeared to have resulted 
in significant racemization (based on optical rotation, 28][ Dα -6.1 (c = 1.9, MeOH) 
(lit.16 25][ Dα -40.5 (c = 2.0, MeOH)). However, the 1H NMR spectrum of the resulting 
dipeptide diastereomer 2.27 showed no obvious additional peaks for the N-tert-
butoxy-D-alanyl-L-alanine diastereomer. The 13C NMR spectrum showed the 
appearance of additional peaks, but these were in no way distinctive enough to be a 
reliable method for assessing epimerization.  
As these observations meant we would be unable to easily assess what level of 
epimerisation was occurring at the C-terminal amino-acids, we sidestepped the issue 
by replacing alternate alanine residues with glycine residues (Scheme 5). As glycine 
does not have a stereogenic centre, it could be used at the C-terminal end of the 
peptide without epimerisation being a concern. It was also hoped that the mix of 
amino-acids in the peptide chain would improve the solubility of the final peptides, 
but still retain a ‘native peptide-like’ character. 
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Scheme 5: Block synthetic route to the pentapeptide CTLP, 2.39 
Initially, the N- and C- protected alanylglycine dipeptide was produced as both the 
benzyl and methyl esters using this method (2.31 and 2.33, Scheme 5). It became 
apparent that, despite only catalytic amounts of Oxyma being used, by-products were 
formed during the dipeptide formation that were difficult to completely remove 
during work up. This has been previously commented on, but we hoped that the side 
reactions leading to these impurities would be suppressed if Oxyma was present in 
substoichiometric amounts.13, 17 However, we found that both dipeptides required 
further purification by silica chromatography to remove these persistent by-products. 
Boc-deprotection of the methyl ester dipeptide was performed with methanolic HCl, 
and the benzyl ester of the N-terminal dipeptide removed using catalytic 
hydrogenation. Coupling was again performed using the catalytic Oxyma/EDCI 
method to give the tetrapeptide methyl ester (2.35, Scheme 5). The low yield at this 
step is possibly due to the formation of diketopiperazines, a known side products of  
couplings involving glycine-containing dipeptides.18, 19  
While the C-terminal benzyl ester would potentially have been easier to isolate and 
purify due to increased organic solubility compared to the methyl ester, it was 
decided to avoid the use of palladium catalysed hydrogenation to produce the C-
deprotected tetrapeptide after the difficulties experienced in the previous syntheses. 
To avoid loss of the tetrapeptide during aqueous work-up, the crude reaction mixture 
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was purified by column chromatography in reasonable yield. Hydrolysis was 
achieved using aqueous lithium hydroxide in EtOH and, as isolation of the product 
proved problematic, the crude carboxylic acid was used in solution without further 
purification. After a number of attempts, the crude pentapeptide was synthesised by a 
final coupling using an excess of the lactam. This required purification by column 
chromatography and reverse phase HPLC to give the final tetrapeptide, 2.39, in 1 % 
overall yield over 5 steps (Scheme 5). 
2.3 CONCLUSIONS 
In all, ten CTLPs were synthesised. Ultimately, due to a change in direction by our 
industrial collaborators, it has not yet been possible to assess the sstr2 binding or 
somatotaxin activity of these synthesised compounds. However, in the process of 
synthesising these peptides, we identified a number of issues that warranted further 
investigation. 
A major concern was maintaining the chiral integrity of the stereocentre of the 
lactam and the amino-acid chain. The linear C to N terminal synthesis would be 
expected to have minimal levels of epimerisation, as the C-terminal amino-acids 
were supplied as the urethane-protected monomers, which are much less prone to 
epimerisation than other amides.20 This linear method suffered from extremely low 
overall yields and issues with purification, and the convergent block-synthesis of the 
peptides still appeared to provide a more useful strategy for the production of 
CTLPs. Unfortunately, our inability to accurately assess levels of epimerisation 
limited us to the use of glycine as the C-terminal amino-acid. 
A recent review listed over 280 different peptide coupling agents, used both in 
solution and solid phase.21  Despite a huge quantity of research, epimerisation, side-
reactions and removal of by-products remain a problem. Even with advances in solid 
phase peptide synthesis, the process is still wasteful and size of peptide limited. 
Amide bond formation is still seen as expensive and clumsy, and a recent review 
stated ‘amide bond formation avoiding poor atom economy reagents’ as a 
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fundamental challenge for organic chemistry.22, 23 As implied by the huge diversity 
of coupling  agents available, none of the current reagents provide a particular 
advantage for a general method of peptide bond formation.24 Those related to HOBt 
(the so-called uronium/aminium salts), and the related phosphonium and ammonium 
salts all rely on the in situ formation of a C-terminal active ester, and hence are likely 
to induce a certain level of epimerization, no matter how low. Obviously, all 
synthetic methods for amide bond preparation require some activation of the acid, 
and hence run some risk of epimerisation, but we felt that moving away from the 
‘onium’ based reagents could provide a more robust alternative. 
While investigating new methods of performing the final amide bond formation 
between the lactam and the amino-acid tailgroup, we additionally hoped to quantify 
the level of epimerisation occurring during the peptide coupling, and so minimise it 
as far as possible. 
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2.5 EXPERIMENTAL 
All the reagents and solvents used were purchased from the Sigma-Aldrich, Alfa-
Aesar, TCI, Bachem or Fluorochem Chemical Company and were used as received 
unless stated otherwise. pH 2 buffer was made as a solution of 0.75 M of Na2SO4 
and 0.25 M H2SO4 in H2O. 
 
1H- and 13C-NMR spectra were recorded on a Bruker AVII-700 MHz, AVIII-600 
MHz, DRX-500 MHz, DPX-400 MHz or DPX-300 MHz Fourier transform 
spectrometer at room temperature unless stated otherwise. Chemical shifts are 
quoted in parts per million (ppm) downfield from tetramethylsilane. Solvents were 
used as an internal standard when assigning NMR spectra (δH: CDCl3 7.26 ppm, 
CD3OD 3.31 ppm, DMSO-d6 2.50 ppm, D2O 4.79 ppm, d1-TFA 11.5 ppm; δC: 
CDCl3 77.1 ppm, CD3OD 49.0 ppm, DMSO-d6 39.5 ppm, d1-TFA 164.2, 116.6 
ppm). Coupling constants (J) are quoted in Hertz (Hz), rounded to the nearest 0.5 
Hz. Abbreviations used in the descriptions of spectra are as follows; s = singlet, d = 
doublet, t = triplet, q = quartet, quin. = quintet, sept. = septet, oct. = octet, m = 
multiplet, br = broad, i = ipso, o = ortho, m = meta, p = para, ax. = axial and eq. = 
equatorial. 13 C-NMR spectra were recorded with broadband proton decoupling and 
spectra were assigned on the basis of COSY, PENDANT, HMQC and HMBC 
spectra. In aromatic characterisations, the ipso carbon is taken to be the carbon 
bonded to the group with the highest molecular weight 
 
Infrared spectra were recorded on a Nicolet Avatar 320 FT-IR spectrophotometer 
using EZ OMNIC software package 1, Bruker ALPHA Platinum ATR 
spectrophotometer or Perkin ELMER Spectrum 100 FT-IR spectrophotometer using 
OPUS software and are quoted in wavenumber (cm-1). 
Optical rotations were recorded on an Optical Activity Ltd. AA-1000 millidegree 
auto-ranging polarimeter (using the sodium D line; 589 nm) and [α]Ds are given in 
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units of 10-1deg cm2 g-1. The samples were made using spectroscopic grade MeOH, 
CHCl3 or H2O. 
ESI mass spectra were obtained on a Bruker Esquire 2000 mass spectrometer or an 
Agilent 6130B single Quad (ESI). HRMS ESI spectra were obtained by Dr Lijiang 
Song, Mr Philip Aston or Dr Rebecca Wills using a Bruker micro-TOF ESI attached 
to a time of flight (TOF) analyser.  
HPLC data was obtained on a Varian Prostar 335LC detector using an ChiralPak AS 
column, (4.6mm x 250mm) using a solvent system of 1: 1 (n-hexane: iso-propyl 
alcohol) and a flow rate of 0.5mL / minute. Reverse Phase HPLC was performed on 
an Agilent 1100, with an Agilent Zorbax RP-C18 Column, 100x21mm, 5um, UV at 
220nm.Flow rate: 5ml/min, Solvent: water(A) and ACN (B) both with 0.1% FA, 
Gradient (B%): 0-10mins, 20% B; 10-12mins, 20-80%B; 12-17mins, 80%B; 17-
20mins, 80 to 20% B, then equilibrate for 15min before next run. 
Melting points for solid crystalline products were determined on a Stuart Scientific 
SMP10 Digital Melting Point Apparatus, with three runs of each compound, and a 
range given in ˚C rounded to the nearest degree. They are uncorrected.  
 
Thin Layer Chromatography (TLC) was performed using silica (0.25 mm) coated 
aluminium plates.  
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δ-N-(Benzyloxycarbonyl)-L-ornithine 2.11 
Prepared according to the method of Rosowsky et al.1 Aqueous NaOH solution 
(0.5M, 200 mL, 100 mmol) was added to L-ornithine hydrochloride (16.9 g, 100 
mmol) with stirring to give a clear, colourless solution. CuSO4.H2O (12.5 g, 50.0 
mmol) was added and the reaction mixture was stirred at room temperature for 40 
minutes. K2CO3 (13.8 g, 100 mmol) was added, followed by benzyl chloroformate 
(19.0 mL, 128 mmol) and the mixture stirred at room temperature overnight.  The 
resulting purple precipitate was isolated by filtration and washed with MeOH (2 x 50 
mL). The filtercake was added to a solution of EDTA (14.6 g, 50.0 mmol) in 
aqueous sodium hydroxide solution (0.25M, 400 mL, 100 mmol) to give a purple 
slurry. After heating to 95 °C for 1 hour, the reaction mixture was cooled to room 
temperature. The mixture was filtered and the crude product isolated by filtration as 
a sticky blue solid. This was washed with H2O (10 x 300 mL) until no further blue 
colour was observed to give the free amine 2.11 as a white solid (17.1 g; 63.9 mmol, 
64 %); m.p. 257 - 258 ºC (lit.2 255 - 256 °C);  υ
 max/cm-1(neat) 3328 (N-H), 2945 
(broad O-H), 1683 (acid C=O), 1606 (amide C=O), 1535 (N-H);  δH (400 MHz, d1-
TFA) 7.60 - 6.90 (5H, m, 5 x Ar CH), 5.28 (2H, s, CH2Ph), 4.46 (1H, t, J 6.5 Hz, 
CHNH2), 3.44 (2H, t, J 6.5 Hz, CH2NH), 2.51 - 2.11 (2H, m, CHCH2CH2), 2.06 - 
1.77 (2H, m, CHCH2CH2); δC (100 MHz, d1-TFA)  173.0 (CO2H), 160.2 (CO2Bn), 
134.5 (ipso C), 128.6, 128.3, 127.7 (ortho, meta and para CH), 69.1 (CH2Ph), 53.8 
(CHNH2), 39.8 (CH2NH), 24.4, 22.1, (2 x CH2,); m/z (ESI+) 289.1 ([M+Na]+, 
100.0%), 267.1 ([M+H]+, 15.2%); HR-ESIMS: calculated for C11H19N2O4: 
267.1339, found: 267.1346 [M+H]+. Data are consistent with that previously 
reported. 2, 3 
65 
 
δ-N-(Benzyloxycarbonyl)-L-ornithine methyl ester hydrochloride 2.12 
Acetyl chloride (35 mL, 492.3 mmol) was added dropwise with stirring and cooling 
in an icebath to MeOH (450 mL). δ-N-(Benzoyloxycarbonyl)-L-ornithine 2.11 (17.1 
g, 63.9 mmol) was added to this solution and stirred at room temperature overnight. 
The reaction was concentrated in vacuo to afford the 2.12 as a white fluffy solid 
(20.2 g, 63.8 mmol, quantitative yield);  m.p. 137 - 138ºC, (lit.1 138 - 139 °C); 34][ Dα  
+16.0 (c = 0.59, MeOH), (lit.4 20][ Dα  +13.8 (c = 2.0, MeOH)); υ max/cm-1 (neat) 3336 
(amide N-H), 3016 (N+-H), 1742 (ester C=O), 1689 (amide C=O), 1535 (N-H); δH 
(400 MHz, DMSO-d6) 8.59 (3H, br. s., NH3), 7.48 - 7.20 (6H, m, 5 x Ar CH, 
CH2NH), 5.01 (2H, s, CH2Ph), 4.00 (1, t, J 6.5 Hz, CHCH2), 3.73 (3H, s, OCH3), 
3.00 (2H, q, J 6.5 Hz, CH2NH), 1.86 - 1.70 (2H, m, CH2CH2NH), 1.62 - 1.36 (2H, 
m, CHCH2); δC (100 MHz, DMSO-d6) 169.8 (CO2Me), 156.1 (CO2Bn), 137.2 (ipso 
C), 128.3, 127.7, 127.7 (ortho, meta and para CH), 65.2 (CH2Ph), 52.7 (OCH3), 51.6 
(CHCH2), 40.1 (CH2NH), 27.4 (CH2CH2NH), 24.9, (CHCH2); m/z (ESI+) 281.1 
([M-Cl]+, 100%); HR-ESIMS: calculated for C14H21N2O4: 281.1496, found: 
281.1493 [M-Cl]+. Data are consistent with that previously reported.1  
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α-N-(N-tert-Butoxycarbonyl-L-alanyl)-δ-N-(benzyloxycarbonyl)-L-ornithine 
methyl ester 2.13 
N-tert-Butoxycarbonyl-L-alanine (5.97 g, 31.6 mmol) and HATU (12.0 g, 31.6 
mmol) were stirred in CH2Cl2 (90 mL). After 5 minutes δ-N-(benzyloxycarbonyl)-L-
ornithine methyl ester hydrochloride 2.12 (10.0 g, 31.6 mmol) was added and the 
suspension cooled to 0 °C using an ice-salt bath. The mixture was stirred at 0 °C for 
10 minutes and triethylamine (9.60 mL, 94.8 mmol) was added slowly. The yellow 
suspension was stirred at 0 °C to room temperature until the reaction mixture became 
a clear yellow solution (1-3 hours) indicating completion.  pH 2 buffer (50 mL) was 
added and the phases separated. The organic layer was washed with pH 2 buffer (50 
mL), aqueous saturated sodium NaHCO3 solution (2 x 50 mL) and water (50 mL). 
The organic phase was concentrated in vacuo and the yellow residue taken into 
toluene (100 mL). pH 2 buffer (50 mL) was added and the toluene layer was washed 
as before. The organic phase was concentrated in vacuo and dried by toluene 
azeotrope (4 x 50 mL). Residual solvent was removed under vacuum to afford 2.13 
as a colourless oil that crystallised on standing to give a colourless crystalline solid 
(12.6 g, 27.9 mmol, 88 %); m.p. 77 - 79 ºC; 26][ Dα -3.8 (c = 1.0, CHCl3), (lit.5 20][ Dα -
5.0 (c = 1.74, CHCl3)) ; υ max/cm-1 (neat) 3325 (N-H), 1736 (ester C=O), 1689 
(carbamate C=O), 1652 (amide C=O), 1519 (N-H); δH (400 MHz, CDCl3) 7.19 - 
7.05 (5H, m, 5 x Ar CH), 6.90 (1H, br. s., CH2CHNH), 5.17 (2H, br.s., CH3CHNH, 
CH2NH), 5.02 (2H, s, CH2Ph), 4.50 (1H, td, J 8.0, 5.5 Hz, CH2CHNH), 4.18 - 4.07 
(1H, m, CHCH3), 3.65 (3H, s, OCH3), 3.12 (2H, q, J 6.5 Hz, CH2NH), 1.88 - 1.76 
(1H, m, CH2CH) 1.69 - 1.55 (1H, m, CH2CH), 1.54 - 1.41 (2H, CH2CH2NH), 1.36 
(9H, s, C(CH3)3), 1.27 (3H, d, J 7.0 Hz, CHCH3); δC (100 MHz, CDCl3) 172.8, 172.5 
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(CHCONH, CO2Me), 156.6, 155.6 (CO2Bn, CO2tBu), 136.7 (ipso C), 128.5, 128.1 
(ortho, meta and para CH),  80.1 (C(CH3)3), 66.6 (PhCH2), 52.4 (OCH3), 51.8 
(NHCHCH2), 50.1 (NHCHCH3), 40.4 (NHCH2), 29.4 (CH2), 28.3 (C(CH3)3), 25.9 
(CH2), 18.2 (NHCHCH3); m/z (ESI+) 474.1 ([M+Na]+, 100.0%), 374.1 ([M-Ph]+, 
21.0%); HR-ESIMS: calculated for C22H33N3O7Na: 474.2214, found: 474.2211 
[M+Na]+. This compound has been previously reported,5 but without any 
spectroscopic data.  
(S)-3-[(N-tert-butoxycarbonyl)-L-alanyl]-aminopiperidine-2-one 2.07 
α-N-(N-tert-Butoxycarbonyl-L-alanyl)-δ-N-(benzyloxycarbonyl)-L-ornithine methyl 
ester 2.13 (1.5 g, 3.32 mmol) was dissolved in MeOH (20 mL) and catalytic 
palladium (~20 mg, 10% on activated carbon) was added. The reaction vessel was 
purged with H2 and the reaction mixture was stirred under 1 atm H2 atmosphere for 
72 hours. The reaction was filtered through celite and the filtrate concentrated in 
vacuo to give sticky white crystals. This was purified by silica chromatography (5% 
MeOH:CHCl3) to give 2.07 as a colourless crystalline solid (0.31 g, 1.05 mmol, 32 
%); m.p. 136 - 137°C; 26][ Dα  +30.3 (c = 0.31, CHCl3); υ max/cm-1 (neat) 3285 (N-H), 
1664, (amide C=O), 1511 (N-H); δH (400 MHz, CDCl3) 7.63 (1H, d, J 5.0 Hz, 
NHCHCH2), 7.17 (1H, br. s., NHCH2), 5.70 (1H, d, J 6.5 Hz, NHCHCH3), 4.23 - 
4.19 (2H, m, CHCH3, NHCHCH2), 3.23 (2H, t, J 5.0 Hz, NHCH2), 2.34 - 2.24 (1H, 
m, NHCHCH2), 1.88 - 1.73 (2H, m, NHCH2CH2), 1.55 (1H, qd, J 11.5, 5.5 Hz, 
NHCHCH2), 1.35 (9H, s, C(CH3)3), 1.27 (3H, d, J 7.0 Hz, CHCH3); δC (100 MHz, 
CDCl3) 173.9 (CONH), 171.7 (CONH), 155.4 (CO2tBu), 79.8 (C(CH3)3), 50.1, 50.0 
(NHCHCH3, NHCHCH2), 41.5 (NHCH2), 28.3 (C(CH3)3), 27.1, 20.9 (2 x CH2), 18.8 
(CHCH3); m/z (ESI+) 474.1 ([M+Na]+, 100.0%), 374.1 ([M-Ph]+, 21.0%); m/z 
(ESI+) 307.9 ([M+Na]+, 100.0%); HR-ESIMS: calculated for C13H23N3O4Na: 
308.1581, found: 308.1581 [M+Na]+.  
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α-N-(L-Alanyl)-δ-N-(benzyloxycarbonyl)-L-ornithine methyl ester 
hydrochloride 2.14 
 α-N-(N-tert-Butoxycarbonyl-L-alanyl)-δ-N-(benzyloxycarbonyl)-L-ornithine methyl 
ester 2.13 (12.6 g, 27.9 mmol) was deprotected by stirring in methanolic HCl (2M, 
60.0 mL) for 3 hours at room temperature. Concentration in vacuo followed by 
trituration in Et2O gave the amine 2.14 as a white semi-crystalline oil (10.3 g; 25.9 
mmol, 93 %); 30][ Dα  +6.6 (c = 1.55, CHCl3); υ max/cm-1 (neat) 3231, 2952 (N-H), 
1703 (ester C=O), 1681 (amide C=O), 1520 (N-H); δH (400 MHz, DMSO-d6) 8.92 
(1H, d, J 7.0, NHCH), 8.41 - 8.24 (3H, m, CHNH3), 7.44 - 7.28 (6H, m, 5 x Ar CH, 
NHCH2), 5.02 (2H, s, CH2Ph), 4.28 (1H, ddd, J 8.5, 7.5, 5.0 Hz, NHCHCH2), 3.93 - 
3.84 (1H, m, NHCHCH3), 3.61 (3H, s, OCH3), 3.02 (2H, q, J 5.5 Hz, NHCH2), 1.83 
- 1.58 (2H, m, CHCH2), 1.58 - 1.43 (2H, m, CH2), 1.39 (2H, d, J 7.0 Hz, CHCH3); δC 
(100 MHz, DMSO-d6) 172.0 (CHCONH), 170.0 (CO2Me), 156.1 (CO2Bn), 137.2 
(ipso C), 128.1, 127.7, 127.3 (ortho, meta and para CH), 65.1 (CH2Ph), 51.4 (OCH3, 
CHCH2), 48.5 (CHCH3), 38.0 (NHCH2), 27.8, 23.3 (2 x CH2) 17.2 (CHCH3); m/z 
(ESI+) 352.2 ([M-Cl]+, 100%), 374.1 ([M-HCl+Na]+, 7%).  
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α-N-(N-Acetyl-L-alanyl)-δ-N-(benzyloxycarbonyl)-L-ornithine methyl ester 2.15 
α-N-(L-Alanyl)-δ-N-(benzyloxycarbonyl)-L-ornithine methyl ester hydrochloride 
2.14 (1.00 g, 2.52 mmol) and triethylamine (0.70 mL, 5.05 mmol) were stirred on ice 
in CH2Cl2 (20 mL). Acetic anhydride (0.27 g, 2.78 mmol) was added slowly to give 
a colourless solution. This was stirred to room temperature over 2 hours. Water (20 
mL) was added and the phases separated. The organic phase was washed with citric 
acid solution (10% w/w, 2 x 20 mL) and saturated aqueous NaHCO3 solution (2 x 20 
mL), dried over Na2SO4, and concentrated in vacuo to give 2.15 as a white 
crystalline solid (0.73 g, 1.83 mmol, 74 %); m.p. 153 - 154ºC;
 
33][ Dα  -2.1 (c = 1.0, 
CHCl3); υ max/cm-1 (neat) 3291 (N-H), 3066 (aromatic C-H), 2951 (aliphatic C-H), 
1736 (ester C=O), 1681, 1631 (amide C=O), 1536 (N-H); δH (400 MHz, CDCl3) 7.45 
- 7.26 (6H, m, Ar CH, NHCHCH2), 6.69 (1H, d, J 7.5 Hz, NHCHCH3), 5.48 - 5.33 
(1H, m, NHCH2), 5.09 (2H, s, CH2Ph), 4.66 - 4.49 (2H, m, NHCHCH3, NHCHCH2), 
3.73 (3H, s, OCH3), 3.18 (2H, q, J 6.5 Hz, NHCH2), 1.96 (3H, s, COCH3), 1.88 (1H, 
m, NHCHCH2), 1.70 (1H, m, NHCHCH2), 1.62 - 1.44 (2H, m, NHCH2CH2), 1.37 
(3H, d, J 6.5 Hz, CHCH3); δC (100 MHz, CDCl3) 172.7, 172.4, 170.3 (2 x CONH, 
CO2Me), 156.7 (CO2Bn), 136.6 (ipso C), 128.5, 128.1 (ortho, meta and para CH),  
66.7 (CH2Ph), 52.5 (COCH3), 52.1 (CHCH3), 48.9 (NHCHCH2), 40.4 (NHCH2), 
28.9 (NHCHCH2), 25.9 (NHCH2CH2), 23.0 (CH3CO), 18.4 (CHCH3); m/z (ESI+) 
416.1 ([M+Na]+, 100.0%); HR-ESIMS: calculated for C19H27N3O6Na: 416.1792, 
found: 416.1790 [M+Na]+. 
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 (3S)-3-(Acetyl-L-alanyl)-aminopiperidine-2-one 2.02 
10% palladium on activated carbon (~10 mg) was added to a solution of α-N-(N-
acetyl-L-alanyl)-δ-N-(benzyloxycarbonyl)-L-ornithine methyl ester 2.15 (4.01 g, 10.2 
mmol) in MeOH (25 mL). The reaction mixture was purged with hydrogen and 
stirred at 40°C under 1 atm pressure of hydrogen for 5 days. The reaction was 
filtered over celite and concentrated in vacuo to give a sticky white solid. 
Recrystallisation (CHCl3:Et2O) gave the lactam 2.02 as a white powdery solid  (1.76 
g, 7.74mmol, 76%); m.p. 210-210°C; 28][ Dα  -38.8 (c = 1.0, MeOH); υ max/cm-1 (neat) 
3264 (N-H), 1625 (amide C=O), 1539 (N-H); δH (400 MHz, DMSO-d6) 8.02 (1H, d, 
J 7.5 Hz, NHCHCH3), 7.99 (1H, d, J 8.0 Hz, NHCHCH3), 7.59 (1H, br. s., NHCH2), 
4.29 (1H, quin, J 7.5 Hz, NHCHCH3), 4.13 (1H, ddd, J 11.0, 8.0, 6.0 Hz, 
NHCHCH2), 3.14 - 3.00 (2H, m, NHCH2), 1.99 - 1.91 (1H, m, lactam NHCHCH2), 
1.84 (3H, s, CH3CO), 1.82 - 1.68 (2H, m, NHCH2CH2), 1.57 (1H, qd, J 11.5, 4.5 Hz, 
NHCHCH2), 1.20 (3H, d, J 7.5 Hz, CHCH3); δC (100 MHz, DMSO-d6) 172.1, 169.7 
(2 x CONH), 168.8 (CONHCH2), 48.8 (NHCHCH2), 47.9 (NHCHCH3), 40.9 
(NHCH2), 27.5 (NHCHCH2), 22.5 (CH3CO), 21.0 (NHCH2CH2), 18.5 (CHCH3); 
m/z (ESI+) 249.8 ([M+H]+, 100.0%); HR-ESIMS: calculated for C10H17N3O3Na: 
250.1162, found: 250.1162 [M+Na]+. 
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α-N-(N-Undecanoyl-L-alanyl)-δ-N-(benzyloxycarbonyl)-L-ornithine methyl ester 
2.16 
Undecanoic acid (3.0 g, 16.3 mmol) and DMF (3 drops) were stirred on ice in 
CH2Cl2 (50 mL). Oxalyl chloride (4.13 g, 32.2 mmol) was added dropwise with 
exotherm. The reaction was allowed to reach room temperature over 1 hour. The 
product was obtained by concentration in vacuo to give an orange oil which was 
used without further purification (3.37 g, 16.5 mmol, 100%); υ
 max/cm-1 2923 (C-H), 
1801 (C=O); δH (400 MHz, CDCl3) 2.90 (2H, t, J 7.5 Hz, CH2CO), 1.73 (2H, quin, J 
7.5 Hz, CH2CH2CO), 1.42 - 1.26 (14H, m, 7 x CH2), 0.91 (3H, t, J 7.0 Hz, CH3); δC 
(100 MHz, CDCl3) 179.8 (COCl), 47.1 (CH2COCl), 31.9 (CH2CH2COCl), 29.5, 
29.3, 29.1, 28.5, 28.4 25.1, 22.7 (7 x CH2), 14.1 (CH3); m/z (ESI+) 169.2 ([M-Cl]+, 
10.3%); HR-ESIMS: calculated for C11H21O: 169.1587, found: 169.1601 [M-Cl]+. 
Data are consistent to that previously reported.6 
α-N-(L-Alanyl)-δ-N-(benzyloxycarbonyl)-L-ornithine methyl ester hydrochloride 
2.14 (1.00 g, 2.52 mmol) and triethylamine (0.70 mL, 5.05 mmol) were stirred on ice 
in CH2Cl2 (20 mL). Undecanoyl chloride (0.52 g, 2.52 mmol) was added slowly to 
give a white solid. This was broken up with the addition of CH2Cl2 (10 mL) and the 
resulting suspension was stirred to room temperature over 2 hour affording a pale 
yellow suspension. Water (20 mL) was added and the phases were separated. The 
organic phase was washed with citric acid solution (10% w/w, 2 x 20 mL) and 
saturated aqueous NaHCO3 solution (2 x 20mL), dried over Na2SO4, and 
concentrated in vacuo to give 2.16 as a white crystalline solid (1.09 g, 2.10 mmol, 83 
%); m.p. 116 - 118 ºC; 33][ Dα  -11.2 (c = 1.0, CHCl3); υ max/cm-1 3307 (N-H), 1739 
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(ester C=O), 1691 (amide C=O), 1612 (N-H); δH (400 MHz, CDCl3)  7.47 - 7.21 
(5H, m, 5 x Ar CH), 6.91 (1H, d, J 7.5 Hz, NHCHCH3), 6.18 (1H, d, J 7.5 Hz, 
NHCHCH2), 5.08 (1H, br. s., NHCH2), 5.02 (2H, s, CH2Ph), 4.62 - 4.40 (2H, m, 
NHCHCH3, NHCHCH2), 3.66 (3H, s, OCH3), 3.12 (2H, q, J 6.5 Hz, NHCH2), 2.10 
(2H, t, J 8.0 Hz, CH2CO), 1.90 - 1.69 (1H, m, NHCHCH2), 1.71 - 1.39 (5H, m, 
NHCHCH2, NHCH2CH2, CH2CH2CO), 1.30 (3H, d, J 7.0 Hz, CHCH3), 1.26 - 1.08 
(14H, m, 7 x CH2), 0.83 - 0.79 (3H, m, CH2CH3); δC (400 MHz, CDCl3)  173.3, 
172.4, 172.3 (2 x CONH, CO2Me), 156.6 (CO2Bn), 136.6 (ipso C), 128.5, 128.1 
(ortho, meta and para CH), 66.7 (CH2Ph), 52.5, 52.0, 48.7 (CHCH3, CHCH2, 
OCH3), 40.4 (NHCH2), 36.5 (CH2CO), 31.9, 29.6, 29.5, 29.4, 29.3, 29.0, 25.9, 25.6, 
22.7 (9 x CH2), 18.2 (CHCH3), 14.2 (CH2CH3); m/z (ESI+) 542.3 ([M+Na]+, 100%), 
281.1 ([M-(C14H23NO2)+, 17.9%), 520.2 ([M+H]+, 5.1%); HR-ESIMS: calculated 
for C28H45N3O6Na: 169.1587, found: 542.3194 [M+Na]+. 
(3S)-3-(Undecanoyl-L-alanyl)-aminopiperidine-2-one 2.01 
10% Palladium on activated carbon (~10 mg) was added to a solution of α-N-(N-
undecanoyl-L-alanyl)-δ-N-(benzyloxycarbonyl)-L-ornithine methyl ester 2.16 (0.50 
g, 0.96 mmol) in MeOH (20 mL). The reaction mixture was purged with hydrogen 
and stirred at room temperature under a constant 1 atm pressure hydrogen for 48 
hours. The reaction was filtered over celite and concentrated in vacuo to give a 
sticky white solid. Recrystallisation (CHCl3:Et2O) afforded the lactam 2.01 as a 
white powdery solid (0.10 g, 0.31 mmol, 32 %); mp 179 - 180°C; 28][ Dα +17.3 (c = 
1.11, MeOH); υ
 max/cm-1 (neat) 3294, 3242 (N-H), 1683 (amide C=O), 1631 (N-H); 
δH (400 MHz, DMSO-d6) 7.94 (2H, m, NHCHCH2, NHCHCH3), 7.59 (1H, br. s., 
NHCH2), 4.29 (1H, quin., J 7.5 Hz, NHCHCH3), 4.20 - 4.05 (1H, m, NHCHCH3), 
3.14 (2H, br. s., NHCH2), 2.10 (2H, t, J 7.5 Hz, CH2CONH), 2.03 - 1.93 (1H, m, 
NHCHCH2), 1.83 - 1.65 (2H, m, NHCH2CH2), 1.65 - 1.53 (1H, m, NHCHCH2), 1.52 
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- 1.42 (2H, m, CH2CH2CO), 1.25 (14H, m, 7 x CH2), 1.20 (3H, d, J 7.0 Hz, CHCH3), 
0.91 - 0.83 (3H, m, CH2CH3); δC (100 MHz, DMSO-d6) 172.1, 171.8, (2 x CONH), 
169.7 (CONHCH2), 48.8 (CHCH3), 47.8 (NHCHCH2), 40.9 (NHCH2), 35.1 
(COCH2), 31.3, 29.0, 28.9, 28.7, 28.6, 25.2, 22.1, 20.9 (9 x CH2), 18.3 (CHCH3), 
14.0 (CH2CH3); m/z (ESI+) 354.2 ([M+H]+, 100%); HR-ESIMS: calculated for 
C19H35N3O3Na: 376.2570, found: 376.2569 [M+Na]+. 
α-N-[(N-tert-Butoxycarbonyl-L-alanyl)-L-alanyl]-δ-N-(benzyloxycarbonyl)-L-
ornithine methyl ester 2.17 
N-tert-Butoxycarbonyl-L-alanine (0.87 g, 4.6 mmol) and HATU (1.74 g, 4.6 mmol) 
were stirred in CH2Cl2 (20 mL). After 5 minutes, α-N-(L-alanyl)-δ-N-
(benzyloxycarbonyl)-L-ornithine methyl ester hydrochloride 2.14 (1.82 g, 4.6 mmol) 
was added and the suspension cooled to 0 °C using an ice-salt bath. The mixture was 
stirred at 0 °C for 10 minutes and triethylamine (1.9 mL, 13.7 mmol) was added 
slowly. The yellow suspension was stirred at room temperature until the reaction 
mixture became a clear yellow solution (3 hours) indicating completion.  pH 2  
buffer (20 mL) was added and the phases separated. The organic layer was washed 
with pH 2 buffer (20 mL), aqueous saturated NaHCO3 solution (2 x 20 mL) and 
water (20 mL). The organic phase was concentrated in vacuo and the yellow residue 
taken into toluene. pH 2 buffer (20 mL) was added and the toluene layer was washed 
as before. The organic phase was concentrated in vacuo and dried by toluene 
azeotrope (4 x 20 mL). Residual solvent was removed under vacuum to afford 2.17 
as a white crystalline solid (2.71 g; 5.1 mmol; 74 %); m.p. 119 - 120ºC; 33][ Dα  -17.6 
(c =1.0, CHCl3); υ max/cm-1 3304 (N-H), 2972 (aromatic C-H), 2931 (aliphatic C-H), 
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1735 (ester C=O), 1689, 1636 (amide C=O), 1517 (N-H); δH (400 MHz, DMSO-d6) 
8.25 (1H, d, J 7.5 Hz, NHCHCH2), 7.82 (1H, d, J 7.5 Hz, CONHCHCH3), 7.40 - 
7.29 (5H, m, 5 x Ar CH), 7.27 (1H, t, J 5.5 Hz, NHCH2), 6.95 (1H, d, J 7.5 Hz, 
tBuCO2NH), 5.02 (2H, s, CH2Ph), 4.34 - 4.25 (1H, m, NHCHCH3), 4.20 (1H, ddd, J 
8.5, 7.5, 5.0 Hz, NHCHCH2), 3.99 - 3.90 (1H, m, tBuCO2NHCH), 3.62 (3H, s, 
OCH3), 3.00 (2H, q, J 6.0 Hz, NHCH2), 1.79 - 1.65 (1H, m, NHCHCH2), 1.65 - 1.52 
(1H, m, NHCHCH2), 1.51 - 1.32  (11H, m, NHCH2CH2, C(CH3)3), 1.21 (3H, d, J 7.0 
Hz, CONHCHCH3), 1.16 (3H, d, J 7.5 Hz, tBuCO2NHCHCH3); δC (100 MHz, 
DMSO-d6) 172.3, 172.2 (2 x CONH, CO2Me), 156.0, 155.0 (CO2Bn, CO2tBu), 137.2 
(ipso C), 128.3, 127.7 (ortho, meta and para CH), 78.0 (C(CH3)3), 65.1 (CH2Ph), 
51.8, 51.7 (OCH3, NHCHCH2), 49.5 (tBuCO2NHCH), 47.6 (CONHCHCH3), 40.2 
(NHCH2), 28.2 (C(CH3)3), 28.1 (NHCHCH2), 25.8 (NHCH2CH2), 18.3 (CHCH3), 
18.0 (CHCH3); m/z (ESI+) 545.2 ([M+Na]+, 100.0%), 445.2 ([M-Ph], 9.6%); HR-
ESIMS: calculated for C25H38N4O8Na: 545.2582, found: 545.2587 [M+Na]+. 
(3S)-3-[(N-tert-Butoxycarbonyl-L-alanyl) -L-alanyl]-aminopiperidine-2-one 2.08 
10% Palladium on activated carbon (10 mg) was added to a solution of α-N-(N-tert-
butoxycarbonyl-L-alanyl-L-alanyl)-δ-N-(benzyloxycarbonyl)-L-ornithine methyl 
ester 2.17 (1.00 g, 1.91 mmol) in MeOH (10 mL). The reaction mixture was purged 
with hydrogen and stirred at 40°C under 1 atm of hydrogen for 2 days. The reaction 
was filtered over celite and concentrated in vacuo to give a sticky off-white solid. 
This was purified by reverse phase HPLC and lyophilisation to give the peptide as a 
bright white solid (0.065 g, 0.182 mmol, 10 %); Decomposed 220 - 222°C; 28][ Dα  
+17.3 (c = 1.13, MeOH); υ
 max/cm-1 (neat) 3300 (N-H), 1659 (amide C=O) , 1571 (N-
H); δH (700 MHz, CD3OD) 4.37 (1H, q, J 7.0 Hz, CONHCHCH3), 4.31 - 4.13 (1H, 
m, NHCHCH2), 4.05 (1H, m, tBuCO2NHCH), 3.30 - 3.27 (2H, m, NHCH2), 2.16 - 
2.04 (1H, m, NHCHCH2), 1.96 - 1.89 (1H, m, NHCH2CH2), 1.89 - 1.59 (2H, m, 
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NHCHCH2, NHCH2CH2), 1.44 (9H, s, C(CH3)3), 1.38 (3H, d, J 7.0 Hz, 
CONHCHCH3), 1.31 (3H, d, J 7.5 Hz, tBuCO2NHCHCH3); δC (175 MHz, CD3OD) 
173.1, 172.2, 170.1 (3 x CONH), 155.7 (CO2tBu), 78.5 (C(CH3)3, 49.5 
(CONHCHCH3), 48.9 (NHCHCH2), 47.8 (tBuCO2NHCH), 40.2 (NHCH2), 26.6 
(C(CH3)3), 26.3 (NHCHCH2), 20.1 (NHCH2CH2), 15.9, 15.9 (2 x CHCH3); m/z 
(ESI+) 379.2 ([M+Na]+, 100.0%); HR-ESIMS: calculated for C16H28N4O5Na: 
379.1952, found: 379.1951 [M+Na]+. 
α-N-(L-Alanyl-L-alanyl)-δ-N-(benzyloxycarbonyl)-L-ornithine methyl ester 
hydrochloride 2.18 
α-N-[(N-tert-Butoxycarbonyl-L-alanyl)-L-alanyl]-δ-N-(benzyloxycarbonyl)-L-
ornithine methyl ester 2.17 (6.70 g, 12.8 mmol) was deprotected by stirring in 
methanolic HCl (2M, 25.0 mL) for 3 hours at room temperature. Concentration in 
vacuo gave the crude product as a sticky brown oil. Recrystallisation (MeOH:Et2O) 
afforded 2.18 as a white crystalline solid (5.20 g, 11.4 mmol, 89 %); m.p. >300ºC; υ
 
max/cm-1 3278 (br. NH3), 3050 (aromatic C-H), 2951 (aliphatic C-H), 1735 (ester 
C=O), 1655 (amide C=O), 1560 (N-H); δH (400 MHz, DMSO-d6) 8.68 (1H, d, J 7.5 
Hz, NHCHCH3), 8.41 (1H, d, J 7.0 Hz, NHCHCH2), 8.30 (3H, br. s., NH3CH), 7.46 
- 7.23 (5H, m, 5 x Ar CH), 5.02 (2H, s, CH2Ph), 4.37 (1H, quin, J 7.0 Hz, 
NHCHCH3), 4.25 - 4.18 (1H, m, NHCHCH2), 3.90 - 3.82 (1H, m, NH3CH), 3.60 
(3H, s, OCH3), 3.00 (2H, q, J 6.5 Hz, NHCH2), 1.82 - 1.55 (2H, m, NHCHCH2), 
1.55 - 1.38 (2H, m, NHCH2CH2), 1.36 (3H, d, J 7.0 Hz, NHCHCH3), 1.27 (3H, d, J 
7.0 Hz, NHCHCH3); δC (100 MHz, DMSO-d6) 172.3, 172.0, 169.0 (2 x CONH, 
CO2Me), 156.1 (CO2Bn), 137.2 (ipso C), 128.3, 127.7 (ortho, meta and para CH), 
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65.1 (CH2Ph), 51.8, 48.1, 47.9 (OCH3, NHCHCH3, NH3CHCH3, NHCHCH2), 47.9 
(NHCH2), 29.7, 27.3 (2 x CH2), 18.0 (CHCH3), 17.7 (CHCH3). 
α-N-[(N-Acetyl-L-alanyl)-L-alanyl]-δ-N-(benzyloxycarbonyl)-L-ornithine methyl 
ester 2.19 
Acetic anhydride (0.26 g, 2.6 mmol) was added slowly to a cooled and stirred 
solution of 2.18 (1.0 g, 2.4 mmol) and triethylamine (0.77 g, 5.5 mmol) in CH2Cl2 
(20 mL). The reaction was allowed to reach room temperature overnight. pH 2 buffer 
was added and the phases separated. The organic phase was further washed with 
saturated aqueous NaHCO3 (20 mL), dried over Na2SO4 and concentrated in vacuo 
to give 2.19 as a bright white solid (0.50 g, 1.3 mmol, 50 %); m.p. 200 - 201ºC; 
27][ Dα -39.6 (c = 0.35, MeOH); υ max/cm-1 3301 (N-H), 2971 (Ar C-H),  2901 
(aliphatic C-H), 1736 (ester C=O), 1689 (amide C=O), 1626 (amide C=O), 1533 (N-
H); δH (400 MHz,  DMSO-d6)  8.14 (1H, d, J 7.5 Hz, NHCH), 8.04 (1H, d, J 7.5 Hz, 
NHCH), 7.96 (1H, d, J 7.5 Hz, NHCH), 7.43 - 7.30 (m, 5H, 5 x Ar CH), 7.27 (1H, t, 
J 5.5 Hz, NHCH2), 5.02 (2H, s, CH2Ph), 4.36 - 4.15 (3H, m, NHCHCH2, 2 x 
NHCHCH3), 3.62 (3H, s, OCH3), 3.01 (2H, q, J 6.5 Hz, NHCH2), 1.84 (3H, s, 
CH3CO), 1.79 - 1.66 (1H, m, NHCHCH2), 1.65 - 1.55 (1H, m, NHCHCH2), 1.53 - 
1.38 (2H, m, NHCH2CH2), 1.22 (2H, d, J 7.0 Hz, CHCH3), 1.18 (3H, d, J 7.0 Hz, 
CHCH3); δC (100 MHz,  DMSO-d6)  172.3 (2 x CONHCHCH3), 172.0 (CO2Me), 
169.1 (CH3CO), 156.1 (CO2Ph), 137.2 (ipso C), 128.3, 127.7 (ortho, meta and para 
CH), 65.1 (CH2Ph), 51.8, 51.7 (OCH3, NHCHCH2) 48.1, 47.7 (2 x CHCH3), 40.1 
(NHCH2), 28.1 (NHCHCH2), 25.8 (NHCH2CH2), 22.5 (CH3CO), 18.1 (2 x CHCH3); 
m/z (ESI+) 487.1 ([M+Na]+, 100.0%); HR-ESIMS: calculated for C22H32N4O7Na: 
487.2163, found: 487.2165 [M+Na]+. 
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 (3S)-3-[(N-Acyl-L-alanyl)-L-alanyl]-aminopiperidine-2-one 2.04 
10% Palladium on activated carbon (~20 mg) was added to a solution of 2.19 (1.20 
g, 2.58 mmol) in MeOH (50 mL). The reaction mixture was purged with hydrogen 
and stirred at 40°C under 1 atm of hydrogen for 72 hours. The reaction mixture was 
filtered over celite and the filtrate concentrated in vacuo  to give a powdery white 
solid (0.55 g, 1.9 mmol, 74 %); 25][ Dα -60.6 (c = 0.18, MeOH); m.p. 183 - 185°C 
(Decomposed); υ
 max/cm-1 (neat) 3301 (N-H), 2934 (aliphatic C-H), 1659, 1638 
(Amide C=O); δH (400 MHz, DMSO-d6) 8.03 (1H, d, J 7.0 Hz, NHCHCH3), 7.94 
(1H, d, J 7.0 Hz, NHCHCH3), 7.89 (1H, d, J 8.0 Hz, NHCHCH2), 7.60 - 7.56 (1H, 
m, NHCH2), 4.30 - 4.19 (2H, m, 2 x NHCHCH3), 4.10 (1H, ddd, J 10.5, 7.5, 6.0 Hz, 
NHCHCH2), 3.15 - 3.06 (2H, m, NHCH2), 2.02 - 1.93 (1H, m, NHCHCH2), 1.82 
(3H, s, CH3CO), 1.81 - 1.65 (2H, NHCH2CH2), 1.55 (1H, br. qd,  J 11.5, 4.5 Hz, 
NHCHCH2), 1.21 (3H, d, J 7.0 Hz, CHCH3), 1.18 (3H, d, J 7.0 Hz, CHCH3); δC (100 
MHz, DMSO-d6) 171.9, 171.7 (2 x CONH), 169.6 (CH3CO), 169.0 (CONHCH2), 
49.4, 48.5 (2 x NHCHCH3, NHCHCH2), 40.8 (NHCH2), 27.4 (NHCHCH2), 22.5 
(CH3CO), 20.9 (NHCH2CH2), 18.3, 18.1 (2 x CHCH3); m/z (ESI+) 321.1 ([M+Na]+, 
100.0%); HR-ESIMS: calculated for C13H22N4O4Na: 321.1533, found: 321.1531 
[M+Na]+. 
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α-N-[(N-Octanoyl-L-alanyl)-L-alanyl]-δ-N-(benzyloxycarbonyl)-L-ornithine 
methyl ester 2.20  
Octanoyl chloride (0.42 g, 2.60 mmol) was added slowly to a cooled and stirred 
solution of 2.18 (1.0 g, 2.36 mmol) and triethylamine (0.52 g, 5.2 mmol) in CH2Cl2 
(20 mL). The reaction was allowed to reach room temperature overnight. pH 2 buffer 
was added and the phases were separated. The organic phase was further washed 
with saturated aqueous NaHCO3 (20 mL) and concentrated in vacuo to give a yellow 
waxy solid. This was suspended in boiling toluene and cooled with stirring before 
washing with pH 2 buffer (2 x 20mL), saturated aqueous NaHCO3 (20 mL) and 
water (20 mL). Concentration of the organic phase followed by toluene azeotrope (2 
x 20 mL) afforded the product as a white solid (0.87 g, 1.59 mmol, 67%); m.p. 175-
176ºC; 25][ Dα  -54.1 (c = 0.13, MeOH); υ max/cm-1 (neat) 3292 (N-H), 1736 (ester 
C=O), 1689, (amide C=O), 1534 (N-H); δH (500 MHz, DMSO-d6)  8.16 (1H, d, J 7.5 
Hz, NHCHCH3), 7.94 (1H, d, J 7.0 Hz, NHCHCH2), 7.88 (1H, d, J 7.5 Hz, 
NHCHCH3), 7.42 - 7.30 (5H, m, 5 x Ar CH), 7.25 (1H, t, J 5.5 Hz, NHCH2), 5.01 
(2H, s, CH2Ph), 4.32 - 4.17 (3H, m, 2 x NHCHCH3, NHCHCH2), 3.61 (3H, s, 
OCH3), 3.04 - 2.96 (2H, m, NHCH2), 2.09 (2H, t, J 7.5 Hz, CH2CONH), 1.79 - 1.54 
(2H, m, NHCHCH2), 1.52 - 1.39 (4H, m, NHCH2CH2, CH2CH2CONH), 1.29 - 1.22 
(8H, m, 4 x CH2), 1.20 (3H, d, J 7.5 Hz, CHCH3), 1.19 (3H, d, J 7.0 Hz, CHCH3), 
0.85 (3H, t, J 7.5 Hz, CH2CH3); δC (125 MHz, DMSO-d6) 172.8, 172.6, 172.5 (4 x 
CONH), 156.6 (CO2Bn), 137.7 (ipso C), 128.8, 128.2 (ortho, meta and para CH), 
65.6 (CH2Ph), 52.3 (OCH3), 52.2 (NHCHCH2), 48.4, 48.2 (2 x NHCHCH3), 40.4 
(NHCH2), 35.6 (CH2CONH), 31.6, 29.1, 28.9, 28.6, 26.3, 25.7, 22.5 (7 x CH2), 18.6 
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(CHCH3), 18.5 (CHCH3), 14.4 (CH2CH3); m/z (ESI+) 571.3 ([M+Na]+, 100.0%); 
HR-ESIMS: calculated for C28H44N4O7Na: 571.3102, found: 571.3102 [M+Na]+. 
 
(3S)-3-[(N-Octanoyl-L-alanyl)-L-alanyl]-aminopiperidine-2-one 2.03 
 
 
10% Palladium on activated carbon (~5 mg) was added to a solution of 2.20 (0.18 g, 
0.33 mmol) in MeOH (25 mL). The reaction mixture was purged with hydrogen and 
stirred at 40°C under a 1 atm of hydrogen for 2 days. The reaction was filtered over 
celite and concentrated in vacuo to give a sticky off-white solid. This was purified by 
reverse phase HPLC and lyophilisation to give lactam 2.03 as a bright white solid 
(0.025 g, 0.065 mmol, 20 %); Decomposed 196 - 198 °C; 28][ Dα -4.32 (c = 0.10, 
CHCl3); υ max/cm-1 3287 (N-H), 1628 (amide C=O), 1537 (N-H); δH (600 MHz, 
DMSO-d6) 7.96 (1H, d, J 7.5 Hz, NHCHCH3), 7.92 (1H, d, J 7.5 Hz, NHCHCH2), 
7.87 (1H, d, J 7.5 Hz, NHCHCH3), 7.58 (1H, s, NHCH2), 4.29 - 4.20 (2H, m, 2 x 
NHCHCH3), 4.13 - 4.08 (1H, m, NHCHCH2), 3.13 - 3.09 (2H, m, NHCH2), 2.08 
(2H, t, J 7.0 Hz, CH2CONH), 2.01 - 1.94 (1H, m, NHCHCH2), 1.81 - 1.66 (2H, m, 
NHCH2CH2), 1.59 - 1.50 (1H, m, NHCHCH2), 1.49 - 1.42 (2H, m, CH2CH2CO), 
1.31 - 1.19 (11H, m, 4 x CH2, CHCH3), 1.17 (3H, d, J 7.5 Hz, CHCH3), 0.86 (3H, t, 
J 7.0 Hz, CH2CH3); δC (150 MHz, DMSO-d6) 172.5, 172.4, 172.2, 170.1 (4 x 
CONH), 49.3 (NHCHCH2), 48.4 (2 x NHCHCH3), 41.3 (NHCH2), 35.6 (CH2CO), 
31.6, 39.1, 27.9, 25.7, 22.5, 21.4 (7 x CH2), 18.9, 18.5 (2 x CHCH3), 14.4 (CH2CH3); 
m/z (ESI+) 405.1 ([M+Na]+, 100.0%); HR-ESIMS: calculated for C19H34N4O4Na: 
405.2472, found: 405.2475 [M+Na]+.      
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α-N-[(N-tert-Butoxycarbonyl-L-alanyl)-L-alanyl-L-alanyl]-δ-N-
(benzyloxycarbonyl)-L-ornithine methyl ester 2.21 
N-tert-Butoxycarbonyl-L-alanine (0.90 g, 4.7 mmol) and HATU (1.8 g, 4.7 mmol) 
were stirred in CH2Cl2 (30 mL). After 5 minutes 2.18 (1.8 g, 4.7 mmol) was added 
and the suspension cooled to 0 °C using an ice-salt bath. The mixture was stirred at 0 
°C for 10 minutes and triethylamine (2.0 mL, 14.0 mmol) was added slowly. The 
yellow suspension was stirred to room temperature overnight to give a clear 
gelatinous yellow mixture.  This was stirred with pH 2 buffer (20 mL) and the 
suspension was filtered. The resulting gel-like solid was washed with pH 2 buffer (2 
x 20 mL), saturated aqueous NaHCO3 (20 mL) and water (20 mL). The organic and 
aqueous filtrates were separated, and the organic phase combined with the filtercake. 
This mixture was concentrated in vacuo and the product obtained following toluene 
azeotrope (3 x 20 mL) as a white glassy solid (1.8 g, 3.0 mmol, 63 %); m.p. 98 - 100 
ºC; 34][ Dα -28.4 (c = 0.18, MeOH); υ max/cm-1 3279 (N-H), 2978 (aromatic C-H), 2903 
(aliphatic C-H), 1731 (ester C=O), 1701 (carbamate C=O), 1629 (amide C=O), 1519 
(N-H); δH (400 MHz, DMSO-d6) 8.18 (1H, d, J 7.5 Hz, NHCHCH2), 7.94 (1H, d, J 
7.5 Hz, NHCHCH3), 7.87 (1H, d, J 7.0 Hz, NHCHCH3), 7.51 - 7.30 (5H, m, 5 x Ar 
CH), 7.29 - 7.25 (1H, m, NHCH2), 6.98 (1H, d, J 7.5 Hz, tBuCO2NH), 5.02 (2H, s, 
CH2Ph), 4.36 - 4.18 (3H, m, 2 x NHCHCH3, NHCHCH2), 3.96 (1H, quin., J 7.0 Hz, 
tBuCO2NHCH), 3.62 (3H, s, OCH3), 3.01 (2H, q, J 6.5 Hz, NHCH2), 1.80 - 1.66 
(1H, m, NHCHCH2), 1.66 - 1.53 (1H, m, NHCHCH2), 1.53 - 1.42 (2H, m, 
NHCH2CH2), 1.39 (9H, s, C(CH3)3), 1.26 - 1.12 (9H, m, 3 x CHCH3); δC (100 MHz, 
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DMSO-d6) 172.4, 172.3, 172.2 (3 x CONH), 171.7 (CO2CH3), 156.1, 155.1 (CO2Ph, 
CO2tBu), 137.2 (ipso C), 128.9, 128.3, 127.7 (ortho, meta and para CH), 78.1 
(C(CH3)3), 65.1 (CH2Ph), 51.8, 51.7 (OCH3, NHCHCH3), 49.7 (tBuCO2NHCH), 
47.9, 47.7 (2 x NHCHCH3), 38.9 (NHCH2), 28.2 (C(CH3)3), 28.1 (NHCHCH2), 25.9 
(NHCH2CH2), 18.1, 18.0 (3 x CHCH3); m/z (ESI+) 616.1 ([M+Na]+, 100.0%); HR-
ESIMS: calculated for C28H43N5O9Na: 616.2953, found: 616.2978 [M+Na]+. 
(3S)-3-[(N-tert-Butoxycarbonyl-L-alanyl)-L-alanyl-L-alanyl]-aminopiperidine-2-
one 2.09 
10% Palladium on activated carbon (~10 mg) was added to a solution of 2.21 (0.34 
g, 0.57 mmol) in MeOH (20 mL). The reaction mixture was purged with hydrogen 
and stirred at 40°C under 1 atm of hydrogen for 72 hours. The reaction mixture was 
filtered over celite and the filtrate concentrated in vacuo to give the crude product. 
This was purified by reverse phase HPLC followed by lypophilisation to give 2.09 as 
bright white solid (0.023 g, 0.054 mol, 9 %); Decomposed at 255 - 257 °C; υ
 max/cm-1 
3342, 3305 (N-H), 2953 (aliphatic C-H), 1683 (amide C=O); δH (700 MHz, DMSO-
d6) 7.93 - 7.89 (2H, m, tBuCO2NHCH, NHCHCH2), 7.84 (1H, d, J 7.5 Hz, 
NHCHCH3), 7.58 - 7.56  (1H, m, NHCH2), 6.94 (1H, d, J 7.5 Hz, NHCHCH3), 4.31 
- 4.17 (2H, m, 2 x NHCHCH3), 4.11 (1H, ddd, J 11.0, 7.5, 6.0 Hz, NHCHCH2), 3.97 
- 3.91 (1H, m, , tBuCO2NHCH), 3.15 - 3.09 (2H, m, NHCH2), 2.01 - 1.95 (1H, m, 
NHCHCH2), 1.83 - 1.65 (2H, m, NHCH2CH2), 1.54 (1H, dq, J 11.5, 4.5 Hz, 
NHCHCH2), 1.37 (9H, s, C(CH3)3), 1.21 (3H, d, J 7.0 Hz, CHCH3), 1.20 (3H, d, J 
7.0 Hz, CHCH3), 1.16 (3H, d, J 7.0 Hz, tBuCO2NHCHCH3); δC (175 MHz, DMSO-
d6)  172.8, 172.7, 172.1, 170.8 (4 x CONH), 155.5 (CO2tBu), 78.5 (C(CH3)3), 50.1 
(tBuCO2NHCH), 49.3 (NHCHCH2), 48.5, 48.4 (2 x NHCHCH3), 41.3 (NHCH2), 
28.6 (C(CH3)3), 27.9 (NHCHCH2), 21.4 (NHCH2CH2), 18.9, 18.8, 18.5 (3 x 
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CHCH3); m/z (ESI+) 450.1 ([M+Na]+, 100%). HR-ESIMS: calculated for 
C19H33N5O6Na: 450.2323, found: 450.2325 [M+Na]+. 
α-N-[(N-Acetyl-L-alanyl)-L-alanyl-L-alanyl]-δ-N-(benzyloxycarbonyl)-L-
ornithine methyl ester 2.23 
2.21 (1.95 g, 3.28 mmol) was deprotected by stirring in methanolic HCl (2M, 12.0 
mL) for 3 hours at room temperature. Concentration in vacuo gave the crude 
deprotected product as a sticky brown oil, which was used immediately without 
further purification. 34][ Dα  -54.7 (c = 0.11, MeOH); 
A solution of the crude amine hydrochloride (3.28 mmol) and triethylamine (1.26 
mL, 8.98 mmol) in THF (10 mL) and water (5 mL) was cooled to 0 - 5 °C. Acetic 
anhydride (0.51 mL, 5.39 mmol) was added dropwise and the reaction stirred at 
room temperature for 18 hours. pH 2 buffer was added, and the reaction was filtered. 
The filtercake was washed with water, and dried by toluene azeotrope to give 2.23 as 
a white solid (0.65 g, 1.21 mmol, 37%);  m.p. 222 - 223 °C; 28][ Dα  -62.3 (c = 0.49, 
MeOH); δH (400 MHz, DMSO-d6) 8.25 (1H, d, J 7.5 Hz, NHCH), 8.15 - 8.11 (2H, 
m, 2 x NHCH), 8.07 (1H, d, J 7.5 Hz, NHCH), 7.42 - 7.28 (6H, m, 5 x Ar CH, 
NHCH2), 5.02 (2H, s, CH2Ph), 4.36 - 4.16 (4H, m, 4 x NHCH), 3.62 (3H, s, OCH3), 
3.06 - 2.96 (2H, m, NHCH2), 1.78 - 1.54 (5H, m, CH3CO, NHCHCH2), 1.53 - 1.39 
(2H, m, NHCH2CH2), 1.22 (3H, d, J 7.0 Hz, CHCH3), 1.21 (d, J 7.5 Hz, CHCH3), 
1.19 (d, J 7.0 Hz, CHCH3); δC (100 MHz, DMSO-d6)  172.3, 172.2 (3 x CONH), 
171.5 (CO2Me), 169.1 (CH3CO), 156.1 (CO2Ph), 137.2 (ipso C), 128.8, 128.3, 127.7 
(ortho, meta and para CH), 65.1 (CH2Ph), 51.8, 51.7 (NHCH, OCH3), 48.2, 48.0, 
47.9 (3 x NHCH), 40.1 (NHCH2), 28.1 (NHCHCH2),, 25.8  (NHCH2CH2), 22.5 
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(CH3CO), 18.1, 18.0, 17.9 (3 x CHCH3); m/z (ESI+) 558.2 ([M+Na]+, 100.0%); 
HR-ESIMS: calculated for C25H37N5O8Na: 558.2534, found 558.2536 [M+Na]+. 
(3S)-[(N-Acetyl-L-alanyl)-L-alanyl-L-alanyl]-aminopiperidine-2-one 2.06 
10% palladium on activated carbon (~20 mg) was added to a solution of 2.23 (0.65 
g, 1.21 mmol) in MeOH (30 mL). The reaction mixture was purged with hydrogen 
and stirred at 40°C under 1 atm of hydrogen for 72 hours. The reaction mixture was 
filtered over celite and the filtrate concentrated in vacuo to give the crude product. 
This was purified by reverse phase HPLC followed by lypophilisation to give 2.06 as 
a bright white solid (0.11 g, 0.31 mmol, 26 %); m.p. 272 - 274 °C (decomposed); 
26][ Dα -106.5 (c = 0.30, MeOH); δH (600 MHz, DMSO-d6) 8.03 (1H, d, J 7.0 Hz, 
NHCHCH3), 8.00 (1H, d, J 7.5 Hz, NHCHCH3), 7.93 (1H, d, J 7.5 Hz, NHCHCH2), 
7.83 (1H, d, J 7.5 Hz, NHCHCH3), 7.58 (1H, br. s., NHCH2), 4.24 (3H, m, 3 x 
NHCHCH3), 4.14 - 4.09 (1H, m, NHCHCH2), 3.12 (2H, m, lactam NHCH2), 2.01 - 
1.93 (1H, m, NHCHCH2), 1.82 (3H, s, COCH3), 1.80 - 1.67 (2H, m, lactam CH2), 
1.53 (1H, br. qd, J 11.5, 4.5 Hz, NHCHCH2), 1.21 (3H, d, J 7.5 Hz, CHCH3), 1.20 
(3H, d, J 7.0 Hz, CHCH3), 1.17 (3H, d, J 7.0 Hz, CHCH3); δC (150 MHz, DMSO-d6) 
172.6, 172.1, 172.1, 170.1, 169.5 (5 x CONH), 49.3 (NHCHCH2), 48.7, 48.5, 48.4 (3 
x NHCH), 41.3 (NHCH2), 28.0 (NHCHCH2), 23.0 (CH3CO), 21.4 (NHCH2CH2), 
18.9, 18.6, 18.5 (3 x CHCH3); m/z (ESI+) 392.1 ([M+Na]+, 100.0%); HR-ESIMS: 
calculated for C16H27N5O5Na: 392.1904, found 392.1910 [M+Na]+. 
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α-N-[(N-Valeryl-L-alanyl)-L-alanyl-L-alanyl]-δ-N-(benzyloxycarbonyl)-L-
ornithine methyl ester 2.24 
2.21 (0.867 g, 1.46 mmol) was deprotected by stirring in methanolic hydrochloric 
acid (2M, 6.0 mL) for 3 hours at room temperature. Concentration in vacuo gave the 
crude deprotected product as a sticky brown oil, which was used immediately 
without further purification.  
A solution of the crude amine hydrochloride (1.46 mmol) and triethylamine (0.41 
mL, 2.91 mmol) in THF (5 mL) and water (2 mL) was cooled to 0 - 5 °C. Valeryl 
chloride (0.17 mL, 1.46 mmol) was added dropwise and the reaction stirred at room 
temperature for 18 hours. pH 2 buffer was added, and the reaction was filtered. The 
aqueous and organic filtrates were separated, and the organic phase was combined 
with the filtercake. This was concentrated in vacuo, and dried by toluene azeotrope 
to give 2.24 as a white solid (0.82 g, 1.42 mmol, 98 %);  m.p. 182 - 184 °C; 26][ Dα -
32.9 (c = 0.2, MeOH); δH (700 MHz, DMSO-d6) 8.19 (1H, d, J 7.5 Hz, NHCH), 8.02 
(1H, d, J 7.0 Hz, NHCH), 7.96 (1H, d, J 7.5 Hz, NHCH), 7.90 (1H, d, J 7.5 Hz, 
NHCH), 7.36 - 7.28 (5H, m, Ar CH), 7.26 (1H, t, J 5.5 Hz, NHCH2), 4.99 (2H, s, 
CH2Ph), 4.32 - 4.16 (4H, m, NHCHCH2, 3 x NHCHCH3), 3.60 (3H, s, OCH3), 3.03 - 
2.94 (2H, m, NHCH2), 2.11 - 2.07 (2H, q, J 8.0 Hz, NHCOCH2), 1.73 - 1.67 (1H, m, 
NHCHCH2), 1.62 - 1.56 (1H, m, NHCHCH2), 1.48 - 1.40 (4H, m, CH2, 
NHCH2CH2), 1.27 - 1.15 (11H, m, CH2, 3 x CHCH3), 0.86 - 0.82 (3H, m, CH2CH3); 
δC (175 MHz, DMSO-d6) 172.8, 172.7, 172.4, 172.1 (4 x CONH), 156.4 (CO2Bn), 
137.7 (ipso C), 128.8, 128.2, 128.1 (ortho, meta and para CH), 65.6 (CH2Ph), 52.3, 
52.2 (NHCHCH2, OCH3), 48.5, 48.3, 48.1 (3 x NHCHCH3), 40.5 (NHCH2), 35.2 
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(CH2CO), 28.5 (NHCHCH2), 27.8, 26.3, 22.2 (NHCH2CH2, 2 x CH2), 18.6, 18.4, 
17.4 (3 x CHCH3), 14.2 (CH2CH3); m/z (ESI+) 600.3 ([M+Na]+, 100.0%); HR-
ESIMS: calculated for C28H43N5O8Na: 600.3004, found 600.3008 [M+Na]+. 
(3S)-[(N-Valeryl-L-alanyl)-L-alanyl-L-alanyl]-aminopiperidine-2-one 2.05 
10% Palladium on activated carbon (~20 mg) was added to a solution of 2.24 (0.82 
g, 1.42 mmol) in MeOH (30 mL). The reaction mixture was purged with hydrogen 
and stirred at 40 °C under 1 atm of hydrogen for 48 hours. The reaction mixture was 
filtered over celite and the filtrate concentrated in vacuo to give the crude product. 
This was purified by reverse phase HPLC and lyophilisation to give 2.05 as a bright 
white crystalline solid (0.03g, 0.07 mmol, 5 %); m.p. 167 - 169 °C; 26][ Dα -56.3 (c = 
0.47, MeOH); δH (500 MHz, DMSO-d6) 7.99 - 7.88 (4H, m, 3 x NHCHCH3, 
NHCHCH2), 7.59 - 7.55 (1H, m, NHCH2), 4.34 - 4.20 (3H, m, 3 x NHCHCH3), 4.15 
- 4.08 (1H, m, NHCHCH2), 3.15 - 3.09 (2H, m, NHCH2), 2.10 (2H, t, J 7.5 Hz, 
CH2CO), 2.03 - 1.94 (1H, m, NHCHCH2), 1.83 - 1.66 (2H, m, 1H, NHCH2CH2), 
1.65 - 1.50 (1H, m, NHCHCH2), 1.50 - 1.42 (2H, m, CH2CH2CO), 1.30 - 1.18 (11H, 
m, 3 x CHCH3, CH2), 0.86 (3H, t, J 7.5 Hz, CH2CH3); δC (125 MHz, DMSO-d6) 
172.6, 172.4, 172.3, 172.2 (4 x CONH), 170.1 (CONHCH2), 52.3 (NHCHCH2), 
49.3, 48.5, 47.9 (3 x NHCHCH3), 41.5 (NHCH2), 35.5 (CH2CO), 28.0 (NHCHCH2), 
27.8, 22.2 (2 x CH2), 21.4 (NHCH2CH2), 18.9, 18.6, 18.5 (3 x CHCH3), 14.2 
(CH2CH3); m/z (ESI+) 412.3 ([M+H]+, 15.0%), 434.2 ([M+Na]+, 100.0%); HR-
ESIMS: calculated for C19H33N5O5Na: 434.2374, found 434.2379 [M+Na]+. 
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N-tert-Butoxycarbonyl-L-alanine benzyl ester 2.25 
Sodium hydride (60% dispersion in mineral oil, 0.32 g, 7.9 mmol) was washed with 
hexane and added with stirring to CH2Cl2 (25 mL) at 0 °C under nitrogen. Boc-L-
Ala-OH (1.5 g, 7.9 mmol) was added, followed by benzyl bromide (1.63 g, 9.5 
mmol). The reaction was stirred at 0 °C for 1 hour and at room temperature for 18 
hours. TMEDA (5 mL) was added, the reaction mixture was partitioned between 
EtOAc (50 mL) and pH 2 buffer (100 mL), and the aqueous phase was extracted 
with EtOAc (2 x 50 mL). The organic extract was washed with pH 2 buffer (50mL), 
water (50 mL) and saturated aqueous NaHCO3 (2 x 50 mL) dried over Na2SO4 and 
concentrated in vacuo to give 2.25 as a pale yellow oil (2.04 g, 7.3 mmol, 92 %);
28][ Dα -6.1 (c = 1.9, MeOH) (lit.7 25][ Dα -40.5 (c = 2.0, MeOH)); υ max/cm-1 3348 (N-
H), 2978 (aromatic C-H), 2934 (aliphatic C-H), 1710 (ester C=O), 1696, (amide 
C=O); δH (400 MHz, CDCl3) 7.39 - 7.28 (5H, m, 5 x Ar CH), 5.22 - 5.07 (3H, m, 
CH2Ph, NHCH), 4.36 (1H, quin, J 7.5 Hz, NHCH), 1.43 (9H, s, C(CH3)3), 1.39 (3H, 
d, J 7.5 Hz, CHCH3); δC (100 MHz, CDCl3) 173.0 (CO2Bn), 155.1 (CO2tBu), 135.7 
(ipso C), 128.6, 128.3, 128.1 (ortho, meta and para CH), 79.7 (C(CH3)3), 66.8 
(CH2Ph), 49.3 (NHCH), 28.3 (C(CH3)3), 18.5 (CHCH3). Data are consistent with 
that previously reported, with the exception of the optical rotation due to apparent 
racemisation during the reaction.8 
(N-tert-butoxycarbonyl-L-alanyl)-L-alanine benzyl ester 2.26 
Acetyl chloride (3.1 mL, 44 mmol) was added dropwise to cooled and stirred MeOH 
(20 mL) at 0°C. The resulting solution was added to 2.25 (2.0 g, 7.3 mmol) and the 
reaction mixture stirred at room temperature for 18 hours. Complete deprotection 
was confirmed by TLC (1:1 EtOAc:hexane). The solvent was removed in vacuo to 
O
O
N
H
O
O
H
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give the crude L-alanine benzyl ester hydrochloride salt, which was used 
immediately.  
A solution of the crude amine (7.3 mmol) and N-methyl morpholine (0.8 mL, 7.3 
mmol) in EtOH (30 mL) was stirred at room temperature. Boc-L-Ala-OH (1.6 g, 8.0 
mmol), Oxyma (0.16 g, 1.1 mmol) and N-methyl morpholine (1.7 mL, 16 mmol) 
were added and the reaction was cooled to 0 ˚C. EDCI (1.7 g, 8.7 mmol) was added 
and the reaction stirred overnight.  The reaction mixture was concentrated in vacuo 
and the residue was partitioned between EtOAc (30 mL) and pH 2 buffer (30 mL). 
The separated  organic phase was washed with pH 2 buffer (30 mL), water (30 mL) 
and saturated NaHCO3 solution (30 mL) and saturated aqueous NaCl solution (30 
mL), dried over Na2SO4 and concentrated in vacuo  to give 2.26 as a viscous orange 
oil (1.8 g, 5.14 mmol, 70 %) (; 25][ Dα  -104.1 (c = 1.60, MeOH); (lit. 9 22][ Dα = -60.2 (c 
= 1.0, MeOH)); υ
 max/cm-1 3321 (N-H), 2979 (Ar C-H), 2934 (aliphatic C-H), 1732 
(ester C=O), 1682 (amide C=O), 1520 (N-H); δH (400 MHz, CDCl3) 7.39 - 7.29 (5H, 
m, 5 x Ar CH), 6.80 (1H, br. s., CO2NH), 5.20 - 5.10 (3H, m, CH2Ph, CONHCH), 
4.64 - 4.52 (1H, m, CO2NHCH), 4.18 (1H, q, J 7.0 Hz, CONHCH), 1.43 (9H, s, 
C(CH3)3), 1.42 - 1.30 (6H, m, 2 x CHCH3); δC (100 MHz, CDCl3) 172.6, 172.3 
(CO2Bn, CONH), 155.5 (tBuCO2NH), 135.4 (ipso C), 128.6, 128.3, 128.1 (ortho, 
meta and para CH), 80.1 (C(CH3)3),  67.9 (CH2Ph), 48.1, 48.0 (2 x NHCH), 28.3 
(C(CH3)3), 18.4, 18.2 (2 x CHCH3). Spectroscopic data are consistent with that 
previously reported.10 
(N-tert-Butoxycarbonyl-L-alanyl)-L-alanine 2.27 
10% Palladium on activated carbon (~20 mg) was added to a solution of 2.26 (1.2 g, 
3.4 mmol) in MeOH (20 mL). The reaction mixture was purged with hydrogen and 
stirred at room temperature under 1 atm of hydrogen for 18 hours. The reaction was 
filtered over celite and concentrated in vacuo to give a white tacky waxy (0.58 g, 2.2 
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mmol, 65 %); 34][ Dα  -20.4 (c = 1.0, MeOH), (lit.11 22][ Dα -39.1 (c = 1.0, MeOH)); υ 
max/cm-1 3321 (O-H), 2979 (aliphatic C-H), 1711 (ester C=O), 1660 (amide C=O); δH 
(400 MHz, CDCl3) 7.34 - 7.24 (1H, br. s., CONHCH), 5.64 - 5.54 (1H, br. s., 
CO2NHCH), 4.65 - 4.47 (1H, m, CONHCH), 4.33 (1H, br. s., CO2NHCH), 1.54 - 
1.33 (15H, m, C(CH3)3, 2 x CHCH3); δC (100 MHz, CDCl3) 175.3, 173.0 (CONH), 
155.9 (tBuCO2NH), 77.3 (C(CH3)3), 48.4, 48.0 (2 x NHCH), 28.3 (C(CH3)3), 18.7, 
18.1 (2 x CH3). Data are consistent with that previously reported.9,12 
N-tert-Butoxycarbonyl-D-alanine benzyl ester 2.28 
Method as for 2.25 gave the product as a yellow oil (2.1 g, 7.5 mmol, 95 %). 28][ Dα  
+37.6 (c = 1.52, MeOH) (lit. 13 25][ Dα +23.2 (c = 1.5, MeOH)); υ max/cm-1 3332 (N-H), 
2977 (aromatic C-H), 2934 (aliphatic C-H), 1710 (ester C=O), 1669 (amide C=O); 
δH (400 MHz, CDCl3) 7.37 - 7.16 (5H, m, 5 x Ar CH), 5.22 - 5.00 (3H, m, CH2Ph, 
NHCH), 4.27 (1H, quin, J 7.5 Hz, NHCH), 1.35 (9H, s, C(CH3)3), 1.30 (3H, d, J 7.5 
Hz, CHCH3); δC (100 MHz, CDCl3) 173.2 (CO2Bn), 155.2 (tBuCO2NH), 135.5 (ipso 
C), 128.6, 128.3, 128.1 (ortho, meta and para CH), 79.7 (C(CH3)3), 66.9 (CH2Ph), 
49.3 (NHCH), 28.3 (C(CH3)3), 18.5 (CHCH3); m/z (ESI+) 302.1 ([M+Na]+, 100%), 
580.7 ([[2 x M]+Na], 7.7%); HR-ESIMS: calculated for C13H16NO4Na: 302.1363, 
found 302.1369 [M+Na]+. Spectroscopic data are consistent with that previously 
reported.14 
(N-tert-Butoxycarbonyl-L-alanyl)-D-alanine benzyl ester 2.29 
Acetyl chloride (3.4 mL, 48 mmol) was added dropwise to cooled and stirred MeOH 
(20 mL) at 0°C. The resulting solution was added to 2.28 (2.2 g, 7.9 mmol) and the 
reaction mixture stirred at room temperature for 18 hours. Complete deprotection 
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was confirmed by TLC (1:1 EtOAc:hexane). The solvent was removed in vacuo to 
give the crude D-alanine benzyl ester hydrochloride salt, which was used 
immediately.  
A solution of the crude amine (7.9 mmol) and N-methyl morpholine (0.9 mL, 7.9 
mmol) in EtOH (30 mL) was stirred at room temperature. Boc-L-Ala-OH (1.7 g, 8.7 
mmol), Oxyma (0.17 g, 1.2 mmol) and N-methyl morpholine (1.9 mL, 17 mmol) 
were added and the reaction was cooled to 0 ˚C. EDCI (1.8 g, 9.7 mmol) was added 
and the reaction stirred overnight.  The reaction mixture was concentrated in vacuo 
and the residue was partitioned between EtOAc (30 mL) and pH 2 buffer (30 mL). 
The separated  organic phase was washed with pH 2 buffer (30 mL), water (30 mL) 
and saturated NaHCO3 solution (30 mL) and saturated aqueous NaCl solution (30 
mL), dried over Na2SO4 and concentrated in vacuo to give 2.29 as a viscous orange 
oil afforded the coupled product as a waxy low melting point orange solid (2.14 g, 
6.7 mmol, 81 %); 25][ Dα  -15.2 (c = 2.20, MeOH); υ max/cm-1 3332 (N-H), 2978 
(aromatic C-H), 2931 (aliphatic C-H), 1666 (amide C=O), 1518 (N-H); δH (400 
MHz, CDCl3) 7.37 - 7.29 (5H, m, Ar CH), 6.93 - 6.85 (1H, br. s., tBuCO2NH), 5.20 - 
5.09 (3H, m, CH2Ph, CONH), 4.64 - 4.53 (1H, m, tBuCO2NHCH), 4.29 - 4.14 (1H, 
m, CONHCH), 1.46 - 1.41 (9H, m, C(CH3)3), 1.41 - 1.36 (6 H, m, 2 x CHCH3); δC 
(100 MHz, CDCl3) 172.6, 172.4 (CO2Bn, CONH), 155.5 (tBuCO2NH), 135.4 (ipso 
C), 128.6, 128.3, 128.1 (ortho, meta and para CH), 80.1 (C(CH3)3), 67.1 (CH2Ph), 
48.1, 48.0 (2 x CHCH3), 28.3 (C(CH3)3), 18.6, 18.2 (2 x CHCH3); m/z (ESI+) 373.1 
([M+Na]+, 100%); HR-ESIMS: calculated for C18H26N2O5Na: 373.1734, found 
373.1740 [M+Na]+. This compound is known but no data has been previously 
reported.15 
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(N-tert-Butylcarbonyl-L-alanyl)-D-alanine 2.30 
10% Palladium (~20 mg) on activated carbon was added to a solution of 2.29 (1.2 g, 
3.4 mmol) in MeOH (20 mL). The reaction mixture was purged with hydrogen and 
stirred at room temperature under a constant positive pressure of hydrogen for 18 
hours. The reaction was filtered over celite and concentrated in vacuo to give 2.30 as 
a colourless oil (0.86 g, 3.3 mmol, 97 %); 25][ Dα  -34.1 (c = 0.13, MeOH); υ max/cm-1 
3317 (O-H), 2979 (aliphatic C-H), 1712 (acid C=O), 1660 (amide C=O); δH (300 
MHz, CDCl3) 8.74 (1H, br. s., CO2H), 7.23 (1H, d, J 7.0, CONHCH), 5.75 - 5.48 
(1H, m., CO2NHCH, major rotamer), 5.42 - 5.00 (1H, m., CO2NHCH, minor 
rotamer), 4.54 - 4.31 (1H, m, CONHCH), 4.33 - 4.14 (1H, m, CO2NHCH), 1.58 - 
1.03 (15H, m, C(CH3)3, 2 x CHCH3); δC (100 MHz, CDCl3) 175.4, 172.8 (CONH, 
CO2H), 155.8 (tBuCO2), 77.4 (C(CH3)3), 48.2, 48.1 (2 x NHCH), 28.3 (C(CH3)3), 
18.7, 18.2 (2 x CHCH3). This compound is known but only the 15N NMR spectrum 
has been reported.16 
(N-tert-Butoxycarbonyl-L-alanyl)glycine benzyl ester 2.31 
Method modified from literature procedure of Pu et al.17 N-Methyl morpholine (1.72 
ml, 15.8 mmol) was added to a solution of glycine benzyl ester p-toluenesulfonate 
(2.81 g, 8.3 mmol) in EtOH (10 mL) to give a white suspension. Te mixture was 
cooled to 0 - 5°C, and Oxyma (0.17 g, 1.2 mmol) was added, followed by Boc-L-
alanine (1.50 g, 7.9 mmol) and N-methyl morpholine (1.0 mL, 9.6 mmol). EDCI 
(1.82 g, 9.5 mmol) was added and the reaction was stirred to room temperature over 
16 hours to give a dark orange solution. The reaction mixture was concentrated in 
vacuo and the residue was partitioned between CH2Cl2 (30 mL) and pH 2 buffer (30 
mL). The separated organic phase was washed with pH 2 buffer (30 mL), water 
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(30mL) and saturated NaHCO3 solution (30mL) and saturated aqueous NaCl 
solution (30 mL), dried over Na2SO4 and concentrated in vacuo to give a bright 
orange oil. This was purified by silica chromatography (75 % EtOAc: hexanes) to 
give 2.31 as a bright white solid (2.12 g, 6.30 mmol, 80 %, Rf  = 0.29); m.p. 88 - 89 
°C, (lit.18 83 - 84 °C); 33][ Dα  -23.4 (c = 1.20, MeOH), (lit.6 20][ Dα  -25.4 (c = 1.26, 
MeOH)); υ
 max/cm-1 3322 (N-H), 2972 (aromatic C-H), 2934 (aliphatic C-H), 1734 
(ester C=O), 1682, 1653 (amide C=O), 1523 (N-H); δH (400 MHz, DMSO-d6) 8.22 
(1H, t, J 6.0 Hz, NHCH2), 7.50 - 7.23 (5H, m, 5 x Ar CH), 6.92 (1H, d, J 7.5 Hz, 
NHCH), 5.12 (2H, s, CH2Ph), 4.07 - 3.90 (3H, m, NHCH, NHCH2), 1.37 (9H, s, 
C(CH3)3), 1.17 (3H, d, J 7.5 Hz, CHCH3); δC (100 MHz, DMSO-d6)  173.3 
(CONH), 169.7 (CO2Bn), 155.0 (CO2tBu), 135.9 (ipso C), 128.4, 128.0, 127.9 
(ortho, meta and para CH), 78.0 (C(CH3)3), 65.8 (CH2Ph), 49.5 (NHCH), 40.7 
(NHCH2), 28.2 (C(CH3)3), 18.2 (CHCH3); m/z (ESI+) 359.1 ([M+Na]+, 100%); HR-
ESIMS: calculated for C17H24N4O5Na: 359.1577, found 359.1578 [M+Na]+.Data are 
consistent with that previously reported.19 
(N-tert-butoxycarbonyl-L-alanyl)glycine 2.32 
(N-tert-butoxycarbonyl-L-alanyl)glycine benzyl ester (1.5 g, 4.46 mmol) was 
dissolved in MeOH (15 mL) and palladium (10% on activated carbon, ~20 mg) was 
added. The mixture was purged with hydrogen and stirred at 1 atm of hydrogen 
atmosphere for 12 hours. The reaction mixture was filtered over celite and the filtrate 
concentrated in vacuo to afford 2.32 as a clear oil (1.2 g, 4.45 mmol, 99 %); 28][ Dα  -
22.1 (c = 0.95, MeOH), (lit.20 20][ Dα  -26.9 (c = 0.98, MeOH)); δH (400 MHz, DMSO-
d6) 8.00 (1H, t, J 6.0 Hz, NHCH2), 6.89 (1H, d, J 8.0 Hz, NHCH), 4.01 (1H, quin, J 
7.5 Hz, NHCH), 3.79 (1H, dd, J 17.5, 6.0 Hz, NHCH2), 3.71 (1H, dd, J 17.5, 6.0 Hz, 
NHCH2), 1.38 (9H, s, C(CH3)3), 1.19 (3H, d, J 7.0 Hz, CHCH3); δC (100 MHz,  
DMSO-d6)  173.0 (CONH), 171.1 (CO2H), 155.0 (CO2tBu), 78.0 (C(CH3)3), 49.5 
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(NHCH), 40.7 (NHCH2), 28.1 (C(CH3)3), 18.1 (CHCH3); m/z (ESI+) 161.1 
([M+Na]+, 100%); HR-ESIMS: calculated for C10H18N2O5Na: 269.1108, found 
269.1111 [M+Na]+. Data are consistent with that previously reported.21 
(N-tert-butoxycarbonyl-L-alanyl)glycine methyl ester 2.33 
Method modified from literature procedure of Pu et al.17 N-Methyl morpholine (1.7 
ml, 15.0 mmol) was added to a solution of glycine methyl ester hydrochloride (1.98 
g, 15.8 mmol) in EtOH (15 mL) to give a white suspension. The mixture was cooled 
to 0-5°C, and Oxyma (0.32 g, 2.3 mmol) was added, followed by Boc-L-alanine 
(2.84 g, 15.0 mmol) and N-methyl morpholine (3.5 mL, 32.2 mmol). EDCI (5.75 g, 
30.0 mmol) was added and the reaction was stirred to room temperature over 16 
hours to give a dark orange solution. The reaction mixture was concentrated in vacuo 
and the residue was partitioned between CH2Cl2 (30 mL) and pH 2 buffer (30 mL). 
The separated organic phase was washed with pH 2 buffer (30 mL), water (30mL) 
and saturated NaHCO3 solution (30mL) and saturated aqueous NaCl solution (30 
mL), dried over Na2SO4 and concentrated in vacuo to give a bright orange oil. This 
was purified by silica chromatography (EtOAc) to give 2.33 as a clear oil (3.3 g, 
12.5 mmol, 83 %, Rf = 0.15); 28][ Dα -27.0 (c = 1.04, MeOH), (lit. 20][ Dα -28.4 (c = 
1.0, MeOH));  υ
 max/cm-1 3307 (N-H), 2978 (aliphatic C-H), 1741 (ester C=O), 1659 
(amide C=O); δH (400 MHz, DMSO-d6)  8.18 (1H, t, J 6.0 Hz, NHCH2), 6.93 (1H, d, 
J 7.5 Hz, NHCH), 4.03 (1H, quin., J 7.0 Hz, NHCH), 3.88 (1H, dd, J 17.5, 6.5 Hz, 
NHCH2), 3.81 (1H, dd, J 17.5, 6.5 Hz, NHCH2), 3.64 (s, 3H, OCH3), 1.39 (9H, s, 
C(CH3)3), 1.20 (3H, d, J 7.0 Hz, CHCH3); δC (100 MHz, DMSO-d6) 173.0 (CONH), 
169.6 (CO2Me), 155.0 (CO2tBu), 78.0 (C(CH3)3), 50.8 (OCH3), 48.5 (NHCH), 40.7 
(NHCH2), 28.1 (C(CH3)3), 18.1 (CHCH3);  m/z (ESI+) 283.1 ([M+Na]+, 100%); 
HR-ESIMS: calculated for C11H20N2O5Na: 283.1264, found 283.1260 [M+Na]+.  
Data are consistent with that previously reported.22 
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L-Alanylglycine methyl ester hydrochloride 2.34 
2.33 (2.7 g, 10.4 mmol) was stirred in methanolic hydrochloric acid solution (2M, 40 
mL) for 9 hours. The reaction was deemed complete by TLC (50% EtOAc:Hexane) 
and concentrated in vacuo to afford the product as a white sticky solid (1.7 g, 8.64 
mmol, 83 %); 34][ Dα  +10.2 (c = 0.59, MeOH), (lit.23 5.27][ Dα  +11.6 (c = 2.41, DMF)); 
υ
 max/cm-1 2939 (br., N-H), 1736 (ester C=O), 1672 (amide C=O), 1555 (N-H); δH 
(400 MHz, DMSO-d6) 9.12 - 9.01 (1H, m, NHCH), 8.39 (3H, br. s., NH3CH), 4.01 - 
3.82 (3H, m, NH3CH, NHCH2), 3.65 (3H, s, OCH3), 1.46 - 1.35 (3H, m, CHCH3); δC 
(100 MHz, DMSO-d6) 170.9 (CONH), 169.3 (CO2Me), 51.8 (OCH3), 47.7 (NHCH), 
40.6 (NHCH2), 17.1 (CHCH3); m/z (ESI+) 161.1 ([M-Cl]+, 77.5%), 139.2 ([M-
ClNH3CHCH3, +Na]+, 22.5%); HR-ESIMS: calculated for C6H13N2O3: 161.0921, 
found 161.0922 [M+-Cl]+. 1H NMR data are consistent with that previously 
reported.24 
(N-tert-butoxycarbonyl-L-alanyl)glycyl-L-alanylglycine methyl ester 2.35 
Method modified from literature procedure of Pu et al.17 To a solution of 2.34 (4.90 
g, 19.9 mmol) and N-methyl morpholine (2.16 mL, 19.9 mmol) in EtOH (20 mL) 
was added Oxyma (0.42 g, 3.00 mmol), 2.32 (4.33 g, 22.0 mmol) and N-methyl 
morpholine (4.76 mL, 43.8 mmol), and the resulting yellow suspension cooled to 0 
°C on ice. After stirring for 10 minutes, EDCI (4.60 g, 23.9 mmol) was added and 
the reaction stirred to room temperature overnight. The resultant orange solution was 
concentrated in vacuo and the crude product isolated by silica chromatography (10-
15 % MeOH:CHCl3). Repeated trituration (EtOAc/hexanes) afforded the product as 
a cream powdery solid (0.99 g, 2.54 mmol, 13 %); m.p. 192 - 193 °C; 33][ Dα  -25.4 (c 
= 1.0, MeOH); υ
 max/cm-1 3307, 3278 (N-H), 2978 (aliphatic C-H), 1721 (ester C=O), 
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1671, 1633 (amide C=O); δH (400 MHz, CDCl3) 7.48 (1H, t, J 5.0 Hz, NHCH2), 7.44 
- 7.36 (2H, m, NHCH2, NHCH), 5.50 (1H, d, J 5.5 Hz, tBuCO2NH), 4.67 (1H, quin., 
J 7.5 Hz, NHCH), 4.33 - 4.23 (1H, m, tBuCO2NHCH), 4.11 - 4.00 (4H, m, 2 x 
NHCH2), 3.76 (3H, s, OCH3), 1.47 - 1.43 (12H, m, (C(CH3)i, CHCH3), 1.41 (3H, d, J 
7.5 Hz, CHCH3); δC (100 MHz, CDCl3) 173.9, 172.9, 170.3 (3 x CONH), 169.0 
(CO2CH3), 155.9 (CO2tBu), 80.4 (C(CH3)3), 52.3 (OCH3), 50.6, 49.1 (2 x NHCH), 
43.3, 41.1 (2 x CH2), 28.3 (C(CH3)3), 18.5, 18.1 (2 x CHCH3); m/z (ESI+) 411.1 
([M+Na]+, 100%); HR-ESIMS: calculated for C16H28N4O7Na: 411.1850, found 
411.1851 [M+Na]+. 
(S)-3-Benzyloxycarbonylaminopiperidine-2-one  2.37 
L-Ornithine hydrochloride (10.0 g, 59.3 mmol) was added to a stirred solution of 
acetyl chloride (9.3 mL, 118.6 mmol) in MeOH (50 mL) at 0 ºC. The mixture was 
heated to reflux for 3 hours, after which the reaction was seen to be complete by 1H 
NMR affording the crude methyl ester (59.3 mmol, assuming complete conversion) 
in solution, which was used immediately without further purification. 
The lactam was synthesized using a method modified from the literature procedure 
of Abe et al.25 The crude methyl ester (59.3 mmol) was cooled to 0 ºC under N2 with 
stirring and sodium methoxide solution in MeOH (25% w/w, 128.2 mmol, 28.0 mL) 
was added over 2 hours at 5-10 ºC. The reaction mixture was stirred for 2 hours at 0 
ºC and then was concentrated in vacuo at 20 ºC to give the crude lactam as a waxy 
white solid. This was dissolved in THF (50 mL), cooled to 0 °C, and water (50mL) 
and sodium bicarbonate (9.96 g, 118.6 mmol) were added. Benzyl chloroformate 
(12.5 mL, 83.1 mmol) was added slowly, maintaining the reaction temperature 
below 5ºC. The reaction was held at below 5 ºC for 3 hours, then allowed to stir at 
room temperature over 72 hours to afford a biphasic mixture. To this was added 
EtOAc (50 mL) and water (50 mL) and the phases were separated. The aqueous 
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phase was further extracted with EtOAc (2 x 30 mL) and the combined organics 
were washed with aqueous HCl solution (1M, 50 mL), aqueous saturated Na2CO3 
solution (50 mL) and saturated aqueous NaCl solution (50 mL), dried over Na2SO4 
and concentrated in vacuo to give the crude product as a yellow oil. Recrystallisation 
from EtOAc and hexanes gave 2.37 as a glassy, white crystalline solid (12.4 g, 50.0 
mmol, 84 %); m.p. 114 - 116 ºC (lit. 25101 - 102 °C) ; 26][ Dα +35.2 (c=1.0, CHCl3), 
34][ Dα -11.9 (c=1.0, MeOH), (lit.25 23][ Dα -18.5 (c=1.0, MeOH)); υ max/cm-1 3324 (N-
H), 1683 (carbamate C=O), 1655, 1617 (lactam C=O), 1521 (C=C); δH (400 MHz, 
CDCl3) 7.57 - 7.02 (5 H, m, 5 x Ar CH), 6.46 (1H, s, CONHCH2), 5.85 (1H, d, J 4.5 
Hz, CHNH), 5.14 (2H, m, PhCH2), 4.11 (1H, dt, J 11.5, 5.5 Hz, NHCHCH2), 3.31 
(2H, t, J 5.0 Hz, NHCH2), 2.64 - 2.36 (1H, m, NHCHCH2), 2.00 - 1.79 (2H, m, 
NHCH2CH2), 1.64 (1H, dtd, J 13.0, 11.5, 5.5 Hz, NHCHCH2); δC (100 MHz, CDCl3)  
171.5 (CHCONH), 156.4 (NHCO2), 136.5 (ipso C), 128.5, 128.1, 127.0 (ortho, meta, 
para CH), 66.8 (PhCH2), 51.7 (NHCHCH2), 41.7(NHCH2), 27.4, 21.0 (2 x CH2); m/z 
(ESI+) 271.1 ([M+Na]+, 100%); HR-ESIMS: calculated for C13H16N2O3Na: 
271.1052, found 271.1063 [M+Na]+. Enantiomeric excess: >99.9% by HPLC by 
comparison with known standards. The data are consistent with that previously 
reported.26 
S-(-)-3-aminopiperidine-2-one hydrobromide salt 2.38 
The amine was deprotected using a method modified from literature procedure of 
Ben-Ishai et al.27 2.37  (1.0 g, 4.03 mmol) was stirred ina solution hydrobromic acid 
in acetic acid (45 % w/w solution, 4.0mL, 22.0 mmol) for 2 hours. The resulting 
solid was washed with ether (2 x 30 mL) and dried by toluene azeotrope to give 2.38 
as a beige solid (0.78 g, 4.01 mmol, 99 %); m.p. 179 - 180ºC; 26][ Dα +10.2 (c=1.0, 
MeOH); υ
 max/cm-1 2916 (N-H), 2392 (aliphatic C-H), 1737 (lactam C=O), 1654, 
1578 (amide C=O); δH (400 MHz, D2O) 3.45 - 3.22 (1H, m, NH3CH), 3.26 - 3.20 
NH
H3N
O
Br
H
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(2H, m, NHCH2), 2.37 - 2.18 (1H, m, NHCHCH2), 2.14 - 1.67 (3H, m, NHCH2CH2, 
NHCHCH2); δC (100 MHz, D2O) 170.1 (CONH), 52.3 (CHNH3), 41.3 (NHCH2), 
24.6, 19.3 (2 x CH2); m/z (ESI+) 115.3 ([M-Br]+, 70.6%), 137.2 ([M+Na]+, 22%); 
HR-ESIMS: calculated for C5H11N2O: 115.0866, found 115.0865 [M-Br]+. Data are 
consistent to that previously reported. 25 
(N-tert-butoxycarbonyl-L-alanyl)glycyl-L-alanylglycine 2.36 
To a solution of 2.35 (0.99 g, 2.54 mmol) in EtOH (8 mL) was added a solution of 
lithium hydroxide (0.12 g, 5.09 mmol) in EtOH and water (1:1, 2 mL). The resulting 
suspension was stirred at room temperature for 8 hours. A sample was concentrated 
in vacuo at <30 °C, and complete hydrolysis of the ester confirmed by 1H NMR. The 
bulk product was not isolated, and was used as the solution in EtOH. 
 (3S)-3-[(N-tert-Butoxycarbonyl-L-alanyl)glycyl-L-alanylglycyl]-
aminopiperidine-2-one 2.39 
N-Methylmorpholine (0.67 mL, 6.18 mmol) was added to a solution of S-(-)-3-
aminopiperidine-2-one hydrobromide salt (1.21 g, 6.18 mmol) in EtOH (5 mL). 
After stirring for 5 minutes, the resulting white suspension was added to an ethanolic 
solution of 2.36 (10 mL, 2.54 mmol), Oxyma (0.054 g, 0.38 mmol) and N-
methylmorpholine (0.32 mL, 3.05 mmol). The reaction mixture was cooled to 0 °C 
on ice and stirred for 10 minutes, after which EDCI (0.56 g, 3.06 mmol) was added 
and the reaction was stirred at room temperature over 16 hours. The resulting orange 
solution was concentrated in vacuo and the crude product isolated by silica 
chromatography (15 - 20 % MeOH:CHCl3), along with trace amounts of N-
methylmorpholine hydrochloride and probable Oxyma hydrolysis products. 2.39 was 
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obtained by reverse phase HPLC and lyophilisation as white shiny platelets (0.14 g, 
0.30 mmol, 12%); m.p. 122 - 124 °C; 26][ Dα  -2.31 (c = 0.23, MeOH); υ max/cm-1 3286 
(br., N-H), 3074 (aromatic C-H), 2981 (aliphatic C-H), 1649 (amide C=O), 1529 (N-
H); δH (700 MHz, CD3OD) 4.26 - 4.22 (1H, m, NHCHCH2), 4.22 - 4.18 (1H,  m, 
NHCHCH3), 3.97 - 3.94 (1H, m, NHCHCH3), 3.90 - 3.70 (4H, m, 2 x NHCH2CO), 
3.32 - 3.27 (2H, m, NHCH2CH2), 2.02 - 1.95 (1H, m, NHCHCH2), 1.86 - 1.81 (1H, 
m, NHCH2CH2), 1.80 - 1.66 (2H, m, NHCHCH2, NHCH2CH2), 1.35 (9H, s, 
C(CH3)3), 1.32 - 1.29 (3H, m, CHCH3), 1.26 - 1.20 (3H, m, CHCH3); δC (175 MHz, 
CD3OD) 175.5, 173.9, 171.4, 170.4, 170.0 (5 x CONH), 156.8 (CO2tBu), 79.5 
(C(CH3)3), 50.6 (tBuCO2NHCH), 49.6, 49.4 (NHCHCH2, NHCHCH3), 42.6, 42.3 (2 
x NHCH2CO), 42.2 (NHCH2CH2), 27.2 (C(CH3)3), 27.0 (NHCHCH2), 21.0 
(NHCH2CH2), 16.5, 16.0 (2 x CHCH3); m/z (ESI+) 493.1 ([M+Na]+, 100%), 244.2 
([M-C5H9O2]+, 50%); HR-ESIMS: calculated for C20H35N6O7: 471.2562, found 
471.2560 [M+H]+.  
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CHAPTER 3: THIOACIDS AND ISOLEUCINE 
 
3.1 THIOACIDS FOR PEPTIDE COUPLING 
Thioacid mediated amide bond formation is seen as a particularly attractive 
alternative to standard peptide couplings, as they react quite differently from 
carboxylic acids, allowing amide bond formation by direct reaction with azides,1, 2 
isonitriles,3 isocyanates4 and sulfonamides5-8 without the need for traditional peptide 
coupling reagents.9 
In 1998, Tomkinson et al. described the treatment of a series of 2,4-
nitrobenzenesulfonamides with thioacids in the presence of cesium carbonate to 
provide the corresponding mono- and di-substituted amide (Scheme 6).7, 8   These 
reactions proceed via nucleophilic substitution by the thioacid on the extremely 
electron poor sulfonamide to give the intermediate Meisenheimer complex. The 
collapse of this leads to loss of sulfur dioxide and the formation of the extremely 
reactive thioester, with introduction of the amine leading to the rapid formation of 
the amide bond. 
Scheme 6: The route to amide bond formation using an aromatic sulfonamide and thioacid 
The original paper only studied the reaction of the achiral sulfonamides with achiral 
thioacids. In addition, the scope for the reaction seemed to be limited by the lack of 
commercially available thioacids, while most laboratory preparations of thioacids 
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required H2S, which is both toxic and extremely malodorous.10, 11 It was not until 
2007, when Crich et al. revisited the chemistry, that the synthesis of a peptidyl 
thioacid was linked with the synthesis of a peptidyl sulfonamide to allow a block 
synthesis of a peptide.5 Cleavage of a preformed fluorenylmethyl thioester provided 
a convenient source of a thioacid for further reaction (Scheme 7). This chemistry was 
successfully applied to the synthesis of a number of peptides, from small dipeptides 
to larger linear and cyclic hexapeptides.6, 12, 13 14 
Scheme 7: Amide formation using the Crich method of thioacid preparation, via a fluorenomethylthiol donor 
Importantly, the reaction appeared to proceed with very low levels of epimerization, 
reportedly lower than a variety of commonly used peptide coupling agents including 
PyBOP, HATU, HOBt and ECDI.12  Further investigation showed that, though the 
thioacid reacted preferentially with the sulfonamide, unprotected amines would also 
react with the thioacid to form amides (Scheme 8). 
Scheme 8: Reaction of thioacids with free amines compared to sulphonamides 
Wang et al. noticed a similar result when attempting to form amides in a three 
component reaction using isocyanates, thioacids and amines.15 The planned reaction 
involved the initial formation of a thioformimidate carboxylate (thio-FMCA) mixed 
anhydride, which could then be intercepted by an amine to form the amide bond. In 
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order to prevent the rapid conversion of the thio-FMCA to the corresponding 
oxazolone, the reaction was performed in the presence of HOBt. However, control 
reactions which excluded the isocyanate showed comparable yields of the 
corresponding peptides. 
When an oxidising agent such as iodine was added, conversions of up to 89% were 
observed. It is proposed that oxidative initiation is involved, possibly by the 
formation of a disulphide.16 This activated species can then react with HOBt to form 
both the HOBt ester and the reactive perthio- species, from which the disulphide can 
be reformed. (Scheme 9). 
Scheme 9: Proposed oxidative initiation reaction to form amides15 
It appeared that, due to the unique properties of thioacids, coupling agents are not 
necessarily required for rapid, epimerisation-free, amide bond formation. A literature 
search provided multiple earlier examples of the oxidative coupling of thioacids to 
produce amides.17-20 
It should be noted that block-peptide coupling reactions between thioesters and a 
variety of peptide fragments have also been reported.21 The thioesters are prepared 
using similar conditions to Crich et al. (Scheme 7), but are then reacted directly with 
the relevant amine without being deprotected to the relevant thioacid, and without 
the need for additional coupling reagents. 
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3.1.1 THIOACIDS FOR BLOCK PEPTIDE SYNTHESIS 
The use of the Crich method of thioacid synthesis, followed by amide formation 
seemed to provide a promising alternative route to the block synthesis of small 
molecule CTLPs. Ultimately, we hoped to investigate whether a peptide coupling 
reagent was needed at all or whether, as implied above, it was possible to form an 
amide bond from direct reaction of a thioacid and amine.  
Our first priority was to confirm the retention of stereochemical integrity at the C-
terminal amino-acids during thioacid synthesis and the following peptide bond 
formation; for this, we looked to the literature for a simple, rapid method of 
identifying racemisation at this site. 
 
3.2 ISOLEUCINE AS AN INDICATOR FOR C-TERMINAL EPIMERISATION 
Epimerisation during peptide coupling is normally assessed by the preparation of 
model di- or tri-peptide sequences (e.g. H-Gly-L-Ser-L-Phe-NH2, prepared using a 
solid phase Fmoc strategy), deprotection and separation of the epimerised product 
(H-Gly-D-Ser-L-Phe-NH2) by HPLC, and comparison with a prepared standard.22, 23 
Alternatively, a sample of the final peptide can be hydrolysed and the constituent 
amino-acids reacted with a chiral derivitising agent, commonly Marfey’s reagent.24 
Calculation of the amount of epimerised product can then be achieved by HPLC 
separation of the diastereomeric pairs.25 1H, 13C and 15N NMR spectroscopy can also 
be used to calculate the level of epimerisation, either from identifying shifts caused 
by a mix of diastereomers or by association of the enantiomers with a chiral shift 
reagent.26-28 
L-Isoleucine is one of 22 proteinogenic amino-acids found in eukaryotic and 
prokaryotic proteins,29 but is unusual in that it possesses two stereocentres (Figure 
26It can therefore exist as four distinct stereoisomers.30 
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Figure 26: The 4 stereoisomers of isoleucine, showing the interconversion pathways for epimerisation at the α 
and β carbons 
Epimerisation at the α-centre is relatively rapid due to resonance stabilisation and 
electron-withdrawing effects from the amino- and carboxy- group to give D-allo-
isoleucine. In contrast, the β-centre is distanced from these effects and so is more 
difficult to epimerise to give the uncommon L-allo-isoleucine diastereomer.30, 31 This 
lack of reactivity allows the β-configuration at the carbon to act as a marker for 
epimerisation at the α-carbon. Isoleucine as a marker for the study of racemisation 
during peptide synthesis has been known for a number of years,23, 32, 33 but the final 
assessment of chiral purity is usually performed by hydrolysis followed by amino-
acid analysis.34 
To our knowledge, only two references exist describing the differentiation of L-
isoleucine and D-allo-isoleucine by 1H NMR spectroscopy. In 1983, Khatskevich et 
al. reported that both the chemical shift and the coupling constants for the hydrogen 
at the α-carbon differed for N-benzoyl-L-isoleucine methyl ester and N-benzoyl-D-
allo-isoleucine methyl ester ((2S, 3S) diastereomer, δ ppm 4.70, dd, 3JCH-CH 5.15 Hz,  
3JCH-NH 8.62 Hz; ((2R, 3S) diastereomer, δ ppm 4.90, dd, 3JCH-CH 4.30 Hz,  3JCH-NH 9.0 
Hz).35 Similarly, in 2003 Biron and Kessler noted that, when hydrolysing Nα-methyl-
Nα-o-NBS-L-isoleucine methyl ester, epimerisation at the α-stereocentre could be 
observed by the appearance of a new peak (corresponding to the D-allo diastereomer 
α-CH) downfield from the usual peak observed for the L- diastereomer.36 
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We hoped to exploit this distinction between the proton signals for L-isoleucine and 
its epimer, D-allo-isoleucine, to assess epimerisation of C-terminal during Crich’s 
synthesis of thioacids, and their resulting amide-bond formation, compared to that 
occurring for the same peptide bond formed using the amino-acid and a coupling 
agent, PyBOP.12 PyBOP (1H-benzotriazol-1-yloxy)tris(pyrrolidino)phosphonium 
hexafluorophosphate) has been shown to avoid epimerisation during thioester 
formation, particularly when combined with an excess of the thiol precursor and low 
reaction temperatures.37              
3.3 INITIAL RESEARCH AIMS 
Undec-10-enoyl-L-isoleucine, 3.02 (Scheme 1) was chosen as the C-terminal amino-
acid, and npropyl amine as the amide to give a very simple peptide with only one 
epimerisable stereocentre. We planned to synthesise this model peptide by two 
different routes:  
1. Crich method of amide bond formation, via a thioacid 
Scheme 10: The proposed route to the model peptide using Crich’s method 
2. A ‘traditional’ peptide coupling, according to Crich’s procedure, but 
using a carboxylic acid rather than a thioacid 
Scheme 11: The proposed route to the model peptide using a standard peptide coupling 
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Both reactions would be performed using undec-10-enoyl-L-isoleucine, 3.02, and 
then repeated for comparison with a mix of undec-10-enoyl-L-isoleucine and undec-
10-enoyl-D-allo-isoleucine, 3.03. We hoped that the products would be sufficiently 
disparate by 1H NMR spectroscopy to allow us to make an approximate 
measurement of the amount, if any, of epimerised product formed.  
 
3.3.1 SYNTHESIS AND EPIMERISATION OF UNDEC-10-ENOYL-L-
ISOLEUCINE 
Undec-10-enoyl-L-isoleucine was easily synthesised in two steps via the equivalent 
acid chloride (Scheme 12). 
Scheme 12: The synthesis of undec-10-enoyl-L-isoleucine  
In order to identify the appearance of the epimerised product by 1H NMR , a sample 
of this was deliberately epimerised using acetic anhydride and aqueous sodium 
hydroxide, by the method of du Vigneaud and Meyer.38 It seems likely that this 
promotes the formation of the 5-(4H)-oxazolone by forming the mixed anhydride, 
providing a good leaving group (Figure 27). An epimeric mixture of approximately 
4:1 ratio of undec-10-enoyl-L-isoleucine and undec-10-enoyl-D-allo-isoleucine was 
obtained. 
 Figure 27: Epimerisation at α
Pleasingly, comparison of the 
of the mix showed a noticeable difference in shift for the 
D-allo-isoleucine (Figure 
Figure 28: The dd caused by the 
mixture 3.03, bottom spectrum) of 
isoleucine (around 4.62 ppm)
 
 
-CH of undec-10-enoyl-L-isoleucine by 5-(4H)-oxazolone formation
1H NMR spectra for the single diastereomer with that 
α-CH of 
28). 
α–CH of undec-10-enoyl-L-isoleucine, 3.02 (top spectrum
undec-10-enoyl-D-allo-isoleucine (around 4.74 ppm) and 
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L-isoleucine and 
) and the epimeric 
undec-10-enoyl-L-
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3.3.2 CRICH AMIDE SYNTHESIS VIA THIOESTER 
The fluorenylmethyl coupled thioester, 3.04, was prepared according to Crich’s 
method (Scheme 13).5 The product from the coupling with the single diastereomer, 
undec-10-enoyl-L-isoleucine, 3.04, showed that a significant proportion of the 
coupled thioester (39% of the crude product, 48% following purification by silica 
chromatography) was present as the D-allo-isoleucine diastereomer, shown by the 
presence of a new peak for the α-CH downfield from the L-diastereomer peak 
(Figure 29). This was confirmed by comparison with the coupled product formed 
using the 4:1 mix of L-isoleucine and D-allo-isoleucine diastereomers, 3.05, (Scheme 
13), which also showed a distinct peak for each diastereomer at the same chemical 
shifts (65% D-allo to 35% L-isoleucine for the crude product, 40% D-allo-isoleucine 
to 60% L-isoleucine following purification by silica chromatography). 
Scheme 13: The synthetic route to the coupled fluorenyl-methylthioesters, from a single diastereomer and a mix 
of diastereomers of undec-10-enoyl-isoleucine 
 Figure 29: The dd peaks associated with the thioester 
around 4.61 ppm and the signal from 
diastereomer, 3.04 (top spectrum)
This was extremely concerning, as the literature for this method implied that 
extremely low levels of epimerisation were observed during the final peptide 
coupling, yet we were see
acid even before release of the thioacid and amide bond formation. The thioester 
synthesis was repeated a further 
were essentially the same.
The thioester 3.04 was then deprotected to give the 
3.09 was synthesised using the sul
Scheme 14: The preparation of the model peptide 
α-CH signal, showing the signal from 
D-allo-isoleucine at around 4.74 ppm from the reaction with the single 
, and the reaction with the mix of two diastereomers, 3.05
ing near complete epimerisation of the 
three times, but the levels of epimerisation observed 
 
thioacid and the model peptide 
fonamide of propylamine 3.01 (
3.08 via the sulphonamide 3.01 and the thioester 
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L-isoleucine at 
 (bottom spectrum) 
C-terminal amino-
Scheme 14). 
3.04 
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The characterisation data for this compound proved to be identical for that prepared 
by the standard PyBOP coupling (Scheme 15), but still showed ~1:1 mix of the L- 
and D-allo-isoleucine diastereomers. 
 
3.3.3 PYBOP AMIDE SYNTHESIS FROM CARBOXYLIC ACID 
In order to confirm that it was the formation of the thioester causing the 
epimerisation, we compared our results with the formation of the model peptides 
3.09 and 3.10 using the peptide coupling agent PyBOP. As before, this was 
performed twice, once using a single diastereomer of undec-10-enoyl-L-isoleucine 
and once using a mix of undec-10-enoyl-L-isoleucine and undec-10-enoyl-D-allo-
isoleucine (Scheme 15). 
Scheme 15: Preparation of the model peptide, using the PyBOP strategy 
Though significant epimerisation was observed during the coupling of the single 
diastereomer undecylenyl-L-isoleucine to the amine (14% D-allo-isoleucine observed 
in the crude reaction mixture, 12% following purification by silica chromatography 
for 3.10), this was still much lower than the near complete epimerisation observed 
during the thioester formation.  
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3.4 PEPTIDE SYNTHESIS USING A MODEL DIPEPTIDE 
This appeared to confirm that the first step of Crich’s method, the formation of the 
thioester, was responsible for the extremely high levels of epimerisation observed in 
the model peptide. However, we were aware that N-terminal acylated amino-acids 
are more prone to racemisation than N-peptidyl amino-acids (e.g. dipeptides or 
longer), as the former would be expected to have a greater electron withdrawing 
effect on the C-terminal amide than the latter.23, 39 We therefore investigated the 
levels of epimerisation on a more realistic peptide model, octanoyl-glycyl-L-
isoleucine (Scheme 16).  
Scheme 16: The two strategies proposed for the preparation of the model dipeptide 
 
3.4.1 SYNTHESIS OF OCTANOYL-GLYCYL-ISOLEUCINE 
In order to synthesise these compounds, we needed a method to produce a mixture of 
L-isoleucine and D-allo-isoleucine, without introducing an acyl group on the N-
terminus. To do this, we followed the method of Yamada et al., which uses a 
substoichiometric quantity of an aldehyde in acetic acid to reversibly form an imine 
with the amino-acid nitrogen, followed by deprotonation at the α–centre by the 
acetate anion.40 This provided a mixture of 24% D-allo-isoleucine and 76% L-
isoleucine 3.11 which was converted to the methyl ester 3.12 (Scheme 17). These 
were then used for the synthesis of the model dipeptides 3.16 and 3.18 ( Scheme 18). 
Again, we were able to discriminate between the CH peaks for octanoyl-glycyl-L-
isoleucine and octanoyl-glycyl-D-allo-isoleucine by 1H NMR spectroscopy.  
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Both the single diastereomer of octanoylglycyl-L-isoleucine, 3.16, and the mix of 
diastereomers, 3.18, were used for the synthesis of the fluorenylmethyl thioesters 
3.19 and 3.20 respectively (Scheme 19) and, for comparison, the propylamides (3.22 
and 3.23 respectively (Scheme 20). 
Scheme 17: The synthesis of isoleucine methyl ester, as both the single diastereomer and a mix of L-isoleucine 
and D-allo-isoleucine diastereomers 
 Scheme 18: The synthesis of octanoyl-glycyl-isoleucine from the single diastereomer of isoleucine methyl ester 
and from a mix of L- and D-allo-isoleucine diastereomers 
 
3.4.2 MODEL DIPEPTIDE SYNTHESIS USING THIOESTERS 
The synthesis of the two thioesters was performed as before and again, significant 
epimerisation of the C-terminal-L-isoleucine residue (12 % D-allo to 88 % L-
isoleucine for the crude product, 20 % D-allo-isoleucine to 80 % L-isoleucine 
following purification by silica chromatography) was still observed for the thioester 
formation (Scheme 19).  
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 Scheme 19: The synthesis of the dipeptide thioesters from the single diastereomer of octanoylglycyl isoleucine 
and the mix of L- and D-allo-
Figure 30: The dd peaks associated with the thioester 
derivative at around 4.54 ppm and the signal from 
reaction with the single diastereomer 
(bottom spectrum) 
As expected, the degree of epimerisation was lower than observed for the 
undecylenylisoleucine 
less nucleophilic than the equivalent acyl amide carbonyl, due to the presence of an 
electron withdrawing CONH at the 
donating simple alkyl chain of undecylenylisoleucine
Again, the thioester was d
model dipeptide 3.21
 diastereomers   
α-CH signal, showing the signal from 
D-allo-isoleucine derivative at around 4.67 ppm from the 
3.19 (top spectrum) and the reaction with the mix of two diastereomers 
products, as the glycine amide carbonyl of the 
α–carbon, rather than the relatively
 . 
eprotected and coupled with sulphonamide 
 (Scheme 20). This showed comparable levels of epimerisation 
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L-isoleucine 
3.20 
dipeptide is 
 electron-
3.01 to give the 
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at the isoleucine α-CH, with around 27 % epimer present in the purified product (27 
% D-allo-isoleucine derivative present before purification, judged by 1H NMR). This 
appears to confirm that the epimerisation occurs during the initial thioester 
formation, rather than during the peptide coupling step. 
Scheme 20: The formation of the model dipeptide from thioester 3.19 
 
3.4.3 MODEL DIPEPTIDE SYNTHESIS USING PYBOP 
As before, the equivalent peptide coupling reaction, performed using the single 
diastereomer of carboxylic acid to give the propyl amide 3.22 (Scheme 21), showed 
significantly lower levels of epimerised product (~7% D-allo-isoleucine by 1H NMR 
spectroscopy, Figure 31). 
Scheme 21: The synthesis of the dipeptide propylamines 3.22 and 3.23 
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Figure 31: The dd peaks associated with the amide α-CH signal, showing the signal from L-isoleucine derivative 
at around 4.12 ppm and the signal from D-allo-isoleucine derivative at around 4.25 ppm. The top spectrum shows 
the dipeptide 3.21 from the thioester 3.19, the middle spectrum 3.22 from the PyBOP coupling of reaction with 
the single diastereomer  and the bottom spectrum shows 3.23 from the reaction with the mix of two diastereomers  
 
3.5 CONCLUSIONS 
From these reactions, we concluded that, at least in terms of epimerisation, the Crich 
method of thioester synthesis, followed by thioacid formation and amide bond 
synthesis, was significantly worse than the equivalent peptide coupling reaction 
using just the phosphonium salt. It appears that the initial thioester formation was 
much slower than the equivalent peptide coupling, leading to a much greater risk of 
epimerisation by 5-(4H)-oxazolone formation. We therefore abandoned this thioester 
precursor as a new method for the formation of CTLPs or other peptides.  
In constrast, we were extremely interested by the reliability and predictability by 
which D-allo-isoleucine and L-isoleucine could be distinguished by 1H NMR. We 
noted that there was a consistent trend in the relative shifts of the α-CH, as well as 
the coupling constants for these diastereomers, with the D-allo-diastereomer 
appearing downfield to the L-diastereomer. For our purposes, this had served as an 
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extremely useful method of assessing levels of epimerisation. It should be stated 
however, that the sensitivity of this method has not been fully explored, though we 
expect it to be accurate to <5%. As such, it proved to be a valuable tool to rapidly 
estimate the chiral integrity of a C-terminal isoleucine and, while it may lack the 
sensitivity of HPLC methods, it has the potential to be an extremely useful tool for 
the comparison for a number of peptide coupling methods. 
A further, potentially more valuable, function of this spectroscopic occurrence is to 
allow the differentiation of isoleucine diastereomers in natural products. 
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3.6 TRENDS IN THE 1H NMR SPECTRA OF TWO DIASTEREOMERS OF 
ISOLEUCINE 
While L-isoleucine is the most common diastereomer in natural products, D-allo-
isoleucine is also fairly common in microbial peptides, including the sporidemolides, 
stendomycin, angolide, actinomycin C and peptidolipin N.A.41 In addition, D-allo-
isoleucine has been identified in peptides isolated from the skin of the yellow bellied 
toad, Bombina variegate.42 Unsurprisingly, considering the comparative stability of 
the β-CH of isoleucine (vide supra), peptides containing L-allo-isoleucine and D-
isoleucine are much more uncommon, though a few examples do exist. Among these 
are the bacterial peptide, cypemycin, which contains two L-allo-isoleucine residues 
that occur during post-translational modification.43 D-Isoleucine is found in the 
bacterial peptide monocycin,44 while some members of the actinomycin family of 
Streptomyces derived peptides are known to contain both D-isoleucine and N-methyl-
L-isoleucine.45, 46 It is also to be noted that, in the case of the metabolic disorder, 
maple syrup urine disease, L-allo-isoleucine can be produced by the body, via keto-
formation at the α-centre of L-isoleucine.47 
The ability to distinguish between the isoleucine diastereoisomers without the 
hydrolysis of the parent protein would be valuable, particularly for complex natural 
proteins, which are often only obtained in minute quantities. A method to distinguish 
between diastereomers by 1H NMR spectroscopy would therefore be of considerable 
use as it is non-destructive. While we cannot distinguish between L-allo- and D-allo-, 
and between the L- and D- isoleucine diastereomers, the comparative rarity of the D- 
and L-allo forms mean that this method could still have utility. 
We investigated whether the trend noted during the synthesis of the isoleucyl 
thioesters would prove a reliable method for differentiating L-isoleucine from D-allo-
isoleucine by 1H NMR within the native peptide. In addition to the compounds 
already synthesized (Figure 32), we included two more compounds, benzoyl-
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isoleucine and benzoyl-isoleucine methyl ester (3.24 - 3.27, Scheme 22), as both the 
single and mix of diastereomers.  
Scheme 22: The synthesis of benzoyl-isoleucine and benzoyl-isoleucine methyl ester as both the single and the 
mix of two diastereomers, for analysis by 1H NMR spectroscopy 
Figure 32: The previously synthesised structures used for analysis by 1H NMR spectroscopy   
We then obtained the 1H NMR spectroscopic data for these 11 compounds, both as a 
mix of diastereomers and, where possible, as the single diastereomer. The data was 
obtained in three deuterated solvents (CDCl3, DMSO-d6, and CD3OD). The spectra 
were obtained on 700 MHz NMR machines, and, after calibration against the internal 
solvent peak, the chemical shifts and coupling constants for the α–CH were 
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measured. Where spectra for the both the single diastereomer and the mix were 
obtained, the values for the L-diastereomer were averaged from the two. 
13C NMR data was also obtained for most of these compounds on the 400 MHz 
NMR machine, though in CDCl3 only. The chemical shifts corresponding to the α–
CH of were measured. 
The results are shown below. 
Table 2: Chemical shifts and coupling constants in CDCl3.  
 
 
 
 
 
 
Compound 
L-isoleucine diastereomer D-allo-isoleucine diastereomer 
α-CH  
(ppm) 
3JCH-CH 
(Hz) 
3JCH-NH 
(Hz) 
α-CH 
(ppm) 
α-CH 
(ppm) 
3JCH-CH 
(Hz) 
3JCH-NH 
(Hz) 
α-CH 
(ppm) 
3.03 4.62 5.1 8.0 56.5 4.75 4.0 8.6 55.2 
3.05 4.63 5.1 8.2 63.2 4.76 4.0 9.1 61.8 
3.10 4.21 7.9 7.9 57.5 4.32 6.6 8.4 57.0 
3.11 n/a n/a n/a n/a n/a n/a n/a n/a 
3.12 n/a n/a n/a n/a n/a n/a n/a n/a 
3.17 4.54 5.3 8.4 56.7 4.65 4.1 8.8 55.6 
3.18 4.53 5.3 7.5 56.9 4.69 4.5 8.5 n/a 
3.20 4.53 4.8 8.8 63.8 4.66 4.0 8.8 62.3 
3.23 4.34 7.5 7.5 56.7 4.45 5.7 8.8 55.6 
3.26 4.86 4.9 8.1 57.0 4.98 3.9 8.5 55.7 
3.27 4.84 5.2 8.4 56.8 4.95 4.0 8.8 55.8 
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Compound 
L-isoleucine diastereomer D-allo-isoleucine diastereomer 
α-CH shift 
(ppm) 
3JCH-CH 
(Hz) 
α-CH shift 
(ppm) 
3JCH-CH 
(Hz) 
3.03 4.37 5.8 4.54 4.7 
3.05 4.31 6.1 4.48 5.1 
3.10 4.15 8.3 4.31 6.7 
3.11 3.47 3.9 3.53 3.6 
3.12 4.00 4.0 4.03 3.9 
3.17 4.42 6.0 4.56 4.4 
3.18 4.40 5.3 4.55 4.0 
3.20 4.33 5.7 4.48 4.8 
3.23 4.20 7.5 4.35 5.7 
3.26 4.57 6.4 4.74 5.0 
3.27 4.56 6.9 4.74 5.6 
Table 3: Chemical shifts and coupling constants in CD3OD 
Compound 
L-isoleucine diastereomer D-allo-isoleucine diastereomer 
α-CH shift 
(ppm) 
3JCH-CH 
(Hz) 
3JCH-NH 
(Hz) 
α-CH shift 
(ppm) 
3JCH-CH 
(Hz) 
3JCH-NH 
(Hz) 
3.03 4.17 6.5 8.1 4.35 5.0 8.5 
3.05 4.15 7.4 7.4 4.33 5.1 8.7 
3.10 4.10 8.5 8.5 4.25 6.3 9.0 
3.11 3.05 3.2 n/a 3.08 2.9 n/a 
3.12 3.91 4.2 n/a 3.92 3.8 n/a 
3.17 4.23 6.6 8.4 4.39 5.1 8.6 
3.18 4.19 5.9 8.6 4.36 4.4 8.8 
3.20 4.15 6.2 8.4 4.33 5.1 8.6 
3.23 4.12 7.5 8.8 4.25 5.7 9.2 
3.26 4.33 7.6 7.6 4.53 5.8 8.5 
3.27 4.36 7.7 7.7 4.55 6.4 8.0 
Table 4: Chemical shifts and coupling constants in DMSO-d6 
 
 The general trends noted earlier were further supported by these results. In summary 
we found that, in the three solvents tested:
• The chemical shift for the 
a higher ppm than that for the 
• The 3JCH-CH coupling constants for the 
always larger than those for the 
• The 3JCH-NH coupling constants for the 
always smaller than those for the 
Generally, the difference in chemical 
and smallest in CDCl
not to overlap. This suggests they would be suitable for the approximate assignment 
of relative stereochemistry of isoleucine residues in novel peptides.
For some compounds, namely the two thioesters
were sufficiently different in both D
separated and identified by 
corresponding to the terminal methyl groups of the isoleucine sidechain were 
particularly obvious. 
Figure 33: From 3.20, chemical shifts for CH
isoleucine derivative (~0.66 ppm) and CHC
isoleucine derivative (~0.52 ppm).
 
D-allo-isoleucine diastereomer always occurred at 
L-isoleucine diastereomer 
L-isoleucine diastereomer 
D-allo-isoleucine diastereomer 
L-isoleucine diastereomer 
D-allo-isoleucine diastereomer 
shift was greatest in DMSO
3, but the two peaks observed were always sufficiently distinct 
, 3.05 and 3.27,
MSO-d6 and CD3OD for other peaks to be well 
1H NMR spectroscopy. The doublet and triplet shifts 
2CH3 for the D-allo-isoleucine derivative 
H3 for the L-isoleucine derivative (~0.57 ppm) and
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-d6, then CD3OD 
 
 the diastereomers 
(~0.70 ppm) and the L-
 the D-allo-
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However, this was not common to all the compounds tested, so would be unsuitable 
for the general identification of the diastereomers.  
Though the data obtained from the 13C NMR spectra was less complete than for the 
1H NMR specta, the measurements obtained also suggest a useful trend. The 
chemical shift corresponding to the α-CH of the D-allo-isoleucine derivative always 
occurred at a lower ppm than that for the L-isoleucine derivative,  in most cases by 
more than 1 ppm. Taken in conjunction with the 1H NMR data, the 13C NMR data is 
also likely to prove extremely useful for the approximate assignment of relative 
stereochemistry of isoleucine residues in novel peptides. 
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3.8 EXPERIMENTAL 
 
All the reagents and solvents used were purchased from the Sigma-Aldrich, Alfa-
Aesar, TCI, Bachem or Fluorochem Chemical Company and were used as received 
unless stated otherwise. pH 2 buffer was made as a solution of 0.75 M of Na2SO4 
and 0.25 M H2SO4 in H2O. 
 
1H- and 13C-NMR spectra were recorded on a Bruker AVII-700 MHz, AVIII-600 
MHz, DRX-500 MHz or DPX-400 MHz Fourier transform spectrometer at room 
temperature unless stated otherwise. Chemical shifts are quoted in parts per million 
(ppm) downfield from tetramethylsilane. Solvents were used as an internal standard 
when assigning NMR spectra (δH: CDCl3 7.26 ppm, CD3OD 3.31 ppm, d6 -DMSO 
2.50 ppm, D2O 4.79 ppm; δC: CDCl3 77.1 ppm, CD3OD 49.0 ppm, d6 -DMSO 39.5 
ppm). Coupling constants (J) are quoted in Hertz (Hz). Coupling constants are 
rounded to the nearest 0.5 Hz for spectra recorded on the AVIII-600 MHz, DRX-500 
MHz or DPX-400 MHz machines. Coupling constants recorded on the AVII-700 
MHz machine are rounded to the nearest 0.1 Hz. Abbreviations used in the 
descriptions of spectra are as follows; s = singlet, d = doublet, t = triplet, q = quartet, 
quin. = quintet, sept. = septet, oct. = octet, m = multiplet, br = broad, i = ipso, o = 
ortho, m = meta, p = para, ax. = axial and eq. = equatorial. 13 C-NMR spectra were 
recorded with broadband proton decoupling and spectra were assigned on the basis 
of COSY, PENDANT, HMQC and HMBC spectra. In aromatic characterisations, 
the ipso carbon is taken to be the carbon bonded to the group with the highest 
molecular weight 
 
Infrared spectra were recorded on a Nicolet Avatar 320 FT-IR spectrophotometer 
using EZ OMNIC software package 1, Bruker ALPHA Platinum ATR 
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spectrophotometer or Perkin ELMER Spectrum 100 FT-IR spectrophotometer using 
OPUS software and are quoted in wavenumber (cm-1). 
Optical rotations were recorded on an Optical Activity Ltd. AA-1000 millidegree 
auto-ranging polarimeter (using the sodium D line; 589 nm) and [α]Ds are given in 
units of 10-1deg cm2 g-1. The samples were made using spectroscopic grade MeOH, 
CHCl3 or H2O. 
ESI mass spectra were obtained on a Bruker Esquire 2000 mass spectrometer or an 
Agilent 6130B single Quad (ESI). HRMS ESI spectra were obtained by Dr Lijiang 
Song, Mr Philip Aston or Dr Rebecca Wills using a Bruker micro-TOF ESI attached 
to a time of flight (TOF) analyser.  
Melting points for solid crystalline products were determined on a Stuart Scientific 
SMP10 Digital Melting Point Apparatus, with three runs of each compound, and a 
range given in ˚C rounded to the nearest degree. They are uncorrected. CHN 
elemental analyses were carried out by Warwick Analytical Services.  
 
Thin Layer Chromatography (TLC) was performed using silica (0.25 mm) coated 
aluminium plates.
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2, 4-Dinitro-N-propylbenzenesulfoniamide 3.01 
Method modified from literature procedure by Crich et al.1 A solution of 2,4-
dinitrophenyl sulfonyl chloride (3.0 g, 11.3 mmol) in THF (30 mL) was added to an 
ice-cold solution of NaHCO3 (2.84 g, 33.8 mmol) and n-propylamine (0.93 mL, 11.3 
mmol) in THF: water (1:1, 72 mL). The reaction mixture was stirred for 3 hours at 
room temperature before acidification with pH 2 buffer. The reaction mixture was 
poured into EtOAc (200 mL) and the phases were separated. The organic phase was 
washed with pH 2 buffer (100 mL), water (100 mL) and saturated aqueous NaCl 
solution (100 mL), dried over Na2SO4 and concentrated in vacuo. Purification by 
silica chromatography (CHCl3) gave the sulfonamide as a bright yellow oil that 
crystallised on standing to give 3.01 as a yellow crystalline solid (1.9 g, 6.6 mmol, 
58 %); m.p. 78 - 80 °C; υmax /cm-1 (neat) 3330 (N-H), 1550, 1534 (S=O), 1347, 
1337(N=O); δH (400 MHz, CDCl3) 8.68 (1H, d, J 2.5 Hz, C3-H), 8.57 (1H, dd, J 8.5, 
2.5 Hz, C5-H), 8.37 (1H, d, J 8.5 Hz, C6-H), 5.35 (1H, t, J 6.0 Hz, NHCH2), 3.14 
(2H, td, J 7.0, 6.0 Hz, NHCH2), 1.58 (2H, sxt, J 7.5 Hz, NHCH2CH2), 0.93 (3H, t, J 
7.5 Hz, CH3); δC (100 MHz, CDCl3) 149.8, 139.5 (C-1, C-2, C-4), 132.6 (C6), 127.1 
(C5), 120.2 (C3), 45.8 (NHCH2), 23.1 (NHCH2CH2), 11.0 (CH3); m/z (ESI+) 311.9 
([M+Na], 100%); HR-ESIMS: calculated for C9H11N3O6SNa: 312.0261, found 
312.0264 [M+Na]+.  
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(3S, 2S)-2-(Undec-10’-enoylamino)-3-methyl-pentanoic acid 3.02 
10-Undecenoic acid (3.00 g, 16.3 mmol) and DMF (3 drops) were stirred on ice in 
CH2Cl2 (50 mL) to give a yellow solution. Oxalyl chloride (4.13 g, 32.6 mmol) was 
added dropwise with exotherm and the reaction was allowed to reach room 
temperature over 1 hour. The reaction mixture was concentrated in vacuo to give the 
crude acid chloride as a brown oil, which was used immediately without further 
purification (3.20 g, 15.7 mmol, 97%); υ
 max/cm-1 2926 (CH), 2856 (CH), 1798 
(C=O), 1463 (C=C); δH (400 MHz, CDCl3) 5.83 (1H, ddt, J 17.0, 10.0, 6.5 Hz, 
CH2=CH), 5.05 - 4.93 (2H, m, CH2=CH), 2.91 (2H, t, J 7.5 Hz, CH2COCl), 2.10 - 
2.01 (2H, m, CH2=CHCH2), 1.73 (2H, quin, J 7.5 Hz, CH2CH2COCl), 1.49 - 1.23 
(12H, m, 6 x CH2); δC (100 MHz, CDCl3) 173.8 (COCl), 139.1 (CH2=CH), 114.2 
(CH2=CH), 47.1 (CH2COCl), 33.8 (CH2CH2COCl), 29.2, 29.0, 28.9, 28.5, 28.4, 25.1 
(6 x CH2); m/z (ESI+) 167.2 ([M-Cl]+, 80.6%); HR-ESIMS: calculated for C11H19O: 
167.1430, found 167.1430 [M-Cl]+. Data are consistent with that previously 
reported.2 
A solution of the 10-undecenoyl chloride (5.10 g, 25 mmol) in THF (25 mL) was 
added over 5 minutes to a stirred solution of L-isoleucine (3.94 g, 30 mmol), 
potassium carbonate (1.68 g, 30 mmol) and potassium hydroxide (4.15 g, 30 mmol) 
in water (60 mL) at room temperature. The reaction mixture was stirred at room 
temperature for 18 hours. The mixture was acidified with pH 2 buffer and reduced in 
vacuo to give a white precipitate. The precipitate was isolated by vacuum filtration 
and the filtercake was washed successively with water (2 x 50 mL) and petroleum 
ether (3 x 50 mL) before drying by toluene azeotrope to afford the product as a 
bright white crystalline solid (6.71 g, 22.6 mmol, 90 %); m.p. 99 - 100 °C (lit.3 100 - 
101 °C); 27][ Dα +20.6 (c = 1.0, CHCl3), 25][ Dα +8.9 (c = 0.97, MeOH), (lit.3 25][ Dα  
OH
N
H
O
O
H
H
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+3.37 (c = 0.1, MeOH)); υ
 max/cm-1(neat) 3304 (N-H), 1699 (C=O), 1600 (C=C), 
1549 (N-H); δH (400 MHz, CDCl3) 5.99 (1H, d, J 8.5 Hz, NHCH), 5.82 (1H, ddt, J 
17.0, 10.0, 6.5 Hz, CH2=CH), 5.00 (1H, dq, J 17.0, 1.5 Hz, CH2=CH), 4.94 (1H, ddt, 
10.0, 2.0, 1.0 CH2=CH), 4.62 (1H, dd, J 8.5, 5.0 Hz, NHCH), 2.29 - 2.24 (2H, m, 
CH2CONH), 2.08 - 2.01 (2H, m, CH2=CHCH2), 2.02 - 1.92 (1H, m, CHCH3), 1.65 
(2H, quin., J 7.5 Hz, CH2CH2CO), 1.52 (1H, dqd, J 15.0, 7.5, 4.5 Hz, CHCH2CH3), 
1.41 - 1.34 (11H, m, CHCH2CH3, 5 x CH2), 0.97 (3H, d, J 7.0 Hz, CHCH3), 0.95 
(3H, t, J 7.5 Hz, CH2CH3); δH (700 MHz, DMSO-d6) 12.44 (1H, br. s., CO2H), 7.88 
(1H, d, J 8.3 Hz, NHCH), 5.79 (1H, ddt J 17.0, 10.1, 6.6 Hz, CH2=CH), 5.02 - 4.97  
(1H, m, CH2=CH), 4.95 - 4.91 (1H, m, CH2=CH), 4.17 (1H, dd, J 7.9, 6.9 Hz, 
NHCH), 2.27 – 2.20 (2H, m, CH2CONH), 2.00 (2H, q, J 6.9 Hz, CH2=CHCH2), 1.79 
- 1.71 (1H, m, CHCH3), 1.51 - 1.43 (2H, m, CH2CH2CO), 1.43 - 1.36 (1H, m, 
CHCH2CH3), 1.36 - 1.31 (2H, m, CH2), 1.28 - 1.21 (8H, m, 4 x CH2), 1.21 - 1.14 
(1H, m, CHCH2CH3), 0.86 - 0.82 (6H, m, CHCH3, CHCH2CH3); δH (700 MHz, 
CD3OD) 5.80 (1H, ddt, J 17.0, 10.2, 6.8 Hz, CH2=CH), 4.97 (1H, dq, J 17.1, 2.1 Hz, 
CH2=CH), 4.91 (1H, dt, J 10.3, 1.0 Hz, CH2=CH), 4.37 (1H, d, J 5.8 Hz, NHCH), 
2.29 - 2.22 (2H, m CH2CONH), 2.07 - 2.02 (2H, m, CH2=CHCH2), 1.92- 1.84 (1H, 
m, CHCH3), 1.64 - 1.58 (2H, m, CH2CH2CO), 1.52 (1H, dqd, J 15.0, 7.5, 4.4 Hz, 
CHCH2CH3), 1.42 - 1.37 (2H, m, CH2), 1.35 - 1.29 (8H, m, 4 x CH2), 1.27 - 1.23 
(1H, m, CHCH2CH3), 0.95 (3H, d, J 6.7 Hz, CHCH3), 0.93 (3H, t, J 7.4 Hz, 
CH2CH3); δC (100 MHz, CDCl3) 175.6, 174.0 (CO2H, CONH), 139.2 (CH2=CH), 
114.2 (CH2=CH), 56.4 (CHNH), 37.7 (CHCH3), 36.7 (CH2CONH), 33.8 
(CH2=CHCH2), 29.3, 29.2, 29.1, 28.9 (5 x CH2), 25.7 (CH2CH2CO), 25.1 
(CHCH2CH3), 15.4 (CHCH3), 11.6 (CHCH2CH3); m/z (ESI) 296.2 ([M-H]-, 100%); 
HR-ESIMS: calculated for C17H31NO3Na: 320.2196, found 320.1297 [M+Na]+.  
Data are consistent with that previously reported.3  
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(3S, 2S)-2-(Undec-10’-enoylamino)-3-methyl-pentanoic acid and (2R, 3S)-2-
(undec-10’-enoylamino)-3-methyl-pentanoic acid 3.03 
Method modified from literature procedure by du Vigneaud and Meyer.4 (2S, 3S)-2-
(Undec-10’-enoylamino)-3-methyl-pentanoic acid 3.02 (2.0 g, 6.7 mmol) was 
dissolved in 3M aqueous sodium hydroxide (2.3 mL, 6.7 mmol), and THF (4 mL) 
and water (4 mL) were added. Acetic anhydride (0.62 mL, 6.7 mmol) was added and 
the reaction mixture was heated to 65 °C for 3 days. The mixture was concentrated 
in vacuo and partitioned between pH 2 buffer (10 mL) and EtOAc (10 mL). The 
aqueous phase was further extracted with EtOAc (2 x 10 mL). The combined organic 
extracts were washed with water (10 mL) and saturated aqueous NaCl solution (10 
mL), dried over Na2SO4 and concentrated in vacuo to afford the mix of 
diastereomeric products 3.03 as a white solid (1.51 g, 5.1 mmol, 76 %, 82: 18  mix 
of (2S, 3S) and (2R, 3S) diastereomers, calculated by 1H NMR); υ
 max/cm-1 (neat) 
3303 (N-H), 1697 (C=O), 1597 (C=C), 1549 (N-H); δH (400 MHz, CDCl3) 7.98 ((2S, 
3S), 1H, s, CO2H; (2R, 3S), 1H,  s, CO2H), 6.16 ((2R, 3S), 1H, d, J 8.0 Hz, CHNH), 
6.07 ((2S, 3S), 1H, d, J 8.0 Hz, CHNH), 5.81 ((2S, 3S), 1H, ddt, J 17.0, 10.0, 6.5 Hz, 
CH2=CH; (2R, 3S), 1H, ddt, J 17.0, 10.0, 6.5 Hz, CH2=CH), 4.99 ((2S, 3S), 1H, m, 
CH2=CH; (2R, 3S), 1H, m, CH2=CH), 4.93 ((2S, 3S), 1H, m, CH2=CH; (2R, 3S), 1H,  
m, CH2=CH), 4.75 ((2R, 3S), 1H, dd, J 9.0, 4.0 Hz, CHNH), 4.63 ((2S, 3S), 1H, dd, J 
8.5, 5.0 Hz, CHNH), 2.26 ((2S, 3S), 2H, td, J 7.5, 4.0 Hz, CH2CONH; (2R, 3S), 2H, 
td, J 7.5, 4.0 Hz, CH2CONH), 2.03 ((2S, 3S), 2H, q, J 6.5 Hz, CH2=CHCH2; (2R, 
3S), 2H, q, J 6.5 Hz, CH2=CHCH2), 1.99 - 1.86 ((2S, 3S), 1H, m, CHCH3; (2R, 3S), 
1H, m, CHCH3), 1.68 - 1.59 ((2S, 3S), 2H, m, CH2CH2CONH; (2R, 3S), 2H, m, 
CH2CH2CONH), 1.55 - 1.13 ((2S, 3S), 12H, m, CHCH2CH3, 5 x CH2; (2R, 3S), 12H, 
OH
N
H
O
O
H
H
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m, CHCH2CH3, 5 x CH2), 1.00 - 0.88 ((2S, 3S), 6H, m, CHCH2CH3, CHCH3; (2R, 
3S), 6H, m, CHCH2CH3, CHCH3); δH (700 MHz, DMSO-d6)  12.43 ((2S, 3S), 1H, br. 
s., CO2H;  (2R, 3S), 1H, br. s., CO2H), 7.88 ((2S, 3S), 1H, d, J 8.3 Hz, NHCH), 7.79 
((2R, 3S), 1H, d, J 8.3 Hz, NHCH), 5.79 ((2S, 3S), 1H, ddt, J 16.9, 10.1, 6.8 Hz, 
CH2=CH; (2R, 3S), 1H, ddt, J J 16.9, 10.1, 6.8 Hz, CH2=CH), 4.99 ((2S, 3S), 1H, d, 
J 17.0 Hz, CH2=CH; (2R, 3S), 1H, d, J 17.0 Hz, CH2=CH), 4.93 ((2S, 3S), 1H, d, J 
10.3 Hz, CH2=CH; (2R, 3S), 1H, d, J 10.3 Hz, CH2=CH), 4.35 ((2R, 3S), 1H, dd, J 
8.5, 5.0 Hz, NHCH), 4.17 ((2S, 3S), 1H, dd, J 8.0, 6.4 Hz, NHCH), 2.20 - 2.08 ((2S, 
3S), 2H, m, CH2CONH; (2R, 3S), 2H, m, CH2CONH), 2.00 ((2S, 3S), 2H, q, J 6.8 
Hz, CH2=CHCH2; (2R, 3S), 2H, q, J 6.8 Hz, CH2=CHCH2), 1.88 - 1.81 ((2R, 3S), 
1H, m, CHCH3), 1.78 - 1.72 ((2S, 3S), 1H, m, CHCH3), 1.51 - 1.43 ((2S, 3S), 2H, m, 
CH2; (2R, 3S), 2H, m, CH2), 1.42 - 1.37 ((2S, 3S), 1H, m, CHCH2CH3; (2R, 3S), 1H, 
m, CHCH2CH3), 1.36 - 1.31 ((2S, 3S), 2H, m, CH2; (2R, 3S), 2H, m, CH2), 1.28 - 
1.21 ((2S, 3S), 8H, m, 4 x CH2; (2R, 3S), 8H, m, 4 x CH2), 1.21 - 1.12 ((2S, 3S), 1H, 
m, CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3), 0.86 - 0.83 ((2S, 3S), 6H, m, CHCH3, 
CHCH2CH3; (2R, 3S), 6H, m, CHCH3, CHCH2CH3); δH (700 MHz, CD3OD) 5.80 
((2S, 3S), 1H, ddt, J 17.0, 10.2, 6.8 Hz, CH2=CH; (2R, 3S), 1H, ddt, J 17.0, 10.2, 6.8 
Hz, CH2=CH), 4.98 ((2S, 3S), 1H, dq, J 17.1, 1.6 Hz, CH2=CH; (2R, 3S), 1H, dq, J 
17.1, 1.6 Hz, CH2=CH), 4.91 ((2S, 3S), 1H, dt, J 10.1, 1.0 Hz, CH2=CH; (2R, 3S), 
1H, dt, J 10.1, 1.0 Hz, CH2=CH), 4.54 ((2R, 3S), 1H, d, J 4.7 Hz, NHCH) 4.37 ((2S, 
3S), 1H, d, J 5.8 Hz, NHCH), 2.31 - 2.22 ((2S, 3S), 2H, m, CH2CONH; (2R, 3S), 2H, 
m, CH2CONH), 2.07 - 2.02 ((2S, 3S), 2H, m, CH2=CHCH2; (2R, 3S), 2H, m, 
CH2=CHCH2), 1.99 - 1.95 ((2R, 3S), 1H, m, CHCH3), 1.92 - 1.85 ((2S, 3S), 1H, m, 
CHCH3), 1.61 ((2S, 3S), 2H, quin, J 7.0 Hz, CH2CH2CONH; (2R, 3S), 2H, quin, J 
7.0 Hz, CH2CH2CONH), 1.52 ((2S, 3S), 1H, dqd, J 15.0, 7.5, 4.2 Hz, CHCH2CH3; 
(2R, 3S), 1H, dqd, J 15.0, 7.5, 4.2 Hz, CHCH2CH3), 1.42 - 1.36 ((2S, 3S), 2H, m, 
CH2; (2R, 3S), 2H, m, CH2), 1.32 ((2S, 3S), 8H, m, 4 x CH2; (2R, 3S), 8H, m, 4 x 
CH2), 1.28 - 1.21 ((2S, 3S), 1H, m, CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3), 0.97 
- 0.92 ((2S, 3S), 6H, m, CHCH2CH3, CHCH3; (2R, 3S), 6H, m, CHCH2CH3, CHCH3); 
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δC (100 MHz, CDCl3) 175.6, 174.1, 174.0 ((2S, 3S), CO2H, CONH; (2R, 3S), CO2H, 
CONH), 139.2 ((2S, 3S), CH2=CH; (2R, 3S), CH2=CH), 114.2 ((2S, 3S), CH2=CH; 
(2R, 3S), CH2=CH), 56.4 ((2S, 3S), CHNH), 55.2 ((2R, 3S), CHNH), 37.7, 37.6 ((2S, 
3S), CHCH3; (2R, 3S),  CHCH3), 36.7 ((2S, 3S), CH2CONH; (2R, 3S), CH2CONH), 
33.8 ((2S, 3S), CH2=CHCH2; (2R, 3S), CH2=CHCH2), 29.3, 29.3, 29.2, 29.1, 28.9 
((2S, 3S), 5 x CH2; (2R, 3S), 5 x CH2), 25.7 ((2S, 3S), CH2CH2CO; (2R, 3S), 
CH2CH2CO), 25.1 ((2S, 3S), CHCH2CH3; (2R, 3S), CHCH2CH3), 15.4, 14.6 ((2S, 
3S), CHCH3; (2R, 3S), CHCH3), 11.6 ((2S, 3S), CHCH2CH3; (2R, 3S), CHCH2CH3); 
m/z (ESI-) 296.1 ([M-H+]-, 100%); HR-ESIMS: calculated for C17H32NO3: 298.2377, 
found 298.2383 [M+H]+.   
9-Fluorenylmethyl p-toluenesulfonate 3.06 
Method modified from literature procedure by Albericio et al.5 To a solution of 9-
fluorenemethanol (4.00 g, 20.4 mmol) in chloroform (20 mL) at 0°C was added 
dropwise a solution of toluenesulfonyl chloride (4.80 g, 24.5 mmol) and pyridine 
(3.2 mL, 40.8 mmol) in chloroform (10 mL). The reaction mixture was allowed to 
reach room temperature overnight to give a bright yellow solution. pH 2 buffer (20 
mL) was added and the organic extract was further washed with pH 2 buffer (20 
mL), water (20 mL) saturated aqueous NaHCO3 solution (2 x 20 mL) and saturated 
aqueous NaCl solution (20 mL), dried over Na2SO4 and concentrated in vacuo to 
give the crude product as a yellow solid. Recrystallisation from CHCl3:hexanes 
afforded 3.06 as glossy white crystals (3.95 g, 11.3 mmol, 55 %); m.p. 111 - 112 °C 
(lit.6 115 °C); υ max/cm-1 (neat) 1356 (S=O); δH (400 MHz, CDCl3) 7.77 (2H, J 8.5 
Hz, fluorenylmethyl 2 x Ar CH), 7.74 (2H, d, J 7.5 Hz, fluorenylmethyl  2 x Ar CH), 
7.55 (2H, d, J 7.5 Hz, 2 x tosyl Ar CH), 7.40 (2H, t, J 7.5 Hz, fluorenylmethyl 2 x Ar 
CH), 7.31 (2H, d, J 8.5 Hz, 2 x tosyl Ar CH), 7.30 (2H, dd, J 7.5, 1.0 Hz, 
fluorenylmethyl 2 x Ar CH), 4.30 - 4.21 (3H, m, CHCH2, CHCH2), 2.43 (3H, s, 
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CH3); δC (100 MHz, CDCl3) 144.9, 142.5 (2 x fluorenylmethyl Ar C), 141.2, 132.8, 
(2 x tosyl Ar C), 129.9, 128.1 (2 x tosyl Ar CH), 127.9, 127.2, 125.2, 120.1 (4 x 
fluorenylmethyl Ar CH), 71.9 (CHCH2), 46.7 (CHCH2), 21.6 (CH3); m/z (ESI+) 
373.0 ([M+Na], 100%); HR-ESIMS: calculated for C21H18O3SNa: 373.0867, found 
373.0869 [M+Na]+. Data are consistent with that previously reported.5  
9-Fluorenylmethyl thioacetate 3.07 
Method modified from literature procedure by Crich et al.1 A solution of potassium 
thioacetate (4.26 g, 37.3 mmol) and 9-fluorenylmethyl p-toluenesulfonate 3.06 (6.49 
g, 18.7 mmol) in DMF (65 mL) was stirred at room temperature for 2 hours to give a 
bright orange solution. EtOAc (150 mL) and water (150 mL) were added and the 
phases separated. The organic phase was washed with water (150 mL) and saturated 
aqueous NaCl solution (150 mL), dried over Na2SO4 and concentrated in vacuo to 
give a bright orange oil. Purification by silica chromatography (4 % EtOAc: hexane)  
gave the thioacetate 3.07 as a cream coloured crystalline solid (3.24 g, 12.7 mmol, 
68%); m.p. 73 – 74 °C (lit.1 72 – 73 °C); υmax /cm-1 (neat) 1681 (C=O); δH (400 MHz, 
CDCl3) 7.77 (2H, d, J 8.0 Hz, 2 x Ar CH), 7.67 (2H, d, J 7.5 Hz, 2 x Ar CH), 7.41 
(2H, t, J 7.5 Hz, 2 x Ar CH), 7.34 (2H, t, J 7.5 Hz, 2 x Ar CH), 4.19 (1H, t, J  6.0 Hz, 
CHCH2), 3.55 (2H, d, J  6.0 Hz, CHCH2), 2.29 (3H, s, CH3); δC (100 MHz, CDCl3) 
195.4 (SCOCH3), 145.4, 141.0 (4 x Ar C), 127.7, 127.1, 124.6, 119.9 (4 x Ar CH), 
46.6 (CHCH2), 32.4 (CHCH2), 30.6 (CH3); m/z (ESI+) 211.0 ([M-SOCH3)], 100%); 
HR-ESIMS: calculated for C16H15OS: 255.0838, found 255.0837 [M+H]+. Data are 
consistent with that previously reported.1 
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(2S, 3S) and (2R, 3S)-(9’-Fluorenylmethyl)-2-(undec-10-enoylamino)-3-methyl 
pentanethioate 3.04 
Method modified from literature procedure by Crich et al.1 A solution of thioacetate 
3.07 (2.40 g, 9.44 mmol) in dry Et2O (80 mL) was cooled to -78°C under N2. A 
solution of DIBAL (25% w/w in toluene, 14 mL, 20.8 mmol) was added dropwise 
and the reaction mixture held at -78°C for 5 minutes. The reaction mixture was 
allowed to warm to 0°C over 1 hour and quenched with EtOAc (30 mL, 102 mmol). 
An aqueous solution of Rochelle’s salt (1.4M, 120 mL) was added and the mixture 
was stirred vigorously for 1 hour to give a biphasic solution. The aqueous phase was 
extracted with Et2O (2 x 40 mL) and the combined organics washed with pH 2 buffer 
(20 mL), water (20 mL), saturated aqueous NaCl solution (20 mL), dried over 
Na2SO4 and concentrated in vacuo to give the crude thiol as a yellow oil, which was 
purified by silica chromatography (2 % EtOAc:hexanes) to give the thiol as a yellow 
oil, which was used immediately (1.41 g, 6.64 mmol, 70%); υmax /cm-1 (neat) 2565 
(S-H);  
A solution of 9-fluorenylmethylthiol (0.93 g, 4.4 mmol) and acid 3.02 (1.00 g, 3.36 
mmol) in DMF (55 mL) was stirred at -20°C for 20 minutes. PyBOP (4.37 g, 8.41 
mmol) and diisopropylethylamine (1.40 mL, 8.41 mmol) were added and the 
reaction mixture was stirred at -20 °C for 4 hours. The reaction mixture was 
quenched with pH 2 buffer (30 mL) and extracted with CH2Cl2 (2 x 20 mL). The 
combined organic extracts were concentrated in vacuo and the residue was 
partitioned between water (20 mL) and EtOAc (20 mL). The separated organic phase 
was washed with pH 2 buffer (10 mL), water (10 mL), saturated aqueous NaHCO3 
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solution (10 mL) and saturated aqueous NaCl solution (10 mL), dried over Na2SO4 
and concentrated in vacuo to give the crude thioester (61: 39  mix of (2S, 3S) and 
(2R, 3S) diastereomer before purification, calculated by 1H NMR). The thioester 3.04 
was obtained as by silica column chromatography (100 % pet. ether to 90 % 
pet.ether: EtOAc) as a yellow waxy solid (0.56 g, 1.14 mmol, 34 %, 52: 48  mix of 
(2S, 3S) and (2R, 3S) diastereomers, calculated by 1H NMR);  υ max/cm-1 (neat) 3283 
(N-H), 1686 (thioester C=O), 1635 (amide C=O), 1531 (N-H); δH (400 MHz, CDCl3) 
7.73 ((2S, 3S), 2H, d, J 7.5 Hz, 2 x Ar CH; (2R, 3S), 2H, d, J 7.5 Hz, 2 x Ar CH), 
7.63 - 7.59 ((2S, 3S), 2H, m, 2 x Ar CH; (2R, 3S), 2H, m, 2 x Ar CH), 7.37 ((2S, 3S), 
2H, t, J 7.5 Hz, 2 x Ar CH; (2R, 3S), 2H, t, J 7.5 Hz, 2 x Ar CH), 7.32 - 7.27 ((2S, 
3S), 2H, m, 2 x Ar CH; (2R, 3S), 2H, m, 2 x Ar CH), 5.80 ((2S, 3S), 1H, ddt, J 17.0, 
10.0, 6.5 Hz, CH2=CH; (2R, 3S), 1H, ddt, J 17.0, 10.0, 6.5 Hz, CH2=CH), 5.73 ((2S, 
3S), 1H, t, J 9.0 Hz, NHCH; (2R, 3S), 1H, t, J 9.0 Hz, NHCH), 5.02 - 4.90 ((2S, 3S), 
2H, m, CH2=CH; (2R, 3S), 2H, m, CH2=CH), 4.74 ((2R, 3S), 1H, dd, J 9.5, 4.0 Hz, 
NHCH),  4.61 ((2S, 3S), 1H, dd, J 9.0, 5.0 Hz, NHCH), 4.17 ((2S, 3S), 1H, t, J 5.5 
Hz, CHCH2S; (2R, 3S), 1H, t, J 5.5 Hz,  CHCH2S), 3.63 - 3.52 ((2S, 3S), 2H, m, 
CHCH2S; (2R, 3S), 2H, m, CHCH2S), 2.20 ((2S, 3S), 2H, q, J 7.0 Hz, CH2CONH; 
(2R, 3S), 2H, q, J 7.0 Hz, CH2CONH), 2.03 ((2S, 3S), 2H, q, J 7.0 Hz, CH=CH2CH2; 
(2R, 3S), 2H, q, J 7.0 Hz, CH=CH2CH2), 1.93 - 1.77 ((2S, 3S), 1H, m, CHCH3; (2R, 
3S), 1H, m, CHCH3), 1.67 - 1.56 ((2S, 3S), 2H, m, CH2CH2CONH; (2R, 3S), 2H, m, 
CH2CH2CONH), 1.40 - 1.01 ((2S, 3S), 12H, m, CHCH2CH3, 5 x CH2; (2R, 3S), 12H, 
m, CHCH2CH3, 5 x CH2), 0.81 - 0.60 ((2S, 3S), 6H, m, CHCH2CH3, CHCH3; (2S, 
3S), 6H, m, CHCH2CH3, CHCH3); δH (700 MHz, DMSO-d6) 8.07 ((2R, 3S), 1H, d, J 
8.0 Hz, NHCH), 8.01 ((2S, 3S), 1H, d, J 8.7 Hz, NHCH), 7.84 ((2S, 3S), 2H, t, J 6.3 
Hz, 2 x Ar CH; (2R, 3S), 2H, t, J 6.3 Hz, 2 x Ar CH), 7.68 - 7.56 ((2S, 3S), 2H, m, 2 
x Ar CH; (2R, 3S), 2H, m, 2 x Ar CH), 7.38 ((2S, 3S), 2H, dd, J 12.2, 5.8 Hz, 2 x Ar 
CH; (2R, 3S), 2H, dd, J 12.2, 5.8 Hz, 2 x Ar CH), 7.34 - 7.26 ((2S, 3S), 2H, m, 2 x 
Ar CH; (2R, 3S), 2H, m, 2 x Ar CH), 5.78 ((2S, 3S), 1H, ddt, J 16.7, 10.3, 6.7 Hz, 
CH2=CH; (2R, 3S), 1H, ddt, J 16.7, 10.3, 6.7 Hz, CH2=CH), 4.98 ((2S, 3S), 1H, d, J 
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17.0 Hz, CH2=CH; (2R, 3S), 1H, d, J 17.0 Hz, CH2=CH), 4.93 ((2S, 3S), 1H, d, J 
10.3 Hz, CH2=CH; (2R, 3S), 1H, d, J 10.3 Hz, CH2=CH), 4.33 ((2R, 3S), 1H, dd, J 
8.7, 5.1 Hz, NHCH), 4.29 - 4.25 ((2S, 3S), 1H, m, CHCH2S; (2R, 3S), 1H, m, 
CHCH2S), 4.15 ((2S, 3S), 1H, t, J 7.4 Hz, NHCH), 3.72 - 3.65 ((2S, 3S), 1H, m, 
CHCH2S; (2R, 3S), 1H, m, CHCH2S), 3.58 ((2S, 3S), 1H, J 13.6, 5.0 Hz, CHCH2S; 
(2R, 3S), 1H, J 13.6, 5.0 Hz, CHCH2S), 2.13 - 2.06 ((2S, 3S), 2H, m, NHCOCH2; 
(2R, 3S), 2H, m, NHCOCH2), 1.99 ((2S, 3S), 2H, q, J 6.9 Hz, CH2=CHCH2; (2R, 
3S), 2H, q, J 6.9 Hz, CH2=CHCH2), 1.75 - 1.67, 1.64- 1.58 (2S, 3S), 1H, m, CHCH3; 
(2R, 3S), 1H, m, CHCH3), 1.46 - 1.39 ((2S, 3S), 2H, m, CH2; (2R, 3S), 2H, m, CH2), 
1.37 - 1.29 ((2S, 3S), 2H, m, CH2; (2R, 3S), 2H, m, CH2), 1.26 - 1.15 ((2S, 3S), 8H, 
m, 4 x CH2; (2R, 3S), 8H, m, 4 x CH2), 1.09 - 1.01 ((2S, 3S), 1H, m, CH2CH3; (2R, 
3S), 1H, m, CH2CH3), 1.01 - 0.89 ((2S, 3S), 1H, m, CH2CH3; (2R, 3S), 1H, m, 
CH2CH3), 0.71 ((2R, 3S), 3H, t, J 7.4 Hz, CHCH2CH3), 0.67 ((2S, 3S), 3H, t, J 7.4 
Hz, CHCH2CH3), 0.59 ((2S, 3S), 3H, J 6.7 Hz, CHCH3), 0.55 ((2R, 3S), 3H, J 6.7 
Hz, CHCH3); δH (700 MHz, CD3OD) 7.75 ((2S, 3S), 2H, d, J 7.5 Hz, 2 x Ar CH; 
(2R, 3S), 2H, d, J 7.5 Hz, 2 x Ar CH), 7.61 ((2S, 3S), 2H, dd, J 12.3, 7.6 Hz, 2 x Ar 
CH; (2R, 3S), 2H, dd, J 12.3, 7.6 Hz, 2 x Ar CH), 7.36 ((2S, 3S), 2H, t, J 7.5 Hz, 2 x 
Ar CH; (2R, 3S), 2H, t, J 7.5 Hz, 2 x Ar CH), 7.30 - 7.26 ((2S, 3S), 2H, m, 2 x Ar 
CH; (2R, 3S), 2H, m, 2 x Ar CH), 5.84 – 5.77 ((2S, 3S), 1H, m, CH2=CH; (2R, 3S), 
1H, m, CH2=CH), 4.99 - 4.94 ((2S, 3S), 1H, m, CH2=CH; (2R, 3S), 1H, m, 
CH2=CH), 4.93 - 4.90 ((2S, 3S), 1H, m, CH2=CH; (2R, 3S), 1H, m, CH2=CH), 4.48 
((2R, 3S), 1H, d, J 5.3 Hz, NHCH), 4.31 ((2S, 3S), 1H, d, J 6.1 Hz, NHCH), 4.23 - 
4.20 ((2S, 3S), 1H, m, CHCH2S; (2R, 3S), 1H, m, CHCH2S), 3.73 - 3.68 ((2S, 3S), 
1H, m, CHCH2S; (2R, 3S), 1H, m, CHCH2S), 3.63 - 3.58 ((2S, 3S), 1H, m, CHCH2S; 
(2R, 3S), 1H, m, CHCH2S), 2.30 - 2.16 ((2S, 3S), 2H, m, NHCOCH2; (2R, 3S), 2H, 
m, NHCOCH2), 2.05 - 2.02 ((2S, 3S), 2H, m, CH=CH2CH2; (2S, 3S), 2H, m, 
CH=CH2CH2), 1.87 - 1.80,  1.78 - 1.72 ((2S, 3S), 1H, m, CHCH3; (2R, 3S), 1H, m, 
CHCH3), 1.59 - 1.49 ((2S, 3S), 2H, m, CH2; (2R, 3S), 2H, m, CH2), 1.40 - 1.34 ((2S, 
3S), 2H, m, CH2; (2R, 3S), 2H, m, CH2), 1.33 - 1.25 ((2S, 3S), 8H, m, 4 x CH2; (2R, 
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3S), 8H, m, 4 x CH2), 1.21 - 1.10 ((2S, 3S), 1H, m, CH2CH3; (2R, 3S), 1H, m, 
CH2CH3), 1.09 - 0.97 ((2S, 3S), 1H, m, CH2CH3; (2R, 3S), 1H, m, CH2CH3), 0.81 
((2R, 3S), 3H, t, J 7.4 Hz, CHCH2CH3), 0.77 ((2S, 3S), 3H, t, J 7.4 Hz, CHCH2CH3), 
0.71 ((2S, 3S), 3H, d, J 6.7 Hz, CHCH3), 0.63 ((2S, 3S), 3H, d, J 6.9 Hz, CHCH3); δC 
(100 MHz, CDCl3) 200.3, 199.7 (SCOCH3), 173.1, 173.0 (NHCOCH2), 145.2, 
145.2, 141.2 ((2S, 3S), 4 x Ar C; (2R, 3S), 4 x Ar C), 139.2 ((2S, 3S), CH2=CH; (2R, 
3S), CH2=CH), 127.7, 127.1, 124.7, 119.9 ((2S, 3S), 8 x Ar CH; (2R, 3S), 8 x Ar 
CH), 114.2 ((2S, 3S), CH2=CH; (2R, 3S), CH2=CH), 63.2 ((2S, 3S), NHCH), 61.8 
((2R, 3S), NHCH), 46.7 ((2S, 3S), CHCH2S; (2R, 3S), CHCH2S), 37.8 ((2S, 3S), 
CH2CHCH3; (2R, 3S), CH2CHCH3), 36.7 ((2S, 3S), NHCOCH2; (2R, 3S), 
NHCOCH2), 33.8 ((2S, 3S), CH2=CHCH2; (2R, 3S), CH2=CHCH2), 31.9, 31.8 ((2S, 
3S), SCH2; (2R, 3S), SCH2), 29.3, 29.3, 29.2, 29.1, 28.9 ((2S, 3S), 5 x CH2; (2R, 3S), 
5 x CH2), 26.5 ((2S, 3S), NHCOCH2CH2; (2R, 3S), NHCOCH2CH2), 25.6 ((2S, 3S), 
CHCH2CH3; (2R, 3S), CHCH2CH3), 15.5, 14.2, 13.9, 11.7 ((2S, 3S), CHCH3, 
CH2CH3; (2R, 3S), CHCH3, CH2CH3); m/z (ESI+) 514.3 ([M+Na], 100%), 492.3 
([M+H], 13%); HR-ESIMS: calculated for C31H42NO2S: 492.2931, found 492.2951 
[M+H]+.  
This compound was also prepared by the same method using a mix of L- and D-
alloisoleucine (0.22 g, 0.72 mmol) to give 3.05 as an orange waxy solid (0.134 g, 
0.27 mmol, 38%. 35: 65  mix of (2S, 3S) and (2R, 3S) diastereomers, calculated by 
1H NMR before purification; 60: 40 mix of (2S, 3S) and (2R, 3S) diastereomers, 
calculated by 1H NMR of product after silica column chromatography). All 
characterisation data was identical to that obtained for 3.04 above.  
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(2S, 3S) and (2R,3S)-(propyl)-2-(undec-10-enoylamino)-3-methyl pentaneamide 
3.09 
A solution of n-propylamine (0.36 mL, 4.37 mmol) and ((2S, 3S)-2-(undec-10’-
enoylamino)-3-methyl-pentanoic acid (1.0 g, 3.36 mmol) in DMF (55 mL) was 
stirred at -20 °C for 20 minutes. PyBOP (4.37 g, 8.41 mmol) and 
diisopropylethylamine (1.4 mL, 8.41 mmol) were added and the reaction mixture 
stirred at -20 °C for 4 hours. The reaction mixture was acidified with pH 2 buffer and 
extracted with CH2Cl2 (2 x 20 mL). The combined organic extracts were 
concentrated in vacuo and the residue was partitioned between water (20 mL) and 
EtOAc (20 mL). The separated organic phase was washed with pH 2 buffer (10 mL), 
water (10 mL), saturated aqueous NaHCO3 solution (10 mL) and saturated aqueous 
NaCl solution (10 mL), dried over Na2SO4 and concentrated in vacuo to give the 
crude amide 3.09 (86: 14  mix of (2S, 3S) and (2R, 3S) diastereomer before 
purification, calculated by 1H NMR). 3.09 was obtained by silica chromatography 
(0.81 g, 2.39 mmol, 71 %, 88:12 mix of (2S, 3S) and (2R, 3S) diastereomers, 
calculated by 1H NMR); υ
 max/cm-1 3282 (N-H), 1631 (C=O), 1539 (N-H); δH (400 
MHz, CDCl3) 7.30 - 7.15 ((2S, 3S), 1H, m, CONH; (2R, 3S), 1H, m, CONH), 7.00 - 
6.82 ((2S, 3S), 1H, m, CONH; (2R, 3S), 1H, m, CONH), 5.77 ((2S, 3S), 1H, ddt, J 
17.0, 10.5, 6.5 Hz, CH2=CH; (2R, 3S), 1H, ddt, J 17.0, 10.5, 6.5 Hz, CH2=CH), 4.96 
((2S, 3S), 1H, dq, J 17.0, 2.0 Hz, CH2=CH; (2R, 3S), 1H, dq, J 17.0, 2.0 Hz, 
CH2=CH), 4.95 - 4.90 ((2S, 3S), 1H, m, CH2=CH; (2R, 3S), 1H, m, CH2=CH), 4.42 
((2R, 3S), 1H, dd, J 9.0, 7.0 Hz, NHCH), 4.34 ((2S, 3S), 1H, t, J 9.0 Hz, NHCH), 
3.33 - 3.19 ((2S, 3S), 1H, m, NHCH2; (2R, 3S), 1H, m, NHCH2), 3.14 - 3.02 ((2S, 
3S), 1H, m, NHCH2; (2R, 3S), 1H, m, NHCH2), 2.28 - 2.11 ((2S, 3S), 2H, m, 
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COCH2; (2R, 3S), 2H, m, COCH2), 2.05 - 1.97 ((2S, 3S), 2H, m, CH2=CHCH2; (2R, 
3S), 2H, m, CH2=CHCH2), 1.84 - 1.72 ((2S, 3S), 1H, m, CHCH3; (2R, 3S), 1H, m, 
CHCH3), 1.62 - 1.53 ((2S, 3S), 5H, m, NHCH2CH2, COCH2CH2, CHCH2; (2R, 3S), 
5H, m, NHCH2CH2, COCH2CH2, CHCH2), 1.37 - 1.20 ((2S, 3S), 10H, m, 5 x CH2; 
(2R, 3S), 10H, m, 5 x CH2), 1.14 - 1.01 ((2S, 3S), 1H, m, CHCH2; (2R, 3S), 1H, m, 
CHCH2), 0.92 - 0.81 ((2S, 3S), 9H, m, CHCH3, CHCH2CH3, CH2CH3; (2R, 3S), 9H, 
m, CHCH3, CHCH2CH3, CH2CH3); δH (700 MHz, DMSO-d6) 7.88 ((2S, 3S), 1H, t, J 
5.3 Hz, NHCH2), 7.81 ((2R, 3S), 1H, t, J 5.0 Hz, NHCH2), 7.74 ((2S, 3S), 1H, d, J 
8.7 Hz, NHCH), 7.64 ((2R, 3S), 1H, d, J 9.0 Hz, NHCH), 5.78 ((2S, 3S), 1H, ddt, J 
16.7, 9.6, 6.7 Hz, CH2=CH; (2R, 3S), 1H, ddt, J 16.7, 9.6, 6.7 Hz, CH2=CH), 4.99 
((2S, 3S), 1H, d, J 17.3 Hz, CH2=CH; (2R, 3S), 1H, d, J 17.3 Hz, CH2=CH), 4.93 
((2S, 3S), 1H, d, J 10.3 Hz, CH2=CH; (2R, 3S), 1H, d, J 10.3 Hz, CH2=CH), 4.25 
((2R, 3S), 1H, dd, J 9.0, 6.1 Hz, NHCH), 4.10 ((2S, 3S), 1H, t, J 8.3 Hz, NHCH), 
3.08 - 3.00 ((2S, 3S), 1H, m, NHCH2; (2R, 3S), 1H, m, NHCH2), 3.00 - 2.91 ((2S, 
3S), 1H, m, NHCH2; (2R, 3S), 1H, m, NHCH2), 2.22 - 2.04 ((2S, 3S), 2H, m, 
NHCOCH2; (2R, 3S), 2H, m, NHCOCH2), 2.00 ((2S, 3S), 2H, q, J 6.9 Hz, 
CH2=CHCH2; (2R, 3S), 2H, q, J 6.9 Hz, CH2=CHCH2), 1.78 - 1.71 ((2R, 3S), 1H, m, 
CHCH3), 1.71 - 1.64 ((2S, 3S), 1H, m, CHCH3), 1.52 - 1.43 ((2S, 3S), 2H, m, CH2; 
(2R, 3S), 2H, m, CH2), 1.41 - 1.37 ((2S, 3S), 2H, m, CH2; (2R, 3S), 2H, m, CH2), 
1.36 - 1.30 ((2S, 3S), 2H, m, CH2; (2R, 3S), 2H, m, CH2), 1.27 – 1.19 ((2S, 3S), 9H, 
m, 4 x  CH2, CHCH2CH3; (2R, 3S), 9H, m, 4 x CH2, CHCH2CH3), 1.12 - 1.01 ((2S, 
3S), 1H, m, CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3), 0.85 - 0.77 ((2S, 3S), 9H, m, 
CHCH3, CHCH2CH3, CH2CH2CH3; (2R, 3S), 9H, m, CHCH3, CHCH2CH3, 
CH2CH2CH3); δH (700 MHz, CD3OD) 5.80 ((2S, 3S), 1H, ddt, J 17.0, 10.2, 6.7 Hz, 
CH2=CH; (2R, 3S), 1H, ddt, J 17.0, 10.2, 6.7 Hz, CH2=CH), 4.99 - 4.95 ((2S, 3S), 
1H, m, CH2=CH; (2R, 3S), 1H, m, CH2=CH), 4.92 - 4.89 ((2S, 3S), 1H, m, CH2=CH; 
(2R, 3S), 1H, m, CH2=CH), 4.30 ((2R, 3S), 1H, d, J 6.7 Hz, NHCH), 4.14 ((2S, 3S), 
1H, d, J 8.3 Hz, NHCH), 3.19 - 3.09 ((2S, 3S), 2H, m, NHCH2; (2R, 3S), 2H, m, 
NHCH2), 2.31 - 2.19 ((2S, 3S), 2H, m, NHCOCH2; (2R, 3S), 2H, m, NHCOCH2), 
140 
 
2.04 ((2S, 3S), 2H, q, J 7.3 Hz, CH2=CHCH2; (2R, 3S), 2H, q, J 7.3 Hz, 
CH2=CHCH2), 1.89 - 1.83 ((2R, 3S), 1H, m, CHCH3), 1.83 - 1.76 ((2S, 3S), 1H, m, 
CHCH3), 1.63 - 1.56 ((2S, 3S), 2H, m, CH2; (2R, 3S), 2H, m, CH2), 1.55 - 1.48 (2S, 
3S), 3H, m, CH2, CHCH2CH3; (2R, 3S), 3H, m, CH2, CHCH2CH3), 1.42 - 1.36 ((2S, 
3S), 2H, m, CH2; (2R, 3S), 2H, m, CH2), 1.35 – 1.28 ((2S, 3S), 8H, m, 4 x CH2; (2R, 
3S), 8H, m, 4 x CH2), 1.21 - 1.13 ((2S, 3S), 1H, m, CHCH2CH3; (2R, 3S), 1H, m, 
CHCH2CH3), 0.88 - 0.95 ((2S, 3S), 9H, m, CHCH3, CHCH2CH3, CH2CH2CH3; (2R, 
3S), 9H, m, CHCH3, CHCH2CH3, CH2CH2CH3); δC (100 MHz, CDCl3) 173.2 ((2S, 
3S), CHCO; (2R, 3S), CHCO), 171.7 ((2S, 3S), CH2CO; (2R, 3S), CH2CO), 139.0 
((2S, 3S), CH2=CH; (2R, 3S), CH2=CH), 114.1 ((2S, 3S), CH2=CH; (2R, 3S), 
CH2=CH), 57.5 ((2S, 3S), CHNH),  57.0 (2R, 3S), CHNH), 41.0 ((2S, 3S), NHCH2; 
(2R, 3S), NHCH2),  37.5, 37.1 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 36.4 ((2S, 3S), 
COCH2; (2R, 3S), COCH2), 33.7 ((2S, 3S), CH2=CHCH2; (2R, 3S), CH2=CHCH2), 
29.3, 29.2, 29.0, 28.8, 25.93, 25.7 ((2S, 3S), 5 x CH2, CHCH2CH3; (2R, 3S), 5 x CH2, 
CHCH2CH3), 25.1 ((2S, 3S), NHCH2CH2; (2R, 3S), NHCH2CH2), 15.3, 14.6 ((2S, 
3S), CH2CH2CH3, CHCH3; (2S, 3S), CH2CH2CH3, CHCH3), 11.4, 11.1 ((2R, 3S), 
CHCH2CH3; (2S, 3S), CHCH2CH3); HR-ESIMS: calculated for C20H38N2O2Na: 
361.2825, found 361.2825 [M+Na]+. 
This compound was also prepared using the same method using a mix of L- and D-
alloisoleucine (0.30 g, 1.00 mmol) to give the amide 3.10 as a bright white solid 
(0.29 g, 0.86 mmol, 86%, 65:35 mix of (2S, 3S) and (2R, 3S) diastereomers, 
calculated by 1H NMR); All characterisation data was identical to that obtained  for 
3.09 above.  
 
 
 
141 
 
(2S, 3S) and (2R,3S)-(propyl)-2-(undec-10-enoylamino)-3-methyl pentaneamide 
3.08 from thioester 
Method modified from literature procedure by Crich et al.1 A solution of (2S, 3S) 
and (2R, 3S)-(9’-fluorenylmethyl)-2-(undec-10-enoylamino)-3-methyl 
pentanethioate 3.04 (52: 48  mix of (2S, 3S) and (2R, 3S) diastereomers, calculated 
by 1H NMR; 0.13 g, 0.25 mmol) in 40% piperidine in DMF (2.5 mL) was stirred at 
room temperature for 1.5 hours. The solution was reduced in vacuo and the residue 
was partitioned between EtOAc (10 mL) and 1M aqueous HCl solution (10 mL). 
The separated organic phase was washed with water (10 mL) and saturated aqueous 
NaCl solution (10 mL), dried over Na2SO4 and concentrated in vacuo to give the 
crude thioacid, which was used immediately without further purification. 
Cs2CO3 (0.11 g, 0.32 mmol) was added to a solution of the thioacid (0.25 mmol) in 
DMF (0.5 mL) under a nitrogen atmosphere. After 10 minutes, a solution of the 
sulfonamide (0.06 g, 0.21 mmol) in DMF (0.4 mL) was added to give a dark red 
solution. The reaction mixture was stirred at room temperature for 1 hour, then 
poured into EtOAc (30 mL). The organics were washed with ice-cold 1M aqueous 
NaOH solution (10 mL), water (10 mL) and saturated aqueous NaCl solution (10 
mL), dried over Na2SO4 and concentrated in vacuo (86: 14  mix of (2S, 3S) and (2R, 
3S) diastereomer before purification, calculated by 1H NMR). Purification by silica 
chromatography (25 % - 50 % EtOAc: pet. ether) gave 3.08 as a yellow oil (29 mg, 
0.09 mmol, 35 %, 45:55 mix of (2S, 3S) and (2R, 3S) diastereomers, calculated by 1H 
NMR). All characterisation data was identical to the products 3.09 and 3.10 prepared 
previously.  
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L-Isoleucine and D-allo-isoleucine 3.11 
Method modified from literature procedure by Yamada et al.7 A suspension of L-
isoleucine (10.0 g, 76.2 mmol) and acetaldehyde (1.30 mL, 22.9 mmol) in acetic acid 
(50 mL) was heated to 100 °C for 3 hours to give a dark red solution. The reaction 
mixture was cooled to room temperature and poured into petroleum ether (300 mL). 
The mixture was stirred vigorously until a dense brown precipitate formed (ca. 1 
hour) and the reaction was filtered. The filter cake was triturated with boiling 
MeOH, filtered and dried in vacuo to give a light brown crystalline solid (6.52 g, 
49.7 mmol, 65%, 76:24 mix of (2S, 3S) and (2R, 3S) diastereomers, calculated by 1H 
NMR); υ
 max/cm-1(neat) 3010 (N-H), 2577 (O-H), 1588 (C=O); δH (400 MHz, D2O) 
3.71 ((2R, 3S), 1H, d, J 3.5 Hz, NH2CH), 3.64 ((2S, 3S), 1H, d, J 4.0 Hz, NH2CH), 
2.10 - 1.88 ((2S, 3S), 1H, m, CHCH3; (2R, 3S), 1H, m, CHCH3), 1.51 - 1.16 ((2S, 
3S), 2H, m, CH2CH3; (2R, 3S), 2H, m, CH2CH3), 1.03 - 0.86 ((2S, 3S), 6H, m, 2 x 
CH3; (2R, 3S), 6H, m, 2 x CH3); δH (700 MHz, DMSO-d6) 7.27 ((2S, 3S), 1H, br. s., 
CO2H; (2R, 3S), 1H, br. s., CO2H), 4.64 - 4.50 ((2S, 3S), 2H, m, NH2CH; (2R, 3S), 
2H, m, NH2CH), 3.08 ((2R, 3S), 1H, d, J 2.9 Hz, NHCH), 3.05 ((2S, 3S), 1H, d, J 3.2 
Hz, NHCH) 1.98 - 1.86 ((2R, 3S), 1H, m, CHCH3), 1.85 - 1.73 ((2S, 3S), 1H, m, 
CHCH3), 1.54 - 1.32 ((2S, 3S), 1H, m, CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3), 
1.22 - 1.12 ((2S, 3S), 1H, m, CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3), 0.90 - 0.75 
((2S, 3S), 6H, m, CHCH3, CHCH2CH3; (2R, 3S), 6H, m, CHCH3, CHCH2CH3); δC 
(100 MHz, D2O) 171.5 ((2S, 3S), CO2H; (2R, 3S), CO2H), 57.2, 56.8 ((2S, 3S), 
CHNH; (2R, 3S), CHNH), 35.7,  35.3 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 25.0, 
24.7 ((2S, 3S), CH2CH3; (2R, 3S), CH2CH3), 14.1, 13.3 ((2S, 3S), CHCH3; (2R, 3S), 
CHCH3) 10.9, 10.8 ((2S, 3S), CH2CH3; (2R, 3S), CH2CH3); m/z (ESI+) 132.1 
([M+H+], 100%). 
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L-Isoleucine methyl ester hydrochloride and D-allo-isoleucine methyl ester 
hydrochloride 3.12 
Acetyl chloride (4.5 mL, 63 mmol) was added dropwise to stirred and cooled MeOH 
(30 ml) to give a solution of methanolic hydrochloric acid. To this was added a 
mixture of L-isoleucine and D-allo-isoleucine 3.11 (76:24 mix of (2S, 3S) and (2R, 
3S) diastereomers, calculated by 1H NMR; 1.9 g, 16 mmol) and the reaction mixture 
was heated to reflux for 18 hours. The resulting clear, colourless solution was 
concentrated in vacuo to give the methyl ester hydrochloride salt (2.8 g, 99%, 67:33 
mix of (2S, 3S) and (2R, 3S) diastereomers, calculated by 1H NMR); υ
 max/cm-1(neat) 
2963 (br. NH), 1742 (C=O); δH (400 MHz, CD3OD) 4.04 ((2R, 3S), 1H, J 4.0 Hz, 
NH3CH), 4.02 ((2S, 3S), 1H, d, J 4.0 Hz, NH3CH), 3.85 ((2S, 3S), 3H, s, OCH3; (2R, 
3S), 3H, s, OCH3), 2.10 - 1.96 ((2S, 3S), 1H, m, CHCH3; (2R, 3S), 1H, m, CHCH3), 
1.68 - 1.46 ((2S, 3S), 1H, m, CH2CH3; (2R, 3S), 1H, m, CH2CH3), 1.47 - 1.23 ((2S, 
3S), 1H, m, CH2CH3; (2R, 3S), 1H, m, CH2CH3), 1.03 ((2R, 3S), 3H, d, J 7.0 Hz, 
CHCH3), 1.02 ((2S, 3S), 1H, d, J 7.0 Hz, CHCH3), 1.00 ((2S, 3S), 3H, t, J 7.5 Hz, 
CH2CH3; (2S, 3S), 3H, t, J 7.5 Hz, CH2CH3); δH (700 MHz, DMSO-d6) 8.55 ((2S, 
3S), 3H, br. s., NH3CH; (2R, 3S), 3H, br. s., NH3CH), 3.92 ((2R, 3S), 1H, d, J 3.8 Hz, 
NH3CH), 3.90 ((2S, 3S), 1H, d, J 4.2 Hz, NH3CH), 3.78 - 3.71 ((2S, 3S), 3H, m, 
OCH3; (2R, 3S), 3H, m, OCH3), 1.98 - 1.87 ((2S, 3S), 1H, m, CHCH3; (2R, 3S), 1H, 
m, CHCH3), 1.53 ((2R, 3S), 1H, dquin, J 13.1, 6.7 Hz, CHCH2CH3), 1.46 ((2S, 3S), 
1H, dquin, J 13.6, 6.8 Hz, CHCH2CH3), 1.27 ((2S, 3S), 1H, dquin, J 15.4, 7.7 Hz, 
CHCH2CH3), 1.11 ((2R, 3S), 1H, dqd, J 14.7, 7.7, 5.8 Hz, CHCH2CH3), 0.95 - 0.85 
((2S, 3S), 6H, m, CHCH2CH3, CHCH3; (2R, 3S), 6H, m, CHCH2CH3, CHCH3); δC 
(100 MHz, CD3OD) 170.2 ((2S, 3S), CO2CH3; (2R, 3S), CO2CH3),  58.2,  ((2S, 3S), 
NH3CH; (2R, 3S), NH3CH), 53.7 ((2S, 3S), OCH3; (2R, 3S), OCH3), 37.9, 37.5 ((2S, 
3S), CHCH3; (2R, 3S), CHCH3), 26.8, 26.3 ((2S, 3S), CH2CH3; (2R, 3S), CH2CH3), 
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15.0, 14.9 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 12.1 ((2S, 3S), CH2CH3; (2R, 3S), 
CH2CH3); m/z (ESI+) 146.1 ([M+H], 100%); HR-ESIMS: calculated for C7H17NO2: 
146.1176, found 146.1176 [M-Cl]+. 
L-Isoleucine methyl ester hydrochloride 3.13 
Acetyl chloride (15.6 mL, 220 mmol) was added dropwise to stirred and cooled 
MeOH (100 ml) to give a solution of methanolic hydrochloric acid. To this was 
added L-isoleucine (6.54 g, 54.9 mmol) and the reaction mixture was heated to reflux 
for 18 hours. The resulting clear, colourless solution was concentrated in vacuo to 
give the methyl ester hydrochloride salt as a sticky white gum (9.91 g, 54.6 mmol, 
99%); υ
 max/cm-1(neat) 2940 (br. N-H), 1736 (C=O); 25][ Dα  +35.8 (c = 0.98, MeOH), 
(lit.8 20][ Dα  +37.8 (c = 2.0, MeOH)) δH (400 MHz, CD3OD) 4.02 (1H, d, J 4.0 Hz, 
CHNH3), 3.84 (3H, s, OCH3), 2.16 - 1.89 (1H, m, CHCH3), 1.67 - 1.48 (1H, m, 
CH2CH3), 1.46 - 1.26  (1H, m, CH2CH3), 1.02 (3H, d, J 7.0 Hz, CHCH3), 0.99 (3H, 
t, J 7.5 Hz, CH2CH3); δH (700 MHz, DMSO-d6) 8.52 (3H, br. s., NH3CH), 3.91 (1H, 
d, J 4.2 Hz, NH3CH), 3.75 (3H, s, OCH3), 1.96 - 1.86 (1H, m, CHCH3), 1.46 (1H, 
dquin, J 13.5, 7.1 Hz, CHCH2CH3), 1.27 (1H, dquin, J 14.7, 7.4 Hz, CHCH2CH3), 
0.94 - 0.84 (6H, CHCH3, CHCH2CH3);  δC (100 MHz, CD3OD) 170.2 (CO2CH3), 
58.2 (NH3CH), 53.3 (OCH3), 37.7 (CHCH3), 26.6 (CH2CH3), 14.9 (CHCH3), 11.9 
(CH2CH3); m/z (ESI+) 146.1 ([M-Cl], 100%); HR-ESIMS: calculated for C7H17NO2: 
146.1176, found 146.1177 [M-Cl]+. The data are consistent with that previously 
reported.8  
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Octanoyl glycine 3.14 
A solution of octanoyl chloride (17.0 mL, 99.6 mmol) in THF (100 mL) was added 
dropwise to a stirred solution of glycine (9.0 g, 120 mmol), KOH (6.73 g, 120 mmol) 
and K2CO3 (16.6 g, 120 mmol) in water (250 mL). The reaction mixture was stirred 
at room temperature for 72 hours. The reaction mixture was acidified with conc. 
H2SO4 (~10.7 mL) and water (100 mL) was added. The reaction mixture was 
reduced in vacuo and filtered. The filtercake was washed with water (4 x 100 mL) 
and dried under vacuum to give a bright white powdery solid (17.2 g, 85.7 mmol, 
86%); m.p. 105-106 °C (lit.9 103 - 105 °C); υ max/cm-1 (neat) 3310 (N-H), 1708 (acid 
C=O), 1641 (amide C=O), 1543 (N-H); δH (400 MHz, CDCl3) 6.14 (1H, br. s., 
NHCH2), 4.09 (2H, d, J 5.0 Hz, NHCH2), 2.28 (2H, t, J 7.5 Hz, CH2CONH), 1.65 
(2H, quin, J 7.5 Hz, CH2CH2CONH), 1.38 - 1.22 (8H, m, 4 x CH2), 0.89 (3H, t, J 6.5 
Hz, CH3); δC (100 MHz, CDCl3) 173.1, 172.8 (CONH, CO2H), 41.5 (NHCH2), 36.3 
(CH2CONH), 31.7, 29.2, 29.0 (3 x CH2), 25.5 (CH2CH2CONH), 22.6 (CH2), 14.1 
(CH3); m/z (ESI+) 224.0 ([M+Na]; HR-ESIMS: calculated for C10H19NO3Na: 
224.1257, found 224.1255 [M+Na]+. The data are consistent with that previously 
reported.10 
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Octanoylglycyl-L-isoleucine methyl ester 3.15 
A solution of L-isoleucine methyl ester hydrochloride 3.13 (6.9 g, 38.1 mmol) and 
N-methylmorpholine (4.1 mL, 38.1 mmol) in EtOH (75 mL) was added dropwise to 
a solution of octanoyl-glycine (7.45 g, 37.0 mmol) and HOBt (88%, 0.85 g, 5.55 
mmol) in EtOH (100 mL). The reaction mixture was cooled to 0 - 5 °C and N-
methylmorpholine (8.2 mL, 81.4 mmol) was added. The reaction mixture was stirred 
at 0-5 °C for 15 minutes, EDCI (8.49 g, 44.4 mmol) was added and the reaction 
allowed to reach room temperature overnight. The reaction was acidified with pH 2 
buffer and filtered. The filtrate was reduced in vacuo and EtOAc (200 mL) was 
added. The phases were separated and the organic phase was washed with pH 2 
buffer (100 mL), water (100 mL), saturated aqueous NaHCO3 solution (100 mL) and 
saturated aqueous NaCl solution (100 mL), dried over Na2SO4 and concentrated in 
vacuo. The dipeptide was obtained by silica chromatograohy (EtOAc) as a white low 
melting point solid (5.7 g, 17.3 mmol, 47%); 25][ Dα -9.47 (c = 1.0, MeOH); υ max/cm-1 
(neat) 3296 (N-H), 1744 (ester C=O), 1640 (amide C=O), 1534 (N-H);  δH (400 
MHz, CDCl3) 7.24 (1H, d, J 8.5 Hz, NHCH), 6.76 (1H, t, J 5.0 Hz, NHCH2), 4.52 
(1H, dd, J 8.0, 5.0 Hz, NHCH), 4.00 (2H, d, J 5.0 Hz, NHCH2), 3.71 (3H, s, OCH3), 
2.22 (2H, t, J 8.0 Hz, COCH2H2), 1.94 - 1.83 (1H, m, Ile CHCH3), 1.61 (2H, quin, J 
7.5 Hz, CH2CH2CONH), 1.41 (1H, dqd, J 13.0, 7.5, 5.0 Hz, Ile CH2CH3), 1.35 - 1.12 
(9H, m, Ile CH2CH3, 4 x CH2), 0.90 (3H, d, J 7.0 Hz, Ile CHCH3), 0.88 - 0.83 (6H, 
m, Ile CH2CH3, CH2CH3); δH (700 MHz, DMSO-d6) 8.08 (1H, d, J 7.9 Hz, NHCH), 
7.98 (1H, t, J 5.7 Hz, NHCH2), 4.23 (1H, dd, J 8.1, 6.4 Hz, NHCH), 3.75 (1H, dd, J 
16.3, 5.7 Hz, NHCH2), 3.71 (1H, dd, J 16.7, 6.2 Hz, NHCH2), 3.67 - 3.62 (3H, m, 
OCH3), 2.10 (2H, t, J 7.3 Hz, NHCOCH2), 1.80 – 1.74 (1H, m, CHCH3), 1.47 (2H, 
quin, J 7.3 Hz, COCH2CH2), 1.38 (1H, dqd, J 14.9, 7.5, 4.2 Hz, CHCH2CH3), 1.30 - 
1.19 (8H, m, 4 x CH2), 1.19 - 1.12 (1H, m, CHCH2CH3), 0.87 - 0.81 (9H, m, 
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CHCH3, CHCH2CH3, CH2CH2CH3); δH (700 MHz, CD3OD)  4.41 (1H, d, J 5.7 Hz, 
NHCH), 3.92 (1H, d, J 16.7 Hz, NHCH2), 3.85 (1H, d, J 16.7 Hz, NHCH2), 3.71 
(3H, s, OCH3), 2.25 (2H, t, J 7.7 Hz, CH2CH2CO), 1.91 - 1.85 (1H, m, CHCH3), 
1.62 (2H, quin, J 7.4 Hz, COCH2CH2), 1.47 (1H, dqd, J 15.0, 7.4, 4.6 Hz, 
CHCH2CH3), 1.35 - 1.27 (8H, m, 4 x CH2), 1.26 - 1.19 (1H, m, CHCH2CH3), 0.95 - 
0.87 (9H, m, CHCH3, CHCH2CH3, CH2CH2CH3) δC (100 MHz, CDCl3) 174.0 
(CH2CH2CONH), 172.1 (CO2Me), 169.3 (HNCH2CONH), 56.7 (Ile NHCH), 52.1 
(OCH3), 43.3 (CH2CH2CONH), 37.6 (CHCH3), 36.3 (NHCH2CONH), 31.7, 29.3, 
29.0 (3 x CH2), 25.7, 25.3, 22.6 (CH2CH2CONH, CHCH2CH3, CH2), 15.5, 14.1 
(CH2CH2CH3, CHCH3), 11.5 (CHCH2CH3); m/z (ESI+) 351.2 ([M+Na]; HR-
ESIMS: calculated for C17H32N2O4Na: 351.2254, found 351.2252 [M+Na]+. 
Octanoylglycyl-L-isoleucine methyl ester and octanoylglycyl-D-allo-isoleucine 
methyl ester 3.17 
Prepared as for the single diastereomer, using a mix of L- and D-alloisoleucine 
methyl ester 3.12 (2.76 g, 15.2 mmol) and octanoylglycine (2.98 g, 14.8 mmol) to 
give dipeptide 3.17 as a clear oil (1.61 g, 4.90 mmol, 33 %, 76:24  mix of (2S, 3S) 
and (2R, 3S) diastereomers, calculated by 1H NMR); υ max/cm-1 (neat) 3297 (N-H), 
1744 (ester C=O), 1641 (amide C=O), 1533 (N-H); δH (400 MHz, CDCl3) 7.17 ((2S, 
3S), 1H, d, J 8.5 Hz, NHCH), 7.13 ((2R, 3S), 1H, d, J 9.5 Hz, NHCH), 6.73 - 6.66 
((2S, 3S), 1H, m, NHCH2; (2R, 3S), 1H, m, NHCH2), 4.64 ((2R, 3S), 1H, dd, J 9.0, 
4.5 Hz, NHCH), 4.53 ((2S, 3S), 1H, dd, J 8.5, 5.0 Hz, NHCH), 4.03 - 3.98 ((2S, 3S), 
2H, m, NHCH2; (2R, 3S), 2H, m, NHCH2), 3.72 ((2S, 3S), 3H, s, OCH3; (2R, 3S), 
3H, s, OCH3), 2.23 ((2S, 3S), 2H, t, J 7.5 Hz, CH2CH2CONH; (2R, 3S), 2H, t, J 7.5 
Hz, CH2CH2CONH), 1.99 - 1.84 ((2S, 3S), 1H, m, CHCH3; (2R, 3S), 1H, m, 
CHCH3), 1.62 ((2S, 3S), 2H, quin, J 7.5 Hz, CH2CH2CONH; (2R, 3S), 2H, quin, J 
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7.5 Hz, CH2CH2CONH), 1.47 - 1.34 ((2S, 3S), 1H, m, CHCH2CH3; (2R, 3S), 1H, m, 
CHCH2CH3), 1.33 - 1.23 ((2S, 3S), 9H, m, 4 x CH2, CHCH2CH3; (2R, 3S), 9H, m, 4 
x CH2, CHCH2CH3), 0.94 - 0.84 ((2S, 3S), 9H, m, (CH2)2CH3, CHCH3, CHCH2CH3; 
(2R, 3S), 9H, m, (CH2)2CH3, CHCH3, CHCH2CH3); δH (700 MHz, DMSO-d6) 8.08 
((2S, 3S), 1H, d, J 8.4 Hz, NHCH), 8.02 - 7.95 ((2S, 3S), 1H, m, NHCH2; (2R, 3S), 
2H, m, NHCH, NHCH2), 4.39 ((2R, 3S), 1H, dd, J 8.6, 5.1 Hz, NHCH), 4.23 ((2S, 
3S), 1H, dd, J 8.4, 6.6 Hz, NHCH), 3.79 - 3.68 ((2S, 3S), 2H, m, NHCH2; (2R, 3S), 
2H, m, NHCH2), 3.65 - 3.61 ((2S, 3S), 3H, m, OCH3; (2R, 3S), 3H, m, OCH3), 2.13 - 
2.06 ((2S, 3S), 2H, m, CH2CH2CO; (2R, 3S), 2H, m, CH2CH2CO), 1.87 - 1.80 ((2R, 
3S), 1H, m, CHCH3), 1.80 – 1.74 ((2S, 3S), 1H, m, CHCH3), 1.48 ((2S, 3S), 2H, 
quin, J 6.9 Hz, CH2CH2CONH; (2R, 3S), 2H, quin, J 6.9 Hz, CH2CH2CONH), 1.38 
((2S, 3S), 1H, dqd, J 15.0, 7.5, 4.4 Hz, CHCH2CH3), 1.30 - 1.19 ((2S, 3S), 8H, m, 4 x 
CH2; (2R, 3S), 9H, m, CHCH2CH3, 4 x CH2), 1.19 - 1.08 ((2S, 3S), 1H, m, 
CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3), 0.87 - 0.81 ((2S, 3S), 9H, m, 
CH2CH2CH3, CHCH3, CHCH2CH3; (2R, 3S), 9H, m, CH2CH2CH3, CHCH3, 
CHCH2CH3); δH (700 MHz, CD3OD) 4.56 ((2R, 3S), 1H, d, J 4.5 Hz, NHCH), 4.42 
((2S, 3S), 1H, d, J 6.2 Hz, NHCH), 3.95 - 3.83 ((2S, 3S), 2H, m, NHCH2; (2R, 3S), 
2H, m, NHCH2), 3.72 ((2R, 3S), 3H, s, OCH3) 3.71 ((2S, 3S), 3H, s, OCH3),  2.26 
((2S, 3S),  2H, t, J 7.5 Hz, CH2CH2CO; (2R, 3S),  2H, t, J 7.5 Hz, CH2CH2CO), 2.00 
- 1.92 ((2R, 3S), 1H, m, CHCH3),  1.91 - 1.84 ((2S, 3S), 1H, m, CHCH3), 1.62 ((2S, 
3S), 2H, quin, J 7.4 Hz, CH2CH2CO; (2R, 3S), 2H, quin, J 7.4 Hz, CH2CH2CO), 1.47 
((2S, 3S), 1H, dqd, J 13.6, 7.5, 4.4 Hz, CHCH2CH3) 1.43 - 1.37 ((2R, 3S), 1H, m, 
CHCH2CH3), 1.36 - 1.27 ((2S, 3S), 8H, m, 4 x CH2; (2R, 3S), 9H, m, 4 x CH2, 
CHCH2CH3), 1.25 - 1.17 ((2S, 3S), 1H, m, CHCH2CH3) 0.96 - 0.88 ((2S, 3S), 9H, m, 
3 x CH3; (2R, 3S), 9H, m, 3 x CH3); δC (100 MHz, CDCl3) 174.0 ((2S, 3S), 
CH2CH2CONH; (2R, 3S), CH2CH2CONH), 172.4, 172.1 ((2S, 3S), CO2Me; (2R, 3S), 
CO2Me), 169.5, 169.3 ((2S, 3S), NHCH2CONH; (2R, 3S), NHCH2CONH), 56.7, 
55.6 ((2S, 3S), NHCH; (2R, 3S), NHCH), 52.2, 52.1 ((2S, 3S), OCH3; (2R, 3S), 
OCH3), 43.4, 43.3 ((2S, 3S), NHCH2CONH; (2R, 3S), NHCH2CONH), 37.6, 37.4 
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((2S, 3S), CHCH3; (2R, 3S), CHCH3), 36.4 ((2S, 3S), CH2CH2CONH; (2R, 3S), 
CH2CH2CONH), 31.7, 29.3, 29.0 ((2S, 3S), CH2; (2R, 3S), CH2), 25.7, 25.7, 25.0, 
22.6 ((2S, 3S), CH2CH2CONH, CHCH2CH3, CH2; (2R, 3S), CH2CH2CONH, 
CHCH2CH3, CH2), 15.5, 14.6, 14.1 ((2S, 3S), (CH2)2CH3, CHCH3; (2R, 3S), 
(CH2)2CH3, CHCH3), 11.7, 11.5 ((2S, 3S), CHCH2CH3; (2R, 3S), CHCH2CH3); m/z 
(ESI+) 351.2 ([M+Na]; HR-ESIMS: calculated for C17H32N2O4Na: 351.2254, found 
351.2253 [M+Na]+. 
Octanoylglycyl-L-isoleucine 3.16 
LiOH (1.66 g, 69.2 mmol) was added to a biphasic solution of the dipeptide 3.15 
(5.70 g, 17.3 mmol) in THF (30 mL) and water (30 mL), and the mixture was stirred 
at room temperature for 4 hours. The reaction mixture was acidified and reduced in 
vacuo. EtOAc (100 mL) was added and the phases were separated. The aqueous 
phase was further extracted with EtOAc (4 x 10 mL), and the combined organics 
were washed with water (50 mL) and saturated aqueous NaCl solution (50 mL), 
dried over Na2SO4 and concentrated in vacuo to give the acid as a bright white solid 
(4.51 g, 14.3 mmol, 83 %); m.p. 98 - 99 °C; 25][ Dα +7.01 (c = 2.0, MeOH)) υ max/cm-1 
(neat) 3297 (N-H), 1717 (acid C=O), 1640 (amide C=O), 1519 (N-H); δH (400 MHz, 
CDCl3) 9.72 (1H, br. s., CO2H), 7.37 (1H, d, J 8.5 Hz, NHCH), 7.13 (1H, t, J 5.0 Hz, 
NHCH2), 4.53 (1H, dd, J 8.5, 5.0 Hz, NHCH), 4.10 (1H, dd, J 16.5, 5.5 Hz, 
NHCH2), 3.98 (1H, dd, J 16.5, 5.0 Hz, NHCH2), 2.25 (2H, t, J 8.0 Hz, CH2CH2CO), 
2.00 - 1.87 (1H, m, CHCH3), 1.67 - 1.57 (2H, m, CH2CH2CO), 1.56 - 1.42 (1H, m, 
CHCH2CH3), 1.34 - 1.14 (9H, m, CHCH2CH3, 4 x CH2), 0.96 - 0.84 (9H, m, 
CHCH2CH3, CHCH3, CH2CH2CH3); δH (700 MHz, DMSO-d6) 12.63 (1H, br. s., 
CO2H), 8.00 (1H, t, J 5.9 Hz, NHCH2), 7.87 (1H, d, J 8.8 Hz, NHCH), 4.19 (1H, dd, 
J 8.6, 5.9 Hz, NHCH), 3.75 (1H, dd, J 16.7, 5.7 Hz, NHCH2), 3.71 (1H, dd, J 15.8, 
5.7 Hz, NHCH2), 2.10 (2H, t, J 7.5 Hz, COCH2CH2), 1.82 - 1.73 (2H, m, CHCH3), 
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1.48 (2H, quin, J 7.2 Hz, COCH2CH2), 1.39 (1H, dqd, J 15.0, 7.5, 4.8 Hz, 
CHCH2CH3), 1.30 - 1.19 (8H, m, 4 x CH2), 1.19 - 1.11 (1H, m, CHCH2CH3), 0.87 - 
0.82 (9H, m, CH2CH2CH3, CHCH3, CHCH2CH3); δH (700 MHz, CD3OD) 4.40 (1H, 
d, J 5.3 Hz, NHCH), 3.93 (1H, d, J 16.3 Hz, NHCH2), 3.86 (1H, d, J 16.7 Hz, 
NHCH2), 2.26 (2H, t, J 7.5 Hz, COCH2CH2), 1.95 - 1.86 (1H, m, CHCH3), 1.67 - 
1.58 (2H, m, COCH2CH2), 1.55 - 1.48 (1H, m, CHCH2CH3), 1.37 - 1.27 (8H, m, 4 x 
CH2), 1.26 - 1.18 (1H, m, CHCH2CH3), 0.96 - 0.85 (9H, m, CHCH2CH3, CHCH3, 
CH2CH2CH3); δC (100 MHz, CDCl3) 174.9, 174.4 (2 x CONH), 169.9 (CO2H), 56.9 
(CHNH), 43.1 (NHCH2), 37.4 (CHCH3), 36.3 (CH2CH2CO), 31.7, 29.2, 29.0, 25.7, 
25.0, 22.6 (CHCH2CH3, 5 x CH2), 15.4, 14.1, 11.6 (2 x CH2CH3, CHCH3); m/z 
(ESI+) 337.1 ([M+Na]; HR-ESIMS: calculated for C16H30N2O4Na: 337.2098, found 
337.2097 [M+Na]+. 
Octanoylglycyl-L-isoleucine and octanoylglycyl-D-allo-isoleucine 3.18 
Prepared as for the single diastereomer, using a mix of L- and D-allo-isoleucine 
dipeptide 3.17 (1.61 g, 4.89 mmol) to give the acid as a bright white solid (1.34 g, 
4.26 mmol, 87 %, 70:30  mix of (2S, 3S) and (2R, 3S) diastereomers, calculated by 
1H NMR); υmax /cm-1 (neat) 3285 (N-H), 1718 (acid C=O), 1636 (amide C=O), 1557 
(N-H); δH (400 MHz, DMSO-d6) 12.63 ((2S, 3S), 1H, br. s., CO2H; (2R, 3S), 1H, br. 
s., CO2H), 8.06 - 7.96 ((2S, 3S), 1H, m, NHCH2; (2R, 3S), 1H, m, NHCH2), 7.86 
((2S, 3S), 1H, d, J 8.5 Hz, NHCH), 7.79 ((2R, 3S), 1H, d, J 9.0 Hz, NHCH), 4.35 
((2R, 3S), 1H, dd, J 8.5, 4.5 Hz, NHCH), 4.19 ((2S, 3S), 1H, dd, J 8.5, 6.0 Hz, 
NHCH), 3.80 - 3.67 ((2S, 3S), 2H, m, NHCH2; (2R, 3S), 2H, m, NHCH2), 2.10 ((2S, 
3S), 2H, t, J 7.5 Hz, CH2CH2CO; (2R, 3S), 2H, t, J 7.5 Hz, CH2CH2CO), 1.90 - 1.70 
((2S, 3S), 1H, m, CHCH3; (2R, 3S), 1H, m, CHCH3), 1.48 ((2S, 3S), 2H, quin, J 7.5 
Hz, CH2CH2CO; (2R, 3S), 2H, quin, J 7.5 Hz, CH2CH2CO), 1.43 - 1.33 ((2S, 3S), 
1H, m, CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3), 1.31 - 1.20 ((2S, 3S), 8H, m, 4 x 
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CH2; (2R, 3S), 8H, m, 4 x CH2), 1.19 - 1.04 ((2S, 3S), 1H, m, CHCH2CH3; (2R, 3S), 
1H, m, CHCH2CH3), 0.89 - 0.80 ((2S, 3S), 9H, m, CH2CH2CH3, CHCH3, 
CHCH2CH3; (2R, 3S), 9H, m, CH2CH2CH3, CHCH3, CHCH2CH3); δH (700 MHz, 
DMSO-d6) 12.65 ((2S, 3S), 1H, br. s., CO2H; (2R, 3S), 1H, br. s., CO2H), 8.03 - 7.99 
((2S, 3S), 1H, m, NHCH2; (2R, 3S), 1H, m, NHCH2), 7.87 ((2S, 3S), 1H, d, J 8.8 Hz, 
NHCH), 7.79 ((2R, 3S), 1H, d, J 8.8 Hz, NHCH), 4.36 ((2R, 3S), 1H, dd, J 8.8, 4.4 
Hz, NHCH), 4.19 ((2S, 3S), 1H, dd, J 8.6, 5.9 Hz, NHCH), 3.78- 3.68 ((2S, 3S), 2H, 
m, NHCH2; (2R, 3S), 2H, m, NHCH2), 2.10 ((2S, 3S), 2H, t, J 7.5 Hz, COCH2CH2; 
(2R, 3S), 2H, t, J 7.5 Hz, COCH2CH2), 1.88 - 1.82 ((2R, 3S), 1H, m, CHCH3), 1.80 - 
1.72 ((2S, 3S), 1H, m, CHCH3), 1.48 ((2S, 3S), 2H, quin, J 7.0 Hz, COCH2CH2; (2R, 
3S), 2H, quin, J 7.0 Hz, COCH2CH2), 1.39 ((2S, 3S), 1H, dqd, J 15.0, 7.5, 4.6 Hz, 
CHCH2CH3; (2R, 3S), 1H, dqd, J 15.0, 7.5, 4.6 Hz, CHCH2CH3), 1.31 - 1.19 ((2S, 
3S), 8H, 4 x CH2; (2R, 3S), 8H, 4 x CH2), 1.19 - 1.10 ((2S, 3S), 1H, m, CHCH2CH3; 
(2R, 3S), 1H, m, CHCH2CH3), 0.90 - 0.81 ((2S, 3S), 9H, CH2CH2CH3, CHCH3, 
CHCH2CH3; (2R, 3S), 9H, CH2CH2CH3, CHCH3, CHCH2CH3); δH (700 MHz, 
CD3OD) 4.55 ((2R, 3S), 1H, d, J 4.0 Hz, NHCH), 4.40 ((2S, 3S), 1H, d, J 5.3 Hz, 
NHCH), 3.96 - 3.90 ((2S, 3S), 1H, m, NHCH2; (2R, 3S), 1H, m, NHCH2), 3.89 - 3.84 
((2S, 3S), 1H, m, NHCH2; (2R, 3S), 1H, m, NHCH2), 2.26 ((2S, 3S), 2H, t, J 7.5 Hz, 
COCH2CH2; (2R, 3S), 2H, t, J 7.5 Hz, COCH2CH2), 2.01 - 1.95 ((2R, 3S), 1H, m, 
CHCH3), 1.93 - 1.87 ((2S, 3S), 1H, m, CHCH3), 1.63 ((2S, 3S), 2H, quin, J 7.4 Hz, 
COCH2CH2; (2R, 3S), 2H, quin, J 7.4 Hz, COCH2CH2), 1.51 ((2S, 3S), 1H, dqd, J 
15.0, 7.5 Hz, 4.4 Hz, CHCH2CH3), 1.42 ((2R, 3S), 1H, dquin, J 14.1, 7.2 Hz, 
CHCH2CH3), 1.37 - 1.27 ((2S, 3S), 8H, m, 4 x CH2; (2R, 3S), 8H, m, 4 x CH2), 1.26 
- 1.19 ((2S, 3S), 1H, m, CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3), 0.97 - 0.88 ((2S, 
3S), 9H, m, CH2CH2CH3, CHCH3, CHCH2CH3; (2R, 3S), 9H, m, CH2CH2CH3, 
CHCH3, CHCH2CH3); δH (700 MHz, CDCl3)  7.22 ((2S, 3S), 1H, d, J 7.5 Hz, 
NHCH; (2R, 3S), 1H, d, J 7.5 Hz, NHCH), 6.84 ((2S, 3S), 1H, br. s., NHCH2; (2R, 
3S), 1H, br. s., NHCH2), 4.67 ((2R, 3S), 1H, dd, J 8.5, 3.5 Hz, NHCH), 4.53 ((2S, 
3S), 1H, dd, J 7.0, 5.3 Hz, NHCH), 4.19 ((2S, 3S), 1H, dd, J 16.7, 5.3 Hz, NHCH2; 
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(2R, 3S), 1H, dd, J 16.7, 5.3 Hz, NHCH2), 3.90 ((2S, 3S), 1H, dd, J 16.5, 4.6 Hz, 
NHCH2; (2R, 3S), 1H, dd, J 16.5, 4.6 Hz, NHCH2), 2.25 ((2S, 3S), 2H, t, J 7.5 Hz, 
CH2CH2CO; (2R, 3S), 2H, t, J 7.5 Hz, CH2CH2CO), 2.05 - 1.87 ((2S, 3S), 1H, m, 
CHCH3; (2R, 3S), 1H, m, CHCH3), 1.63 ((2S, 3S), 2H, quin., J 6.7 Hz, CH2CH2CO; 
(2R, 3S), 2H, quin., J 6.7 Hz, CH2CH2CO), 1.53 - 1.46 ((2S, 3S), 1H, m, 
CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3),  1.35 - 1.17 ((2S, 3S), 9H, m, 
CHCH2CH3, 4 x CH2; (2R, 3S), 9H, m, CHCH2CH3, 4 x CH2) 0.97 - 0.86 ((2S, 3S), 
9H, m, 3 x CH3; (2R, 3S), 9H, m, 3 x CH3); δC (100 MHz, DMSO) 174.3 ((2S, 3S), 
CH2CH2CONH; (2R, 3S), CH2CH2CONH), 172.8, 172.5 ((2S, 3S), CO2H; (2R, 3S), 
CO2H), 169.1 ((2S, 3S), NHCH2CONH; (2R, 3S), NHCH2CONH), 56.1 ((2S, 3S), 
NHCH), 54.6 ((2R, 3S), NHCH), 41.7 ((2S, 3S), CH2CH2CONH; (2R, 3S), 
CH2CH2CONH), 36.5 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 35.1 ((2S, 3S), 
NHCH2CONH; (2R, 3S), NHCH2 CONH), 31.1, 28.6, 28.5 ((2S, 3S), CH2; (2R, 3S), 
CH2), 25.7, 25.2, 24.6, 22.0 ((2S, 3S), CH2CH2CONH, CHCH2CH3, CH2; (2R, 3S), 
CH2CH2CONH, CHCH2CH3, CH2), 15.5, 14.7, 13.9 ((2S, 3S), (CH2)2CH3, CHCH3; 
(2R, 3S), (CH2)2CH3, CHCH3), 11.5, 11.3 ((2S, 3S), CHCH2CH3; (2R, 3S), 
CHCH2CH3); m/z (ESI+) 337.1 ([M+Na]; HR-ESIMS: calculated for C16H30N2O4Na: 
337.2098, found 337.2093 [M+Na]+. 
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S-((9H-Fluoren-9-yl)methyl)-(2S, 3S)-3-methyl-2-(2-
octanamidoacetamido)pentanethioate and  S-((9H-fluoren-9-yl)methyl)-(2R, 
3S)-3-methyl-2-(2-octanamidoacetamido)pentanethioate 3.19 
Method modified from literature procedure by Crich et al.1 4 Å Molecular sieves 
were added to a solution of 9-fluorenylmethylthiol (0.20 g, 0.94 mmol) and acid 3.16 
(0.23 g, 0.72 mmol) in DMF (12 mL), and the mixture was stirred at - 20 °C for 20 
minutes. PyBOP (0.94 g, 1.82 mmol) and diisopropylethylamine (0.30 mL, 1.82 
mmol) were added and the reaction mixture stirred at -20 °C for 4 hours. The 
reaction mixture was filtered, quenched with pH 2 buffer (15 mL) and extracted with 
CH2Cl2 (3 x 20 mL). The combined organics were concentrated in vacuo. EtOAc (15 
mL) and pH 2 buffer (10 mL) were added and the phases were separated. The 
organics were washed with pH 2 buffer (10 mL), water (3 x 10 mL), saturated 
aqueous NaHCO3 solution (10mL) and saturated aqueous NaCl solution (10 mL), 
dried over Na2SO4 and concentrated in vacuo (88: 12  mix of (2S, 3S) and (2R, 3S) 
diastereomers in crude product, calculated by 1H NMR). The thioester 3.19 was 
obtained by silica column chromatography (0 - 2% MeOH: CH2Cl2) as a white solid 
(87 mg, 0.17 mmol, 28 %, 80: 20  mix of (2S, 3S) and (2R, 3S) diastereomers, 
calculated by 1H NMR); υ max/cm-1 (neat) 3261 (N-H), 1689 (C=O), 1672, 1632 
(amide C=O), 1521 (N-H); δH (400 MHz, CDCl3) 7.73 ((2S, 3S), 2H, d, J 7.5 Hz, 2 x 
Ar CH; (2R, 3S), 2H, d, J 7.5 Hz, 2 x Ar CH), 7.60 ((2S, 3S), 2H, t, J 7.0 Hz, 2 x Ar 
CH; (2R, 3S), 2H, t, J 7.0 Hz, 2 x Ar CH), 7.42 - 7.35 ((2S, 3S), 2H, m, 2 x Ar CH; 
(2R, 3S), 2H, m, 2 x Ar CH), 7.33 – 7.27 ((2S, 3S), 2H, m, 2 x Ar CH; (2R, 3S), 2H, 
m, 2 x Ar CH), 6.95 - 6.87 ((2S, 3S), 1H, m, NHCH; (2R, 3S), 1H, m, NHCH), 6.44 - 
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6.36 ((2S, 3S), 1H, m, NHCH2; (2R, 3S), 1H, m, NHCH2), 4.65 ((2R, 3S), 1H, dd, J 
9.0, 4.0 Hz), 4.53 ((2S, 3S), 1H, dd, J 8.5, 5.0 Hz, NHCH), 4.17 ((2S, 3S), 1H, t, J 
5.5 Hz, CHCH2S; (2R, 3S), 1H, t, J 5.5 Hz, CHCH2S), 4.06 - 3.89 ((2S, 3S), 2H, m, 
NHCH2; (2R, 3S), 2H, m, NHCH2), 3.63 - 3.52 ((2S, 3S), 2H, m, CHCH2S; (2R, 3S), 
2H, m, CHCH2S), 2.18 ((2S, 3S), 2H, t, J 8.0 Hz, CH2CH2CONH; (2R, 3S), 2H, t, J 
8.0 Hz, CH2CH2CONH), 2.00 - 1.84 ((2S, 3S), 1H, m, CHCH3; (2R, 3S), 1H, m, 
CHCH3), 1.61 ((2S, 3S), 2H, quin, J 7.0 Hz, CH2CH2CONH; (2R, 3S), 2H, quin, J 
7.0 Hz, CH2CH2CONH), 1.35 - 1.23 ((2S, 3S), 8H, m, 4 x CH2; (2R, 3S), 8H, m, 4 x 
CH2), 1.19 - 1.07 ((2S, 3S), 1H, m, CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3), 1.03 
- 0.91 ((2S, 3S), 1H, m, CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3), 0.91 - 0.57 ((2S, 
3S), 9H, m, CHCH3, CHCH2CH3, CH2CH2CH3; (2S, 3S), 9H, m, CHCH3, 
CHCH2CH3, CH2CH2CH3); δH (700 MHz, DMSO-d6) 8.11 ((2S, 3S), 1H, d, J 8.4 Hz, 
NHCH), 8.05 ((2R, 3S), 1H, d, J 8.4 Hz, NHCH), 7.97 - 7.92 ((2S, 3S), 2H, m, 
NHCH2; (2R, 3S), 2H, m, NHCH2), 7.86 -7.83 ((2S, 3S), 2H, m, 2 x Ar CH; (2R, 3S), 
2H, m, 2 x Ar CH), 7.65 - 7.57 ((2S, 3S), 2H, m, 2 x Ar CH; (2R, 3S), 2H, m, 2 x Ar 
CH), 7.40 - 7.36 ((2S, 3S), 2H, m, 2 x Ar CH; (2R, 3S), 2H, m, 2 x Ar CH), 7.33 - 
7.27 ((2S, 3S), 2H, m, 2 x Ar CH; (2R, 3S), 2H, m, 2 x Ar CH), 4.31 ((2R, 3S), 1H, 
dd, J 8.6, 5.1 Hz, NHCH), 4.29 - 4.26 ((2S, 3S), 2H, m, CHCH2S; (2R, 3S), 2H, m, 
CHCH2S), 4.15 ((2S, 3S), 1H, dd, J 8.4, 6.2 Hz, NHCH), 3.76 - 3.57 ((2S, 3S), 4H, 
m, CHCH2S, NHCH2; (2R, 3S), 4H, m, CHCH2S, NHCH2), 2.06 ((2S, 3S), 1H, t, J 
7.5 Hz, COCH2CH2; (2S, 3S), 1H, t, J 7.5 Hz, COCH2CH2), 1.71 - 1.64 ((2R, 3S), 
1H, m, CHCH3), 1.63 - 1.55 ((2S, 3S), 1H, m, CHCH3), 1.45 ((2S, 3S), 1H, dt, J 7.0 
Hz, COCH2CH2; (2R, 3S), 1H, quin., J 7.0 Hz, COCH2CH2), 1.28 - 1.18 ((2S, 3S), 
8H, m, 4 x CH2; (2R, 3S), 8H, m, 4 x CH2), 1.09 - 0.97 ((2S, 3S), 1H, m, 
CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3), 0.96 - 0.87 ((2S, 3S), 1H, m, 
CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3), 0.84 ((2S, 3S), 3H, t, J 7.0 Hz, 
CH2CH2CH3; (2R, 3S), 3H, t, J 7.0 Hz, CH2CH2CH3), 0.70 ((2R, 3S), 3H, t, J 7.5 Hz, 
CHCH2CH3), 0.67 ((2S, 3S), 3H, t, J 7.3 Hz, CHCH2CH3), 0.57 ((2S, 3S), 3H, d, J 
6.6 Hz, CHCH3), 0.52 ((2R, 3S), 3H, d, J 6.6 Hz, CHCH3); δH (700 MHz, CD3OD) 
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7.75 ((2S, 3S), 2H, d, 7.5 Hz, 2 x Ar CH; (2R, 3S), 2H, d, 7.5 Hz, 2 x Ar CH), 7.60 
((2S, 3S), 2H, t, 7.5 Hz, 2 x Ar CH; (2R, 3S), 2H, t, 7.5 Hz, 2 x Ar CH), 7.36 ((2S, 
3S), 2H, t, 7.3 Hz, 2 x Ar CH; (2R, 3S), 2H, t, 7.3 Hz, 2 x Ar CH), 7.31 - 7.23 ((2S, 
3S), 2H, m, 2 x Ar CH; (2R, 3S), 2H, m, 2 x Ar CH), 4.48 ((2R, 3S), 1H, d, J 4.8 Hz, 
NHCH), 4.33 ((2S, 3S), 1H, d, J 5.7 Hz, NHCH), 4.22 ((2S, 3S), 1H, t, J 4.8 Hz, 
SCHCH2; (2R, 3S), 1H, t, J 4.8 Hz, SCHCH2), 3.86 ((2S, 3S), 1H, dd, J 16.3, 10.6 
Hz, NHCH2; (2R, 3S), 1H, dd, J 16.3, 10.6 Hz, NHCH2), 3.81 - 3.76 ((2S, 3S), 1H, 
m, NHCH2; (2R, 3S), 1H, m, NHCH2), 3.75 - 3.70 ((2S, 3S), 1H, m, SCHCH2; (2R, 
3S), 1H, m, SCHCH2), 3.67 - 3.59 ((2S, 3S), 1H, m, SCHCH2; (2R, 3S), 1H, m, 
SCHCH2), 2.20 ((2S, 3S), 2H, t, J 7.5 Hz, COCH2CH2; (2R, 3S), 2H, t, J 7.5 Hz, 
COCH2CH2), 1.85 - 1.78 ((2R, 3S), 1H, m, CHCH3), 1.77 - 1.69 ((2S, 3S), 1H, m, 
CHCH3), 1.65 - 1.55 ((2S, 3S), 2H, m, COCH2CH2; (2R, 3S), 2H, m, COCH2CH2), 
1.38 - 1.24 ((2S, 3S), 8H, m, 4 x CH2; (2R, 3S), 8H, m, 4 x CH2), 1.20 - 1.12 ((2R, 
3S), 1H, m, CHCH2CH3), 1.13 - 1.00 ((2S, 3S), 1H, m, CHCH2CH3; (2R, 3S), 1H, m, 
CHCH2CH3), 0.98 - 0.92 ((2S, 3S), 1H, m, CHCH2CH3), 0.89 ((2S, 3S), 3H, t, J 7.0 
Hz, CH2CH2CH3; (2R, 3S), 3H, t, J 7.0 Hz, CH2CH2CH3), 0.81 ((2R, 3S), 3H, t, J 7.5 
Hz, CHCH2CH3), 0.76 ((2S, 3S), 3H, t, J 7.5 Hz, CHCH2CH3), 0.70 ((2S, 3S), 3H, d, 
J 7.0 Hz, CHCH3), 0.60 ((2R, 3S), 3H, d, J 7.0 Hz, CHCH3); δC (100 MHz, CDCl3) 
199.9, 198.3 ((2S, 3S), SCO; (2R, 3S), SCO), 174.2, 174.1 ((2S, 3S), CHNHCO; (2R, 
3S), CHNHCO), 169.7, 169.5 ((2S, 3S), CH2NHCO; (2R, 3S), CH2NHCO), 145.2, 
141.2, 141.2 ((2S, 3S), Ar C; (2R, 3S), Ar C), 127.7, 127.1, 124.7, 119.9 ((2S, 3S), Ar 
CH; (2R, 3S), Ar CH), 63.8, ((2S, 3S), NHCH), 62.3 ((2R, 3S), NHCH), 46.7 ((2S, 
3S), CHCH2S; (2R, 3S), CHCH2S), 43.7, 43.6 ((2S, 3S), NHCH2; (2R, 3S), NHCH2), 
37.5 ((2S, 3S), CHCHCH3; (2R, 3S), CHCHCH3), 36.3 ((2S, 3S), CH2CH2CO; (2R, 
3S), CH2CH2CO), 31.9, 31.7, 31.6, 29.3, 29.1, 26.4, 26.2, 26.1, 25.7, 24.1, 22.6 ((2S, 
3S), CH2CH2CO, CHCH2S, CH2; (2R, 3S), CH2CH2CO, CHCH2S, CH2), 15.5, 14.1, 
13.9 ((2S, 3S), CH2CH2CH3, CHCH3; (2R, 3S), CH2CH2CH3, CHCH3), 11.7 ((2S, 
3S), CHCH2CH3; (2R, 3S), CHCH2CH3); m/z (ESI+) 531.2 ([M+Na]; HR-ESIMS: 
calculated for C30H40N2O3SNa: 531.2652, found 531.2628 [M+Na]+. 
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This compound was also prepared using the same method using a mix of L-
isoleucine and D-allo-isoleucine dipeptide 3.18 (0.20 g, 0.64 mmol) to give the 
coupled product  3.20 as a bright white solid (38 mg, 0.075 mol, 12 %. 65: 35 mix of 
(2S, 3S) and (2R, 3S) diastereomers in crude product, calculated by 1H NMR; 61:39 
mix of (2S, 3S) and (2R, 3S) diastereomers following purification, calculated by 1H 
NMR); All characterisation data was identical to that obtained above.  
N-(Propyl)-(2S, 3S)-3-methyl-2-(2-octanamidoacetamido)pentaneamide 3.22 
Method modified from literature procedure by Crich et al.1 4 Å Molecular sieves 
were added to a solution of propylamine (0.09 mL, 1.34 mmol) and acid 3.17 (0.25 
g, 0.80 mmol) in DMF (14 mL), and the mixture was stirred at - 20 °C for 20 
minutes. PyBOP (1.0 g, 2.0 mmol) and diisopropylethylamine (0.33 mL, 2.0 mmol) 
were added and the reaction mixture stirred at - 20 °C for 4 hours. The reaction 
mixture was filtered, quenched with pH 2 buffer (15 mL) and extracted with CH2Cl2 
(3 x 20 mL). The combined organics were concentrated in vacuo. EtOAc (15 mL) 
and pH 2 buffer (10 mL) were added and the phases were separated. The organics 
were washed with pH 2 buffer (10 mL), water (3 x 10 mL), saturated aqueous 
NaHCO3 solution (10mL) and saturated aqueous NaCl solution (10 mL), dried over 
Na2SO4 and concentrated in vacuo (>99 % (2S, 3S) diastereomer in crude product, 
calculated by 400 MHz 1H NMR). The product was obtained by silica column 
chromatography (10% MeOH: CH2Cl2) to give 3.22 as a bright white solid (0.21g, 
0.59 mmol, 74 %; >99 % (2S, 3S) diastereomer, calculated by 400 MHz 1H NMR; 
>93 % (2S, 3S) diastereomer, calculated by 700 MHz 1H NMR); m.p. 151 - 153 °C; 
υ max/cm-1 (neat) 3294 (N-H), 1629 (C=O), 1532 (N-H); 25][ Dα -13.2 (c = 0.42, 
MeOH)), δH (400 MHz, DMSO-d6) 8.06 (1H, t, J 6.0 Hz, NHCH2CO), 7.98 (1H, t, J 
5.5 Hz, NHCH2CH2CH3), 7.72 (1H, d, J 8.5 Hz, NHCH), 4.12 (1H, dd, J 9.0 Hz, 7.5 
Hz, NHCH), 3.73 (1H, dd, J 16.5, 5.5 Hz, NHCH2), 3.67 (1H, dd, J 16.5, 5.5 Hz, 
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NHCH2), 3.12 - 2.89 (2H, m, NHCH2CH2CH3), 2.10 (2H, t, J 7.5 Hz, CH2CH2CO), 
1.71 - 1.61 (1H, m, CHCH3), 1.53 - 1.44 (2H, m, CH2CH2CO), 1.44 - 1.32 (3H, m, 
CHCH2, NHCH2CH2CH3), 1.29 - 1.21 (8H, m, 4 x CH2), 1.11 - 0.98 (1H, m, 
CHCH2), 0.89 - 0.98 (12H, m, CHCH3, 3 x CH2CH3); δH (700 MHz, CDCl3) 7.27 
(1H, br. s., NH), 6.94 (1H, br. s., NH), 6.73 (1H, br. s., NH), 4.34 (1H, dd, J 8.8, 7.5 
Hz, NHCH), 4.06 (1H, dd, J 17.2, 5.3 Hz, NHCH2), 3.97 (1H, dd, J 16.3, 4.8 Hz, 
NHCH2), 3.33 - 3.19 (1H, m, NHCH2CH2), 3.17 - 3.12 (1H, m, NHCH2CH2CH3), 
2.29 - 2.24 (2H, t, J 8.4 Hz, CH2CH2CO), 1.90 - 1.83 (1H, m, CHCH3), 1.63 (2H, 
quin, J 7.5 Hz, CH2CH2CO), 1.58 - 1.41 (3H, m, NHCH2CH2, CHCH2CH3), 1.34 - 
1.22 (8H, m, 4  x CH2), 1.19 - 1.02 (1H, m, CHCH2CH3), 0.94 - 0.44 (12H, m, 4 x 
CH3); δH (700 MHz, CD3OD) 4.20 (1H, d, J 7.5 Hz, NHCH), 3.21 - 3.06 (2H, m, 
NHCH2CO), 2.26 (2H, t, J 7.7 Hz, CH2CH2CO), 1.88 - 1.82 (1H, m, CHCH3), 1.62 
(2H, quin, J 7.2 Hz, CH2CH2CO), 1.57 - 1.46 (2H, m, CH2CH2NH), 1.37 - 1.26 (9H, 
m, CHCH2CH3, 4 x CH2), 1.25 - 1.09 (1H, m, CHCH2CH3), 0.96 - 0.86 (12H, m, 4 x 
CH3); δC (100 MHz, DMSO-d6) 172.6 (NHCH2CO), 170.6 (CH2CH2CO), 168.8 
(NHCHCO), 56.7 (NHCHCO), 41.9 (NHCH2CO), 40.2 (CH3CH2CONH), 36.8 
(CHCH3), 35.1 (CH2CH2NH), 31.1, 28.5, 26.0, 25.3, 24.3, 22.2 (6 x CH2), 15.3, 
13.9, 11.4, 11.1 (4 x CH3); m/z (ESI+) 378.2 ([M+Na]; HR-ESIMS: calculated for 
C19H37N3O3Na: 378.2727, found 378.2728 [M+Na]+. 
N-(Propyl)-(2S, 3S)-3-methyl-2-(2-octanamidoacetamido)pentaneamide and N-
(propyl)-(2R, 3S)-3-methyl-2-(2-octanamidoacetamido)pentaneamide 3.23 
Method modified from literature procedure by Crich et al.1 4 Å Molecular sieves 
were added to a solution of propylamine (0.09 mL, 1.34 mmol) and acid 3.18 (70: 30 
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mix of (2S, 3S) and (2R, 3S) diastereomers, calculated by 1H NMR; 0.25 g, 0.80 
mmol) in DMF (14 mL), and the mixture was stirred at - 20 °C for 20 minutes. 
PyBOP (1.0 g, 2.0 mmol) and diisopropylethylamine (0.33 mL, 2.0 mmol) were 
added and the reaction mixture stirred at - 20 °C for 4 hours. The reaction mixture 
was filtered, quenched with pH 2 buffer (15 mL) and extracted with CH2Cl2 (3 x 20 
mL). The combined organics were concentrated in vacuo. EtOAc (15 mL) and pH 2 
buffer (10 mL) were added and the phases were separated. The organics were 
washed with pH 2 buffer (10 mL), water (3 x 10 mL), saturated aqueous NaHCO3 
solution (10mL) and saturated aqueous NaCl solution (10 mL), dried over Na2SO4 
and concentrated in vacuo (61: 39  mix of (2S, 3S) and (2R, 3S) diastereomers in 
crude product, calculated by 1H NMR). The product was obtained by silica column 
chromatography (10% MeOH: CH2Cl2) to give 3.23 as a bright white solid (83 mg, 
0.23 mmol, 29 %; 59: 41  mix of (2S, 3S) and (2R, 3S) diastereomers in crude 
product, calculated by 1H NMR); υ max/cm-1 (neat) 3280 (N-H), 1627 (C=O), 1532 
(N-H); δH (400 MHz, DMSO-d6) 8.09 ((2R, 3S), 1H, t, J 6.0 Hz, NHCH2CO), 8.05 
((2S, 3S), 1H, t, J 6.0 Hz, NHCH2CO), 7.98 ((2S, 3S), 1H, t, J 5.5 Hz, 
NHCH2CH2CH3), 7.92 ((2R, 3S), 1H, t, J 5.5 Hz, NHCH2CH2CH3), 7.71 ((2S, 3S), 
1H, d, J 9.0 Hz, NHCH), 7.66 ((2R, 3S), 1H, d, J 9.0 Hz, NHCH), 4.25 ((2R, 3S), 
1H, dd, J 9.0, 5.5 Hz, NHCH), 4.12 ((2S, 3S), 1H, dd, J 9.0, 7.5 Hz, NHCH), 3.81 - 
3.61 ((2S, 3S), 2H, m, NHCH2CO; (2R, 3S), 2H, m, NHCH2CO), 3.11 - 2.87 ((2S, 
3S), 2H, m, NHCH2CH2CH3; (2R, 3S),  2H, m, NHCH2CH2CH3), 2.10 ((2S, 3S), 2H, 
t, J 7.5 Hz, CH2CH2CO; (2R, 3S),  2H, t, J 7.5 Hz, CH2CH2CO), 1.83 - 1.61 ((2S, 
3S), 1H, m, NHCHCH2; (2R, 3S), 1H, m, NHCHCH2), 1.55 - 1.33 ((2S, 3S), 5H, m, 
NHCHCH2, NHCH2CH2CH3, CH2CH2CO; (2R, 3S), 5H, m, NHCHCH2, 
NHCH2CH2CH3, CH2CH2CO), 1.30 - 1.14 ((2S, 3S), 8H, m, 4 x CH2; (2R, 3S), 8H, 
m, 4 x CH2), 1.14 - 0.98 ((2S, 3S), 1H, m, NHCHCH2; (2R, 3S), 1H, m, NHCHCH2), 
0.91 - 0.72 ((2S, 3S), 12H, m, CHCH3, 4 x CH3; (2R, 3S), 12H, m, CHCH3, 4 x 
CH3); δH (700 MHz, CDCl3) 7.20 ((2S, 3S), 1H, d, J 8.8 Hz, NHCH), 7.13 ((2R, 
3S),1 H, d, J 8.8 Hz, NHCH), 6.81 ((2S, 3S), 1H, br. s., NHCH2), 6.78 ((2R, 3S), 1H, 
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br. s., NHCH2), 6.61 ((2S, 3S), 1H, br. s., NHCH2), 6.59 ((2R, 3S), 1H, br. s., 
NHCH2), 4.45 ((2R, 3S), 1H, dd, J 8.8, 5.7 Hz, NHCH), 4.34 ((2S, 3S), 1H, t, J 7.9 
Hz, NHCH), 4.12 - 4.04 ((2S, 3S), 1H, m, NHCH2CO; (2R, 3S), 1H, m, NHCH2CO), 
4.00 - 3.95 ((2S, 3S), 1H, m, NHCH2CO; (2R, 3S), 1H, m, NHCH2CO), 3.32 - 3.22 
((2S, 3S), 1H, m, NHCH2CH2; (2R, 3S), 1H, m, NHCH2CH2), 3.22 - 3.08 ((2S, 3S), 
1H, m, NHCH2CH2; (2R, 3S), 1H, m, NHCH2CH2), 2.26 ((2S, 3S), 2H, t, J 7.7 Hz, 
CH2CH2CO; (2R, 3S), 2H, t, J 7.7 Hz, CH2CH2CO), 1.95 - 1.89 ((2R, 3S), 1H, m, 
CHCH3), 1.89 - 1.82 ((2S, 3S), 1H, m, CHCH3), 1.63 ((2S, 3S), 2H, quin, J 7.5 Hz, 
CH2CH2CO; (2R, 3S), 2H, quin, J 7.5 Hz, CH2CH2CO), 1.57 - 1.47 ((2S, 3S), 3H, m, 
NHCH2CH2, CHCH2CH3; (2R, 3S), 2H, m, NHCH2CH2), 1.47 - 1.38 ((2R, 3S), 3H, 
m, CHCH2CH3), 1.37 - 1.22 ((2S, 3S), 8H, m, 4 x CH2; (2R, 3S), 8H, m, 4 x CH2), 
1.22 - 1.06 ((2S, 3S), 1H, m, CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3), 0.96 - 0.81 
((2S, 3S), 12H, m, 4 x CH3; (2R, 3S), 12H, m, 4 x CH3); δH (700 MHz, CD3OD) 4.35 
((2R, 3S), 1H, d, J 5.7 Hz, NHCH), 4.20 ((2S, 3S), 1H, d, J 7.0 Hz, NHCH), 3.90 
((2S, 3S), 1H, d, J 16.7 Hz, NHCH2CO; (2R, 3S), 1H, d, J 16.7 Hz, NHCH2CO), 
3.86 ((2S, 3S), 1H, d, J 17.6 Hz, NHCH2; (2R, 3S), 1H, d, J 17.6 Hz, NHCH2), 3.19 - 
3.08 ((2S, 3S), 2H, m, CH2CH2NH; (2R, 3S), 2H, m, CH2CH2NH), 2.26 ((2S, 3S), 
2H, t, J 7.7 Hz, CH2CH2CO; (2R, 3S), 2H, t, J 7.7 Hz, CH2CH2CO), 1.96 - 1.88 ((2R, 
3S), 1H, m, CHCH3), 1.87 - 1.79 ((2S, 3S), 1H, m, CHCH3), 1.62 ((2S, 3S), 2H, quin, 
J 7.0 Hz, CH2CH2CO; (2R, 3S), 2H, quin, J 7.0 Hz, CH2CH2CO), 1.56 - 1.48 ((2S, 
3S), 2H, m, CH2CH2NH; (2R, 3S), 2H, m, CH2CH2NH), 1.43 - 1.27 ((2S, 3S), 9H, m, 
CHCH2CH3, 4  x CH2; (2R, 3S), 9H, m, CHCH2CH3, 4 x CH2), 1.25 - 1.12 ((2S, 3S), 
1H, m, CHCH2CH3; (2R, 3S), 1H, m, CHCH2CH3), 0.96 - 0.86 ((2S, 3S), 12H, m, 4 x 
CH3; (2R, 3S), 12H, m, 4 x CH3); δC (100 MHz, DMSO-d6) 172.7, 172.6 ((2S, 3S), 
NHCH2CO; (2R, 3S), NHCH2CO), 170.7, 170.6 ((2S, 3S), CH2CH2CO; (2R, 3S), 
CH2CH2CO), 169.1, 168.8  ((2S, 3S), NHCHCO; (2R, 3S), NHCHCO), 56.7 ((2S, 
3S), NHCHCO), 55.6 ((2R, 3S), NHCHCO), 42.1, 41.9 ((2S, 3S), NHCH2CO; (2R, 
3S), NHCH2CO), 40.3 ((2S, 3S), CH3CH2CH2NH; (2R, 3S), CH3CH2CH2NH), 36.9, 
36.8 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 35.1 ((2S, 3S), CH2CH2CONH; (2R, 3S), 
160 
 
CH2CH2CONH), 31.1, 28.6, 28.5, 25.7, 25.2, 24.2, 22.2, 22.1 ((2S, 3S), 6 x CH2; 
(2R, 3S), 6 x CH2), 15.3, 14.4, 13.9, 11.5, 11.4, 11.1 ((2S, 3S), 4 x CH3; (2R, 3S), 4 x 
CH3); m/z (ESI+) 378.1 ([M+Na]; HR-ESIMS: calculated for C19H37N3O3Na: 
378.2727, found 378.2712 [M+Na]+. 
N-(Propyl)-(2S, 3S)-3-methyl-2-(2-octanamidoacetamido)pentaneamide and N-
(propyl)-(2R, 3S)-3-methyl-2-(2-octanamidoacetamido)pentaneamide 3.21 from 
thioester 
This compound was also prepared from the thioester 3.19, according to the method 
of Crich et al.1 A solution of the thioester 3.19 (66 mg, 0.14 mmol, 80: 20 mix of 
(2S, 3S) and (2R, 3S) diastereomers) in 40 % piperidine in DMF (1.5 mL) was stirred 
at room temperature for 1.5 hours. The solution was reduced in vacuo and the 
residue was partitioned between EtOAc (5 mL) and 1M aqueous HCl solution (5 
mL). The separated organic phase was washed with water (3 x 5 mL) and saturated 
aqueous NaCl solution (5 mL), dried over Na2SO4 and concentrated in vacuo to give 
the crude thioacid, which was used immediately without further purification. 
Cs2CO3 (53 mg, 0.16 mmol) was added to a solution of the thioacid (0.14 mmol) in 
DMF (0.25 mL) under a nitrogen atmosphere. After 10 minutes, a solution of the 
sulfonamide 3.01 (31 mg, 0.11 mmol) in DMF (0.2 mL) was added to give a dark 
red solution. The reaction mixture was stirred at room temperature for 1 hour, then 
poured into EtOAc (10 mL). The organics were washed with ice-cold 1M aqueous 
NaOH solution (5 mL), water (3 x 5mL) and saturated aqueous NaCl solution (5 
mL), dried over Na2SO4 and concentrated in vacuo (73: 27 mix of (2S, 3S) and (2R, 
3S) diastereomers present in crude product, calculated by 1H NMR). Purification by 
silica chromatography (2% MeOH: CH2Cl2 to 10% MeOH: CH2Cl2) gave the 
peptide 3.21 as a yellow oil (21 mg, 0.06 mmol, 43%, 73: 27 mix of (2S, 3S) and 
(2R, 3S) diastereomers, calculated by 1H NMR); All characterisation data was 
identical to the product prepared previously.  
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Benzoyl-L-isoleucine 3.24 
A solution of benzoyl chloride (2.9 mL, 25 mmol) in THF (30 mL) was added 
slowly to a solution of L-isoleucine (3.9 g, 30 mmol), potassium carbonate (4.2 g, 30 
mmol) and potassium hydroxide (1.7 g, 30 mmol) in water (60 mL) at room 
temperature to give a cloudy suspension. The reaction was stirred at room 
temperature overnight. The reaction mixture was acidified to pH 2 with aqueous 
hydrochloric acid (3M solution) and concentrated in vacuo.  EtOAc (50 mL) was 
added and the phases separated. The organic phase was washed with pH 2 buffer (20 
mL) and saturated aqueous NaCl solution (20 mL), dried over Na2SO4 and 
concentrated in vacuo to give the product as a waxy solid (6.81 g, 29.0 mmol, 96 %); 
m.p. 115 - 116 °C (lit.11 135 – 136 ˚C); 28][ Dα +37.7 (c = 0.42, CHCl3), (lit.12 28][ Dα
+31.6 (c = 2.25, CDCl3); υ max/cm-1(neat) 3309 (O-H), 2965 (N-H), 1712 (acid C=O), 
1619 (amide C=O), 1533 (N-H); δH (400 MHz, CDCl3) 9.81 (1H, br. s., CO2H), 7.81 
(2H, d, J 8.5 Hz, 2 x ortho Ar CH), 7.57 - 7.50 (1H, m, para Ar CH), 7.50 - 7.39 
(2H, m, 2 x meta Ar CH), 6.75 (1H, d, J 8.0 Hz, CHNH), 4.86 (1H, dd, J 8.5, 5.0 Hz, 
CHNH), 2.17 - 2.06 (1H, m, CHCH3), 1.68 - 1.52 (1H, m, CH2CH3), 1.39 - 1.23 (1H, 
m, CH2CH3), 1.03 (3H, d, J 6.5 Hz, CHCH3), 0.98 (3H, t, J 7.5 Hz, CH2CH3); δH 
(700 MHz, DMSO-d6) 12.57 (1H, br. s., CO2H), 8.39 (1H, d, J 8.0 Hz, NHCH), 7.88 
(2H, d, J 8.0 Hz, 2 x ortho Ar CH), 7.54 (1H, t, J 7.1 Hz, para Ar CH), 7.46 (2H, t, J 
7.7 Hz, 2 x meta Ar CH), 4.33 (1H, t, J 7.5 Hz, NHCH), 1.98 - 1.92 (1H, m, 
CHCH3), 1.55 - 1.49 (1H, m, CHCH2CH3), 1.32 - 1.23 (1H, m, CHCH2CH3), 0.93 
(3H, d, J 7.1 Hz, CHCH3), 0.87 (3H, t, J 7.4 Hz, CH2CH3); δH (700 MHz, CD3OD) 
7.83 (2H, d, J 7.2 Hz, 2 x ortho Ar CH), 7.54 (1H, t, J 7.5 Hz, para Ar CH), 7.47 
(2H, t, J 7.8 Hz, 2 x meta Ar CH), 4.56 (1H, d, J 6.4 Hz, NHCH), 2.06 - 2.01 (1H, 
m, CHCH3), 1.62 (1H, dqd, J 14.5, 7.5, 4.4 Hz, CHCH2CH3), 1.38 - 1.31 (1H, m, 
CHCH2CH3), 1.03 (3H, d, J 6.9 Hz, CHCH3), 0.97 (3H, t, J 7.5 Hz, CH2CH3); δC 
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(100 MHz, CDCl3) 176.0 (CO2H), 167.8 (CONH), 133.8 (ipso Ar C), 131.9 (ortho 
Ar CH), 128.7 (para Ar CH), 127.1 (meta Ar CH), 56.9 (CHNH), 37.9 (CHCH3), 
25.2 (CH2CH3), 15.5 (CHCH3), 11.6 (CH2CH3); m/z (ESI-) 234.0 ([M-H], 100%); 
HR-ESIMS: calculated for C13H18NO3: 236.1284, found 236.1281 [M+H]+.The data 
is consistent with that previously reported.12 
Benzoyl-L-isoleucine 3.25 
Acetyl chloride (1.8 mL, 15.5 mmol) was added dropwise to stirred and cooled 
methanol (10 mL) to give a methanolic solution of HCl. To this was added benzoyl-
L-isoleucine 3.24 (1.5 g, 6.4 mmol) and the reaction mixture was heated to reflux for 
3 hours. The reaction mixture was concentrated in vacuo to give the methyl ester as a 
white crystalline solid (1.6 g, 6.4 mmol, 99 %); m.p. 88 – 90 °C (lit.13 89 °C); 22][ Dα
+44.3 (c = 1.04 CHCl3), (lit.14 D][α +32.0 (c = 10.0 CHCl3)); υ max/cm-1(neat) 3339 
(N-H), 1735 (ester C=O), 1638 (amide C=O), 1517 (N-H); δH (400 MHz, CDCl3) 
7.90 - 7.13 (2H, m, 2 x ortho Ar CH), 7.45 - 7.40 (1H, m, para Ar CH), 7.37 - 7.32 
(2H, m, 2 x meta Ar CH),  6.87 (1H, d, J 8.0 Hz, NHCH), 4.75 (1H, dd, J 8.5, 5.5 
Hz, NHCH), 3.69 (3H, s, OCH3), 2.06 - 2.00 (1H, m, CHCH3), 1.48 (1H, dqd, J 
13.5, 7.5, 4.5 Hz, CH2CH3), 1.22 (1H, ddq, J 13.5, 9.0, 7.5 Hz, CH2CH3),0.93 (3H, 
d, J 7.0 Hz, CHCH3), 0.91 (3H, t J 7.5 Hz, CH2CH3); δH (700 MHz, DMSO-d6) 8.58 
(1H, d, J 7.7 Hz, NHCH), 7.87 (2H, d, J 8.3 Hz, 2 x ortho Ar CH), 7.54 (1H, t, J 6.7 
Hz, para Ar CH), 7.47 (2H, t, J 8.0 Hz, 2 x meta Ar CH), 4.35 (1H, t, J 7.7 Hz, 
NHCH), 3.65 (3H, s, OCH3), 2.01 - 1.93 (1H, m, CHCH3), 1.56 - 1.47 (1H, m, 
CH2CH3), 1.31 - 1.22 (1H, m, CH2CH3), 0.90 (3H, d, J 6.7 Hz, CHCH3), 0.87 (3H, t, 
J 7.5 Hz, CH2CH3); δH (700 MHz, CD3OD)  7.83 (2H, dd, J 8.3, 1.1 Hz, 2 x ortho Ar 
CH), 7.56 - 7.53 (1H, m, para Ar CH), 7.47 (2H, t, J 7.8 Hz, 2 x meta Ar CH), 4.56 
(1H, d, J 6.9 Hz, NHCH), 3.75 (3H, s, OCH3), 2.06 - 1.99 (1H, m, CHCH3), 1.59 
(1H, dqd, J 13.5, 7.5, 4.2 Hz, CH2CH3), 1.36 - 1.28 (1H, m, CH2CH3), 0.99 (3H, d, J 
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6.7 Hz, CHCH3), 0.96 (3H, t, J 7.5 Hz, CH2CH3); δC (100 MHz, CDCl3) 172.4 
(CO2CH3), 167.0 (CONH), 133.8 (ipso Ar C), 131.4 (para Ar CH), 128.3 (meta 
CH), 126.9 (ortho CH), 56.6 (NHCH), 51.9 (CO2CH3), 37.8 (CHCH3), 25.1 
(CH2CH3), 15.2 (CHCH3), 11.3 (CH2CH3);  m/z (ESI+) 272.0 ([M+Na]+), 100%), 
250.0 ([M+H]+), 43%); HR-ESIMS: calculated for C14H20NO3: 250.1438, found 
250.1439 [M+H]+. 1H NMR spectroscopic data is consistent with that previously 
reported.14 
Benzoyl-L-isoleucine and benzoyl-D-allo-isoleucine 3.26 
Prepared as for the single diastereomer, using a mixture of L- and D-allo-isoleucine 
(0.50 g, 3.8 mmol) to give the product as a waxy yellow solid (0.81 g, 3.4 mmol, 90 
%, 78: 22 mix of (2S, 3S) and (2R, 3S) diastereomers, calculated by 1H NMR); υmax 
/cm-1(neat) 3346 (O-H), 2874 (N-H), 1720 (acid C=O), 1628 (amide C=O), 1535 (N-
H); δH (400 MHz, CDCl3) 9.57 ((2S, 3S), 1H, br.s., CO2H; (2R, 3S), 1H, br.s., 
CO2H), 7.81 ((2S, 3S), 2H, d, J 8.0 Hz, 2 x ortho Ar CH; (2R, 3S), 2H, d, J 8.0 Hz, 2 
x ortho Ar CH), 7.56 - 7.49 ((2S, 3S), 1H, m, para Ar CH; (2R, 3S), 1H, m, para Ar 
CH), 7.48 - 7.42 ((2S, 3S), 2H, m, 2 x meta Ar CH; (2R, 3S), 2H, m, 2 x meta Ar 
CH), 6.74 ((2S, 3S), 1H, d, J 8.0 Hz, CHNH), 6.66 ((2R, 3S), 1H, d, J 9.0 Hz, 
CHNH), 4.97 ((2R, 3S), 1H, dd, J 9.0, 4.0 Hz, CHNH), 4.85 ((2S, 3S), 1H, dd, J 8.5, 
5.0 Hz, CHNH), 2.23 - 2.02 ((2S, 3S), 1H, m, CHCH3; (2R, 3S), 1H, m, CHCH3), 
1.69 - 1.47 ((2S, 3S), 1H, m, CH2CH3; (2R, 3S), 1H, m, CH2CH3), 1.41 - 1.21 ( (2S, 
3S), 1H, m, CH2CH3; (2R, 3S), 1H, m, CH2CH3), 1.03 ((2S, 3S), 3H, d, J 6.5 Hz, 
CHCH3; (2R, 3S), 3H, d, J 6.5 Hz, CHCH3), 1.05 - 0.95 ((2R, 3S), 3H, m, CH2CH3; 
(2S, 3S), 3H, m, CH2CH3); δH (700 MHz, DMSO-d6) 12.57 ((2S, 3S), 1H, br. s., 
CO2H; (2R, 3S), 1H, br. s., CO2H), 8.39 ((2S, 3S), 1H, d, J 7.7 Hz, NHCH), 8.28 
((2R, 3S), 1H, d, J 8.3 Hz, NHCH), 7.88 ((2S, 3S), 2H, d, J 8.0 Hz, 2 x ortho Ar CH; 
(2R, 3S), 2H, d, J 8.0 Hz, 2 x ortho Ar CH), 7.54 ((2S, 3S), 1H, t, J 7.4 Hz, para Ar 
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CH; (2R, 3S), 1H, t, J 7.4 Hz, para Ar CH), 7.47 ((2S, 3S), 2H, t, J 7.4 Hz, 2 x meta 
Ar CH; (2R, 3S), 2H, t, J 7.4 Hz, 2 x meta Ar CH), 4.53 ((2R, 3S), 1H, dd, J 8.3, 5.8 
Hz, NHCH), 4.33 ((2S, 3S), 1H, t, J 7.5 Hz, NHCH), 2.03 - 1.98 ((2R, 3S), 1H, m, 
CHCH3), 1.98 - 1.92 ((2S, 3S), 1H, m, CHCH3), 1.56 - 1.48 ((2S, 3S), 1H, m, 
CH2CH3), 1.47 - 1.38 ((2R, 3S), 1H, m, CH2CH3), 1.32 - 1.24 ((2S, 3S), 1H, m, 
CH2CH3), 1.24 - 1.16 ((2R, 3S), 1H, m, CH2CH3), 0.95 ((2R, 3S), 3H, d, J 7.1 Hz, 
CHCH3), 0.94 ((2S, 3S), 3H, d, J 6.7 Hz, CHCH3), 0.91 - 0.86 ((2S, 3S), 3H, m, 
CH2CH3; (2R, 3S), 3H, m, CH2CH3); δH (700 MHz, CD3OD) 7.85 - 7.82 ((2S, 3S), 
2H, m, 2 x ortho Ar CH; (2R, 3S), 2H, m, 2 x ortho Ar CH), 7.57 - 7.52 ((2S, 3S), 
1H, m, para Ar CH; (2R, 3S), 1H, m, para Ar CH), 7.45 - 7.49 ((2S, 3S), 2H, m, 2 x 
meta Ar CH; (2R, 3S), 2H, m, 2 x meta Ar CH), 4.74 ((2R, 3S), 1H, d, J 4.99 Hz, 
NHCH), 4.56 ((2S, 3S), 1H, d, J 6.38 Hz, NHCH), 2.13 - 2.07 ((2R, 3S), 1H, m, 
CHCH3), 2.07 - 2.01 ((2S, 3S), 1H, m, CHCH3), 1.62 ((2S, 3S), 1H, dqd, J 14.7, 7.5, 
4.4 Hz, CH2CH3), 1.57 - 1.50 ((2R, 3S), 1H, m, CH2CH3), 1.39 - 1.28 ((2S, 3S), 1H, 
m, CH2CH3; (2R, 3S), 1H, m, CH2CH3), 1.05 - 0.95 ((2S, 3S), 6H, m, CHCH3, 
CH2CH3; (2R, 3S), 6H, m, CHCH3, CH2CH3); δC (100 MHz, CDCl3) 176.6, 176.0 
((2S, 3S), CO2H; (2R, 3S), CO2H), 167.9, 167.7 ((2S, 3S), CONH; (2R, 3S), CONH), 
133.8 ((2S, 3S), ipso Ar C; (2R, 3S), ipso Ar C), 131.9 ((2S, 3S), 2 x ortho Ar CH; 
(2R, 3S), 2 x ortho Ar CH), 128.7 ((2S, 3S), para Ar CH; (2R, 3S), para Ar CH), 
127.1 ((2S, 3S), 2 x meta Ar CH; (2R, 3S), 2 x meta Ar CH), 56.9, 55.7 ((2S, 3S), 
CHNH; (2R, 3S), CHNH), 38.9, 37.8 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 26.3, 
25.2 ((2S, 3S), CH2CH3; (2R, 3S), CH2CH3), 15.5, 14.7 ((2S, 3S), CHCH3; (2R, 3S), 
CHCH3), 11.7, 11.6 ((2S, 3S), CH2CH3; (2R, 3S), CH2CH3); m/z (ESI+) 258.0 
([M+Na]+), 100%); HR-ESIMS: calculated for C13H18NO3: 236.1284, found 
236.1281 [M+H]+.This compound as a mix of diastereomers has not been previously 
reported. 
 
165 
 
Benzoyl-L-isoleucine methyl ester and benzoyl-D-allo-isoleucine methyl ester 
3.26 
Prepared as for the single diastereomer, using a mixture of L-isoleucine and D-allo-
isoleucine to give the methyl ester as a white crystalline solid (0.18 g, 7.2 mmol, 85 
%, 50:50  mix of (2S, 3S) and (2R, 3S) diastereomers, calculated by 1H NMR); υ
 
max/cm-1(neat) 3340 (N-H), 1736 (ester C=O) 1638, (amide C=O), 1517 (N-H); δH 
(400 MHz, CDCl3) 7.81 ((2S, 3S), 2H, d, J 7.5 Hz, 2 x ortho Ar CH; (2R, 3S), 2H, d, 
J 7.5 Hz, 2 x ortho Ar CH), 7.58 - 7.49 ((2S, 3S),  1H, m, para Ar CH; (2R, 3S), 1H, 
m, para Ar CH), 7.48 - 7.41 ((2S, 3S), 2H, m, 2 x meta Ar CH; (2R, 3S), 2H, m, 2 x 
meta Ar CH), 6.70 ((2S, 3S), 1H, d, J 8.0 Hz, CHNH), 6.62 ((2R, 3S), 1H, d, J 8.5 
Hz, CHNH), 4.93 ((2R, 3S), 1H, dd, J 9.0, 4.0 Hz, CHNH), 4.82 ((2S, 3S), 1H, dd, J 
8.5, 5.0 Hz, CHNH), 3.77 ((2S, 3S), 3H, s, OCH3; (2R, 3S), 3H, s, OCH3), 2.11 - 
1.95 ((2S, 3S), 1H, m, CHCH3; (2R, 3S), 1H, m, CHCH3), 1.61 - 1.44 ((2S, 3S), 1H, 
m, CH2CH3; (2R, 3S), 1H, m, CH2CH3), 1.35 - 1.16 ((2S, 3S), 1H, m, CH2CH3; (2R, 
3S), 1H, m, CH2CH3), 1.01 - 0.93 ((2S, 3S), 6H, m, CH2CH3, CHCH3; (2R, 3S), 6H, 
m, CH2CH3, CHCH3); δH (700 MHz, DMSO-d6) 8.58 ((2S, 3S), 1H, d, J 7.7 Hz, 
NHCH), 8.48 ((2R, 3S), 1H, d, J 8.0 Hz, NHCH), 7.87 ((2S, 3S), 2H, d, J 7.7 Hz, 2 x 
ortho Ar CH; (2R, 3S), 2H, d, J 7.7 Hz, 2 x ortho Ar CH ), 7.55 ((2S, 3S), 1H, t, J 7.1 
Hz, para Ar CH; (2R, 3S), 1H, t, J 7.1 Hz, para Ar CH), 7.50 - 7.44 ((2S, 3S), 2H, 
m, 2 x meta Ar CH; (2R, 3S), 2H, m, 2 x meta Ar CH), 4.54 ((2R, 3S), 1H, dd, J 8.0, 
6.4 Hz, NHCH), 4.35 ((2S, 3S), 1H, t, J 7.7 Hz, NHCH), 3.66 ((2R, 3S), 3H, s, 
OCH3), 3.65 ((2S, 3S), 3H, s, OCH3), 2.04 - 1.94 ((2S, 3S), 1H, m, CHCH3; (2R, 3S), 
1H, m, CHCH3), 1.52 ((2S, 3S), 1H, dqd, J 13.9, 7.1, 4.0 Hz, CH2CH3), 1.41 ((2R, 
3S), 1H, dquin, J 13.9, 6.9 Hz, CH2CH3), 1.31 - 1.24 ((2S, 3S), 1H, m, CH2CH3), 
1.19 ((2R, 3S), 1H, dquin, J 14.1, 7.3 Hz, CH2CH3), 0.95 ((2R, 3S), 3H, d, J 6.7 Hz, 
CHCH3), 0.92 - 0.85 ((2S, 3S), 6H, CHCH3, CH2CH3; (2R, 3S), 3H, CH2CH3); δH 
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(700 MHz, CD3OD) 7.84 - 7.81 ((2S, 3S), 2H, m, 2 x ortho Ar CH; (2R, 3S), 2H, m, 
2 x ortho Ar CH), 7.57 - 7.53 ((2S, 3S), 1H, m, para Ar CH; (2R, 3S), 1H, m, para 
Ar CH), 7.50 - 7.44 ((2S, 3S), 2H, m, 2 x meta Ar CH; (2R, 3S), 2H, m, 2 x meta Ar 
CH), 4.73 ((2R, 3S), 1H, d, J 5.5 Hz, NHCH), 4.56 ((2S, 3S), 1H, d, J 6.9 Hz, 
NHCH), 3.76 ((2R, 3S), 3H, s, OCH3), 3.75 ((2S, 3S), 3H, s, OCH3), 2.11 - 2.05 
((2R, 3S), 1H, m, CHCH3), 2.05 - 1.98 ((2S, 3S), 1H, m, CHCH3), 1.59 ((2S, 3S), 1H, 
dqd, J 13.5, 7.7, 4.4 Hz, CH2CH3), 1.53 - 1.46 ((2R, 3S), 1H, m, CH2CH3), 1.36 - 
1.21 ((2S, 3S), 1H, m, CH2CH3; (2R, 3S), 1H, m, CH2CH3), 1.01 - 0.93 ((2S, 3S), 6H, 
m, CHCH3, CH2CH3; (2R, 3S), 6H, m, CHCH3, CH2CH3) δC (100 MHz, CDCl3) 
172.9, 172.6 ((2S, 3S), CO2CH3; (2R, 3S) CO2CH3), 167.3, 167.1 ((2S, 3S), CONH; 
(2R, 3S), CONH); 134.1 ((2S, 3S), ipso Ar C; (2R, 3S), ipso Ar C), 131.7 ((2S, 3S), 
para Ar CH; (2R, 3S), para Ar CH), 128.6 ((2S, 3S), meta Ar CH; (2R, 3S), meta Ar 
CH), 127.0 ((2S, 3S), ortho Ar CH; (2R, 3S), ortho Ar CH), 56.7, 55.7 ((2S, 3S), 
CHNH; (2R, 3S), CHNH), 52.3, 52.1 ((2S, 3S), CO2CH3; (2R, 3S), CO2CH3), 38.1 
((2S, 3S), CHCH3; (2R, 3S), CHCH3), 26.3, 25.3  ((2S, 3S), CH2CH3; (2R, 3S), 
CH2CH3), 15.4, 14.7  ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 11.7, 11.5  ((2S, 3S), 
CH2CH3; (2R, 3S), CH2CH3); m/z (ESI+) 272.1 ([M+Na]+), 100%), 250.1 
([M+Na]+), 32%); HR-ESIMS: calculated for C14H19NO3Na: 272.1257, found 
272.1257 [M+H]+. 1H NMR spectroscopic data is consistent with that previously 
reported.14 
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CHAPTER 4: THE TOTAL SYNTHESIS OF THE 
AZOLEMYCINS AND RELATED COMPOUNDS 
4.1 AZOLEMYCIN 
The azolemycins are a group of compounds recently isolated from the soil 
bacterium, Streptomyces sp. FXJ1.264. Professor Challis and Dr Song (Department 
of Chemistry, University of Warwick) used a combination of mass spectrometry and 
1D and 2D NMR to identify the structure as a modified heptapeptide, with four 
linked azoles and an N-terminal oxime. The major isolated azolemycin is the N-
hydroxy derivative, azolemycin A, 4.01, while the minor, azolemycin B, 4.02, has an 
N-methoxy group (Figure 34). There is currently some doubt as to whether 
azolemycin B is actually a microbially derived peptide, or a relic of the purification 
techniques used.  
Figure 34: The structures of azolemycins A and B 
The bacterial genome of Streptomyces sp. FXJ1.264. has been sequenced, so it has 
been possible to identify the associated genes involved in the biosynthesis of 
azolemycin A, based on the peptide sequence VVSTCTI. It is proposed that a 
ribosomally synthesised peptide precursor containing the seven amino-acid sequence 
is first dehydrated and then oxidised to give the tetra-azole sequence. The 
surrounding amino-acids are then cleaved, and the N-terminal amine is oxidised to 
give the oxime, and the isoleucine methyl ester is formed (Figure 35). Oxidation of 
an amine to an oxime is unusual in natural products and, as far as we know, this is an 
unprecedented reaction for the enzyme responsible for the azolemycin oxime 
formation, a flavin dependent mono-oxygenase.  
 
 Figure 35: The biosynthesis of azolemycin A in 
proposed by Professor Challis (University of Warwick)
It has been proposed that this flavin dependent 
hydroxylamine and nitroso
literature, including the oxidation of an amine to an oxime in the biosynthesis 
norcardicin A, a β-lactam antibiotic derived from an actinomycete
However, this oxidation is controlled by a heme
enzyme. Reported reactions for non
compounds, as in the biosynthesis of pyrollnitrin.
involved in the biosynthesis of azolemycin A follows a similar mechanism to the 
55 amino acids
55 amino acids
55 amino acids
Streptomyces sp. FXJ1.264 and the associated gene clusters 
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cytochrome P450 reaction, stopping at the oxime, but utilises a non-heme dependent 
enzyme as seen in the biosynthesis of pyrollnitrin.  
Figure 36: The two oxidation pathways proposed for the biosynthesis of Norcardicin and pyrollnitrin 
 
4.2 ASSIGNMENT OF STEREOCHEMISTRY OF C-TERMINAL ISOLEUCINE 
4.2.1 USE OF BENZOYL-ISOLEUCINE MODEL 
At the time we became involved in the project, the amino-acid sequence and 
structure of azolemycin A had been solved, but there was some ambiguity over the 
stereochemistry of the C-terminal isoleucine. We realised that the benzoyl-isoleucine 
methyl ester diastereomers we had previously synthesized, 3.25 and 3.27, (Scheme 
22) could act as a model for the last two C-terminal residues. We compared the 1H 
NMR spectrum for the mix of benzoyl-L-isoleucine methyl ester and benzoyl-D-allo-
isoleucine methyl ester with that of azolemycin A (Figure 37, Figure 38). The signal 
associated with the isoleucine α-CH of azolemycin occurred at a lower field than 
either of the diastereomers of benzoyl-isoleucine methyl ester, but the chemical shift 
and coupling constant led us to tentatively assign the stereochemistry as that of L-
isoleucine rather than that of D-allo-isoleucine.  
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Figure 37: The 1H NMR spectra for the mix of diastereomers of benzoyl-isoleucine methyl esters (top spectrum) 
and for azolemycin A (bottom spectrum), with the signals associated with the α-CH highlighted 
Figure 38: Highlighting the signals associated with the α-CH for mix of diastereomers of benzoyl-isoleucine 
methyl esters (top) and azolemycin (bottom) 
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4.2.2 RETROSYNTHESIS OF THE OXAZOLE MODEL 
In order to reinforce this stereochemical assignment, we decided to synthesise an 
extended analogue, 5-methyl-2-phenyl-oxazole-4-carboxy-isoleucine methyl ester, 
(Figure 39), again as both the L-isoleucine diastereomer 4.06, and the mix of L- and 
D-allo-isoleucine diastereomers, 4.07. This would hopefully provide a more accurate 
model for the C-terminus of azolemycin A. 
Figure 39: Proposed mimic for the last three C-terminal residues of azolemycin A, and the retrosynthesis to the 
phenyl oxazole , 4.04, and isoleucine methyl ester, 3.14 
 
4.3 SYNTHESIS OF OXAZOLES 
Oxazoles, particularly the 3, 5-substituted oxazoles seen in azolemycin, are relatively 
common in natural products,4 and a number of methods have been developed for 
their synthesis.5, 6 When the starting point is a natural amino-acid (here benzoyl-L-
threonine methyl ester, 4.03, the general route involves a dehydration followed by an 
oxidation ( Figure 40, A), or an oxidation followed by dehydration (Figure 39, B). 
While this limits the substituents at the 2- position to either a hydrogen or a methyl 
group, it has the advantage of simplicity, and does allow a certain range of 
substituents at the 3- and 5- positions.  
 
 
 
 
173 
 
 Figure 40: A general route to oxazoles from C- and N-substituted serine or threonine.  
In the case of route A, a range of dehydrating agents have been utilised to form the  
oxazoline intermediate, including thionyl chloride,7 sulfonyl chlorides,8-10  PPh3 with 
DEAD or CCl4,10, 11 Burgess reagent,12-14 and the fluorinating agents DAST and 
Deoxo-Fluor.15 A similarly wide range of oxidation agents have been reported to 
produce the oxazole, including BrCCl3 and DBU,16 CuBr2,17 MnO2,18 DDQ,19 and  
NiO2.20  
In route B, the initial oxidation is generally performed using Parikh-Doering 
conditions,21, 22 Dess-Martin periodinane,23 Jones reagent,24 or similar, before a 
Robinson-Gabriel type dehydration is performed to give the oxazole.25, 26 Again, a 
wide variety of dehydrating agents have been reported, but most commonly these 
include PPh3-I2-NEt3,27 thionyl chloride,28 H2SO4,29 POCl3,30 and P2O5.31 
Considering the gamut of reagents available for these two, relatively simple, routes, 
it was obvious that the ideal combination could depend on the particular substrate 
used. We planned to synthesise the phenyl oxazole 4.04 using the amino-acid 
precursor, benzoyl-L-threonine methyl ester 4.03. Having considered the literature, 
we successfully used DAST for the initial oxazoline formation, followed by a 
BrCCl3-DBU oxidation to give the phenyl oxazole methyl ester (Scheme 23), as 
described by Pattenden et al. in their synthesis of the polyoxazole cyclopeptide YM-
216391 (Figure 46).32 
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The methyl ester was hydrolysed and a peptide coupling reaction gave the 5-methyl-
2-phenyl-oxazole-4-carboxy-L-isoleucine methyl ester, 4.06. A portion of this was 
hydrolysed to the carboxylic acid and epimerised using the method previously 
described (Chapter 3, Scheme 17). The methyl ester was reformed to give the 5-
methyl-2-phenyl-oxazole-4-carboxy-isoleucine methyl ester as a 1: 1 mix of L-
isoleucine and D-allo-isoleucine diastereomers, 4.07. The 1H NMR spectra of 4.06 
and 4.07 were compared to confirm the shifts associated with the α-CH of the two 
diastereomers.  
Scheme 23: The route to the 5-methyl-2-phenyl-oxazole-4-carboxy-isoleucine methyl ester as both the single L-
isoleucine diastereomer, 4.06, and the mix of L- and D-allo-isoleucine diastereomers, 4.07 
Comparison of the 1H NMR spectra of the mix of diastereomers and azolemycin A 
showed a near complete overlap between the peak associated with the α-CH of the 
isoleucine in azolemycin A and the peak of the L-diasteromer of 5-methyl-2-phenyl-
oxazole-4-carboxy-isoleucine methyl ester (within 0.01 ppm), and similarly close 
coupling constants (Figure 41, Figure 42). This reinforced our tentative assignment 
of the relative stereochemistry of the isoleucine residue in azolemycin A as either L-
isoleucine or D-isoleucine, with L-isoleucine being the most likely enantiomer.  
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Figure 41: The 1H NMR spectra for the mix of diastereomers, 4.07, (top spectrum) and for azolemycin A 
4.01(bottom spectrum), with the signals associated with the α-CH highlighted 
 
 
 
Figure 42: Highlighting the signals associated with the α-CH for mix of diastereomers of benzoyl-isoleucine 
methyl esters, 4.07, (top), and azolemycin A, 4.01 (bottom) 
The stereochemistry of the terminal isoleucine was later confirmed by Marfeys' 
analysis of the natural product, and it was extremely pleasing to see our hypothesis 
proved in the characterisation of a new natural product. 
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4.4 THE TOTAL SYNTHESIS OF POLYAZOLE NATURAL PRODUCTS 
With the successful synthesis of the model oxazole 4.07, our interest in the natural 
product, azolemycin A, increased. At the time, only 1 mg of the product had been 
extracted and it was from this that the structure had been obtained and the 
stereochemistry confirmed. Azolemycin A is a relatively simple natural product, and 
we realised it could be entirely synthesised from naturally occurring amino-acids. In 
addition, it has only two stereocentres that would be at risk of epimerisation, and we 
were confident that the experience we had gained in peptide coupling would allow us 
to complete a total synthesis of azolemycin A without risking epimerisation of the 
valine and isoleucine α-CH centres.  
Until the 1980's, very few thiazole and oxazole-containing natural products had been 
known, but an increasing array have since been identified, particularly derived from 
marine sources.5, 6, 33-35 These products range from single oxazoles and thiazoles to 
more complicated linked chains or macrocycles of concatenated azoles. The 
combination of potent biological activity of many of these azole products and the 
exciting synthetic challenges they pose has made them extremely attractive targets 
for total syntheses.4, 36, 37  
Polyazoles, or polyazole-containing, natural products tackled in total syntheses range 
from the relatively simple linked bis- and triazole motifs, as found in the 
hennoxazoles,38 muscorides (Figure 43),39, 40 bleomycins,41, 42 and myxothiazols,43, 44 
to more complicated macrocyclic molecules such as the heptazole telemestatin and 
the related YM-216391.    
Figure 43: The structures of the bisoxazoles (-)-hennoxazole and muscaride A 
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The inclusion of azoles, particularly multiple linked azoles, into a total synthesis 
obviously provides a greater challenge than the synthesis of a single isolated 
oxazole. Many of the reagents and methods classically used for oxazole synthesis 
may be unsuitable for inclusion in a total synthesis, due to incompatibility with 
protecting groups and the need to conserve the stereochemistry in other areas of the 
molecules. New strategies to cope with these problems have been developed, of 
which a few are described below. 
 
4.4.1 SYNTHESIS OF POLYOXAZOLE COMPOUNDS 
Wipf's synthesis of (+)-hennoxazole (the enantiomer of the natural product, Scheme 
24) involved an iterative bisoxazole synthesis.45 The first serine residue was 
dehydrated using Burgess reagent to give the oxazoline, then oxidised using CuBr2 
and DBU to give the A oxazole unit. In contrast, the second serine-derived B oxazole 
unit was formed via oxidation to the aldehyde using Dess-Martin reagent, followed 
by cyclodehydration using 1,2-dibromotetrachloroethane, PPh3 and an extremely 
hindered base, 2,6-di-tert-butyl-4-methylpyridine, which stopped at the intermediate 
10-bromooxazoline. The AB bisoxazole unit was then obtained using a DBU 
mediated dehydrohalogenation reaction.46 
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Scheme 24: Wipf's synthesis of oxazoles A and B of (+)-hennoxazole45 
Alternative syntheses of the hennoxazoles have also used a convergent synthesis of 
the bisoxazole moiety, though the reagents differ.47-49 Most simply, this was 
achieved by Williams et al. using a DAST mediated cyclodehydration and 
BrCCl3/DBU oxidation to form the A oxazole unit, followed by a peptide coupling 
and repetition of these dehydration/oxidation condition to give the AB bisoxazole 
(Scheme 25).47  
Scheme 25: Williams' synthesis of oxazoles A and B of (-)-hennoxazoles47 
Wipf's synthesis of the threonine derived bisoxazole fragment of muscoride A was 
also obtained by an iterative sequence of oxidation and dehydration, using a Dess-
Martin oxidation, followed by dehydration using PPh3/I2/NEt3 (Scheme 26).39, 46  
This was found to be a superior strategy to tandem formation of the oxazoles, as the 
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extremely polar tripeptide precursor (Pro-Thr-Thr) was difficult to handle in organic 
solvents.  
Scheme 26: Wipf's synthesis of the bisoxazole moiety in muscoride A 
 
4.4.2 THIAZOLES IN NATURAL PRODUCTS 
The inclusion of thioazoles in natural products requires further consideration. It is 
possible to synthesise them in a biomimetic fashion from cysteine, as performed by 
Hecht et al. in the synthesis of the bisthiazole unit of bleomycin B2 (Scheme 27).50  
Scheme 27: The bisthiazole synthesis developed by Hecht et al50  
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The two thiazoles were synthesised in succession. Treatment of the cysteine residue 
with HCl gave the initial thiazoline, which was then oxidised using NiO2 to give the 
first thiazole. Saponification of the ester was followed by a peptide coupling and 
deprotection of the cysteine thiol to give a tripeptide. This was dehydrated and 
oxidised as before, though in substantially poorer yields.  
An alternative method was used by Pattenden et al. for the synthesis of the  
bisthiazole moiety of myxothiazol (Scheme 28).51 This involved preparation of a 
thioamide, followed by a modified Hantzsch thiazole synthesis with ethyl 
bromopyruvate. This proceeded via the hydroxythiazoline, which was then 
dehydrated to give thiazole ester.52 This sequence was then repeated to give the 
bisthiazole.  
Scheme 28: The synthesis of the bisthiazole moiety of myxothiazol51 
The Hantzsch thiazole synthesis has been used extensively in natural product 
synthesis,52-55 but can be limited by the α-halo ketones used, meaning the thiazoles 
can only be built up sequentially.  
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4.4.3 TELOMESTATIN AND OTHER MACROCYLIC POLYAZOLES 
The synthesis of natural products containing mixed threonine and serine-derived 
oxazoles and thiazoles adds a new level of complexity to the choice of reagents and 
route. Telomestatin is a complex macrocyclic polyazole derived from Streptomyces 
anulatus 3533-SV4 and has been shown to be a potent telomerase inhibitor.56, 57 The 
total syntheses of this has been completed as both the (R)- and (S)- enantiomers by 
two groups, Doi et al.58, 59 and Moody et al.60 While both groups exploited the same 
disconnections, giving two trisoxazole building blocks, the method by which the 
oxazoles were synthesised were markedly different (Figure 44).  
Figure 44: (R)-Telomestatin, and the common disconnections by Doi et al. and Moody et al. 
In the synthesis of the natural (R)- and unnatural (S)-enantiomers, Doi et al. used 
relatively simple reagents to build up the two building blocks, based on three 
common synthetic units (Scheme 29). Oxazole A was synthesised using a Parikh-
Doering oxidation,21 followed by a PPh3/I2/NEt3 dehydration, while synthesis of 
oxazole B used a Burgess cyclodehydration, followed by  BrCCl3/DBU mediated 
oxidation to give the 2 trisoxazoles. 
182 
 
Scheme 29: Synthesis of the ABC trisoxazole by Doi et al 
The serine derived oxazoles, G, F, E and C were synthesised using cyclodehydration 
with DAST and BrCCl3/DBU mediated oxidation (Scheme 30). 
Scheme 30: Synthesis of the EFG trisoxazole by Doi et al. 
The two trisoxazole units were joined by the peptide bond formation between 
oxazole G and the cysteine residue. Following a peptide coupling between the 
deprotected serine residue of oxazole E and the deblocked carboxylic acid of oxazole 
C, attempts to form the oxazole D using the methods previously employed did not 
work. Instead, the serine residue was dehydrated and treatment of this alkene with 
NBS in the presences of 4Å molecular sieves afforded the α-methoxy-β-peptide. 
Dehalogenative cyclisation provided the methoxy-oxazoline which was dehydrated 
by treatment with camphor sulfonic acid to give oxazole D (Scheme 31).  
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Scheme 31: Formation of oxazole D 
Finally, the sulfur was deblocked and the thiazoline formed by treatment with 
PPh3(O)/TFAA/anisole to give (R)-telomestatin. 
The synthesis by Moody et al. utilised a rhodium catalysed oxazole formation to 
build up the two trisoxazole units.60 In this, the oxazoles were built up sequentially 
using reactive rhodium carbene intermediates in reactions with either a nitrile or a 
carboxamide (Figure 45). This synthesis showcases the robustness and utility of 
these transition metal reactions already seen in the total synthesis of a number of 
other oxazole conataining natural products,27, 61-63 though the overall yields still do 
not approach those seen in more conventional approaches.  
Figure 45: Routes to the rhodium catalysed synthesis of substituted oxazoles (adapted from Moody et al.60) 
We were particularly interested in the synthesis of two structurally related 
macrocycles, YM-216391 synthesised by Pattenden et al.,32, 64and IB-01211 by 
Albericio et al.,65 as these have a number of structural similarities to azolemycin. 
Specifically, they contain a mix of oxazoles, amino-acid residues (YM-216391, Gly-
Val-D-allo-Ile; IB-01211, Val-D-allo-Ile) and a thiazole flanked by oxazoles (Figure 
46).  
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Figure 46: The structurally related IB-01211 and YM-216391  
Both syntheses used a DAST cyclodehydration followed by an oxidation to form the 
four oxazoles, though Albericio et al. reported significant formation of the 
elimination product rather than the desired oxazoline when the β-phenyl-serine 
residue was treated with DAST. Interestingly, they also reported what they believe to 
be the first one pot formation of two concatenated oxazoles (Scheme 32) by 
cyclodehydration and oxidation. The oxidation of the concatenated oxazolines 
proved significantly more difficult than for the sequentially formed oxazolines, 
requiring the use of CCl4/DBU in MeCN/pyridine to obtain the bisoxazole in 57% 
over 2 steps.  
Scheme 32: The one-pot synthesis of the concatenated oxazoles by Albericio et al. 
The syntheses of YM-216391 and IB-0211 differed significantly in the formation of 
the thiazole. Albericio et al. used a Hantzsch thiazole synthesis to effect the final 
macrocyclisation. Deprotection of the C-terminal bromo ketone, formation of the 
hydroxythiazoline and dehydration to the thiazole were performed in a one-pot 
process to give the final macrocycle in 11 % yield.  Conversely, while Pattenden et 
al. also performed the thiazole formation last, they did not use it to close the 
macrocycle. Instead, a protected serine residue was carried through the synthesis, 
N
O
O
N
N S
N
O
N
OO
NH
NHO
NH
O
H
H
H
N
O
O
N
N S
N
O
N
OO
NH
NHO
NH
O
H
H
H
IB-01211 YM-216391
185 
 
before treatment with Lawesson’s reagent to give the equivalent thioamide. 
Deprotection of the serine oxygen was followed by two peptide couplings to form 
the macrocycle before cyclodehydration gave the thiazoline. This heterocycle was 
oxidised with MnO2 to give the thiazole and complete the synthesis (Scheme 33). In 
this case, late stage thiazole formation gave the additional conformational flexibility 
required for the formation of the macrocycle.  
Scheme 33: Formation of the thiazole in a diastereomer of YM-216391 by Pattenden et al 
An interesting sidenote to the synthesis of YM-216391 is the apparent discrepancy 
for the stereochemical assignment of the isoleucine. Sohda et al. assigned this as D-
allo isoleucine, though it is drawn as D-isoleucine in the article.66 They were unable 
to differentiate between D- and D-allo-isoleucine by Marfey’s analysis, but the 
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absolute configuration was assigned as D-allo-isoleucine by chiral HPLC. Pattenden 
et al. do not explicitly state their stereochemical assignment for natural (+)-YM-
216391, but they originally synthesised it as the D-Val-L-Ile streeoisomer (-)-YM-
216391, which gave an equal and opposite optical rotation to the natural product 
((+)-YM-216391,  

 +48 (c = 0.1, CH3CN); synthesised (-)-YM-216391,    -
56 (c = 0.5, CHCl3)). They therefore concluded that the compounds had the same 
relative stereochemistry, but exactly opposite absolute stereochemistry, implying the 
isoleucine is present in the natural product as the D-isoleucine rather than D-allo-
isoleucine stereoisomer. In fact, a recent paper describing the biosynthesis of natural 
(+)-YM-216391 has again confirmed the stereochemistry as D-allo-isoleucine.67 This 
further validates the utility of our method for differentiating between the relative 
diastereomers of isoleucine, especially in cases such as the synthesis of YM-216391, 
where the introduction of isoleucine occurs at a relatively late stage. In this case, it 
would be possible to produce the product as a mix of L- and D-allo isoleucylpeptides, 
allowing ready confirmation of the relative stereochemistry.    
 
4.5 APPROACHES TO THE TOTAL SYNTHESIS OF AZOLEMYCIN A 
Having considered these previously synthesised natural products, especially the 
mixed polyazoles, we made the preliminary disconnections for the synthesis of 
azolemycin A. We immediately rejected a linear synthesis, as it would almost 
certainly be extremely low yielding, and instead focussed on a convergent synthesis, 
with late stage formation of the central thiazole, cf. the synthesis of YM-216391.32 
We therefore disconnected to give 4 distinct units: the isopropyl oxime 4.08, the left 
hand mixed bisoxazole fragment 4.09, the right-hand methyl oxazole 4.10 and the 
isoleucine methyl ester 3.14 (Figure 47). 
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Figure 47: Preliminary disconnections for the synthesis of azolemycin A 
4.5.1 SYNTHESIS OF MODEL OXAZOLES 
Our main concern at this early stage was preserving the stereochemistry of the N-
terminal valine during the formation of oxazoles A and B. We therefore synthesised 
carboxylbenzoyl-L-isoleucyl-threonine-methyl ester 4.12 to assess the level, if any, 
of epimerisation occuring during the two oxazole syntheses (Scheme 34). The dipeptide 
was converted to the oxazole by the two different methods we hoped to use in the 
synthesis of azolemycin A. The first was the DAST mediated cyclodehydration, 
followed by a BrCCl3/DBU oxidation. This gave the oxazole with no apparent 
epimerisation of the isoleucine α–stereocentre by 1H NMR spectroscopy, though a 
significant amount of the elimination product 4.13 was also obtained in a ratio of 
around 2:1 (oxazole 4.12: alkene 4.13).  
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Scheme 34: The preparation of the model oxazole, 4.12,  as a single diastereomer 
As we did not want to risk the formation of this elimination by-product during the 
synthesis of oxazole B, we also synthesised oxazole 4.12 using a different method. 
By first oxidising the threonine residue to a ketone, then performing a 
cyclodehydration, we hope to avoid this side reaction. Though there are a range of 
oxidation reagents available for this, we chose to follow the method set out by Doi et 
al.,58 using a Parikh-Doering oxidation to give the β-ketoester. Whilst being mild and 
compatible with a range of functional groups, the Parikh-Doering oxidation has the 
advantage over the related Swern oxidation of being able to tolerate a wider range of 
temperatures, and reduced risk of by-products.68 The cyclodehydration was 
performed according to the method developed by Wipf,46 which provides a milder 
route to oxazoles compared to the traditional Robinson-Gabriel conditions.26  This 
again produced oxazole 4.12 with no apparent epimerisation at the isoleucine 
stereocentre, and, as expected, in better yield than the DAST route.  For comparison, 
the oxazole was also synthesised as a mix of diastereomers 4.17 from the previously 
epimerised isoleucine 3.12 (Scheme 35).  
 Scheme 35: Synthetic route to the model oxazole 
diastereomers 
As noted previously, the 
for us to confirm that neither method of oxazole synthesis appeared to markedly 
affect the stereo integrity of the 
Figure 48: The dd peaks associated with the amide 
4.80 ppm and the signal from
4.12 (bottom spectrum) and the reaction with the mix of two diastereomers 
 
4.17 as a mix of L-isoleucine and 
1H signal for the isoleucine α-CH was sufficiently different 
N-terminal amino-acid (Figure 48)
α-CH signal, showing the signal from 
 D-allo-isoleucine at around 4.91 ppm from the reaction with the single diastereomer 
4.17 (top spectrum)
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Finally, to test the hydrolysis conditions needed to unblock the methyl ester, both the 
single diastereomer 4.12 and the mix 4.17 were hydrolysed to the corresponding 
acids 4.14 and 4.18 using lithium hydroxide. Again, no apparent epimerisation was 
observed by 1H NMR spectroscopy. 
 
4.5.2 SYNTHESIS OF THE AB BISOXAZOLE FRAGMENT 
The preparation of model oxazoles 4.12 and 4.17 gave us confidence that we could 
bring the N-terminal valine though the synthesis (including peptide couplings, 
oxazole synthesis and hydrolysis) without risking significant epimerisation of the 
stereocentre. The initial dipeptide was formed by an HOBt catalysed peptide 
coupling in consistently high yields. Initially, the cyclodehydration to the 
intermediate oxazoline was performed using CCl4/PPh3/NEt3 before oxidation with 
BrCCl3/DBU to give the oxazole (Scheme 36). However, the stoichiometric 
quantities of triphenylphosphine oxide produced complicated the work-up, leading to 
disappointing yields. Switching to a DAST mediated cyclodehydration did not 
significantly increased the yield, but gave a more straightforward work-up so the 
reaction was easier to perform on larger scales.  
Scheme 36: The route to AB bisoxazole unit 
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Saponification of oxazole 4.21 and a further amide coupling gave threonine 
tripeptide 4.23 in excellent yields. Formation of the second oxazole proved more 
difficult than the first. The residue was first oxidised using the Parikh-Doering 
conditions before cyclodehydration with PPh3/I2. The yields were, at best, moderate 
and removal of the triphenylphosphine byproducts again proved an issue. However, 
attempts to use DAST to perform the initial dehydration gave a roughly 1:1 mixture 
of the elimination product and desired oxazoline. These had to be separated by 
column chromatography, as the alkene was extremely difficult to separate from the 
final oxazole if carried through to future steps, and the final oxazole yields were too 
low for this to be a viable alternative. Despite these issues, sufficient quantities of the 
AB bisoxazole unit 4.09 were synthesised to continue the synthesis.  
 
4.5.3 SYNTHESIS OF THE D OXAZOLE DIPEPTIDE 
The N, O-protected serine derivative 4.26 underwent a peptide coupling to the 
threonine dipeptide 4.27 (Scheme 37) in excellent yields. As before, oxidation of the 
threonine residue using the Parikh-Doering conditions and cyclodehydration using 
PPh3/I2/NEt3 gave the oxazole in moderate to low yields. It was not entirely obvious 
why the yields were so low, but there were a number of problems with both steps of 
the reaction.  
It was difficult to track the progression of the oxidation, either by TLC or 1H NMR, 
probably due to ready enolisation of the β-keto ester. Though the Parikh-Doering 
reaction is known to be more tolerant to increased reaction temperatures than the 
Swern oxidation, it was difficult to consistently maintain a low internal temperature 
when performed on a large scale, and this is known to have an effect on the yield of 
the reaction.68 As noted previously, the cyclodehydration produced an equivalent of 
triphenylphosphine oxide, making the work-up and purification of the oxazole non-
trivial, particularly on a multigram scale 
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Scheme 37: The synthesis of the D oxazole unit 
When scaling up the oxidation we also found that removing excess starting material 
by silica chromatography was not straightforward, and in a number of batches some 
unreacted alcohol was carried through to the cyclodehydration. In these cases, the 
elimination product, 4.28, was obtained and, as before, this was extremely difficult 
to separate from the desired oxazole. As the oxazole was not easy to synthesise in 
large batches, we turned to an unusual method to remove the alkene. A Sharpless 
asymmetric dihydroxylation was performed,69, 70 which did not affect the oxazole, 
but gave what we assumed to be an extremely unstable diol (Scheme 38). As a 
simple aqueous work-up afforded only the clean oxazole, we assume this diol 
decomposed to give two water soluble by-products - an amide and a carbonyl ester. 
Scheme 38: The cleavage of the unwanted alkene 4.20 using a Sharpless asymmetric dihydroxylation (L* = 
(DHQD)2PHAL )  
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4.5.4 SYNTHESIS OF THE PENTAPEPTIDE 
 
4.5.4.1 Lawesson’s Reagent 
The AB oxazole unit 4.09 was coupled to the deblocked serine residue of the D 
oxazole unit 4.29 in good yields using the HOBt/EDCI strategy previously employed 
(Scheme 39).  Initially, we hoped to form the thiazoline in one step using Lawesson's 
reagent, according the procedure described by Zarantonello et al. in their preparation 
of althiomycin analogues.71  However, the majority of the product obtained was the 
elimination product 4.31, with no isolated thiazoline or thioamide.  
Scheme 39: Attempted synthesis of the internal thiazoline 
As this approach failed, we chose to undertake a slightly longer synthetic route, with 
a much lower risk of elimination. The serine alcohol was protected, and the 
thioamide formed using Lawesson's reagent. As suggested by the lack of thioamide 
formation in our previous attempt (Scheme 40), this was a relatively slow process, 
requiring around 40 hours reaction time at reflux in a combination of toluene and 
THF. Despite this, the thioamide was obtained in relatively high yields following 
purification by silica chromatography. 
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Scheme 40: Revised route to thiazole-containing pentapeptide 
Conveniently, the 1H NMR spectrum of the thioamide 4.33 was significantly 
different from the carboxamide precursor 4.32. The chemical shift for the α-C14H 
adjacent to the thioamide group was around 0.5 ppm downfield, and the associated 
α-N13H nearly 2 ppm downfield compared to the equivalent carboxamide starting 
material (Figure 49). This allowed for rapid assessment of conversion from the crude 
1H NMR spectrum. 
Figure 49: The 1H NMR spectra for the thioamide 4.33 (bottom spectrum), highlighting the CH and NH shifts, 
and the equivalent carboxamide starting material 4.32 (top spectrum) 
 
 X = O, C14-H X = O, N13-H 
 X = S, C14-H X = S, N13-H 
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4.5.4.2 Formation of the Thiazole 
Following deprotection of the alcohol, the thiazoline was obtained using the same 
DAST cyclodehydration strategy as for the serine derived oxazolines (Scheme 40). 
However, the previous oxidation conditions (BrCCl3/DBU) did not appear to be 
sufficient, with incomplete thiazole formation observed even in the case of large 
excesses of reagent. Instead, a modified oxidation procedure using 
CCl4/pyridine/DBU was utilised, according the method of Jung et al.72 This route 
allowed us to complete the synthesis of the pentapeptide polyazole core 4.35, but 
initial efforts yielded only 22 mg, insufficient to reliably complete the total 
synthesis.  
 
4.5.5 REVISED SYNTHESIS OF THE PENTAPEPTIDE CORE 
Our initial approach to the pentapeptide core 4.35 (Figure 47), though successful, 
suffered from low yielding reactions early in the synthesis, particularly in the 
production of the AB oxazole unit 4.09. While re-examining the synthetic route, we 
noticed symmetry within the molecule that we had missed during our preliminary 
disconnections. As the thiazole was derived from a serine residue, the tetraazole core 
could be divided into two repeating serine-threonine dimers, corresponding to the 
previously synthesised oxazole D 4.10 (Figure 50). We therefore revised our 
disconnections using oxazole D as a common precursor. An additional benefit to this 
synthetic route was the late addition of the N-terminal valine, reducing even further 
the possibility of epimerisation of the stereocentre. 
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Figure 50: Revised disconnections for the pentapeptide  
 
4.5.5.1 Synthesis of the BCD unit 
Following an EDCI/HOBt mediated peptide coupling between two differently 
deprotected oxazole units 4.25 and 4.36, thiazole 4.41 was installed using the same 
chemistry as before (Scheme 40) to give the protected BCD trisazole unit (Scheme 
41).  
Scheme 41: Synthesis of the BCD azole unit 
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Deblocking of the N-terminal serine residue and a further peptide coupling installed 
the N-terminal valine residue 4.19 (Scheme 42). This was readily converted to the 
corresponding oxazoline using DAST, and attempts were then made to convert the 
crude mixture to the oxazole. However, neither of the previously employed oxidation 
strategies (DBU/BrCCl3 or DBU/Pyr/CCl4) resulted in any significant oxazole 
formation. Some conversion was noted with commercial activated MnO2, but the 
yields were extremely low (<1 %) and irreproducible.  
Scheme 42: Revised synthesis of the pentapeptide 4.35 
We expected the oxidation to be comparatively more difficult than for oxazolines 
with an electron withdrawing group at the 5-position, but considering the relative 
ease of the oxidation for the internal thiazole 4.41 (Scheme 41) we did not anticipate 
such difficulty. It appears that, while an electron withdrawing group at the 5-
position, especially an ester, is important for the oxidation of oxazolines (where 
CuBr2 is used, it is apparently essential), the reaction also benefits from conjugation 
with neighbouring azoles. In the case of the oxazoline 4.44, there is neither 
significant conjugation nor a strong electron withdrawing group. Though this would 
be expected to disfavour oxazole formation, we were encouraged by the small 
quantity of oxazole produced by MnO2 oxidation. Though oxidations of this type of 
unactivated oxazoline are not common in the literature, examples do exist which 
utilise either MnO2 or NiO2,20 both of which are assumed to follow a similar 
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mechanism.73-76 As the commercial activated MnO2 gave very poor results, freshly 
activated MnO2 was synthesised according to the method of Carpino et al.77 
Activated carbon is oxidised by potassium permanganate, and the resulting active 
MnO2 is deposited on the remaining unoxidised carbon. Using this preparation, the 
product oxazole 4.35 was obtained, but the yield was still extremely low (4 %). 
 
4.5.5.2 Manganese Dioxide 
Whilst the second set of disconnections provided some significant advantages over 
our first synthetic attempt, namely providing a more convergent synthesis a common 
building block to build the central pentapeptide, it also suffered from extremely poor 
yields. This was primarily due to the poor conversion of the final oxazoline to form 
oxazole A. We were hopeful that by installing this oxazole unit earlier, and 
optimising the MnO2 oxidation for this conversion, we could complete the synthesis 
of the pentapeptide in sufficiently high yields to progress the synthesis. We decided 
that the convenience of having a common building block 4.29 overruled the 
problems associated with the oxidation of the relatively unactivated N-terminal 
oxazoline. In order to mitigate the low yield, we decided to install this earlier in the 
synthesis, choosing to use oxazole 4.29 as a building block for an alternative 
synthesis of the AB oxazole unit 4.09 (Figure 51). 
Figure 51: Revised disconnections for the AB bisoxazole 
We had already found that the MnO2 prepared according to Carpino’s procedure 
gave better results that the commercially obtained reagent. Despite being a widely 
used oxidising agent, many procedures do not state the provenance or preparation 
method of MnO2, and the method of preparation has been shown to have a 
significant effect on the activity.78, 79 Common procedures involve either the 
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pyrolysis of a range manganese salts at high temperatures,80, 81 or, more 
conveniently, by the precipitation of MnO2 from the reaction of a solution of 
potassium permanganate and manganese sulfate in acidic or basic conditions.82-84 
These give preparations of varying activities, and it is reported that the activity can 
be increased by washing with dilute nitric acid.81 In addition, MnO2 can be 
conveniently deposited onto silica,85 aluminium86 or, as previously described, 
carbon.77  
To our knowledge, there is no information regarding the risk, if any, of epimerisation 
of amino-acid stereocentres during MnO2 oxidations. Though not very likely, the 
prolonged heating required for the transformation prompted us to perform the 
reaction first on a model isoleucine compound, to ensure the stereointegrity of the N-
terminal valine could be maintained.  
The Boc-protected dipeptide was synthesised as both the single isoleucine L-
diastereomer 4.47 and a mix of L-isoleucine and D-allo-isoleucine diastereomers 4.48 
(Scheme 43). The oxazoles were prepared by a DAST cyclodehydration, followed by 
heating with a large excess of MnO2, prepared as the Carpino method. 
Scheme 43: Preparation of the model isoleucine containing oxazoles 
Encouragingly, we could see no evidence of epimerisation of the isoleucine α-
stereocentre by 1H NMR (Figure 52) but the yields and conversion of the oxazole 
were still poor.  
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Figure 52: The dd peaks associated with the amide α-CH signal, showing the signal from L-isoleucine at around 
4.86 ppm and the signal from D-allo-isoleucine at around 4.96 ppm from the reaction with the single 
diastereomer, 4.49 (bottom spectrum) and from the reaction with the mix of two diastereomers, 4.50 (top 
spectrum) 
The conversion of the crude reaction was, at best, 50 % over reaction times of 
around 20 hours, and though the oxazoline and oxazole were easily separated by 
silica chromatography, the isolated yields were much lower than would be expected 
(1 - 2 %). 1H NMR showed no obvious by-products being formed competitively, and 
it appeared that the low yield was partially caused by the product complexing with 
the MnO2. 
In order to improve both the yield and the conversion, we investigated a second 
method of producing activated MnO2. Following a method proposed by Ball, 
Goodwin and Morton, an aqueous solution of potassium permanganate was reacted 
with manganese sulfate in neutral medium to give a precipitate of MnO2.84 This was 
then activated as required by azeotropic drying with toluene, as described by 
Goldman.87 Unlike Carpino’s method, this gave us a precipitate of pure MnO2, 
which could be reduced after completion of the reaction to give water soluble 
manganese sulfate and manganese dithionate, allowing for an aqueous work-up. In 
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this case, the reduction of MnO2 was performed by aqueous SO2, produced in situ 
from a solution of H2SO4 and sodium bisulfite (Equation 1).  
Equation 1: The formation of sulphur dioxide and subsequent reaction with manganese dioxide88 
 
4.5.5.3 Revised preparation of AB Oxazole Unit 
With an improved preparation of MnO2 in hand, we again attempted the synthesis of 
the AB oxazole unit 4.09. Again, the peptide coupling to give the tripeptide 4.51 
progressed smoothly, as did the DAST-mediated cyclodehydration to give the crude 
oxazoline (Scheme 44). The MnO2 oxidation was performed using the crude 
unactivated MnO2, prepared according to the method Ball, Goodwin and Morton 
(vide supra). This was calculated as ~50 weight % water by mass. Residual water 
was removed using Dean-Stark apparatus, before addition of the oxazoline as a 
solution in toluene, and the reaction was complete by 1H NMR spectroscopy within 
6 hours at 110 ˚C. Reduction of the MnO2, aqueous work-up and silica 
chromatography gave the clean bisoxazole 4.09 in 27 % yield over 2 steps, a great 
improvement of the oxazole formation of the pentapeptide 4.35 (Scheme 42). It 
appears that the majority of product was lost in the aqueous work-up, so a more 
careful approach to the removal of the MnO2, or use of more robust protecting 
groups, could make this an extremely useful approach to unactivated oxazoles. 
 
 
 
 
H2SO4 + Na2SO3 Na2SO4 + SO2 +H2O
3SO2 + 2MnO2 MnSO4 + MnS2O6
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Scheme 44: The revised route to the AB bisoxazole unit 
This route, though not ideal, provided the AB bisoxazole unit in sufficiently high 
quantities to complete the synthesis. 
 
4.5.6 COMPLETION OF THE AZOLEMYCIN SYNTHESIS 
The synthesis of the bisoxazole AB fragment, 4.09, using the revised method, 
although still relatively low yielding, was substantially easier that the original 
method. Ideally, we would have liked to optimise the synthesis, firstly by improving 
the synthesis of the oxazole D building block 4.10, and secondly by improving the 
work-up for the MnO2 oxidation. However, due to time constraints, we decided to 
continue the synthesis without optimisation.  
The pentapeptide was successfully synthesised using the same route as before 
(Scheme 45). The overall yields were much improved compared to our first attempt, 
mianly to improvements in purifying the thioamide 4.32 and hence being able to 
perform the later reactions on a larger scale, giving the final polyazole in nearly 
tenfold greater yield than the first attempt. 
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Scheme 45: The third, successful, route to the pentapeptide 4.35, showing the yields from the previous attempt 
(route A; Scheme 39, Scheme 40) 
The saponification of the methyl ester was much less straightforward than for 
previous compounds, due to the extremely non-polar character of the polyazole and 
required long reaction times, extremely low dilution and a mix of solvents for 
dissolution and complete reaction (Scheme 46). Once formed however, the resulting 
acid 4.52 was readily coupled to the C-terminal isoleucine residue to give the 
hexapeptide 4.53. L-Valine was converted to 2-hydroxyl-isovaleric acid 4.55 and 
coupled to the deblocked valine residue to give the alcohol precursor 4.56, which 
was oxidised to the ketone 4.57 using Parikh-Doering conditions. Finally, the oxime 
was installed to provide azolemycin A 4.01 in 21 steps (16 steps, longest linear 
sequence), and an overall yield of 0.3 %.  
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Scheme 46: Route to the synthesis of azolemycin A 
Comparison of the 1H spectrum of the synthesised product with that of the extracted 
natural product showed extremely close correlation (Figure 53). 
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Figure 53: Top Spectrum: The 1H NMR spectra for the synthetic azolemycin A, 4.01, prepared as the cis 
isomer. Bottom Spectrum: The 1H NMR spectra of the natural product azolemycin A from bacterial extract as 
the cis isomer 
While the naturally extracted product was isolated separately as both the cis and 
trans geometric isomers, this was not possible for the synthesised product. In fact, 
the major product isolated was the cis oxime, with traces of the trans, based on the 
valine α-CH peaks on 1H NMR spectra. However, as it is likely that the two isomers 
will interconvert in solution we were not concerned about this. 
There had been insufficient natural product obtained by bacterial extract to obtain a 
13C NMR spectrum, and the carbon chemical shifts had been obtained by analysis of 
the HMBC and HMQC spectra. Comparison of the 13C NMR spectrum obtained for 
the synthetised product with the carbon signals in near complete agreement, with the 
only discrepancy occurring in the assignment of the chemical shift for the δ-methyl 
group of isoleucine, given as 18.8 ppm for the bacterial extract but identified as 11.5 
ppm for the synthesised product. The lower shift was confirmed as correct by 
HMQC, HMBC and by comparison with other isoleucine compounds.      
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4.5.7 BIOLOGICAL TESTING 
At present, no biological activity has been identified for azolemycin A, as the limited 
quantities afforded by bacterial extraction restricted the possible assays required to 
identify this. However, our synthetic route presented us with sufficient quantities to 
allow a much greater range of assays to be run in future.                                                                         
 
4.6 SYNTHESIS OF AZOLEMYCIN B 
The methoxy analogue of azolemycin 4.02 was also synthesised using the same 
conditions as the hydroxyl product 4.01 (Scheme 47).  
Scheme 47: Formation of the methoxy analogue of azolemycin A 
This was obtained as primarily the trans-geometric oxime isomer, but in this case the 
interconversion between the oxime isomers was much faster than for the 
hydroxyoxime 4.01, with an NMR sample showing near complete conversion to the 
cis-isomer in around 5 days. Comparison of the 1H NMR spectra of these two 
geometric isomers with the corresponding natural product extracts showed good 
correlation between the synthesized and natural products (Figure 54, Figure 55). 
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Figure 54: Top Spectrum: The 1H NMR spectra showing the synthetic methoxyoxime product 4.02 as 
predominately the trans isomer (obtained on 400 MHz machine). Bottom Spectrum: The 1H NMR spectra 
showing the natural product, azolemycin B, as the trans isomer (obtained on 700 MHz machine) 
 
 
 
 
 
Figure 55: Top Spectrum: The 1H NMR spectra showing the synthetic methoxyoxime product 4.02 as 
predominately the cis isomer. Bottom Spectrum: The 1H NMR spectra showing the natural product, azolemycin 
B, from the bacterial extract as the cis isomer 
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4.7 SYNTHESIS OF A POSSIBLE BIOLOGICAL PRECURSOR OF 
AZOLEMYCIN A 
Following the successful total synthesis of azolemycins A and B, we were left with a 
reasonable amount of the precursor hexapeptide 4.54. We therefore took the 
opportunity to synthesise precursor molecules that could be used to further clarify 
the proposed biosynthetic route (Scheme 48). It is currently uncertain whether the 
oxidation to the oxime or the methylation of the C-terminal acid occurs first. We 
therefore synthesised the reduced precursor 4.58 using the standard peptide coupling 
method. This could be selectively deprotected to give the free amine as both the 
methyl ester and the acid. Since the genes associated with the oxidation have been 
identified, the region associated with the flavin-dependent monooxygenase can be 
amplified. Challis and co-workers intend to achieve this and then attempt oxidation 
of both methyl ester and the acid. The enzyme may only oxidise one of these 
substrates, confirming the order of the methylation/oxidation. 
Scheme 48: Synthesis of the protected precursor peptide, and the proposed route to the selectively deprotected 
products 
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4.8 SYNTHESIS OF A TETRA-OXAZOLE ANALOGUE OF AZOLEMYCIN A 
With the compounds 4.01, 4.02 and 4.58 synthesised, we had time in hand, along 
with sufficient quantities of building blocks 4.24 and 4.29, to perform the synthesis 
of the tetra-oxazole analogue of azolemycin A, 4.65 (Scheme 49). This was achieved 
using the same reaction conditions as used for the synthesis of the natural products 
4.01 and 4.02, and progressed without incident to give 6 mg of oxazole analogue 
4.65. The only noteworthy moment in the synthesis was the comparative ease of the 
formation of the internal oxazole C compared to the N-terminal oxazole A in the 
bisoxazole fragment 4.35. This supports our hypothesis that, while an adjacent 
electron withdrawing group at the 5-position is important for the oxidation of 
oxazolines, the reaction will still proceed in excellent yields if it benefits from 
conjugation with neighbouring azoles.  
Scheme 49: The synthesis of the tetra-oxazole analogue of azolemycin A, 4.65 
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4.10 EXPERIMENTAL 
All the reagents and solvents used were purchased from the Sigma-Aldrich, Alfa-
Aesar, TCI, Bachem or Fluorochem Chemical Company and were used as received 
unless stated otherwise. pH 2 buffer was made as a solution of 0.75 M of Na2SO4 
and 0.25 M H2SO4 in H2O. 
 
1H- and 13C-NMR spectra were recorded on a Bruker AVII-700 MHz, AVIII-600 
MHz, DRX-500 MHz or DPX-400 MHz Fourier transform spectrometer at room 
temperature unless stated otherwise. Chemical shifts are quoted in parts per million 
(ppm) downfield from tetramethylsilane. Solvents were used as an internal standard 
when assigning NMR spectra (δH: CDCl3 7.26 ppm, CD3OD 3.31 ppm, DMSO-d6, 
2.50 ppm, D2O 4.79 ppm; δC: CDCl3 77.1 ppm, CD3OD 49.0 ppm, DMSO-d6, 39.5 
ppm). Coupling constants (J) are quoted in Hertz (Hz) and are rounded to the nearest 
0.5 Hz. Abbreviations used in the descriptions of spectra are as follows; s = singlet, d 
= doublet, t = triplet, q = quartet, quin. = quintet, sept. = septet, oct. = octet, m = 
multiplet, br = broad, i = ipso, o = ortho, m = meta, p = para, ax. = axial and eq. = 
equatorial. 13 C-NMR spectra were recorded with broadband proton decoupling and 
spectra were assigned on the basis of COSY, PENDANT, HMQC and HMBC 
spectra. In aromatic characterisations, the ipso carbon is taken to be the carbon 
bonded to the group with the highest molecular weight 
 
Infrared spectra were recorded on a Nicolet Avatar 320 FT-IR spectrophotometer 
using EZ OMNIC software package 1, Bruker ALPHA Platinum ATR 
spectrophotometer or Perkin ELMER Spectrum 100 FT-IR spectrophotometer using 
OPUS software and are quoted in wavenumber (cm-1). 
Optical rotations were recorded on an Optical Activity Ltd. AA-1000 millidegree 
auto-ranging polarimeter (using the sodium D line; 589 nm) and [α]Ds are given in 
units of 10-1deg cm2 g-1. The samples were made using spectroscopic grade MeOH, 
CHCl3 or H2O. 
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ESI mass spectra were obtained on a Bruker Esquire 2000 mass spectrometer or an 
Agilent 6130B single Quad (ESI). HR ESI spectra were obtained by Dr Lijiang 
Song, Mr Philip Aston or Dr Rebecca Wills using a Bruker micro-TOF ESI attached 
to a time of flight (TOF) analyser.  
Melting points for solid crystalline products were determined on a Stuart Scientific 
SMP10 Digital Melting Point Apparatus, with three runs of each compound, and a 
range given in ˚C rounded to the nearest degree. They are uncorrected. CHN 
elemental analyses were carried out by Warwick Analytical Services.  
 
Thin Layer Chromatography (TLC) was performed using silica (0.25 mm) coated 
aluminium plates. 
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 Numbering system 
N-Benzoyl-L-threonine methyl ester 4.03 
Acetyl chloride (15.6 mL, 200 mmol) was added dropwise with stirring to MeOH 
(100 mL) at 0 - 5°C. L-Threonine (6.54 g, 54.9 mmol) was added and the resulting 
solution heated to reflux from 2 hours. The reaction mixture was concentrated in 
vacuo to give L-threonine methyl ester hydrochloride which was used without further 
purification. The resulting oil was dissolved in CH2Cl2 (160 mL) and triethylamine 
(17.4 mL, 125 mmol) and cooled to 0 °C with stirring. Benzoyl chloride (5.8 mL, 
49.9 mmol) was added dropwise and the reaction mixture allowed to reach room 
temperature over 18 hours. After quenching with saturated sodium hydrogen 
carbonate solution (100 mL), the mixture was separated and the aqueous phase 
extracted with CH2Cl2 (2 x 100 mL).  The combined organic extracts were 
concentrated in vacuo and the resulting yellow oil partitioned between EtOAc (100 
mL) and pH 2 buffer (100 mL). The organic phase was further washed with pH 2 
buffer (100 mL), water (100 mL), saturated aqueous NaHCO3 solution (2 x 100 mL) 
and saturated aqueous NaCl solution (100 mL), dried over Na2SO4 and concentrated 
in vacuo to give the crude product as a bright yellow oil. Recrystallisation 
(EtOAc:petroleum ether) afforded 4.03 as a fluffy white solid (8.03 g, 33.8 mmol, 62 
%);  mp. 96 - 97 °C (lit.1 97 - 98 °C); 25][ Dα +18.4 (c = 1.02, CHCl3), (lit.2 20][ Dα  
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+22.6 (c = 1.0 in CHCl3)); υ max/cm-1 3425 (O-H), 3348 (N-H), 1741 (ester C=O), 
1640 (amide C=O), 1521 (N-H); δH (400 MHz, CDCl3) 7.91 - 7.78 (2H, m, ortho C-
H), 7.55 - 7.48 (1H, m, para C-H), 7.46 - 7.41 (2H, m, meta C-H), 7.04 (1H, d, J 8.5 
Hz, CHNH), 4.82 (1H, dd, J 8.5, 2.5 Hz, CHNH), 4.50 - 4.40 (1H, m, CHOH), 3.78 
(3H, s, OCH3), 2.77 (1H, d, J  4.0 Hz, CHOH), 1.28 (3H, d, J 6.5 Hz, CHCH3); δC 
(100 MHz, CDCl3) 171.7 (CONH), 168.0 (CO2Me), 133.7 (ipso C), 132.0 (para C-
H), 128.6 (ortho C-H), 127.2 (meta C-H), 68.2 (CHOH), 57.7 (CHNH), 52.7 
(OCH3), 20.0 (CHCH3); m/z (ESI+) 260.1 ([M+Na], 100%); HR-ESIMS: calculated 
for C12H15NO4Na: 260.0893, found 260.0888 [M+Na]+.  The data are consistent with 
that previously reported.3 
5-Methyl-2-phenyl-oxazole-4-carboxylic acid methyl ester 4.04 
Method modified from literature procedure by Pattenden et al.4 (Diethylamino)sulfur 
trifluoride (2.4 mL, 18.0 mmol) was added dropwise to a stirred solution of ester 
4.03 (3.6 g, 15.0 mmol) in dry CH2Cl2 (150 mL) at - 78°C under N2. The mixture 
was stirred at – 78 °C for 1.5 hours, then allowed to reach room temperature and 
stirred for a further 15 minutes. The reaction was quenched by addition of saturated 
sodium bicarbonate solution (80 mL) and separated. The organic phase was dried 
and concentrated in vacuo to give the crude oxazolidine as a clear oil, which was 
used immediately without further purification.  
Bromotrichloromethane (4.4 mL, 46 mmol) was added to a stirred solution of the 
crude oxazolidine in dry CH2Cl2 (150 mL) at 0°C under N2 and the mixture was 
stirred at 0°C for 5 minutes. 1, 8-Diazabicyclo[5.4.0]undec-7-ene (6.9 mL, 46 mmol) 
was added dropwise and the mixture allowed to warm to room temperature 
overnight. The reaction was quenched with 10% aqueous citric acid (80 mL) and the 
phases were separated. The aqueous phase was re-extracted with dichloromethane (2 
222 
 
x 80 mL) and the combined organic extracts concentrated in vacuo to give a dark 
brown residue. This was partitioned between EtOAc (100 mL) and 10% aqueous 
citric acid (80 mL) and the separated organic extract washed with saturated NaHCO3 
solution (80 mL), saturated aqueous NaCl solution (80 mL), dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by silica chromatography (9:1 
hexanes:EtOAc, Rf. = 0.33) to give oxazole 4.04 as a white crystalline solid (2.10 g, 
9.7 mmol, 64 % over 2 steps); m.p. 94 - 95°C (lit.5 93 - 94°C); υmax /cm-1 (neat) 2960 
(aromatic C-H), 1722 (C=O); δH (400 MHz, CDCl3) 8.14 - 8.02 (2H, m, ortho C-H), 
7.52 - 7.42 (3H, m, meta, para C-H), 3.96 (3H, s, OCH3), 2.72 (3H, s, CCH3); δC 
(100 MHz, CDCl3) 162.8, 159.6, 156.4 (3 x quaternary C), 130.7 (para C-H), 128.7 
(meta C-H), 128.5 (quaternary C), 126.5 (ortho C-H), 52.0 (OCH3), 12.1 (CCH3). 
One carbon unaccounted for; m/z (ESI+) 240.0 ([M+Na], 100%), 218.0 ([M+H], 
54%); HR-ESIMS: calculated for C12H11NO3Na: 240.0631, found 240.0628 
[M+Na]+.  The data are consistent with that previously reported.6 
5-Methyl-2-phenyl-oxazole-4-carboxylic acid 4.05 
Methyl ester 4.04 (2.04 g, 9.4 mmol) was dissolved in a mixture of 3 M aqueous 
NaOH solution (20 mL, 60 mmol) and MeOH (32 mL) and heated to 45 °C for 2 
hours. The reaction was acidified to pH 1 with 12 M aqueous hydrochloric acid 
solution and extracted with diethyl ether (3 x 100 mL). The combined organic 
extracts were dried over Na2SO4 and concentrated in vacuo to give carboxylic acid 
4.05 as an off white crystalline solid (1.30 g, 6.4 mmol, 68 %); m.p. 182 - 183 °C 
(lit.7 181.5 - 183 °C);  υ
 max/cm-1 2970 (O-H), 1717 (C=O); δH (400 MHz, DMSO-d6) 
13.36 - 12.73 (1H, m, CO2H), 8.15 - 7.89 (2H, m, ortho C-H), 7.68 - 7.25 (3H,  m, 
meta and para C-H), 2.65 (3H, s, CCH3); δC (100 MHz, DMSO-d6) 163.1, 158.5, 
156.2 (3 x quaternary C), 131.0 (para C-H), 129.3 (meta C-H), 128.8, 126.3 (2 x 
quaternary C), 126.0 (ortho C-H), 12.0 (CCH3); m/z (ESI+) 204.0 ([M+H], 100%), 
223 
 
226.0 ([M+Na], 30%); HR-ESIMS: calculated for C11H9NO3Na: 226.0475, found 
226.0478 [M+Na]+.  The data are consistent with that previously reported.6 
N-(5-Methyl-2-phenyl-oxazole-4-carboxy)-L-isoleucine methyl ester 4.06 
Acetyl chloride (16.3 mL, 229 mmol) was added dropwise with stirring to MeOH at 
0°C. L-Isoleucine (5.00 g, 38.1 mmol) was added and the mixture was heated to 
reflux overnight. The reaction mixture was concentrated in vacuo and the crude L-
isoleucine methyl ester hydrochloride was used without further purification.  
A solution of L-isoleucine methyl ester hydrochloride (1.08 g, 6.40 mmol) and 
triethylamine (0.9 mL, 6.4 mmol) in CH2Cl2 (20 mL) was added to a stirred and 
cooled suspension of HATU (2.4 g, 6.4 mmol) and carboxylic acid 4.05 (1.3 g, 6.4 
mmol) in CH2Cl2 (20 mL) at 0 - 5°C. The reaction mixture was stirred at 0 -5 °C for 
15 minutes, and triethylamine (1.8 mL, 12.8 mmol) was added dropwise. The 
reaction mixture was allowed to reach room temperature overnight. To the resulting 
yellow solution was added pH 2 buffer (100 mL), and the separated aqueous phase 
was further extracted in CH2Cl2 (2 x 50 mL). The combined organic residues were 
concentrated in vacuo and the resulting yellow residue partitioned between pH 2 
buffer (100 mL) and toluene (100 mL). The separated organic phase was washed 
with water (2 x 50 mL), saturated aqueous NaHCO3 solution (50 mL) and saturated 
aqueous NaCl solution (50 mL), dried over Na2SO4 and concentrated in vacuo. The 
methyl ester 4.06 was obtained by silica chromatography (2% MeOH: CH2Cl2) as a 
colourless oil (0.8 g, 2.4 mmol, 38 %); 27][ Dα -23.2 (c = 1.1, CHCl3); υ max/cm-1 2964 
(N-H), 1740 (ester C=O), 1670 (amide C=O), 1580 (N-H); δH (600 MHz, CDCl3) 
8.26 - 7.94 (2H, m, ortho C-H), 7.53 (1H, d, J 8.5 Hz, CHNH), 7.49 - 7.41 (3H, m, 
meta and para C-H), 4.74 (1H, dd, J 9.0, 5.5 Hz, NHCH), 3.77 (3H, s, OCH3), 2.71 
(3H, s, CCH3), 2.03 (1H, dqt, J 9.5, 7.0, 5.0 Hz, CHCH3), 1.56 (1H, dqd, J 15.0, 7.0, 
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4.5 Hz, CHCH2), 1.29 (1H, ddq, J 15.0, 9.5, 7.5 Hz,  CHCH2), 1.00 (3H, d, J 7.0 Hz, 
CHCH3), 0.97 (3H, t, J 7.5 Hz, CH2CH3); δC (125 MHz, CDCl3) 172.3 (CO2Me), 
161.8, 158.6, 153.2 (3 x quaternary C), 130.6 (Ar C-H), 129.9 (quaternary C), 128.7 
(Ar C-H), 126.8 (quaternary C), 126.4 (Ar C-H), 56.0 (NHCH), 52.1 (OCH3), 38.0 
(CHCH3), 25.2 (CH2CH3), 15.6 (CHCH3), 11.8 (oxazole CH3), 11.5 (CH2CH3); m/z 
(ESI+) 331.1 ([M+H], 100%), 353.1 ([M+Na], 85%); HR-ESIMS: calculated for 
C18H22N2O4Na: 353.1472, found 353.1479 [M+Na]+.   
(2S, 3S) and (2R, 3S)-2-(N-(5-Methyl-2-phenyl-oxazole-4-carboxyamino)-3-
methyl-pentanoic acid methyl ester 4.07 
Method modified from literature procedure by du Vigneaud and Curtis.8 A solution 
of methyl ester 4.06 (0.10 g, 0.29 mmol) in 3 M aqueous NaOH solution (6 mL, 18.2 
mmol) and MeOH (5 mL) was heated to 45 °C overnight. The reaction was acidified 
to pH 1 with 12 M aqueous hydrochloric acid and extracted with EtOAc (3 x 20 
mL). The combined organic extracts were dried over Na2SO4 and concentrated in 
vacuo to give the acid as a white solid. This was dissolved in 3 M aqueous NaOH  
solution (0.5 mL, 1.8  mmol), THF (0.5 mL) and water (0.5 mL). Acetic anhydride 
was added (0.05 mL, 0.5 mmol) and the reaction mixture was heated to 65 °C for 3 
days. The reaction was cooled to room temperature, acidified with pH 2 buffer (5 
mL) and extracted with EtOAc (5 x 10 mL). The combined organics were dried over 
Na2SO4 and concentrated in vacuo to give the crude epimerisation product.  
This was dissolved in a solution of acetyl chloride (0.43 mL, 6 mmol) in MeOH (2.5 
mL) and heated to reflux for 18 hours. The reaction mixture was concentrated in 
vacuo  to afford methyl ester 4.07 as a mix of diastereomers (brown oil, 0.096 g, 
0.29 mmol, 97%, 50:50  mix of (2S, 3S) and (2R, 3S), calculated by 1H NMR); υ
 
max/cm-1 2962 (N-H), 1739 (ester C=O), 1649 (amide C=O), 1506 (N-H); δH (500 
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MHz, CDCl3) 8.10 - 7.99 ((2S, 3S),  2H, m, ortho C-H; (2R, 3S), 2H, m, ortho C-H), 
7.51 - 7.43 ((2S, 3S), 4H, m, meta and para C-H, NHCH;  (2R, 3S), 4H, m, meta and 
para C-H, NHCH), 4.85 ((2R, 3S), 1H, dd, J 9.5, 4.5 Hz, NHCH), 4.74 ((2S, 3S), 1H, 
dd, J  9.0, 5.5 Hz, NHCH), 3.77 ((2S, 3S),  3H, s, OCH3; (2R, 3S), 3H, s, OCH3), 
2.72 ((2S, 3S), 3H, s, CCH3; (2R, 3S), 3H, s, CCH3), 2.15 - 1.94 ((2S, 3S), 1H, m, 
CHCH3; (2R, 3S), 1H, m, CHCH3), 1.66 - 1.44 ((2S, 3S), 1H, m, CHCH2;  (2R, 3S), 
1H, m, CHCH2), 1.39 - 1.16 ((2S, 3S), 1H, m,  CHCH2;  (2R, 3S), 1H, m, CHCH2), 
1.02 - 0.94 ((2S, 3S), 6H, m, CHCH3, CH2CH3;  (2R, 3S), 6H, m, CHCH3, CH2CH3); 
δC (126MHz, CDCl3) 172.7, 172.3 ((2S, 3S), CO2Me; (2R, 3S), CO2Me), 162.0 
161.8, 158.6, 153.2 ((2S, 3S), 3 x quaternary C; (2R, 3S), 3 x quaternary C), 130.6 
((2S, 3S), Ar C-H; (2R, 3S), Ar C-H), 129.9 ((2S, 3S), quaternary C; (2R, 3S), 
quaternary C), 128.7 ((2S, 3S), Ar C-H; (2R, 3S), Ar C-H), 126.8 ((2S, 3S), 
quaternary C; (2R, 3S), quaternary C), 126.4 ((2S, 3S), Ar C-H; (2R, 3S), Ar C-H), 
56.0, 55.0 ((2S, 3S), NHCH; (2R, 3S), NHCH), 52.2, 52.1 ((2S, 3S), OCH3; (2R, 3S), 
OCH3), 38.0, 37.8 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 26.3 ((2S, 3S), CH2CH3; 
(2R, 3S), CH2CH3), 15.6, 14.8 ((2S, 3S), CHCH3; (2R, 3S), CH2CH3), 11.8 ((2S, 3S), 
oxazole CH3; (2R, 3S), oxazole CH3), 11.7, 11.5 ((2S, 3S), CH2CH3; (2R, 3S), 
CH2CH3); m/z (ESI+) 353.1 ([M+Na], 100%), 331.2 ([M+H], 82%); HR-ESIMS: 
calculated for C18H23N2O4: 331.1652, found 331.1659 [M+H]+.   
N-Carboxybenzyl-L-isoleucyl-L-threonine methyl ester 4.11 
L-Threonine (5.00 g, 42.0 mmol) was added to a solution of acetyl chloride (18.0 
mL, 253 mmol) in MeOH (100 mL), and the reaction mixture was heated to reflux 
for 5 hours. The reaction was cooled to room temperature and concentrated in vacuo 
to give the crude methyl ester hydrochloride as a sticky oil which was used without 
further purification.  
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A solution of N-carboxylbenzyl-L-isoleucine dicyclohexylammonium salt (17.1 g, 
38.2 mmol) and HATU (14.5 g, 38.2 mmol) in CH2Cl2 (200 mL) was cooled to 0 - 5 
°C and stirred for 15 minutes. To this solution was added a solution of the crude L-
threonine methyl ester (42 mmol) and triethylamine (5.3 mL, 38.0 mmol) in CH2Cl2 
(100 mL). The reaction mixture was stirred for a further 10 minutes before 
triethylamine (10.7 ml, 76.7 mmol) was added dropwise. The resulting yellow 
cloudy solution was allowed to reach room temperature overnight. pH 2 buffer (100 
mL) was added and the reaction filtered. The filtercake was washed with CH2Cl2 (2 
x 50 mL). The filtrate was separated, and the separated aqueous filtrate was further 
extracted with CH2Cl2 (3 x 100 mL). The combined organic extracts were 
concentrated in vacuo and the yellow oily solid obtained suspended in toluene: 
EtOAc (3:1, 200 mL). The suspension was filtered and the filtercake recrystallised 
(EtOAc: pet. ether) to give the dipeptide 4.17 as a white solid (6.70 g, 17.6 mmol, 46 
%); m.p. 149 - 150 °C (lit.9 152 - 154 °C); 26][ Dα -19.7 (c = 1.1, MeOH) (lit.9  25][ Dα -
20.5 (c = 3.34, MeOH); υ
 max/cm-1 3307 (N-H), 3272 (O-H), 1731 (ester C=O), 1688 
(carbamate C=O), 1646 (amide C=O), 1536 (N-H); δH (400 MHz, DMSO-d6) 7.89 
(1H, d, J 8.0 Hz, CONHCH), 7.39 (1H, d, J 9.0 Hz, CO2NHCH), 7.37 - 7.28 (5H, m, 
Ar C-H), 5.03 (2H, s, CH2Ph), 4.98 (1 H, d, J 5.5 Hz, CHOH), 4.29 (1H, dd, J 8.5, 
3.5 Hz, CONHCH), 4.12 (1H, qnd, J 6.5, 3.5 Hz, CHOH), 4.03 (1H, dd, J 9.0, 8.0 
Hz, CO2NHCH), 3.61 (3H, s, OCH3) 1.82 – 1.68 (1H, m, CHCH2), 1.43 (1H, dqd, J 
15.0, 7.5, 3.5 Hz, CH2CH3), 1.33 – 1.09 (1H, m, CH2CH3), 1.06 (3H, d, J 6.5 Hz, 
CH(OH)CH3), 0.86 (3H, d, J 7.0 Hz, CH(CH2)CH3), 0.81 (3H, t, J 7.5 Hz, CH2CH3); 
δC (100 MHz, DMSO-d6) 171.9, 171.0 (CO2CH3, NHCO), 156.0 (PhCH2CO), 137.1 
(ipso C-H), 128.3 (Ar C-H), 127.7 (para C-H), 127.6 (Ar C-H), 66.2 (CHOH), 65.3 
(CH2Ph), 59.1 (CO2NHCH), 57.7 (CONHCH), 51.7 (OCH3), 36.3 (CHCH2), 24.3 
(CH2CH3), 20.0 (CH(OH)CH3), 15.2 (CH(CH2)CH3), 10.9 (CH2CH3); m/z (ESI+) 
403.2 ([M+Na], 100%); HR-ESIMS: calculated for C19H29N2O6: 381.2020, found 
381.2014 [M+H]+. This compound has been previously reported, but without any 
spectroscopic data.9 
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Oxazole 4.12 
Method modified from literature procedure by Doi et al.10  A solution of N-
carboxybenzyl-L-isoleucyl-L-threonine methyl ester 4.11 (1.00 g, 2.63 mmol) in dry 
CH2Cl2 (10 mL) was cooled to -20°C under nitrogen. Triethylamine (1.1 mL, 8.0 
mmol) was added dropwise, followed by a suspension of SO3.pyridine complex 
(1.27 g, 7.96 mmol) in dry DMSO (4 mL). The reaction mixture was allowed to 
warm to room temperature and stirred for 30 minutes to give a bright yellow 
solution. This was cooled to -20°C and quenched with saturated sodium hydrogen 
carbonate solution (5 mL). Upon warming to room temperature, the mixture was 
extracted with hexanes: EtOAc (75: 25, 2 x 10 mL). The combined organics were 
washed with saturated aqueous NaCl solution, dried over Na2SO4 and concentrated 
in vacuo to the crude product as a yellow white solid. The keto-ester was obtained by 
silica chromatography (50 % EtOAc: pet. ether) and used immediately. HR-ESIMS: 
calculated for C19H26N2O6Na: 401.1683, found 401.1681 [M+Na]+. 
Iodine (0.83 g, 3.28 mmol) and triethylamine (1.15 mL, 8.20 mmol) were added 
sequentially to a stirred solution of triphenylphosphine (0.95 g, 3.60 mmol) in dry 
THF (15 mL) at room temperature under an atmosphere of nitrogen. The mixture 
was cooled to -78 °C and a solution of the ketone (0.62 g, 1.64 mmol) in dry THF (4 
mL) was added dropwise to give a bright yellow suspension. The reaction mixture 
was allowed to warm to room temperature and stirred under nitrogen for a further 2.5 
hours. The reaction mixture was concentrated in vacuo and partitioned between 
EtOAc (25 mL) and water (25 mL). The phases were separated and the aqueous 
phase extracted with EtOAc (2 x 25 mL). The combined organic phases were washed 
with aqueous hydrochloric acid solution (3M, 20 mL), saturated sodium hydrogen 
carbonate solution (20 mL), saturated aqueous NaCl solution (20 mL), dried over 
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Na2SO4 and concentrated in vacuo. The oxazole 4.12 was obtained by silica 
chromatography (10 % EtOAc: pet. ether to 25 % EtOAc: pet. ether) as a bright 
white solid (0.28 g, 0.78 mmol, 47 %); m.p. 103 - 104 °C; 27][ Dα  -23.2 (c = 1.09, 
CHCl3); υ max/cm-1 3306 (N-H), 1715 (ester C=O), 1686 (carbamate C=O), 1615 
(amide C=O), 1539 (N-H); δH (400 MHz, CDCl3)  7.37 - 7.14 (5H, m, Ar C-H), 5.55 
(1H, d, J  9.5 Hz, NHCH), 5.10 - 4.97 (2H, m, PhCH2), 4.80 (1H, dd, J 8.5, 6.5 Hz, 
NHCH), 3.83 (3H, s, OCH3), 2.53 (3H, s, CCH3), 1.96 - 1.82 (1H, m, CHCH3), 1.50 
- 1.38 (1H, m, CH2CH3), 1.18 - 1.04 (1H, m, CH2CH3), 0.88 - 0.78 (6H, m, CHCH3, 
CH2CH3); δC (100 MHz, CDCl3) 162.6, 161.7, 156.3, 155.9 (CO2Me, CO2Bn, 2 x 
oxazole C), 136.2 (ipso C), 128.5, 128.1, 128.0 (ortho, meta and para CH),  127.6 
(oxazole C), 67.0 (PhCH2), 53.8 (NHCH), 51.9 (OCH3), 39.2 (CHCH3), 25.0 
(CH2CH3), 15.2 (CHCH3), 12.0 (oxazole CH3), 11.3 (CH2CH3); m/z (ESI+) 383.1 
([M+Na]+, 100.0%), 361.2 ([M+H]+, 28%); HR-ESIMS: calculated for C19H25N2O5: 
361.1758, found 361.1761 [M+H]+.  
Oxazole 4.12 was also synthesised using (diethylamino)sulfur trifluoride. A solution 
of the dipeptide 4.11 (1.00 g, 2.63 mmol) in dry CH2Cl2 (25 mL) under nitrogen was 
cooled to -78 °C and (diethylamino)sulfur trifluoride (0.50 mL, 3.68 mmol) was 
added dropwise and the reaction mixture stirred at -78 °C for 1.5 hrs. The mixture 
was allowed to reach room temperature over 15 minutes before carefully quenching 
with saturated aqueous NaHCO3. The mixture was stirred for 15 minutes and the 
phases were separated. The organic phase was dried over Na2SO4 and concentrated 
in vacuo to give the crude oxazoline as a clear yellow oil. This was dissolved in dry 
CH2Cl2 (25 mL) under a nitrogen atmosphere and cooled to 0 °C. BrCCl3 (0.32 mL, 
3.23 mmol) was added dropwise and the reaction mixture was stirred for 5 minutes. 
1, 8-Diazabicyclo[5.4.0]undec-7-ene  (0.42 mmol, 3.02 mmol) was added and the 
reaction mixture was stirred to room temperature overnight.  The reaction was 
quenched with 10% aqueous citric acid solution (20 mL) and the phases were 
separated. The aqueous phase was further extracted with CH2Cl2 (2 x 25 mL) and the 
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organic phases were combined and concentrated in vacuo. The residue was 
partitioned between EtOAc (30 mL) and 10% citric acid solution (30 mL). The 
phases were separated and the organic phase was washed with saturated aqueous 
NaHCO3 solution (10 mL), saturated NaCl solution (10 mL), dried over Na2SO4 and 
concentrated in vacuo to give a beige solid. The oxazole was obtained by silica 
chromatography (60 % pet. ether: EtOAc) as a white solid (0.30 g, 83.9 mmol, 32 %, 
Rf = 0.43). The characterization data was identical to that prepared in the previous 
method. 
Alkene 4.13 
Also isolated was the elimination product 4.13 as a pale yellow solid (0.14 g, 39 
mmol, 15 %, Rf = 0.30); m.p. 149 – 151 °C; υ
 max/cm-1 3289 (N-H), 1728 (ester 
C=O), 1685 (carbamate C=O), 1614 (amide C=O), 1534 (N-H); δH (400 MHz, 
CDCl3) 7.43 - 7.30 (5H, m, Ar C-H), 7.23 (1H, br. s, NHC=C), 6.84 (1H, q, J 7.0 Hz, 
H(CH3)C=C), 5.34 (1H, d, J 8.0 Hz, NHCH), 5.14 (2H, s, PhCH2), 4.19 (1H, dd, J 
8.0, 6.0 Hz, NHCH), 3.76 (3H, s, OCH3), 2.04 - 1.91 (1H, m, CHCH3), 1.76 (3H, d, 
J 7.0 Hz, H(CH3)C=C), 1.62 - 1.50 (1H, m, CH2CH3), 1.20 (1H, ddq, J 13.5, 9.5, 7.0 
Hz, CH2CH3), 1.02 (3H, d, J 6.5 Hz, CHCH3), 0.94 (3H, t, J 7.5 Hz, CH2CH3); δC 
(175 MHz, CDCl3) 169.6 (CONH), 164.7 (CO2Me), 156.4 (COCH2Ph), 136.2 (ipso 
C), 134.7 (H(CH3)C=C), 128.6 (Ar CH), 128.3 (para CH), 128.1 (Ar CH), 125.6 
(H(CH3)C=C), 67.2 (CH2Ph), 60.0 (NHCH), 52.4 (OCH3), 37.3 (CHCH3), 24.8 
(CH2CH3), 15.5 (CHCH3), 14.8 (H(CH3)C=C), 11.5 (CH2CH3); m/z (ESI+) 385.1 
([M+Na]+), 363.1 ([M+H]+); HR-ESIMS: calculated for C19H26N2O5Na: 385.1738, 
found 385.1744 [M+Na]+. 
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Oxazole Carboxylic Acid 4.14 
Lithium hydroxide (0.03 g, 1.11 mmol) was added to a biphasic solution of the 
methyl ester 4.13 (0.10 g, 0.028 mmol) in THF (0.6 mL) and water (0.6 mL), and the 
reaction mixture was stirred at room temperature for 4 hours. The mixture was 
acidified with pH 2 buffer, and concentrated in vacuo. The residue was partitioned 
between pH 2 buffer and EtOAc, and the separated aqueous phase was further 
extracted with EtOAc (3 x 10 mL). The combined organic phases were dried over 
Na2SO4, and concentrated in vacuo to give the acid 4.14 as a bright white solid (0.09 
g, 0.026 mmol, 93 %); 24][ Dα  -64.7 (c = 0.61, CHCl3); m.p. 138 – 140 °C;   υ max/cm-1 
3274 (N-H), 1711 (acid C=O), 1693 (carbamate C=O), 1646 (amide C=O), 1533 (N-
H); δH (400 MHz, CDCl3) 12.32 (1H, br. s., CO2H), 7.48 (1H, d, J 6.5 Hz, NHCH), 
7.23 - 7.10 (5H, m, 5 x Ar C-H), 4.97 (2H, s, CH2Ph), 4.87 (1H, dd, J 10.0, 6.5 Hz, 
NHCH), 2.39 (3H, s, oxazole CH3), 2.01 - 1.89 (1H, m, CHCH3), 1.46 (1H, dqd, J 
15.0, 7.0, 4.0 Hz, CH2CH3), 1.27 - 1.14 (1H, m, CH2CH3), 0.85 - 0.79 (6H, m, 
CHCH3, CH2CH3); δC (100 MHz, CDCl3) 164.4, 163.9, 157.2, 156.8 (CO2H, 
CO2tBu, 2 x oxazole C), 136.3 (ipso C), 128.5, 128.3, 128.0 (ortho, meta, para C-H), 
127.0 (oxazole C), 67.0 (CH2Ph), 54.0 (NHCH), 39.1 (CHCH3), 25.1 (CH2CH3), 
15.5 (CHCH3), 11.7, 11.2 (CH2CH3, oxazole CH3); m/z (ESI+) 347.1 ([M+H]+); 
HR-ESIMS: calculated for C18H23N2O5: 347.1601, found 347.1594 [M+H]+. 
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(2S, 3S) and (2R, 3S) N-carboxybenzyl-isoleucine 4.15 
A solution of benzyl chloroformate (1.3 mL, 9.2 mmol) in THF (10 mL) was added 
dropwise to a stirred and cooled solution of L and D-allo-isoleucine 3.12 (1.0 g, 7.6 
mmol) in aqueous NaOH solution (1M, 17 mL, 17.0 mmol) at 0 °C. Following 
addition, the reaction mixture was allowed to reach room temperature overnight. 
Sufficient aqueous NaOH solution (1M) was added until the mixture was above pH8 
and the mixture extracted with diethyl ether (2 x 10 mL). The aqueous phase was 
acidified to pH 2 with aqueous hydrochloric acid solution (1M) and extracted with 
EtOAc (3 x 10 mL). The combined organic extracts were washed with saturated 
aqueous NaCl solution (10 mL), dried over Na2SO4 and concentrated in vacuo  to 
afford the protected amino-acid 4.15 as a sticky pale yellow oil (1.95 g, 7.40 mmol, 
97 %, 83: 17  mix of (2S, 3S) and (2R, 3S), calculated by 1H NMR); υ
 max/cm-1 3308 
(N-H), 2965 (O-H), 1701 (C=O), 1517 (N-H); δH (400 MHz, CDCl3) 8.75 ((2S, 3S), 
br. s., 1H, CO2H; (2R, 3S), br. s., 1H, CO2H), 7.44 - 7.28 ((2S, 3S), m, 5H, Ar C-H; 
(2R, 3S), m, 5H, Ar C-H), 5.39 ((2S, 3S), d, J 9.0 Hz, NHCH), 5.32 ((2R, 3S), d, J 
9.0 Hz, NHCH) 5.18 - 5.05 ((2S, 3S), 2H, m, CH2Ph; (2R, 3S), 2H, m, CH2Ph), 4.52 
((2R, 3S), 1H, dd, J 9.5, 4.0 Hz, NHCH), 4.40 ((2S, 3S), 1H, dd, J 9.0, 4.5 Hz, 
NHCH), 2.08 - 1.79 ((2S, 3S), 1H, m, CHCH3; (2R, 3S), 1H, m, CHCH3), 1.59 - 1.34 
((2S, 3S), 1H, m, CH2CH3; (2R, 3S), 1H, m, CH2CH3), 1.34 - 1.14 ((2S, 3S), 1H, m, 
CH2CH3; (2R, 3S), 1H, m, CH2CH3), 1.04 - 0.84 ((2S, 3S), 6H, m, CH2CH3, CHCH3; 
(2R, 3S), 6H, m, CH2CH3, CHCH3); δC (100 MHz, CDCl3) 177.2, 176.7 ((2S, 3S), 
CO2H; (2R, 3S), CO2H), 156.5, 156.3 ((2S, 3S), CO2Bn; (2R, 3S), CO2Bn), 136.1 
((2S, 3S), ipso C; (2R, 3S), ipso C), 128.5, 128.2, 128.1 ((2S, 3S), ortho, meta and 
para C-H; (2R, 3S), ortho, meta and para C-H), 67.6, 67.1 ((2S, 3S), CH2Ph; (2R, 
3S), CH2Ph), 58.8, 58.2 ((2S, 3S), NHCH; (2R, 3S), NHCH), 37.7, 37.4 ((2S, 3S), 
CHCH3; (2R, 3S), CHCH3), 26.2, 24.8 ((2S, 3S), CH2CH3; (2R, 3S), CH2CH3), 15.4, 
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14.3 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 11.6 ((2S, 3S), CH2CH3; (2R, 3S), 
CH2CH3); m/z (ESI+) 288.1 ([M+Na]+); HR-ESIMS: calculated for C14H19NO4Na: 
288.1206, found 288.1195 [M+Na]+. 
(2S, 3S) and (2R, 3S) Dipeptide 4.16 
Acetyl chloride (21.0 mL, 298 mmol) was added dropwise to MeOH (130 mL) at 
0°C. To this solution was added L-threonine (5.90 g, 49.7 mmol) and the solution 
was heated at reflux for 18 hours. The reaction mixture was then concentrated in 
vacuo to give L-threonine methyl ester as the hydrochloride salt which was used 
without further purification.  
1-Hydroxybenzotriazole (1.10 g, 7.20 mmol) was added to a solution of N-
carboxybenzyl-isoleucine as a mix of L-isoleucine and D-allo-isoleucine 
diastereomers 4.15 (12.8 g, 48.3mmol) in EtOH (200 mL) and the mixture stirred at 
room temperature for 15 minutes. To this was added a solution of the crude 
threonine methyl ester hydrochloride (49.7 mmol) in EtOH (50 mL) and the reaction 
mixture cooled to 0°C. N-Methylmorpholine (16.8 mL, 155 mmol) was added and 
the reaction mixture stirred at 0-5°C for 15 minutes. EDCI (11.1 g, 57.9 mmol) was 
added and the reaction mixture stirred to room temperature over 18 hours. The 
resulting orange solution was acidified using pH 2 buffer and concentrated in vacuo. 
EtOAc (200 mL) was added and the phases separated. The organic phases was 
washed with pH 2 buffer (100 mL), water (100 mL), saturated aqueous NaHCO3 
solution (100 mL) and saturated aqueous NaCl solution (100 mL), dried over 
Na2SO4 and concentrated in vacuo to give the dipeptide 4.16 as a bright white solid 
(15.0 g, 39.4 mmol, 82 %, 83:17 mix of (2S, 3S) and (2R, 3S), calculated by 1H 
NMR);  υ
 max/cm-1 3307 (N-H), 3185 (O-H), 1729 (ester C=O), 1688 (carbamate 
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C=O), 1647 (amide C=O), 1534 (N-H); δH (400 MHz, DMSO-d6) 8.00 - 7.58 ((2S, 
3S), 1H, m, CONHCHCO2Me; (2R, 3S), 1H, m, CONHCHCO2Me), 7.49 - 7.21 ((2S, 
3S), 6H, m, CO2NHCH, 5 x Ar C-H; (2R, 3S), 6H, m, CO2NHCH, 5 x Ar C-H), 5.09 
- 5.00 ((2S, 3S), 2H, m, CH2Ph; (2R, 3S), 2H, m, CH2Ph), 4.98 ((2S, 3S), 1H, d, J 5.5 
Hz, CHOH; (2R, 3S), 1H, d, J 5.5 Hz, CHOH), 4.29 ((2S, 3S), 1H, dd, J 8.5, 3.5 Hz, 
CONHCHCO2Me; (2R, 3S), 1H, dd, J 8.5, 3.5 Hz, CONHCHCO2Me), 4.21 - 4.07 
((2S, 3S), 1H, m, CHOH; (2R, 3S), 2H, m, CHOH, CO2NHCH), 4.04 ((2S, 3S), 1H, 
dd, J 9.0, 8.0 Hz, CO2NHCH), 3.71 - 3.50 ((2S, 3S), 3H, m, OCH3; (2R, 3S), 3H, m, 
OCH3), 1.93 - 1.59 ((2S, 3S), 1H, m, CHCH2; (2R, 3S), 1H, m, CHCH2), 1.59 - 1.26 
((2S, 3S), 1H, m, CH2CH3; (2R, 3S), 1H, m, CH2CH3), 1.26 - 0.95 ((2S, 3S), 4H, m, 
CH(OH)CH3, CH2CH3; (2R, 3S), 4H, m, CH(OH)CH3, CH2CH3), 0.95 - 0.54 ((2S, 
3S), 6H, m, CH2CH3, CH(CH2)CH3; (2R, 3S), 4H, m, CH2CH3, CH(CH2)CH3); δC 
(100 MHz, DMSO-d6) 171.8, 171.0 ((2S, 3S), CONH, CO2CH3; (2R, 3S), CONH, 
CO2CH3), 156.0 ((2S, 3S), PhCH2OC; (2R, 3S), PhCH2OC), 137.1 ((2S, 3S), ipso C; 
(2R, 3S), ipso C), 128.3 ((2S, 3S), Ar C-H; (2R, 3S), Ar C-H), 127.7 ((2S, 3S), para 
C-H; (2R, 3S), para C-H),127.6 ((2S, 3S), Ar C-H; (2R, 3S), Ar C-H), 66.2 ((2S, 3S), 
CHOH; (2R, 3S), CHOH), 65.5, 65.3 ((2S, 3S), CH2Ph; (2R, 3S), CH2Ph), 59.1, 58.6 
((2S, 3S), CO2NHCH; (2R, 3S), CO2NHCH), 57.7, 57.6 ((2S, 3S), CONHCH; (2R, 
3S), CONHCH), 51.8, 51.7 ((2S, 3S), OCH3; (2R, 3S), OCH3), 36.7, 36.3 ((2S, 3S), 
CHCH2; (2R, 3S), CHCH2), 24.8, 24.3 ((2S, 3S), CH2CH3; (2R, 3S), CH2CH3), 20.0 
((2S, 3S), CH(OH)CH3; (2R, 3S), CH(OH)CH3), 15.2 ((2S, 3S), CH(CH2)CH3; (2R, 
3S), CH(CH2)CH3), 11.4, 10.9 ((2S, 3S), CH2CH3; (2R, 3S), CH2CH3); m/z (ESI+) 
403.1 ([M+Na]+, 100.0%); HR-ESIMS: calculated for C19H29N2O6: 381.2020, found 
381.2019 [M+H]+. 
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(2S, 3S) and (2R, 3S) Oxazole Methyl Ester 4.17 
Prepared as for the single diastereomer, using a mix of L-isoleucine and D-allo-
isoleucine dipeptide 4.16 (2.0 g, 5.55 mmol), SO3.pyridine (0.96 g, 6.04 mmol), 
DIPEA (1.3 mL, 7.89 mmol), dry DMSO (2 mL) and dry CH2Cl2 (15 mL) for the 
oxidation and PPh3 (0.78 g, 2.94 mmol), iodine (0.68 g, 2.70 mmol), triethylamine 
(0.94 mL, 6.74 mmol) and THF (16 mL) for the cyclodehydration to give the 
oxazole methyl ester 4.17 as a bright white solid (0.33 g, 0.92 mmol, 17 % over 2 
steps, 83: 17 mix of (2S, 3S) and (2R, 3S), calculated by 1H NMR); υ
 max/cm-1 3309 
(N-H), 1717 (ester C=O), 1679 (carbamate C=O), 1615 (amide C=O), 1532 (N-H); 
δH (400 MHz, CDCl3) 7.36 - 7.13 ((2S, 3S), 5H, m, Ar C-H; (2R, 3S), 5H, m, Ar C-
H), 5.53 – 5.44 ((2S, 3S), 1H, m, NHCH; (2R, 3S), 1H, m, NHCH), 5.09 - 4.98 ((2S, 
3S), 1H, m, CH2Ph; (2R, 3S), 1H, m, CH2Ph), 4.89 ((2S, 3S), 1H, dd, J 9.5, 5.0 Hz, 
NHCH), 4.79 ((2R, 3S), 1H, dd, J 9.0, 6.5 Hz, NHCH), 3.83 ((2S, 3S), 3H, s, OCH3; 
(2R, 3S), 3H, s, OCH3), 2.53 ((2S, 3S), 3H, s, oxazole CH3; (2R, 3S), 3H, s, oxazole 
CH3), 1.96 – 1.81 ((2S, 3S), 1H, m, CHCH3; (2R, 3S), 1H, m, CHCH3) 1.51 - 1.25 
((2S, 3S), 1H, m, CH2CH3; (2R, 3S), 1H, m, CH2CH3), 1.24 - 1.01 ((2S, 3S), 1H, m, 
CH2CH3; (2R, 3S), 1H, m, CH2CH3), 0.95 - 0.71 ((2S, 3S), 6H, m, CHCH3, CH2CH3; 
(2R, 3S), 6H, m, CHCH3, CH2CH3); δC (100 MHz, CDCl3) 162.6 ((2S, 3S), CO2Me; 
(2R, 3S), CO2Me), 161.8, 161.6 ((2S, 3S), CO2Bn; (2R, 3S), CO2Bn), 156.2, 155.8 
((2S, 3S), oxazole C; (2R, 3S), oxazole C), 136.2 ((2S, 3S), ipso C; (2R, 3S), ipso C), 
128.4, 128.0, 127.9 ((2S, 3S), ortho, meta and para C-H; (2S, 3S), ortho, meta and 
para C-H),  127.3 ((2S, 3S), oxazole C; (2R, 3S), oxazole C), 66.9 ((2S, 3S), PhCH2; 
(2R, 3S), PhCH2), 53.7, 53.0 ((2S, 3S), NHCH; (2R, 3S), NHCH), 51.8 ((2S, 3S), 
OCH3; (2R, 3S), OCH3), 39.1, 39.0 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 25.8, 24.9 
((2S, 3S), CH2CH3; (2R, 3S), CH2CH3), 15.1, 14.5 ((2S, 3S), CHCH3; (2R, 3S), 
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CHCH3), 12.1, 12.0 ((2S, 3S), oxazole CH3; (2R, 3S), oxazole CH3), 11.4, 11.1 ((2S, 
3S), CH2CH3; (2R, 3S), CH2CH3); m/z (ESI+) 383.1 ([M+Na]+, 100.0%), 361.2 
([M+H]+, 8.0%); HR-ESIMS: calculated for C19H25N2O5: 361.1758, found 361.1754 
[M+H]+. 
(2S, 3S) and (2R, 3S) Oxazole Acid 4.18 
Prepared as for the single diastereomer, using a mix of L-isoleucine and D-allo-
isoleucine diastereomers 4.17 (0.10 g, 0.28 mmol), lithium hydroxide (0.03 g, 1.11 
mmol), THF (0.6 mL) and water (0.6 mL) to give the acid 4.18 as a white solid (0.08 
g, 0.23 mmol, 82 %, 84: 16 mix of (2S, 3S) and (2R, 3S), calculated by 1H NMR); υ
 
max/cm-1 3326 (N-H), 1710 (acid C=O), 1620 (amide C=O), 1533 (N-H);  δH (400 
MHz, CDCl3) 7.71 - 7.39 ((2S, 3S), 1H, m, NHCH; (2R, 3S), 1H, m, NHCH), 7.46 - 
7.03 ((2S, 3S), 5H, m, 5 x Ar C-H; (2R, 3S), 5H, m, 5 x Ar C-H), 5.15 - 4.99 ((2S, 
3S), 2H, m, CH2Ph; (2R, 3S), 3H, m, CH2Ph, NHCH), 4.94 ((2S, 3S  , 1H, dd, J 10.0, 
7.0 Hz, NHCH), 2.54 ((2R, 3S), 3H, s, oxazole CH3), 2.48 ((2S, 3S), 3H, s, oxazole 
CH3), 2.06 - 1.93 ((2S, 3S), 1H, m, CHCH3; (2R, 3S), 1H, m, CHCH3), 1.63 - 1.38 
((2S, 3S), 1H, m, CH2CH3; (2R, 3S), 1H, m, CH2CH3), 1.36 - 1.22 ((2S, 3S), 1H, m, 
CH2CH3; (2R, 3S), 1H, m, CH2CH3), 1.02 - 0.85 ((2S, 3S), 1H, m, C(CH3)3; (2R, 3S), 
1H, m, C(CH3)3); δC (100 MHz, CDCl3) 164.4, 164.1, 164.0, 157.4, 157.2, 156.9, 
156.8 ((2S, 3S), CO2H, CO2tBu, 2 x oxazole C; (2R, 3S), CO2H, CO2tBu, 2 x oxazole 
C); 136.5, 136.3 ((2S, 3S), ipso C; (2R, 3S), ipso C), 128.3, 128.0, 127.9, 127.8 ((2S, 
3S), ortho, meta and para  C-H; (2R, 3S), ortho, meta and para  C-H), 126.9 ((2S, 3S  
oxazole C; (2R, 3S),  oxazole C), 67.0, 66.9 ((2S, 3S),  CH2Ph; (2R, 3S),  CH2Ph), 
54.0, 53.4 ((2S, 3S), NHCH; (2R, 3S), NHCH), 39.1, 39.0 ((2S, 3S), CHCH3; (2R, 
3S), CHCH3), 26.0, 25.0 ((2S, 3S), CH2CH3; (2R, 3S), CH2CH3), 15.5, 14.2 ((2S, 3S), 
CHCH3; (2R, 3S), CHCH3), 11.8, 11.7, 11.5, 11.2 ((2S, 3S), oxazole CH3, CH2CH3; 
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(2R, 3S), oxazole CH3, CH2CH3); m/z (ESI-) 345.1 ([M-H], 100.0%);  HR-ESIMS: 
calculated for C18H22N2O5Na: 369.1421, found 369.1425 [M+Na]+. 
N-tert-Butyloxycarbonyl-L-valine 4.19 
Method modified from literature procedure by Garner et al.11 A solution of di-tert-
butyl dicarbonate (112 g, 512 mmol) in dioxane (300 mL) was added dropwise to a 
stirred and cooled solution of L-valine (50.0 g, 427 mmol) in aqueous NaOH solution 
(1 M, 875 mL) at 0 °C. The pH of the solution was adjusted to 9 using aqueous 
NaOH solution and the reaction mixture was allowed to reach room temperature 
overnight. The pH was adjusted to between 9 and 10, and the reaction mixture 
extracted with diethyl ether (3 x 250 mL). The aqueous phase was acidified to pH 2 
with concentrated H2SO4 and extracted with EtOAc (5 x 100 mL). The combined 
organic extracts were washed with saturated aqueous NaCl solution (100 mL), dried 
over Na2SO4 and concentrated in vacuo to give the protected amino-acid as bright 
white crystals (87.5 g, 403 mmol, 94 %); m.p. 76 - 78 °C,  (lit.12 77 - 78 °C); 25][ Dα  
+6.6 (c = 1.1, CHCl3), (lit. 13 23][ Dα  +11.7 (c = 2.35, CHCl3); υ max/cm-1 (neat) 3320 
(NH), 2967 (OH), 1711 (acid C=O), 1640 (amide C=O), 1509 (NH); δH (400 MHz, 
CDCl3) 9.15 (1H, br.s., major and minor rotamer CO2H), 6.21 (1H, d, J 6.5 Hz, 
minor rotamer NHCH), 5.08 (1H, d, J 9.0 Hz, major rotamer NHCH), 4.25 (1H, dd, 
J 9.0, 4.5 Hz, major rotamer NHCH), 4.13 - 3.93 (1H, m, minor rotamer NHCH), 
2.29 – 2.13 (1H, m, major and minor rotamer CH(CH3)2), 1.47-1.40 (9H, m, major 
and minor rotamer C(CH3)3), 0.99 (1H, d, J 7.0 Hz, major and minor rotamer 
CH(CH3)2), 0.93 (1H, d, J 7.0 Hz, major and minor rotamer CH(CH3)2); δC (100 
MHz, CDCl3) 176.8 (CO2H), 155.8 (CONH), 80.0 (C(CH3)3), 58.4 (CHNH),  30.9 
(CH(CH3)2), 28.3 (C(CH3)3), 19.0, 17.4 (CH(CH3)2); m/z (ESI+) 240.1 ([M+Na]+, 
100.0%); HR-ESIMS: calculated for C10H19NO4Na: 240.1206, found 240.1208 
[M+Na]+.The data are consistent with that previously reported.14 
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N-tert-Butyloxycarbonyl-L-valyl-L-serine methyl ester 4.20 
Acetyl chloride (40.6 mL, 571 mmol) was added dropwise with stirring to MeOH 
(240 mL) at 0 °C.  The mixture was allowed to reach room temperature and L-serine 
(10.0 g, 95.2 mmol) was added and the mixture was heated to reflux for 7 hours. The 
reaction mixture was concentrated in vacuo to give the crude methyl ester as the 
hydrochloride salt, which was used without further purification assuming 
quantitative yield.  
A solution of N-tert-butyl carbonyl-L-valine 4.19 (20.0 g, 95.2 mmol) and HOBt (88 
%, 2.20 g, 14.3 mmol) in EtOH (150 mL) was stirred at room temperature for 15 
minutes, then cooled to 0 - 5°C. To this was added a solution of the crude serine 
methyl ester (95.2 mmol) and N-methyl morpholine (33.1 mL, 305 mmol) in EtOH 
(250 mL) and the resulting colourless solution stirred at 0 - 5°C for 15 minutes. 
EDCI (21.8g, 114mmol) was added and the reaction mixture was allowed to reach 
room temperature overnight to give a pale yellow solution. The reaction was 
acidified using pH 2 buffer and N-methyl morpholine hydrosulfate removed by 
filtration. The filtrate was concentrated in vacuo, and extracted with EtOAc (4 x 100 
mL). The combined organic extracts were washed with pH 2 buffer (100 mL), water 
(100 mL), saturated aqueous NaHCO3 solution (100 mL) and saturated aqueous 
NaCl solution (100mL), dried over Na2SO4 and concentrated in vacuo to give the 
dipeptide as a white powdery solid (19.2 g, 60.3 mmol, 63 %. The reaction was also 
performed with 10.0 g of compound 4.20 with a yield of 94 %); m.p. 77 - 78 °C 
(lit.15 77.5 – 79.5 °C); 26][ Dα -22.7 (c = 1.00, MeOD), (lit.15 20][ Dα = -21.1 (c = 1.03, 
MeOH)); υ
 max/cm-1 (neat) 3318 (NH), 2963 (OH), 1747 (ester C=O), 1648 (amide 
C=O), 1519 (NH); δH (400 MHz, CDCl3) 7.41 (1H, d, J 7.5 Hz, N7-H), 5.56 (1H, d, 
J 8.5 Hz, N4-H), 4.61 (1H, td, J 8.0, 4.0 Hz, C8-H), 4.11 (1H, t, J 6.0 Hz, CH2OH), 
3.97 (1H, t, J 8.0 Hz, C5-H), 3.93 - 3.75 (2H, m, CH2OH), 3.68 (3H, s, OCH3), 2.00 
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(1H, m, C26-H), 1.40 - 1.31 (9H, m, C(CH3)3), 0.92 (3H, d, J 7.0 Hz, C26(CH3)2), 
0.88 (d, J 7.0 Hz, C26(CH3)2); 13C (100 MHz, CDCl3) 172.2 (CO), 170.7 (CO), 
156.1 (CO2tBu), 79.7 (C(CH3)3), 62.3 (C8-CH2), 59.7 (C26), 54.4 (C8-H), 52.4 
(OCH3), 31.0 (C26), 28.1 (C(CH3)3), 18.9, 17.8 (C26(CH3)2); m/z (ESI+) 341.2 
([M+Na]+ 100%); HR-ESIMS: calculated for C14H26N2O6Na: 341.1683, found 
341.1676 [M+Na]+. The data are consistent with that previously reported.13 
2-[(S)-N-tert-Butyloxycarbonylamino-2-methylpropyl]-4-carbomethoxyoxazole 
4.21 
Method modified from literature procedure of Zylstra et al.16 Triphenylphosphine 
(22.2 g, 84.8 mmol) was added to a stirred solution of dipeptide 4.20 (15.0 g, 47.1 
mmol) in dry CH2Cl2 (150 mL) and acetonitrile (35 mL) under nitrogen. To this 
solution was added diisopropylethylamine (14.0 mL, 84.8 mmol) and the reaction 
mixture was cooled to 0 -5 °C. After 20 minutes carbon tetrachloride (8.2 mL, 84.8 
mmol) was added dropwise. The reaction was stirred at 0-5 °C for a further 15 
minutes and then allowed to reach room temperature overnight. Water (250 mL) was 
added, and the mixture extracted with CH2Cl2 (2 x 50 mL). The combined organic 
phases were concentrated in vacuo and the residue partitioned between EtOAc (200 
mL) and water (100 mL). The organic phase was washed with saturated aqueous 
NaHCO3 solution (100 mL) and saturated aqueous NaCl solution (100 mL), dried 
over Na2SO4 and concentrated in vacuo to give a brown solid. This was purified by 
silica chromatography (50 % EtOAc: pet. ether) to give the oxazoline as a yellow oil 
(4.82 g, 16.1 mmol) which was used immediately.  
 A solution of oxazoline (4.82 g, 16.1 mmol) in dry CH2Cl2 (100 mL) was cooled to 
0 °C under nitrogen. 1, 8-Diazabicyclo[5.4.0]undec-7-ene  (7.4 mL, 49.7 mmol) was 
added and the mixture stirred at 0 °C for 10 minutes. Bromotrichloromethane (4.9 
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mL, 49.7 mmol) was added dropwise and the reaction stirred at room temperature for 
6 hours. Aqueous citric acid solution (10 % w/w, 250 mL) was added and the phases 
separated. The aqueous phase was extracted with CH2Cl2 (2 x 100 mL) and the 
combined organic phases dried over Na2SO4 and concentrated in vacuo. The oxazole 
4.21 was obtained by silica chromatography (50 % EtOAc: pet. ether) as a bright 
white solid (3.9 g, 13.1 mmol, 28 % over 2 steps. The reaction was also performed 
with 10.0 g of compound 4.20 with a yield of 35 % and with 3.0 g of compound 4.20 
with a yield of 46 %); m.p. 127 - 129 °C (lit.17 120 - 124°C); 23][ Dα  -37.7 (c = 0.60, 
CHCl3), (lit.18 25][ Dα  -36.4 (c = 0.5, CHCl3)); υ max/cm-1 (neat) 3288 (NH), 2967 
(aromatic C-H), 1749 (ester C=O), 1698 (amide C=O), 1538 (NH); δH (400 MHz, 
CDCl3) 8.19 (1H, s,  C29-H), 5.29 (1H, d, J 9.5 Hz, N4-H), 4.81 (1H, dd, J 9.0, 6.5 
Hz, C5-H), 3.92 (3H, s, OCH3), 2.20 (1H, octet, J 6.5 Hz, C26-H), 1.44 (9H, s, 
C(CH3)3), 0.93 (6H, 2 x d, J 8.0 Hz, C26(CH3)2); δC (100 MHz, CDCl3) 165.2 (C6), 
161.6 (CO2Me), 155.3 (CONH), 143.8 (C29-H), 133.1 (C8), 80.0 (C(CH3)3), 54.1 
(C5-H), 52.2 (CO2CH3), 32.9 (C26), 28.2 (C(CH3)3), 18.7, 17.8 (C26(CH3)2); m/z 
(ESI+) 321.1 ([M+Na]+ 100%); HR-ESIMS: calculated for C14H22N2O5Na: 
321.1421, found 321.1418 [M+Na]+. The data are consistent with that previously 
reported.19 
Oxazole 4.21 was also prepared using (diethylamino)sulphur trifluoride. Method 
modified from literature procedure of Pattenden et al.4 A solution of dipeptide 4.20 
(7.0 g, 22.0 mmol) in dry CH2Cl2 (150 mL) under nitrogen was cooled to -78 °C and 
(diethylamino)sulfur trifluoride (4.1 mL, 31 mmol) was added dropwise and the 
reaction mixture stirred at -78 °C for 1.5 hrs. The mixture was allowed to reach room 
temperature over 15 minutes before carefully quenching with saturated aqueous 
NaHCO3 solution. The mixture was stirred for 15 minutes and the phases were 
separated. The organic phase was dried over Na2SO4 and concentrated in vacuo to 
give the crude oxazoline as a clear yellow oil. This was dissolved in dry CH2Cl2 (150 
mL) under a nitrogen atmosphere and cooled to 0 °C. BrCCl3 (2.7 mL, 27.0 mmol) 
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was added dropwise and the reaction mixture was stirred for 5 minutes. 1, 8-
Diazabicyclo[5.4.0]undec-7-ene  (3.8 mmol, 25.3 mmol) was added and the reaction 
mixture was stirred to room temperature overnight.  The reaction was quenched with 
10% aqueous citric acid solution (100 mL) and the phases were separated. The 
aqueous phase was further extracted with CH2Cl2 (2 x 50 mL) and the organic phases 
were combined, washed with saturated NaCl solution (10 mL), dried over Na2SO4 
and concentrated in vacuo to give a beige solid. The oxazole 4.21 was obtained by 
silica chromatography (50 % EtOAc: pet. ether) as a pale yellow solid (3.03 g, 10.2 
mmol, 46 %. The reaction was also performed with 7.0 g of compound 4.20 with a 
yield of 47 % and with 7.0 g of compound 4.20 with a yield of 39 %). The 
characterization data was identical to that prepared in the previous method. 
Oxazole Acid 4.22 
LiOH (0.16 g, 6.70 mmol) and water (3 mL) were added to a solution of methyl ester 
4.21 (0.50 g, 1.68 mmol) in THF (3 mL). The biphasic mixture was stirred at room 
temperature for 4 hours and acidified with pH 2 buffer. The mixture was 
concentrated in vacuo, EtOAc (10 mL) was added and the phases were separated. 
The aqueous phase was extracted with EtOAc (3 x 3mL) and the combined organic 
extracts were dried over Na2SO4 and concentrated in vacuo to give acid 4.22 as a 
bright white solid (0.45 g, 1.58 mmol, 94 %); m.p. 146 - 146 °C, (lit.17 m.p. 154 - 
155 °C); 23][ Dα -76.3 (c = 0.65, CHCl3), (lit.17 23][ Dα -28.9 (c = 1.5, CHCl3)); υ max/cm-
1
 (neat) 3321 (NH), 3074 (OH), 2971 (aromatic C-H), 1737 (acid C=O), 1514 (NH); 
δH (400 MHz, CDCl3) 10.95 (1H, br.s., CO2H), 8.30 (1H, s, C29-H), 6.40 (1H, d, J 
9.0 Hz, N4-H), 4.84 (1H, dd, J 8.5, 7.0 Hz, C5-H), 2.39 - 2.16 (1H, m, C26-H), 1.40 
(9H, s, C(CH3)3), 0.98 (3H, d, J 6.5 Hz, C26(CH3)2), 0.91 (3H, d, J 6.5 Hz, 
C26(CH3)2); δC (100 MHz, CDCl3) 166.7 (C6), 163.6 (CO2H), 155.9 (CONH), 144.6 
(C29-H), 133.2 (C8), 79.9 (C(CH3)3), 54.6 (C5), 32.8 (C26), 28.2 (C(CH3)3), 18.9, 
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18.2 (C26(CH3)2); m/z (ESI-) 283.1 ([M-H] 100%); HR-ESIMS: calculated for 
C13H19N2O5: 283.1299, found 283.1302 [M-H]-. The data are consistent with that 
previously reported.18 
Oxazole Methyl Ester 4.23 
Threonine methyl ester hydrochloride was prepared as before, using L-threonine 
(0.20 g, 1.68 mmol) and was used without further purification and assuming 
quantitative yield.  
A solution of the acid 4.22 (0.45 g, 1.58 mmol) and HOBt (88 %, 0.04 g, 0.25 mmol) 
in EtOH (3 mL) was stirred at room temperature for 5 minutes. To this was added a 
solution of L-threonine methyl ester hydrochloride (1.68 mmol) in EtOH (5 mL), and 
the mixture was cooled to 0 - 5 °C. N-Methyl morpholine (0.60 mL, 5.52 mmol) was 
added and the mixture stirred at 0 - 5 °C for 15 minutes. EDCI (0.39 g, 2.02 mmol) 
was added and the reaction allowed to reach room temperature overnight. The 
reaction was acidified with pH 2 buffer, and the inorganics removed by filtration. 
The filtrate was concentrated in vacuo, and EtOAc (10 mL) added. The phases were 
separated and the aqueous phase further extracted (2 x 5 mL). The combined organic 
extracts were washed with pH 2 buffer (10 mL), water (10 mL), saturated aqueous 
NaHCO3 solution (10 mL) and saturated aqueous NaCl solution, dried over Na2SO4 
and concentrated in vacuo to give the coupled product 4.23 as an off white solid 
(0.63 g, 1.58 mmol, 99 %. The reaction was also performed with 3.31 g of 
compound 4.22 with a yield of 90 %, with 3.25 g of compound 4.22 with a yield of 
88 %, with 2.37 g of compound 4.22 with a yield of 94 % and with 0.50 g of 
compound 4.22 with a yield of 95 %); m.p. 81 - 82 °C; 24][ Dα  -30.1 (c = 1.01, 
CHCl3); υ max/cm-1 (neat) 3368 (NH), 2975 (OH), 1718 (ester C=O), 1645 (amide 
C=O), 1511 (NH); δH (400 MHz, CDCl3) 8.15 (1H, s, C29-H), 7.60 (1H, d, J 9.0 Hz, 
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N10-H), 5.25 (1H, d, J 9.0 Hz, N4-H), 4.78 (1H, dd, J 8.5, 6.0 Hz, C5-H), 4.74 (1H, 
dd, J 9.0, 2.5 Hz, C11-H), 4.49 – 4.41 (1H, m, C30-H), 3.79 (3H, s, OCH3), 2.84 - 
2.71 (1H, m, C30-OH), 2.12 (1H, octet, J 6.5 Hz, C26-H), 1.46 (9H, s, C(CH3)3), 
1.28 (3H, d, J 6.5 Hz, C30-CH3), 0.94 (d, J 7.0 Hz, C26(CH3)2), 0.92 (3H, d, J 6.5 
Hz, C26(CH3)2); δC (100 MHz, CDCl3) 171.1 (CO2Me), 164.0 (C6), 161.0 (CO2tBu), 
155.4 (C9), 141.4 (C29-H), 135.5 (C8), 80.3 (C(CH3)3), 68.0 (C30), 57.1 (C11), 54.3 
(C5), 52.6 (OCH3), 32.7 (C26), 28.3 (C(CH3)3), 19.9 (C30-CH3), 18.7, 18.0 
(C26(CH3)2);  m/z (ESI+) 422.1 ([M+Na] 100%); HR-ESIMS: calculated for 
C18H29N3O7Na: 422.1898, found 422.1902 [M+Na]+. 
Bisoxazole Methyl Ester 4.09 
Method modified from literature procedure of Wipf et al.6 A solution of the 
tripeptide 4.23 (3.37 g, 8.40 mmol) in dry CH2Cl2 (35.0 mL) was cooled to -20 °C 
under an atmosphere of nitrogen. Triethylamine (3.60 mL, 25.6 mmol) was added, 
followed by a suspension of SO3.pyr (4.10 g, 25.6 mmol) in dry DMSO (15.0 mL). 
The mixture was stirred at -20 °C for 20 minutes and then at room temperature for 
2.5 hours. The reaction was cooled to 0 °C and quenched with water (30 mL). The 
resulting mixture was stirred with an aqueous solution of oxone (0.5M, 145 mL) for 
1 hour. The phases were separated, and the aqueous phase extracted with 
dichloromethane (2 x 10 mL). The combined organic extracts were washed with 
saturated aqueous NaHCO3 (5 mL) and saturated aqueous NaCl solution (25 mL), 
dried over Na2SO4 and concentrated in vacuo. The ketone was obtained by silica 
chromatography (1:1 EtOAc: pet. ether) as an off-white solid (1.51 g, 3.98 mmol) 
which was used immediately. 
The oxazole was prepared according to the method of Doi et al.10 A solution of the 
ketone (0.22 g, 0.58 mmol), triphenylphosphine (0.29 g, 1.11 mmol) and CCl4 (0.11 
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mL, 1.11 mmol) in dry CH2Cl2 (7.0 mL) was cooled to 0 °C under an atmosphere of 
nitrogen. To this was added diisopropylethylamine (0.37 mL, 2.21 mmol) and the 
reaction stirred at room temperature overnight. The solvent was evaporated and the 
bisoxazole 4.09 obtained by silica chromatography (1: 1 EtOAc: pet. ether) as a 
bright white crystalline solid (1.03 g, 2.71 mmol, 32% from alcohol 4.23. The 
reaction was also performed with 3.83 g of compound 4.23 with a yield of 10 %); 
m.p. 128 - 130 °C; 24][ Dα -46.6 (c = 0.53, CHCl3);  υ max/cm-1 (neat) 3349 (NH), 2964 
(aromatic C-H), 1712 (ester C=O), 1683 (amide C=O), 1519 (NH); δH (400 MHz, 
CDCl3)  8.25 (1H, s, C29-H), 5.30 (1H, d, J 9.0 Hz, N4-H), 4.82 (1H, dd, J 9.0, 6.5 
Hz, C5-H), 3.93 (3H, s, OCH3), 2.70 (3H, s, C30-CH3), 2.22 (1H, m, C26-H), 1.46 - 
1.39 (9H, m, C(CH3)3), 0.95 (3H, d, J 7.5 Hz, C26(CH3)2),  0.93 (3H, d, J 7.5 Hz, 
C26(CH3)2); δC (100 MHz, CDCl3) 165.4 (C6), 164.5 (CO2Me), 156.5 (C30), 155.3 
(CONH), 153.0 (C9), 138.8 (C29-H), 129.8 (C8), 128.3 (C11), 80.0 (C(CH3)3), 54.3 
(C5), 52.0 (OCH3), 33.0 (C26), 28.3 (C(CH3)3), 18.7, 18.0 (C26(CH3)2), 12.0 (C30-
CH3); m/z (ESI+) 402.0 ([M+Na] 100%); HR-ESIMS: calculated for C18H25N3O6Na: 
402.1636, found 402.1640 [M+Na]+. 
Bisoxazole Acid 4.24 
Lithium hydroxide (0.13 g, 5.27 mmol) and water (3 mL) were added to a solution of 
the bioxazole methyl ester 4.09 (0.50 g, 1.32 mmol) in THF (3 mL) at room 
temperature. The reaction was stirred for 4 hours and then acidified using pH 2 
buffer. The organic solvents were removed in vacuo and the residue was partitioned 
between EtOAc (15 mL) and pH 2 buffer. The separated aqueous phase was further 
extracted with EtOAc (3 x 5 mL) and the combined organic extracts were dried over 
Na2SO4 and concentrated in vacuo to give the acid 4.24 as a white crystalline solid 
(0.46 g, 1.26 mmol, 95 %); m.p. 93 - 94 °C; 26][ Dα  -45.0 (c = 1.05, CHCl3); υ max/cm-
1
 (neat) 3295 (NH), 2117 (OH), 1696 (acid C=O), 1509 (NH); δH (400 MHz, CDCl3) 
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8.29 (1H, s, C29-H), 7.68 (1H, br.s., major and minor rotamer, CO2H), 6.38 (1H, d, J 
6.0 Hz, minor rotamer N4-H), 5.46 (1H, d, J  9.5 Hz, major rotamer N4-H), 4.83 
(1H, dd, J 9.5, 6.5 Hz, major rotamer C5-H), 4.71 - 4.59 (1H, m, minor rotamer C5-
H), 2.72 (3H, s, major and minor rotamer, C30-CH3), 2.21 (1H, oct., J 6.5 Hz, major 
and minor rotamer, C26-H), 1.48 - 1.37 (9H, m, major and minor rotamer,  
C(CH3)3), 0.96 (3H, d, J 7.0 Hz, major and minor rotamer, C26(CH3)2), 0.92 (3H, d, 
J 7.0 Hz, major and minor rotamer, C26(CH3)2); δC (100 MHz, CDCl3) 165.6, 165.4 
(C6, CO2H), 157.3 (C30), 155.4 (CONH), 153.0 (C9), 139.1 (C29-H), 129.5 (C8), 
128.1 (C9), 80.1 (C(CH3)3), 54.3 (C5), 32.8 (C26), 28.2 (C(CH3)3), 18.7, 18.0. 
(C26(CH3)2), 12.2 (C30-CH3): m/z (ESI+) 388.1 ([M+Na] 100%); HR-ESIMS: 
calculated for C17H23N3O6Na: 388.1479, found 388.1474 [M+Na]+. 
N-tert-Butoxy-L-serine 4.25 
A solution of di-tert-butyl dicarbonate (25.0 g, 114.5 mmol) in dioxane (75 mL) was 
added dropwise to a solution of L-serine (10.0 g, 95.2 mmol) in aqueous NaOH 
solution (1M, 195 mL, 195 mmol) at 0 °C. Following complete addition, the pH of 
the reaction mixture was adjusted to pH 9 - 10 and it was stirred at room temperature 
overnight to give a white suspension with a pH of 7 - 8. The pH was adjusted to 9 - 
10 to give a clear, colourless solution. This was washed with Et2O (2 x 50 mL), and 
the organic phases discarded. The aqueous phase was acidified to pH 2 buffer and 
extracted with EtOAc (4 x 100 mL). The organic extracts were combined, washed 
with saturated aqueous NaCl solution (100 mL), dried over Na2SO4 and concentrated 
in vacuo to give the protected amino acid 4.25 as a colourless oil (18.7 g, 91.1 mmol, 
80%); 27][ Dα  -4.5 (c = 1.3, H2O), (lit.20 25][ Dα -7.6 (c = 2.6, H2O)); υ max/cm-1 (neat) 
3333.7 (O-H), 1686 (C=O), 1512 (N-H); δH (400 MHz, CDCl3) 6.67 (1H, br.s., 
major and minor rotamer, CO2H), 5.89 (1H, d, J 7.0 Hz, major and minor rotamer, 
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NH), 4.40 - 4.30 (1H, m, NHCH, major rotamer), 4.28 - 4.17 (1H, m, NHCH, minor 
rotamer), 4.05 (1H, dd, J 11.0, 3.0 Hz, major and minor rotamer, CHCH2), 3.85 (1H, 
dd, J 11.5, 3.0 Hz, major and minor rotamer, CHCH2), 1.44 (9H, s, major and minor 
rotamer, C(CH3)3); δC (100 MHz, CDCl3) 154.1 (CO2H), 156.2 (CO2tBu), 80.5 
(C(CH3)3), 63.0 (NHCH), 55.6 (CH2OH), 28.3 (C(CH3)3; m/z (ESI+) 228.0 ([M+Na] 
100%); HR-ESIMS: calculated for C8H15NO5Na: 228.0842, found 228.0841 
[M+Na]+. The data are consistent with that previously reported.21 
 (S)-3-(tert-Butoxycarbonyl)-2,2-dimethyloxazolidine-4-carboxylic acid 4.26 
Method modified from literature procedure of Trajkovic et al 22. A solution of N-tert-
butyloxycarbonyl-L-serine (13.3 g, 64.8 mmol), dimethoxypropane (64.0 g, 520 
mmol) and toluene sulphonic acid monohydrate (1.11 g, 6.47 mmol) in CH2Cl2 (75 
mL) was heated to reflux for 2 hours. After cooling to room temperature, the reaction 
mixture was concentrated in vacuo and the residue was partitioned between water 
(150 mL) and EtOAc (100 mL). The separated organic phase was washed with water 
(50 mL) and saturated aqueous NaCl solution (50 mL), dried over Na2SO4 and 
concentrated in vacuo. The protected amino-acid 4.25 was obtained, after drying 
under high vacuum, as a low melting point yellow solid (12.7 g, 51.8 mmol, 80%); 
m.p. <30°C; 25][ Dα  -58.2 (c = 1.2, CHCl3), (lit.23 for opposite enantiomer 24][ Dα  + 
63.1 (c = 1.1, CHCl3); υ max/cm-1 (neat) 3307 (O-H), 1687 (C=O), 1646 (C=O); δH 
(400 MHz, CDCl3) 8.59 (1H, br. s., major and minor rotamer CO2H), 4.49 (1H, dd, J 
6.5, 2.0 Hz, minor rotamer CHCH2), 4.37 (1H, dd, J 7.0 Hz, 3.0 Hz, major rotamer 
CHCH2), 4.20 - 4.13 (1H, m, major and minor rotamer CHCH2), 4.09 (1H, td, J 9.0, 
2.5 Hz, CHCH2), 1.64 (3H, s, major rotamer C(CH3)2), 1.59 (3H, s, 3H, s, minor 
rotamer C(CH3)2), 1.51 (3H, s, 3H, s, major rotamer C(CH3)2), 1.47 (12H, s, 3H, s, 
major rotamer C(CH3)2, major rotamer C(CH3)3), 1.40 (9H, s, major rotamer 
C(CH3)3); δC (100 MHz, CDCl3) 176.3, 175.1 (major and minor rotamer CO2H), 
246 
 
152.7, 151.3 (major amd minor rotamer CO2tBu), 95.2 (major and minor rotamer 
C(CH3)2), 82.9, 81.6 (major and minor rotamer C(CH3)3), 66.2, 65.8 (major and 
minor rotamer CHCH2), 59.1 (major and minor rotamer CHCH2), 28.3 (major and 
minor rotamer C(CH3)3), 24.9, 24.3 (major and minor rotamer C(CH3)2); m/z (ESI+) 
268.1 ([M+Na] 100%); HR-ESIMS: calculated for C11H19NO5Na: 268.1155, found 
268.1147 [M+Na]+. Spectroscopic data are consistent with that previously reported.24 
Dipeptide 4.27 
A solution of the acid 4.26 (15.5 g, 62.9 mmol) and HOBt (88%, 1.45 g, 9.44 mmol) 
in EtOH (300 mL) was stirred at room temperature for 15 minutes. To this was 
added a solution of L-threonine methyl ester hydrochloride (11.7 g, 69.2 mmol) in 
EtOH (100 mL) and the mixture was cooled to 0-5 °C. N-Methylmorpholine (22.0 
mL, 202.3 mmol) was added over 5 minutes, and the reaction was stirred at 0-5 °C 
for 15 minutes. EDCI (14.4 g, 75.5 mmol) was added in one portion, and the reaction 
mixture was allowed to reach room temperature overnight. The reaction was 
acidified with pH 2 buffer and was reduced in vacuo. EtOAc (250 mL) was added, 
the mixture was vigorously agitated and the phases were separated. The organic 
phase was washed with pH 2 buffer (100 mL), water (100 mL), saturated aqueous 
NaHCO3 solution, and saturated aqueous NaCl solution (100 mL), dried over 
Na2SO4 and concentrated in vacuo to give the dipeptide 4.27 as an orange crystalline 
solid (19.1 g, 53 mmol, 84 %);  m.p. 77 - 80 °C; 25][ Dα  -61.0 (c = 1.1, CHCl3); υ 
max/cm-1 (neat) 3437 (O-H), 1735 (ester C=O), 1655 (amide C=O), 1524 (N-H); δH 
(500 MHz, CDCl3) 7.27 (1H, s, major and minor rotamer N10-H), 4.55 (1H, dd, J 
9.0, 2.0 Hz, major and minor rotamer C8-H), 4.49 - 4.00 (4H, m, major and minor 
rotamer C11-H, C29-H2, C30-H), 3.73 (3H, s, OCH3), 2.74 (1H, br. s., C30-OH), 
1.85 – 1.36 (17H, m, major and minor rotamer C(CH3)3, C(CH3)2), 1.17 (3H, d, J 6.5 
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Hz, major and minor rotamer C30-CH3); δC (125 MHz, CDCl3) 173.4, 171.0 (major 
and minor rotamer C9, C12), 153.1, 151.8 (major and minor rotamer CO2tBu), 95.12, 
94.6 (major NS minor rotamer C(CH3)2), 81.4 (major and minor rotamer C(CH3)3), 
68.2, 67.7 (major and minor rotamer C8-H), 67.1, 65.5 (major and minor rotamer 
C29-H2), 60.8, 60.2 (major and minor rotamer C30-H), 57.4 (major and minor 
rotamer C11-H), 52.5 (major and minor rotamer OCH3), 28.2, 26.6 (major and minor 
rotamer C(CH3)3, C(CH3)2), 19.9 (major and minor rotamer C30-CH3); m/z (ESI+) 
383.1 ([M+Na] 100%), 361.1 ([M+H] 60%); HR-ESIMS: calculated for C16H28N-
2O7Na: 383.1789, found 383.1785 [M+Na]+. 
Oxazole Methyl Ester 4.10 and Alkene 4.28 
Method modified from literature procedure of Doi et al.10 A solution of the dipeptide 
4.27 (15.9 g, 44.2 mmol) in dry CH2Cl2 (220 mL) was cooled to 0 – 5 °C under a 
nitrogen atmosphere. Diisopropylethylamine (30.0 mL, 176.4 mmol) and dry DMSO 
(16.0 mL, 225.3 mmol) were added sequentially, followed by the addition of SO3.pyr 
over 5 minutes. The reaction mixture was stirred at 0 – 5 °C for 3 hours, then poured 
into ice cold pH 2 buffer (200 ml) and stirred for 5 minutes. The phases were 
separated and the aqueous phase was further extracted with dichloromethane (2 x 10 
mL). The combined organic extracts were dried over Na2SO4 and the ketone 
obtained by silica chromatography (50% EtOAc: pet ether) as a yellow oil (10.7 g, 
29.8 mmol, 68 %). This was used immediately.  
Oxazole 4.10 prepared according to the method of Bagley et al.25 Iodine (14.9 g, 
58.6 mmol) and triethylamine (16.8 mL, 120.2 mmol) were added sequentially to an 
ice cold solution of triphenylphosphine (15.4 g, 58.6 mmol) in CH2Cl2 (150 mL) 
under a nitrogen atmosphere.  A solution of the ketone (10.5 g, 29.3 mmol) in 
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CH2Cl2 was added dropwise and the reaction mixture was allowed to reach room 
temperature overnight. The mixture was concentrated in vacuo and the residue was 
partitioned between EtOAc (150 mL) and pH 2 buffer (100 mL). The phases were 
separated and the organic phase was washed with pH 2 buffer (100 mL), water (100 
mL) and saturated aqueous NaCl solution (100 mL), dried over Na2SO4 and 
concentrated in vacuo. The oxazole was obtained by silica chromatography (25% to 
50% EtOAc: pet. ether) as a pale yellow solid (4.15 g, 12.2 mmol, 28% over 2 
steps); m.p. 60 - 63 °C; 25][ Dα -87.1 (c = 1.1, CHCl3); υ max/cm-1 (neat) 1698 (C=O), 
1609 (C=N); δH (400 MHz, CDCl3) 5.15 - 5.07 (1H, m, minor rotamer C8-H), 4.99 
(1H, dd, J 6.0 Hz, 3.0 Hz, major rotamer C8-H), 4.25 - 4.04 (2H, m, major and 
minor rotamer C29-H2), 3.88 (3H, s, major rotamer OCH3), 3.85 (3H, br. s., minor 
rotamer OCH3), 2.60 (3H, s, major rotamer C30-CH3), 2.57 (3H, br. s., minor 
rotamer C30-CH3), 1.71 (3H, s, major rotamer C(CH3)2), 1.67 (3H, br. s., minor 
rotamer C(CH3)2), 1.58 - 1.52 (3H, m, minor rotamer C(CH3)2), 1.46 (9H, br. s., 
minor rotamer C(CH3)3), 1.28 (9H, s, major rotamer C(CH3)3); δC (100 MHz, 
CDCl3) 162.6 (major and minor rotamer C10), 161.1 (major and minor rotamer C9), 
156.2 (major and minor rotamer C30), 151.2 (major and minor rotamer CO2tBu), 
127.5 (major and minor rotamer C11), 65.1 (major and minor rotamer C(CH3)2), 
81.1, 80.5 (major and minor rotamer C(CH3)3), 67.5, 67.4 (major and minor rotamer 
C29-H2), 55.1 (major and minor rotamer C8-H), 52.3, 51.9 (major and minor 
rotamer OCH3), 28.3 (major and minor rotamer C(CH3)3), 24.9, 24.1 (major and 
minor rotamer C(CH3)2), 11.9 (major and minor rotamer C30-CH3); m/z (ESI+) 
363.1 ([M+Na] 100%), 341.1 ([M+H] 60%); HR-ESIMS: calculated for C16H24N-
2O6Na: 363.1527, found 363.1526 [M+Na]+. This compound has not been previously 
reported. In some cases this method led to the formation of a significant amount of 
the elimination product 4.28 (~20 % of isolated product, inseperable from the desired 
oxazole 4.10), identifiable by 1H spectroscopy; δH (400 MHz, CDCl3) 6.83 (1H, q, J 
7.0 Hz, C30-H), 1.79 (3H, d, J 7.0 Hz, C30-CH3). 
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The oxazole 4.28 was also prepared using (diethylamino)sulfur trifluoride. 
(Diethylamino)sulfur trifluoride (3.6 mL, 27.2 mmol) was added dropwise to a 
solution of the alcohol in dry CH2Cl2 (190 mL) at -78 °C under a nitrogen 
atmosphere. The recation mixture was stirred at -78 °C for 1.5 hours, and at room 
temperature for a further 30 minutes. The reaction was quenched with saturated 
aqueous NaHCO3 solution (200 mL) and was stirred for 15 minutes. The phases 
were separated and the aqueous phase was further extracted with CH2Cl2 (2 x 25 
mL). The organic phases were combined, dried over Na2SO4 and concentrated in 
vacuo to give a mix of the oxazoline and the undesired alkene 4.28 (~3: 1 oxazoline: 
alkene). Purification by silica chromatography (50% EtOAc: pet. ether) gave the 
oxazoline (1.0 g, 2.9 mmol, 15 %), which was used immediately. 
1, 8-Diazabicyclo[5.4.0]undec-7-ene  (0.52 mL, 3.48 mmol) was added dropwise to 
a solution of the oxazoline (1.0 g, 2.9 mmol) in dry CH2Cl2 (30 mL) at 0 °C under a 
nitrogen atmosphere. After 10 minutes, BrCCl3 (0.40 mL, 3.8 mmol) was added 
dropwise, and the reaction was allowed to reach room temperature overnight. The 
reaction mixture was acidified with pH 2 buffer, and the phases were separated. The 
aqueous phase was further extracted with CH2Cl2 (2 x 25 mL) and the combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. The oxazole was 
obtained by silica chromatography (50% EtOAc: pet. ether) as a clear oil that 
crystallised on standing. All characterisation data was identical to the previously 
prepared sample.    
Asymmetric Dihydroxylation of Alkene 4.28  
In cases where the oxazoline and undesired alkene were not separated by silica 
chromatography, an inseparable mixture of the oxazole 4.10 and alkene 4.28 was 
obtained. The alkene was removed using a method modified from literature 
procedure of a Sharpless et al.26 K[Fe(CN)	] (2.01 g, 6.13 mmol), K2CO3 (0.85 g, 
6.13 mmol), (DHQD)2PHAL (0.02 g, 0.02 mmol) and methane sulphonamide (0.19 
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g, 2.04 mmol) were added to a solution of the mixture of oxazole 4.10 and alkene 
4.28 (2.10 g; approximately 0.7 g, 2.04 mmol alkene 4.28) in tBuOH:H2O (1: 1, 50 
mL) at room temperature. After 5 minutes, K2OsO4·2H2O (0.008 g, 0.02 mmol) was 
added and the reaction mixture was stirred at room temperature for 24 hours. Sodium 
sulfite (~0.1 g) was added and the mixture was stirred for a further 30 minutes. The 
phases were separated and the aqueous phase was further extracted with EtOAc (3 x 
10 mL). The combined organic phases were washed with pH 2 buffer (10 mL), water 
(10 mL) and saturated aqueous NaHCO3 solution (10 mL), dried over Na2SO4 and 
concentrated in vacuo. Silica chromatography (50 % EtOAc: pet. ether) gave only 
the desired oxazole 4.10 (0.67 g, 1.98 mmol).  All characterisation data was 
consistent to that previously obtained.  
Pentapeptide 4.30 
Oxazole methyl ester 4.10 (0.67 g, 2.0 mmol) was added to methanolic hydrochloric 
acid solution (4 M, 3 mL) and the reaction mixture was stirred at room temperature 
for 18 hours. The solvent was removed in vacuo to give the crude deprotected amine 
as the hydrochloride salt, 4.29, which was used without further purification. 
HOBt (88 %, 0.03 g, 0.19 mmol) was added to a solution of the bisoxazole (0.46 g, 
1.3 mmol) in EtOH (4 mL) and the mixture stirred at room temperature for 15 
minutes. A solution of the crude amine (2.0 mmol) in EtOH (3 mL) was added and 
the mixture cooled to 0 °C. N-Methylmorpholine (0.58 mL, 5.30 mmol) was added 
and the solution was stirred at 0-5 °C for 15 minutes. EDCI (0.29 g, 1.5 mmol) was 
added and the reaction was stirred to room temperature overnight. The reaction was 
acidified with pH 2 buffer and concentrated in vacuo. The residue was partitioned 
between EtOAc (10 mL) and pH 2 buffer (10 mL) and the phases were separated. 
The aqueous phase was further extracted with EtOAc (3 x 2 mL) and the combined 
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organic phases were washed with saturated aqueous NaCl solution (10 mL), dried 
over Na2SO4 and concentrated in vacuo. The pentapeptide 4.30 was obtained by 
silica chromatography (EtOAc) as yellow solid (0.50 g, 0.77 mmol, 64 %); m.p. 104 
- 105 °C;  25][ Dα  -28.6 (c = 0.54, CHCl3); υ max/cm-1 (neat) 3320 (NH), 2972 (OH), 
1726 (acid C=O), 1683 (amide C=O), 1531 (NH); δH (400 MHz, CDCl3) 8.15 (1H, s, 
C29-H), 7.82 (1H, d, J 8.5 Hz, N13-H), 5.46 (1H, dt, J 9.0, 4.5 Hz, C14-H), 5.41 
(1H, d, J 9.0 Hz, N4-H), 4.86 – 4.79 (1H, m, C5-H), 4.23 (1H, dd, J 11.5, 4.5 Hz, 
CH2OH), 4.05 (1H, dd, J 11.5, 4.5 Hz, CH2OH), 3.90 (3H, s, OCH3), 3.32 - 3.36 
(1H, m, CH2OH), 2.71 (3H, s, C30-CH3), 2.61 (3H, s, C33-CH3), 2.26 - 2.17 (1H, m, 
C26-H), 1.43 (9H, s, C(CH3)3), 0.97 (2H, d, J 7.0 Hz, C26(CH3)2), 0.94 (3H, d, J 6.5 
Hz, C26(CH3)2); δC (150 MHz, CDCl3) 165.8 (C6), 162.4 (CO2Me), 161.5 (C12), 
159.8 (C15), 157.0 (C33), 155.4 (CO2tBu), 154.0 (C30), 152.2 (C9), 138.6 (C29-H), 
129.8 (C8), 159.6 (C11), 127.4 (C17), 80.0 (C(CH3)3), 63.3 (CH2OH), 54.4 (C5), 
52.0 (OCH3), 48.5 (C14), 33.0 (C26), 28.3 (C(CH3)3), 18.8, 18.1 (C26(CH3)2), 12.1 
(C33-CH3), 11.8 (C30-CH3); m/z (ESI+) 570.2 ([M+Na] 100%); HR-ESIMS: 
calculated for C25H33N5O9Na: 570.1270, found 570.2172 [M+Na]+. 
Alkene 4.31 
Method modified from literature procedure of Zarantonello et al.27 Lawesson’s 
reagent (0.07 g, 0.18 mmol) was added to a solution of the alcohol 4.30 (0.10 g, 0.18 
mmol) in dry toluene (3 mL) under a nitrogen atmosphere. The reaction was heated 
to reflux for 1 hour. After cooling to room temperature, the reaction mixture was 
concentrated in vacuo and purified by silica chromatography to give the alkene 
product 4.31 as an yellow oil (0.03 g, 0.057 mmol, 31 %); 25][ Dα  -12.2 (c = 0.35, 
CHCl3); δH (400 MHz, CDCl3) 9.26 (1H, s, N13-H), 8.28 (1H, s, C29-H), 6.56 (1H, 
s, C32-H2), 5.79 (3H, s, C32-H2), 5.35 (1H, d, J 9.5 Hz, N4-H), 4.85 (1H, dd, J 9.0, 
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7.0 Hz, C5-H), 3.94 (3H, s, OCH3), 2.76 (3H, s, C30-H3), 2.69 (3H, s, C33-H3), 2.31 
– 2.19 (1H, m, C26-H), 1.45 (9H, s, C(CH3)3), 0.98 (3H, d, J 6.5 Hz, C26-(CH3)2), 
0.95 (3H, d, J 6.5 Hz, C26-(CH3)2).  
Pentapeptide Silyl Ether 4.32 
Method modified from literature procedure of McKeever et al.28 Imidazole (0.19 g, 
2.80 mmol) was added in one portion to a solution of the alcohol 4.30 (0.75 g, 1.41 
mmol) in dry DMF (6.5 mL) under an atmosphere of nitrogen at 0 °C. The reaction 
mixture was stirred at 0 °C for 5 minutes and tBuMe2SiCl (0.32 g, 2.10 mmol) was 
added in one portion. The ice bath was removed and the reaction stirred at room 
temperature for 3 hours. The reaction mixture was diluted with EtOAc (10 mL) and 
H2O (40 mL), and the phases were separated. The aqueous phase was further 
extracted with EtOAc (5 x 10mL). The combined organic extracts were washed with 
water (5 x 10 mL) and saturated aqueous NaCl solution (10 mL), dried over NaSO4 
and concentrated in vacuo. The protected product 4.31 was obtained by silica 
chromatography (1:1 EtOAc: pet. ether) as a bright white crystalline solid (0.57 g, 
0.86 mmol, 62 %); m.p. 57 - 58 °C;  25][ Dα  -1.05 (c = 0.37, CHCl3); υ max/cm-1 (neat) 
3319 (NH), 1716 (ester C=O), 1672 (amide C=O), 1506 (NH), 836 (Si-C); δH (400 
MHz, CDCl3) 8.16 (1H, s, C29-H), 7.74 (1H, d, J 8.5 Hz, N13-H), 5.42 (1H, dt, J 
8.5, 5.0 Hz, C14-H), 5.29 (1H, d, J 9.0 Hz, N4-H), 4.85 (1H, dd, J 8.5, 6.0 Hz, C5-
H), 4.12 (1H, dd, J 10.0, 4.5 Hz, CH2OH), 4.00 (1H, dd, J 10.0, 5.5 Hz, CH2OH), 
3.90 (3H, s, OCH3), 2.71 (3H, s, C30-CH3), 2.61 (3H, s, C33-CH3), 2.28 - 2.20 (1H, 
m, C26-H), 1.45 (9H, s, OC(CH3)3), 0.98 - 0.94 (6H, m, C26(CH3)2), 0.85 (9H, s, 
SiC(CH3)3), 0.02 (3H, s, SiCH3), 0.00 (3H, s, SiCH3); δC (100 MHz, CDCl3) 165.6 
(C6), 162.7 (CO2Me), 161.3 (C12), 160.2 (C15), 156.6 (C33), 155.3 (COtBu), 153.8 
253 
 
(C30), 152.0 (C9), 138.5 (C29-H), 130.1 (C8), 129.7 (C11), 127.6 (C17), 80.1 
(C(CH3)3), 64.3 (C14-CH2), 54.3 (C5), 51.9 (CO2CH3), 48.9 (C13), 33.0 (C26), 28.3 
(C(CH3)3), 25.7 (SiC(CH3)3), 18.7, 18.0 (C26(CH3)2), 17.9 (SiC(CH3)3), 12.0, 11.8 
(C30-CH3, C33-CH3), -5.4 (Si(CH3)2); m/z (ESI+) 684.3 ([M+Na] 100%); HR-
ESIMS: calculated for C31H47N5O9SiNa: 684.3035, found 684.3023 [M+Na]+. 
Thioamide Silyl Ether 4.33 
Method modified from literature procedure of McKeever et al.28 The silyl ether 4.32 
(0.50 g, 0.76 mmol) was dissolved in dry THF (10 mL) and dry toluene (6.5 mL) 
under nitrogen and Lawesson’s reagent (0.34 g, 0.83 mmol) was added. The reaction 
was heated to reflux under a nitrogen atmosphere for 44 hours, during which 
Lawesson’s reagent (1.08 g, 2.67 mmol) and dry THF (15 mL) were added in 3 equal 
portions after 18, 24 and 40 hours. The reaction mixture was cooled to room 
temperature and concentrated in vacuo. The residue was partitioned between EtOAc 
(20 mL) and aqueous NaHCO3 solution (1: 1 saturated NaHCO3: water, 20 mL). The 
separated aqueous phase was further extracted with EtOAc (3 x 5 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. The 
protected thioamide 4.33 was obtained by silica chromatography (5 % acetone: 
toluene) as a bright yellow oil (0.39 g, 0.58 mmol, 76 %);  22][ Dα  +13.3 (c = 1.2, 
CHCl3); υ max/cm-1 (neat) 3320 (N-H), 1685 (ester C=O), 1504 (N-H), 1252 (C=S), 
833 (Si-C); δH (400 MHz, CDCl3) 9.52 (1H, d, J 8.5 Hz, N13-H), 8.15 (1H, s, C29-
H), 6.01 (1H, dt, J 8.5, 4.5 Hz, C14-H), 5.30 (1H, d, J 9.0 Hz, N4-H), 4.83 (1H, dd, J 
9.0, 6.5 Hz, C5-H), 4.22 (1H, dd, J 10.5, 4.0 Hz, C14-CH2), 4.07 (1H, dd, J 10.5, 5.5 
Hz, C14-CH2), 3.88 (3H, s, OCH3), 2.88 (3H, s, C30-CH3), 2.59 (3H, s, C33-CH3), 
2.28 - 21 (1H, m, C26-H), 1.43 (9H, s, C(CH3)3), 0.96 (2H, d, J 7.0 Hz, C26(CH3)2), 
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0.94 (3H, d, J 6.5 Hz, C26(CH3)2), 0.84 - 0.87 (9H, m, SiC(CH3)3), 0.04 (3H, s, 
SiCH3), -0.01 (3H, s, SiCH3); δC (100 MHz, CDCl3) 186.4 (C12), 165.6 (C6), 162.6 
(CO2Me), 159.5 (C15), 156.7 (C33), 155.4 (COtBu, C30), 150.6 (C9), 138.7 (C29-
H), 134.2 (C11), 129.9 (C8), 127.6 (C17), 80.1 (C(CH3)3), 63.6 (C14-CH2), 54.3 
(C5), 53.4 (C14), 51.9 (CO2CH3), 32.9 (C26), 28.3 (OC(CH3)3), 25.7 (SiC(CH3)3), 
18.7, 18.1 (C26(CH3)2), 18.0 (SiC(CH3)3), 13.8 (C30-CH3), 12.0 (C33-CH3), -5.6 
(Si(CH3)2); m/z (ESI+) 700.3 ([M+Na] 100%); HR-ESIMS: calculated for 
C31H47N5O8SSiNa: 700.2807, found 700.2790 [M+Na]+. 
Thioamide 4.34                                                                                                                                       
Bu4NF (1M solution in THF, 1.0 mL, 1.0 mmol) was added to the thioamide silyl 
ether 4.33 (0.34 g, 0.50 mmol) under a nitrogen atmosphere at 0 °C. The mixture 
was stirred at 0 °C for 1 hour to give a brown solution. The reaction mixture was 
concentrated in vacuo and the residue was partitioned between EtOAc (5 mL) and 
water (2 mL). The phases were separated, and the organic phase was washed with 
water (2 x 2 mL), saturated aqueous NaCl solution (2 mL), dried over Na2SO4 and 
concentrated in vacuo to give a yellow oil. The alcohol 4.34 was obtained by silica 
chromatography (50% EtOAc: petrol) as a yellow glassy solid (0.24 g, 0.45 mmol, 
90 %); m.p. 127 - 129 °C; 27][ Dα -18.3 (c = 0.36, CHCl3); υ max/cm-1 (neat) 3340 
(NH), 2972 (OH), 1708 (ester C=O), 1519 (NH), 1249 (C=S); δH (400 MHz, CDCl3) 
9.56 (1H, d, J 8.0 Hz, N13-H), 8.17 (1H, s, C29-H), 6.15 (1H, dt, J 8.5, 4.5 Hz, C14-
H), 5.53 (1H, d, J 9.0 Hz, N4-H), 4.81 (1H, dd, J 8.5, 6.5 Hz, C5-H), 4.31 (1H, dd, J 
11.5, 4.5 Hz, CH2OH), 4.16 (1H, dd, J 11.5, 4.0 Hz, CH2OH), 3.86 (3H, s, OCH3), 
2.85 (3H, s, C30-CH3), 2.57 (3H, s, C33-CH3), 2.27 – 2.14 (1H, m, C26-H), 1.40 
(9H, s, C(CH3)3), 0.96 (3H, d, J 7.0 Hz, C26(CH3)2), 0.92 (3H, d, J 6.5 Hz, 
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C26(CH3)2); δC (100 MHz, CDCl3) 186.5 (C12), 165.6 (C6), 162.3 (C18), 159.2 
(C15), 157.0 (C33), 155.6, 155.5 (C30, CO2tBu), 150.8 (C9), 138.9 (C29-H), 134.1 
(C11), 129.6 (C8), 127.4 (C17), 80.0 (C(CH3)3), 62.5 (CH2OH), 54.5 (C5), 53.2 
(C14), 51.9 (OCH3), 32.9 (C26), 29.3 (C(CH3)3), 18.8, 18.1 (C26(CH3)2), 13.9 (C30-
CH3), 12.0 (C33-CH3); m/z (ESI+) 586.2 ([M+Na] 100%); HR-ESIMS: calculated 
for C25H33N5O8SNa: 586.1942, found 586.1950 [M+Na]+. 
Pentapeptide 4.35                                                                                                                                   
A solution of the thioamide 4.34 (0.24 g, 0.46 mmol) in dry CH2Cl2 (5 mL) was 
cooled to -78 °C under a nitrogen atmosphere. (Diethylamino)sulfur trifluoride (0.11 
mL, 0.80 mmol) was added dropwise and the reaction mixture was stirred at -78 °C 
for 1 hour, then to room temperature over 30 minutes. The reaction mixture was 
quenched with saturated aqueous NaHCO3 solution (5 mL) and stirred for 15 
minutes. The biphasic mixture was separated and the aqueous phase was extracted 
with CH2Cl2 (2 x 5 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo to give the crude thiazoline as a bright orange oil. This was 
used without further purification. 
The thiazole was prepared using a method modified from the literature procedure of 
Videnov et al.29 The solution of the crude thiazoline (0.46 mmol) in acetonitrile (1.5 
mL), CCl4 (1.1 mL), pyridine (1.5 mL) was cooled to 0 °C under a nitrogen 
atmosphere and 1, 8-Diazabicyclo[5.4.0]undec-7-ene  (0.30 mL, 2.00 mmol) was 
added dropwise. The reaction was allowed to reach room temperature overnight. The 
resulting brown suspension was partitioned between pH 2 buffer (5 mL) and CH2Cl2 
(5 mL) and the phases separated. The aqueous phase was further extracted with 
CH2Cl2 (3 x 5 mL), and the combined organic phases were dried over Na2SO4 and 
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concentrated in vacuo to give the crude thiazole. This was purified by silica 
chromatography (50 % EtOAc: pet. ether) to give the thiazole 4.35 as a bright white 
solid (0.11 g, 0.20 mmol, 45 %); m.p. 206 - 209 °C; 26][ Dα  -3.57 (c = 0.49, CHCl3); υ 
max/cm-1 (neat) 3349 (NH), 1708 (ester C=O), 1686 (amide C=O), 1523 (NH); δH 
(400 MHz, CDCl3) 8.22 (1H, s, C29-H), 8.09 (1H, s, C32-H), 5.32 (1H, d, J 9.0 Hz, 
N4-H), 4.85 (1H, dd, J 8.5, 6.5 Hz, C5-H), 3.97 - 3.92 (3H, m, OCH3), 2.88 (3H, s, 
C30-CH3), 2.74 (3H, s, C33-CH3), 2.22 (1H, s, C26-H), 1.44 (9H, s, C(CH3)3), 0.96 
(3H, d, J 7.0 Hz, C26(CH3)2), 0.94 (8H, d, J 7.0 Hz, M11); δC (150 MHz, CDCl3) 
165.6 (C6), 162.7 (C18), 162.0 (C12), 156.5 (C33), 155.4, 155.3 (CO2tBu, C15), 
153.3 (C9), 148.2 (C30), 143.6 (C14), 138.6 (C29-H), 130.8 (C11), 130.0 (C8), 
128.4 (C17), 120.5 (C32-H), 80.1 (C(CH3)3), 54.4 (C5-H), 52.1 (CO2CH3), 32.4 
(C26-H), 28.3 (C(CH3)3), 18.8, 18.1 (C26(CH3)2), 12.2, 12.1 (C30-CH3, C33-CH3); 
m/z (ESI+) 566.2 ([M+Na] 100%); HR-ESIMS: calculated for C25H29N5O7SNa: 
566.1680, found 566.1679 [M+Na]+. 
 Oxazole Acid 4.36 
Lithium hydroxide (0.26 g, 11.1 mmol) was added to a solution of methyl ester 4.10 
(0.94 g, 2.76 mmol) in THF (6 mL) and water (6 mL), and the biphasic solution was 
stirred at room temperature for 4 hours. The reaction was acidified with pH 2 buffer 
and the THF removed in vacuo. The residue was extracted with EtOAc (4 x 10 mL). 
The combined organic extracts were washed with saturated aqueous NaCl solution 
(10 mL), dried over Na2SO4 and concentrated in vacuo to give the acid 4.36 as bright 
white solid (0.85 g, 2.6 mmol, 94 %); m.p. 116 - 118 °C; 22][ Dα = -85.2 (c = 0.2, 
CHCl3); υ max/cm-1 (neat) 2980 (O-H), 1738 (acid C=O), 1702 (carbonyl C=O); δH 
(500 MHz, CDCl3) 5.19 - 5.05 (1H, m, major and minor rotamer C8-H), 4.31 - 4.10 
(2H, m, major and minor rotamer C29-H2), 2.66 (3H, s, major rotamer C30-CH3), 
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2.63 (3H, br. s., minor rotamer C30-CH3), 1.75 (3H, s, major rotamer C(CH3)2), 1.70 
(3H, br. s., minor rotamer C(CH3)2), 1.60 (3H, s, major rotamer C(CH3)2), 1.57 (3H, 
br. s., minor rotamer C(CH3)2), 1.50 (9H, br. s., minor rotamer C(CH3)3), 1.32 (9H, s, 
major rotamer C(CH3)3); δC (125 MHz, CDCl3) 165.0, 164.6 (major and minor 
rotamer C12), 161.5, 161.1 (major and minor rotamer C9), 157.21 (major and minor 
rotamer C30), 152.1, 151.2 (major and minor rotamer CO2tBu), 127.1 (major and 
minor rotamer C11), 95.2, 94.7 (major and minor rotamer C(CH3)2), 81.4, 80.7 
(major and minor rotamer C(CH3)3), 64.5, 67.3 (major and minor rotamer C29-H2), 
55.0 (C8), 28.3, 28.2 (major and minor rotamer C(CH3)3); 26.4, 25.3, 24.9, 24.1 
(major and minor rotamer C(CH3)2), 12.1 (major and minor rotamer C30-CH3); m/z 
(ESI-) 325.1 ([M-H] 100%); HR-ESIMS: calculated for C15H21N2O6: 325.1405, 
found 325.1401 [M-H]-. 
Tetrapeptide 4.37 
Oxazole methyl ester 4.10 (0.94 g, 2.76 mmol) was dissolved in a solution of 
methanolic hydrochloride (4 M, 7 mL) and stirred at room temperature for 18 hours. 
The reaction mixture was concentrated in vacuo to give the crude deprotected amine 
as the hydrochloride salt, which was used without further purification assuming 
quantitative yield.  
A solution of the oxazole acid 4.36 (0.82 g, 2.5 mmol) and HOBt (88 %, 0.06 g, 0.52 
mmol) in EtOH (5 mL) was stirred at room temperature for 15 minutes. To this was 
added a solution of the crude amine (2.76 mmol) in EtOH (10 mL) and the reaction 
mixture was cooled to 0-5 °C. N-Methylmorpholine (0.9 mL, 8.3 mmol) was added 
and the reaction was stirred at 0-5 °C for 15 minutes. EDCI (0.57 g, 2.98 mmol) was 
added, and the reaction mixture allowed to reach room temperature overnight. The 
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reaction mixture was acidified with pH 2 buffer, and concentrated in vacuo. The 
residue was partitioned between pH 2 buffer (5 mL) and EtOAc (10 mL) and the 
phases were separated. The organic phase was washed with pH 2 buffer (5 mL), 
water (5 mL), saturated aqueous NaHCO3 solution (5 mL) and saturated aqueous 
NaCl solution (5 mL), dried over Na2SO4 and concentrated in vacuo. The 
tetrapeptide 4.37 was obtained by silica chromatography (EtOAc) as a white 
crystalline solid (0.77 g, 1.51 mmol, 61 %); m.p. 88 - 91 °C; 22][ Dα  +1.48 (c = 0.37, 
CHCl3); υ max/cm-1 (neat) 2982 (O-H), 1703 (ester C=O), 1622 (amide C=O); δH (500 
MHz, CDCl3) 7.69 (1H, d, J 7.5 Hz, major and minor rotamer N13-H), 5.41 (1H, br. 
s., major and minor rotamer C14-H), 5.10 - 4.90 (1H, m, major and minor rotamer 
C8-H), 4.26 - 4.00 (4H, m, major and minor rotamer C29-H2, C31-H2,), 3.91 (3H, s, 
major and minor rotamer OCH3), 2.62 (6H, s, major and minor rotamer C30-CH3, 
C33-CH3), 1.73 (3H, br. s., major rotamer C(CH3)2), 1.70 (3H, br. s., minor rotamer 
C(CH3)2), 1.60 (3H, br. s., major rotamer C(CH3)2), 1.57 (3H, br. s., minor rotamer 
C(CH3)2), 1.49 (9H, br. s., minor rotamer C(CH3)3), 1.32 (10H, s, major rotamer 
C(CH3)3); δC (125 MHz, CDCl3) 162.4, 161.7 (major and minor rotamer C12, C18), 
160.4, 159.9, 157.2  (major and minor rotamer C9, C15, C30, C33), 153.7 (major 
and minor rotamer CO2tBu), 128.7 (major and minor rotamer C11, C17), 95.1, 94.6 
(major and rotamer C(CH3)2), 81.2, 80.6 (major and minor rotamer C(CH3)3), 67.3, 
67.0 (major rotamer C29-H2, minor rotamer C29-H2),  63.5 (major and minor 
rotamer C32-H2), 55.0 (C8-H), 52.3 (major and minor rotamer OCH3),  48.3 (C14-
H) 28.3, 28.2 (major and minor rotamer C(CH3)3), 26.4, 25.4, 25.0, 24.2 (major and 
minor rotamer C(CH3)2), 12.1, 11.7 (C30-CH3, C33-CH3); m/z (ESI+) 531.2 
([M+Na] 100%); HR-ESIMS: calculated for C23H32N4O9Na: 531.2061, found 
531.2057 [M+Na]+. 
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Tetrapeptide Silyl Ether 4.38 
Imidazole (0.21 g, 3.0 mmol was added in one portion to a solution of alcohol 4.37 
(0.77 g, 1.51 mmol) in dry DMF (7.0 mL) at 0 °C. The reaction mixture was stirred 
at 0 °C for 5 minutes and tBuMe2SiCl (0.34 g, 2.27 mmol) was added in one portion 
and the ice bath removed. The reaction mixture was stirred at room temperature 
overnight, then diluted with EtOAc (20 mL) and water (80 mL). The phases were 
separated and the aqueous phase was further extracted with EtOAc (5 x 10 mL). The 
combined organic extracts were washed with water (5 x 20 mL) and saturated 
aqueous NaCl solution (20 mL), dried over Na2SO4 and concentrated in vacuo. The 
protected alcohol 4.38 was obtained by silica chromatography (50 % EtOAc: pet. 
ether) as a clear colourless oil (0.57 g, 0.92 mmol, 61 %);  22][ Dα  -50.4 (c = 2.0, 
CHCl3); υ max/cm-1 (neat) 3414 (N-H), 1704 (ester C=O), 1632 (amide C=O), 1508 
(N-H), 835 (Si-C); δH (400 MHz, CDCl3) 7.81 - 7.52 (1H, m, major and minor 
rotamer N13-H), 5.36 (1H, dt, J 8.5 Hz, 4.0 Hz, major and minor rotamer C14-H), 
5.10 - 4.89 (1H, m, major and minor rotamer C8-H), 4.10 - 4.26 (1H, m, major and 
minor rotamer C29-H2), 4.26 - 4.10 (1H, m, major and minor rotamer C29-H2), 4.09 
(1H, dd, J 8.5, 3.0 Hz, major and minor rotamer C32-H2), 3.96 (1H, dd, J 10.0, 4.5 
Hz, major and minor rotamer C32-H2), 3.90 - 3.85 (3H, m, major and minor rotamer 
OCH3), 2.63 - 2.52 (6H, m, major and minor rotamer C30-CH3, C33-CH3), 1.73 (3H, 
br. s., major rotamer C(CH3)2), 1.70 (3H, br. s., minor rotamer C(CH3)2), 1.59 (3H, 
br. s., major rotamer C(CH3)2), 1.56 (3H, br. s., minor rotamer C(CH3)2), 1.49 (9H, 
br. s., minor rotamer OC(CH3)3), 1.29 (9H, br. s., minor rotamer OC(CH3)3), 0.83 - 
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0.79 (9H, m, Si(C(CH3)3), -0.02 (3H, s, Si(CH3)2), -0.05 (3H, s, Si(CH3)2); δC (100 
MHz, CDCl3) 162.7 (C18), 161.5 (C12), 160.2, 159.9 (C9, C15), 156.5 (C33), 153.5 
(C30), 151.2 (CO2tBu), 128.9, 127.6 (C11, C17), 95.1 (C(CH3)2), 80.4 (C(CH3)3), 
67.2 (C29-H2), 64.4 (C32-H2), 54.9 (C8-H), 51.9 (OCH3), 49.0 (C14), 28.3, 28.2 
(OC(CH3)3), 25.6 (SiC(CH3)3), 25.3, 24.3 (C(CH3)2), 17.7 (SiC(CH3)3), 11.9, 11.7 
(C30-CH3, C33-CH3), -5.64 (Si(CH3)2);  m/z (ESI+) 645.2 ([M+Na] 100%); HR-
ESIMS: calculated for C29H46N4O9SiNa: 645.2926, found 645.2928 [M+Na]+. 
Tetrapeptide Thioamide Silyl Ether 4.39 
The silyl ether 4.38 (1.15 g, 1.85 mmol) was dissolved in dry THF (7.5 mL) and dry 
toluene (15 mL) under nitrogen and Lawesson’s reagent (0.60 g, 1.48 mmol) was 
added. The reaction was heated to reflux under a nitrogen atmosphere for 24 hours, 
with Lawesson’s reagent (0.38 g, 0.94 mmol) added in one portion after 12 hours. 
The reaction mixture was cooled to room temperature and concentrated in vacuo. 
The residue was partitioned between EtOAc (20 mL) and aqueous NaHCO3 solution 
(1:1 saturated NaHCO3 solution: water, 20 mL). The separated aqueous phase was 
further extracted with EtOAc (3 x 5 mL). The combined organic phases were dried 
over Na2SO4 and concentrated in vacuo. The thioamide 4.39 was obtained by silica 
chromatography (5 % acetone: toluene) as a bright yellow oil (0.98 g, 1.53 mmol, 83 
%); 22][ Dα -83.0 (c = 0.11, CHCl3); υ max/cm-1 (neat) 3349 (NH), 1704 (ester C=O), 
1505 (NH), 1253 (C=S), 836 (Si-C); δH (600 MHz, CDCl3) 9.69 - 9.27 (1H, m, 
major and minor rotamer N13-H), 6.02 - 5.89 (1H, m, major and minor rotamer C14-
H), 5.11 - 4.89 (1H, m, major and minor rotamer C8-H), 4.29 - 4.23 (1H, m, major 
and minor rotamer C32-H2), 4.21 (1H, dd, J 10.5, 4.0 Hz, 1H, m, major and minor 
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rotamer C29-H2), 4.12 (1H, dd, J  9.5, 2.5 Hz, 1H, m, major and minor rotamer C29-
H2), 4.09 - 4.04 (1H, m, 1H, m, major and minor rotamer C32-H2), 3.90 (3H, s, 1H, 
m, major and minor rotamer OCH3), 2.81 (3H, s, major rotamer C30-CH3), 2.79 (3H, 
br. s., minor rotamer C30-CH3), 2.60 (3H, s, major and minor rotamer C33-CH3), 
1.75 (3H, s, major rotamer C(CH3)2), 1.72 (3H, br. s., minor rotamer C(CH3)2), 1.61 
(3H, s, major rotamer C(CH3)2), 1.58 (3H, br. s., minor rotamer OC(CH3)2), 1.52 - 
1.48 (9H, m, minor rotamer OC(CH3)3), 1.31 (9H, s, major rotamer C(CH3)3), 0.83 
(9H, s, SiC(CH3)3), 0.01 (3H, s, Si(CH3)2), -0.03 (3H, s, Si(CH3)2); δC (150 MHz, 
CDCl3) 186.8 (C12), 162.6 (C18), 159.4, 158.9 (C9, C15), 156.6 (C33), 155.1 (C30), 
151.1 (CO2tBu), 133.5 (C11), 127.6 (C17), 95.1 (C(CH3)2), 81.2 (OC(CH3)3), 67.4 
(C29-H2), 63.8 (C32-H2), 54.9 (C8-H), 53.6 (C14-H), 51.9 (OCH3), 28.3 
(OC(CH3)3), 25.6 (SiC(CH3)3), 25.4, 24.2 (C(CH3)2), 18.1 (SiC(CH3)3), 13.8 (C30-
CH3), 12.0 (C33-CH3), -5.4 (Si(CH3)2); m/z (ESI+) 661.3 ([M+Na] 100%); HR-
ESIMS: calculated for C29H46N4O8SSiNa: 661.2698, found 661.2689 [M+Na]+. 
Thioamide Alcohol 4.40 
Bu4NF (1 M solution in THF, 2.5 mL, 2.5 mmol) was added to silyl ether 4.39 (0.80 
g, 1.25 mmol) under a nitrogen atmosphere at 0 °C. The mixture was stirred at 0 °C 
for 1 hour to give a brown solution. The reaction mixture was concentrated in vacuo 
and the residue was partitioned between EtOAc (5 mL) and water (2 mL). The 
phases were separated, and the organic phase was washed with water (2 x 2 mL), 
saturated aqueous NaCl solution (2 mL), dried over Na2SO4 and concentrated in 
vacuo to give a yellow oil.  The alcohol 4.40 was obtained by silica chromatography 
(EtOAc) as a bright yellow oil (0.52 g, 0.99 mmol, 79 %); 27][ Dα  -81.1 (c = 0.67, 
CHCl3); υ max/cm-1 (neat) 3340 (NH), 1699 (ester C=O), 1615 (amide C=O), 1505 
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(NH), 1365 (C=S); δH (600 MHz, CDCl3) 9.45 (1H, d, J 7.5 Hz, major and minor 
rotamer N13-H), 6.19 - 6.09 (1H, m, major and minor rotamer C14-H), 5.11 - 4.92 
(1H, m, major and minor rotamer C8-H), 4.34 - 4.26 (1H, m, major and minor 
rotamer C32-H2), 4.25 - 4.20 (1H, m, major and minor rotamer C29-H2), 4.16 - 4.05 
(2H, m, major and minor rotamer C29-H2, C32-H2), 3.91 (3H, s, major and minor 
rotamer OCH3), 2.83 (3H, s, major rotamer C30-CH3), 2.80 (3H, s, minor rotamer 
C30-CH3), 2.62 (3H, s, major and minor rotamer C33-CH3), 1.73 (3H, s, major 
rotamer C(CH3)2), 1.70 (3H, br. s., minor rotamer C(CH3)2), 1.60 (3H, s, major 
rotamer C(CH3)2), 1.57 (3H, br. s., minor rotamer C(CH3)2), 1.48 (9H, s, minor 
rotamer C(CH3)3), 1.32 (9H, s, major rotamer C(CH3)3); δC (125 MHz, CDCl3) 
186.9, 186.7 (major and minor rotamer C12), 162.4 (major and minor rotamer C18), 
159.2, 158.7 (major and minor rotamer C9, C15), 157.2 (major and minor rotamer 
C33), 155.7, 155.4 (major and minor rotamer C30), 151.2 (major and minor rotamer 
CO2tBu), 133.5, 133.4 (major and minor rotamer C11), 127.5 (major and minor 
rotamer C17), 95.2, 94.6 (major and minor rotamer C(CH3)2), 81.3, 80.6 (major and 
minor rotamer C(CH3)3), 67.3, 67.0 (major and minor rotamer C29-H2), 62.7 (major 
and minor rotamer C32-H2), 54.9, 54.8 (major and minor rotamer C8-H), 52.4, 52.3, 
52.0 (major and minor rotamer C8-H, OCH3), 28.3, 28.2 (major and minor rotamer 
C(CH3)3), 26.4, 25.4, 25.0, 24.2 (major and minor rotamer C(CH3)2), 13.8, 13.7 
(major and minor rotamer C30-CH3), 12.1 (major and minor rotamer C30-CH3); m/z 
(ESI+) 547.1 ([M+Na] 100%); HR-ESIMS: calculated for C23H32N4O8SNa: 
547.1833, found 547.1837 [M+Na]+. 
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Trisazole 4.41 
 
 
A solution of thioamide 4.40 (0.46 g, 0.88 mmol) in dry CH2Cl2 (8 mL) was cooled 
to -78 °C under a nitrogen atmosphere. (Diethylamino)sulfur trifluoride (0.21 mL, 
1.6 mmol) was added dropwise and the reaction mixture was stirred at -78 °C for 1 
hour, then to room temperature over 30 minutes. The reaction mixture was quenched 
with saturated aqueous NaHCO3 solution (20 mL) and stirred for 15 minutes. The 
biphasic mixture was separated and the aqueous phase was extracted with CH2Cl2 (3 
x 5 mL). The combined organic phases were dried over Na2SO4 and concentrated in 
vacuo to give the crude thiazoline as a brown oil. This was used without further 
purification. 
The solution of the crude thiazoline (0.88 mmol) in acetonitrile (2.9 mL), CCl4 (2.0 
mL), pyridine (2.9 mL) was cooled to 0 °C under a nitrogen atmosphere and 1, 8-
Diazabicyclo[5.4.0]undec-7-ene  (0.50 mL, 3.36 mmol) was added dropwise. The 
reaction was allowed to reach room temperature overnight. The reaction mixture was 
concentrated in vacuo and the residue was partitioned between pH 2 buffer (5 mL) 
and CH2Cl2 (5 mL), and the phases separated. The aqueous phase was further 
extracted with CH2Cl2 (3 x 5 mL), and the combined organic phases were dried over 
Na2SO4 and concentrated in vacuo to give the crude thiazole. This was purified by 
silica chromatography (50 % EtOAc: pet. ether) to give the trisazole 4.41 as a clear 
yellow oil (0.27 g, 67 mmol, 77 %; 27][ Dα  -112.5 (c = 0.11, CHCl3); υ max/cm-1 (neat) 
3373 (NH), 1689 (ester C=O), 1524 (NH); δH (600 MHz, CDCl3) 8.07 (1H, s, (major 
rotamer C32-H), 8.05 (1H, s, minor rotamer C32-H), 5.14 (1H, br. s., minor rotamer 
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C8-H), 5.02 (1H, dd, J 6.0, 3.0 Hz, major rotamer C8-H), 4.31 - 4.21 (1H, m, major 
and minor rotamer C29-H2), 4.16 (1H, dd, J 10.0, 3.0 Hz, major and minor rotamer 
C29-H2), 3.95 (3H, s, major and minor rotamer CO2CH3), 2.81 (3H, m, major 
rotamer C30-CH3), 2.78 (3H, m, minor rotamer C30-CH3), 2.75 (3H, s, major and 
minor rotamer C33-CH3), 1.78 (3H, s, major rotamer C(CH3)2), 1.75 (3H, br. s., 
minor rotamer C(CH3)2), 1.62 (3H, s, major rotamer C(CH3)2), 1.58 (3H, br. s., 
minor rotamer C(CH3)2), 1.51 (9H, s, minor rotamer C(CH3)3), 1.31 (9H, s, major 
rotamer C(CH3)3); δC (150 MHz, CDCl3) 162.7, 162.4 (major and minor rotamer 
C12, C18), 161.5, 161.2 (major and minor rotamer C9), 156.5 (major and minor 
rotamer C33), (major and minor rotamer C15), 155.3 (major and minor rotamer 
C15), 152.0, 151.2 (major and minor rotamer CO2tBu), 148.0, 147.8 (major and 
minor rotamer C30), 143.6, 143.5 (major and minor rotamer C14), 129.8 (major and 
minor rotamer C11), 128.4 (major and minor rotamer C17), 120.3 (major and minor 
rotamer C32-H), 95.1, 94.6 (major and minor rotamer C(CH3)2), 81.1, 80.5 (major 
and minor rotamer C(CH3)3), 67.4, 67.2 (major and minor rotamer C29-H2), 55.1, 
55.0 (major and minor rotamer C8-H), 52.3, 52.1 (major and minor rotamer 
COCH3), 28.3, 28.2 (major and minor rotamer C(CH3)3), 26.3, 25.2, 25.1, 24.3 
(major and minor rotamer C(CH3)2), 12.2, 12.0 (major and minor rotamer C30-CH3, 
C33-CH3); m/z (ESI+) 527.1 ([M+Na] 100%); HR-ESIMS: calculated for 
C23H28N4O7SNa: 527.1571, found 527.1577 [M+Na]+. 
Peptapeptide 4.43 
  
 
 
The protected trisazole 4.41 (0.24 g, 0.47 mmol) was dissolved in a solution of 
methanolic hydrochloric acid solution (4 M, 2.8 mL) and stirred at room temperature 
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for 18 hours. The reaction mixture was concentrated in vacuo to give the crude 
deprotected amine as the hydrochloride salt, 4.42, which was used without further 
purification, assuming quantitative yield.  
A solution of Boc-Val-OH (0.15 g, 0.71 mmol) and HOBt (88 %, 0.017g, 0.11 
mmol) in EtOH (1.5 mL) were stirred at room temperature for 15 minutes. To this 
was added a solution of the crude amine (0.47 mmol) and N-methylmorpholine (0.05 
mL, 0.47 mmol) in EtOH (1.5 mL) and the reaction mixture was cooled to 0-5 °C. N-
Methylmorpholine (0.20 mL, 1.8 mmol) was added and the reaction was stirred at 0-
5 °C for 15 minutes. EDCI (0.16 g, 0.85 mmol) was added, and the reaction mixture 
allowed to reach room temperature overnight. The reaction mixture was acidified 
with pH 2 buffer, and concentrated in vacuo. The residue was partitioned between 
pH 2 buffer (5 mL) and CH2Cl2 (10 mL) and the phases were separated. The aqueous 
phase was further extracted with CH2Cl2 (3 x 5 mL) and the combined organic 
extracts were washed with water (5 mL), dried over Na2SO4 and concentrated in 
vacuo. The pentapeptide 4.43 was obtained by silica chromatography (5 - 10 % 
MeOH: CH2Cl2) as a white crystalline solid (0.11 g, 0.20 mmol, 42 %); m.p. 221 - 
224; 25][ Dα  -17.9 (c = 0.32, CHCl3); υ max/cm-1 (neat) 3314 (NH), 1722 (ester C=O), 
1650 (amide C=O), 1524 (NH);  δH (400 MHz, CDCl3) 8.06 (1H, s, C32-H), 7.10 
(1H, d, J 8.0 Hz, C7-H), 5.30 (1H, dt, J 8.0, 4.0 Hz, C8-H), 5.20 (1H, d, J 8.0 Hz, 
N4-H), 4.23 - 3.97(3H, m, C5-H, C29-H2), 3.95 (3H, s, OCH3), 2.77 (3H, s, C30-
CH3), 2.74 (3H, s, C30-CH3), 2.23 - 2.08 (1H, m, C26-H), 1.46 - 1.41 (9H, m, 
C(CH3)3), 1.04 - 0.93 (6H, m, C28-H3); δC (150 MHz, CDCl3) 171.9 (C6), 162.7, 
161.7, 159.9 (C9, C12, C18), 156.5 (C33), 155.3, C15), 152.8 (CO2tBu), 148.7 
(C30), 143.6 (C14), 129.7 (C11), 128.4 (C17), 120.2 (C32-H), 81.0 (C(CH3)3), 63.2 
(C29-H2), 60.4 (C5-H), 52.1 (OCH3), 49.2 (C8-H), 30.8 (C26-H), 28.3 (C(CH3)3), 
19.2, 18.0 (C28-H3), 12.2, 12.0 (C30-CH3, C33-CH3); m/z (ESI+) 586.1 ([M+Na] 
100%); HR-ESIMS: calculated for C25H33N5O8SNa: 586.1942, found 586.1931 
[M+Na]+. 
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Preparation of activated MnO2, Method 1 
Prepared according to the method of Carpino.30 A solution of KMnO4 (12.0 g, 75 
mmol) in water (150 mL) in a 500 mL beaker was heating to boiling point with 
stirring. The solution was removed from the heat, and activated carbon (7.5 g) was 
added over 10 minutes.  The mixture was heated to boiling point until no purple 
colour was observable (ca. 5 minutes). After cooling for 15 minutes, the reaction 
mixture was filtered, and the filter cake washed with water (4 x 25 mL), until the 
washes were colourless. The filtercake was dried under vacuum for 5 minutes, 
suspended in toluene (75 mL) and residual water was removed by azeotrope using a 
Dean-Stark apparatus. The suspension was cooled, filtered and the filtercake dried in 
vacuo to give carbon supported MnO2 as black powdery solid (8.0 g).   
Pentapeptide 4.35 
(Diethylamino)sulfur trifluoride (0.05 mL, 0.36 mmol) was added to a solution of 
pentapeptide 4.43 (0.10 g, 0.18 mmol) in dry CH2Cl2 (2 mL) at -78 °C under an 
atmosphere of nitrogen. The reaction mixture was stirred at -78 °C for 3.5 hours, and 
then at room temperature for 30 minutes. The mixture was quenched with saturated 
aqueous NaHCO3 solution (2 mL) and was stirred for 15 minutes. The phases were 
separated and the aqueous phase was further extracted with CH2Cl2 (5 x 2 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. The 
oxazoline was obtained by silica chromatography (50 % EtOAc: pet ether) as a white 
solid (69 mg, 0.13 mmol, 70 %) and was used immediately. 
Activated MnO2 (prepared according to Method 1, 0.25 g) was added to a solution of 
the oxaozline (50 mg, 0.09 mmol) in dry toluene (2.5 mL) under a nitrogen 
atmosphere. The reaction mixture was heated to reflux for 13 hours with azeotropic 
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removal of water over 3Å molecular sieves. Additional MnO2 (0.3 g) and dry toluene 
(5 mL) were added after 3 hours. The reaction mixture was cooled to room 
temperature and filtered through celite. The celite was washed with EtOAc (5 x 5 
mL). The filtrate was concentrated in vacuo and purified by silica chromatography to 
give the oxazole 4.35 as a bright white solid (8 mg, 15 µmol, 16 % from oxazoline, 4 
% over 2 steps). The characterization data were identical to that prepared in the 
previous method. 
N-tertButoxycarbonyl-L-isoleucine 4.45 
Prepared as for Boc-Val-OH, 4.19, but using L-isoleucine (10.0 g, 76.2 mmol). The 
Boc-protected product, 4.45, was obtained as a clear, colourless oil (14.5 g, 62.5 
mmol, 82 %); 25][ Dα  + 3.80 (c =1.01, MeOH); (lit.31 20][ Dα +3.9 (c = 2.00, MeOH); υ 
max/cm-1 (neat) 3321 (NH), 2967 (OH ), 1708 (acid C=O), 1503 (NH); δH (400 MHz, 
CDCl3) 10.36 (1H, br. s., major and minor rotamer CO2H), 6.16 (1H, br. s, minor 
rotamer CHNH), 5.13 (1H, d, J 8.5 Hz, major rotamer CHNH), 4.25 (1H, dd, J  8.5, 
4.5 Hz, major rotamer CHNH), 4.12 – 4.06 (1H, m, major rotamer CHNH), 1.99 - 
1.81 (1H, m, CHCH3), 1.53 - 1.42 (10H, m, C(CH3)3, CH2CH3), 1.28 – 1.08 (1H, m, 
CH2CH3), 0.96 (3H, d, J 6.5 Hz, CHCH3), 0.92 (3H, t, J 7.5 Hz, CH2CH3); δC (100 
MHz, CDCl3) 177.2 (CO2H), 155.8 (CO2tBu), 80.0 (C(CH3)3), 58.1 (CHNH), 37.7 
(CHCH3), 28.3 (C(CH3)3), 24.9 (CH2CH3), 15.5 (CHCH3), 11.6 (CH2CH3); m/z 
(ESI+) 230.1 ([M-H] 100%); HR-ESIMS: calculated for C11H21NO4Na: 254.1363, 
found 254.1350 [M+Na]+. The data are consistent with that previously reported.31  
N-tertButoxycarbonyl-L-isoleucine and N-tertButoxycarbonyl-D-allo-isoleucine 
4.46 
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Prepared as for Boc-Val-OH, 4.19, but using a mixture of L-isoleucine and D-allo-
isoleucine 3.11 (0.5 g, 3.81 mmol). The Boc-protected product 4.46 was obtained as 
a clear, colourless oil (0.77 g, 3.34 mmol, 88 %, 73: 27 mix of (2S, 3S) and (2R, 3S), 
calculated by 1H NMR); υ
 max/cm-1 (neat) 3314 (NH), 2966 (OH ), 1711 (acid C=O), 
1506 (NH); δH (400 MHz, CDCl3) 8.71 ((2S, 3S), 1H, br. s., major and minor 
rotamer CO2H; (2R, 3S), 1H, br. s., major and minor rotamer CO2H), 6.17 ((2S, 3S), 
1H, d, J 7.0 Hz, minor rotamer CHNH), 6.08 ((2R, 3S), 1H, d, J 7.0 Hz, minor 
rotamer CHNH), 5.06 ((2S, 3S), 1H, d, J 8.5 Hz, major rotamer CHNH), 5.00 ((2R, 
3S), 1H, d, J 9.0 Hz, major rotamer CHNH), 4.41 ((2R, 3S), 1H, dd, J 9.5, 4.0 Hz, 
major rotamer CHNH), 4.30 ((2S, 3S), 1H, dd, J 9.0, 4.5 Hz, major rotamer CHNH), 
4.24 - 4.17 ((2R, 3S), 1H, m, minor rotamer CHNH), 4.13 - 4.05 ((2S, 3S), 1H, m, 
minor rotamer CHNH), 2.03 - 1.83 ((2S, 3S), 1H, m, major and minor rotamer 
CHCH3; (2R, 3S), 1H, m, major and minor rotamer CHCH3), 1.45 ((2S, 3S), 10H, m, 
major and minor rotamer CH2CH3, C(CH3)3; (2R, 3S), 10H, m, major and minor 
rotamer CH2CH3, C(CH3)3), 1.31 - 1.14 ((2S, 3S), 1H, m, major and minor rotamer 
CH2CH3; (2R, 3S), 1H, m, major and minor rotamer CH2CH3), 0.99 - 0.87 ((2S, 3S), 
6H, m, major and minor rotamer CH2CH3, CHCH3; (2R, 3S), 1H, m, major and 
minor rotamer CH2CH3, CHCH3); δC (100 MHz, CDCl3) 177.8, 177.3 ((2S, 3S), 
CO2H; (2R, 3S), CO2H), 155.8 ((2S, 3S), CO2 tBu; (2R, 3S), CO2tBu), 80.1 ((2S, 3S), 
C(CH3)3; (2R, 3S), C(CH3)3), 59.1, 57.8 ((2S, 3S), CHNH; (2R, 3S), CHNH), 37.7, 
37.4 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 28.3 ((2S, 3S), C(CH3)3; (2R, 3S), 
C(CH3)3), 26.3, 24.9 ((2S, 3S),  CH2CH3; (2R, 3S), CH2CH3), 15.5 ((2S, 3S), CHCH3; 
(2R, 3S), CHCH3), 11.7 ((2S, 3S),  CH2CH3; (2R, 3S), CH2CH3); m/z (ESI+) 230.1 
([M+H] 100%); HR-ESIMS: calculated for C11H20NO4: 230.1398, found 230.1385 
[M+H]+. 
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N-tertButoxycarbonyl-L-isoleucyl-L-serine methyl ester 4.47 
Acetyl chloride (5.2 mL, 73.2 mmol) was added dropwise with stirring to MeOH (30 
mL) at 0 °C.  The mixture was allowed to reach room temperature and L-serine (1.30 
g, 12.2 mmol) was added and the mixture was heated to reflux for 18 hours. The 
reaction mixture was concentrated in vacuo to give the crude methyl ester as the 
hydrochloride salt, which was used without further purification assuming 
quantitative yield.  
A solution of Boc-L-isoleucine 4.45 (0.93 g, 4.0 mmol) and HOBt (88 %, 0.09 g, 
0.60 mmol) in EtOH (13 mL) was stirred at room temperature for 15 minutes, then 
cooled to 0-5°C. To this was added a solution of the crude serine methyl ester (4.42 
mmol) and N-methyl morpholine (1.4 mL, 12.9 mmol) in EtOH (9 mL) and the 
resulting colourless solution stirred at 0-5°C for 15 minutes. EDCI (0.92 g, 4.8 
mmol) was added and the reaction mixture was allowed to reach room temperature 
overnight to give a pale yellow solution. This was acidified using pH 2 buffer and N-
methyl morpholine hydrosulfate was removed by filtration. The filtrate was 
concentrated in vacuo, and extracted with EtOAc (4 x 10 mL). The combined 
organic extracts were washed with pH 2 buffer (10 mL), water (10 mL), saturated 
aqueous NaHCO3 solution (10 mL) and saturated aqueous NaCl solution (10 mL), 
dried over Na2SO4 and concentrated in vacuo to give dipeptide 4.47 as a white 
powdery solid (0.79 g, 2.39 mmol, 60 %); m.p. 83 – 85 ˚C; 25][ Dα  -19.1 (c = 0.26, 
MeOH); υ
 max/cm-1 (neat) 3323 (NH), 1748 (ester C=O), 1688 (amide C=O), 1520 
(NH); δH (400 MHz, CDCl3) 7.20 (1H, d, J 7.5 Hz, Ser NHCH), 5.38 (1H, d, J 8.0 
Hz, Ile NHCH), 4.67 (1H, ddd, J 8.0, 4.0, 3.0 Hz, Ser NHCH), 4.01 - 3.85 (3H, m, 
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Ile NHCH, CH2OH), 3.76 (3H, s, OCH3), 1.88 - 1.74 (1H, m, CHCH3), 1.61 - 1.50 
(1H, m, CH2CH3), 1.42 (9H, s, C(CH3)3), 1.21 - 1.08 (1H, m, CH2CH3), 0.95 (3H, d, 
J 6.5 Hz, CHCH3), 0.89 (3H, t, J 7.5 Hz, CH2CH3); δC (100 MHz, CDCl3) 172.3 
(CO2CH3), 170.8 (CONH), 156.3 (CO2tBu), 80.2 (C(CH3)3), 62.7 (CH2OH), 59.4 (Ile 
CHNH), 57.9 (Ser CHNH), 52.6 (OCH3), 37.2 (CHCH3), 28.3 (C(CH3)3), 24.8 
(CH2CH3), 15.4 (CHCH3), 11.3 (CH2CH3); m/z (ESI+) 355.1 ([M+Na] 100%); HR-
ESIMS: calculated for C15H28N2O6Na: 355.1840, found 355.1823 [M+Na]+. The 1H 
and 13C sprectoscopic data are consistent to that previously reported.32  
N-tertButoxycarbonyl-L-isoleucyl- and N-tertButoxycarbonyl-D-allo-isoleucyl-L-
serine methyl ester 4.48 
Prepared as for the single diastereoisomer using L-serine methyl ester hydrochloride 
(3.44 mmol) and a mixture of L-isoleucine and D-allo-isoleucine, 3.12 (0.72 g, 3.12 
mmol), N-methyl morpholine (1.0 mL, 10 mmol), HOBt (88 %, 0.07 g, 0.5 mmol), 
EDCI (0.72 g, 3.8 mmol) and EtOH (17 mL) to give the dipeptide as a bright white 
solid  (0.79 g,  2.37 mmol, 76 %; 78: 22 mix of (2S, 3S) and (2R, 3S) diastereomers 
by 1H NMR); υ
 max/cm-1 (neat) 3322 (NH), 1748 (ester C=O), 1689 (amide C=O), 
1522 (NH); δH (400 MHz, CDCl3) 7.26 (1H, d, J 8.0 Hz, (2S, 3S), Ser CHNH; 1H, d, 
J 8.0 Hz, (2R, 3S), Ser CHNH), 5.41 (1H, d, J 9.0 Hz, (2S, 3S), Ile CHNH), 5.20 
(1H, d, J 7.5 Hz, (2R, 3S), Ile CHNH), 4.66 (1H, dt, J 7.5, 3.5 Hz, (2S, 3S), Ser 
CHNH; 1H, dt, J 7.5, 3.5 Hz, (2R, 3S), Ser CHNH), 4.19 - 4.11 (1H, m, (2R, 3S), Ile 
CHNH), 3.98 (1H, dd, J 8.5, 7.5 Hz, (2S, 3S), Ile CHNH), 3.98 – 3.83 (2H, m, (2S, 
3S), CH2OH; 2H, m, (2R, 3S  CH2OH), 3.75 (3H, m, (2S, 3S),  OCH3; 3H, m, (2R, 
3S),  OCH3), 2.06 - 1.94 (1H, m, (2R, 3S),  CHCH3), 1.86 – 1.74 (1H, m, (2S, 3S),  
CHCH3), 1.65 - 1.48 (1H, m, (2S, 3S), CH2CH3; 1H, m, (2R, 3S), CH2CH3), 1.42 
(9H, s, (2R, 3S), C(CH3)3), 1.40 (9H, s, (2S, 3S), C(CH3)3), 1.29 – 1.07 (1H, m, (2S, 
3S), CH2CH3; 1H, m, (2S, 3S), CH2CH3), 0.97 - 0.85 (1H, m, (2S, 3S), 
271 
 
CHCH3,CH2CH3; 1H, m, (2S, 3S), CHCH3, CH2CH3); δC (100 MHz, CDCl3) 172.3 
((2S, 3S), CO2H; (2R, 3S), CO2H), 171.0, 170.8 ((2S, 3S), CONH; (2R, 3S), CONH), 
156.3 ((2S, 3S), CO2tBu; (2R, 3S), CO2tBu), 80.4, 80.2 ((2S, 3S), C(CH3)3; (2R, 3S), 
C(CH3)3), 62.6 ((2S, 3S), CH2OH; (2R, 3S), CH2OH), 59.4, 58.4 ((2S, 3S), Ile 
NHCH; (2R, 3S), Ile NHCH), 54.7 ((2S, 3S), Ser NHCH; (2R, 3S), Ser NHCH), 52.7, 
52.6 ((2S, 3S), OCH3; (2R, 3S), OCH3), 37.3, 37.0 ((2S, 3S), CHCH3; (2R, 3S), 
CHCH3), 28.3 ((2S, 3S), C(CH3)3; (2R, 3S), C(CH3)3), 24.8 ((2S, 3S), CH2CH3; (2R, 
3S), CH2CH3), 15.4, 14.2 ((2S, 3S), CHCH3; (2R, 3S), CHCH3), 11.7, 11.2 ((2S, 3S), 
CH2CH3; (2R, 3S), CH2CH3); m/z (ESI+) 355.1 ([M+Na] 100%); HR-ESIMS: 
calculated for C15H28N2O6Na: 355.1840, found 355.1839 [M+Na]+. 
(2S, 3S) Oxazole 4.49 
(Diethylamino)sulfur trifluoride (0.17 mL, 1.3 mmol) was added to solution of the 
dipeptide 4.47 (0.31 g, 0.92 mmol) in dry CH2Cl2 (8.5 mL) at -78 °C under a 
nitrogen atmosphere. The reaction mixture was stirred at -78 °C for 1.5 hours, and at 
room temperature for 30 minutes. The reaction was quenched with saturated aqueous 
NaHCO3 solution (10 mL) and stirred for 15 minutes. The phases were separated and 
the aqueous phase was further extracted with CH2Cl2 (2 x 5 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo to give the crude 
oxazoline as a yellow oil that was used immediately assuming quantitative yield. 
MnO2 (prepared by the method of Carpino,30 vide supra, 5 x mass oxazoline, 1.25 g) 
was added to a solution of the oxazoline (0.25 g, 0.92 mmol) in dry toluene (12 mL) 
under a nitrogen atmosphere. The reaction was heated to reflux with azeotropic 
removal of water over 3Å molecular sieves for 20 hours. After cooling to room 
temperature, the mixture was filtered through celite. The celite was washed with 
EtOAc (5 x 5 mL) and the filtrate was concentrated in vacuo. The oxazole was 
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obtained by silica chromatography (50% EtOAc: pet. ether) as a white solid (7 mg, 
0.02 mmol, 2 %); 25][ Dα  -19.3 (c = 0.64, CHCl3); υ max/cm-1 (neat) 3326 (NH), 2972 
(aromatic C-H), 1727 (ester C=O), 1698 (amide C=O), 1529 (NH); δH (400 MHz, 
CDCl3) 8.18 (1H, s, oxazole C-H), 5.33 (1H, d, J 9.0 Hz, NHCH), 4.86 (1H, dd, J 
9.0, 6.0 Hz, NHCH), 3.91 (3H, s, OCH3), 2.01 - 1.88 (1H, m, CHCH3), 1.51 – 1.39 
(10H, m, CH2CH3, C(CH3)3), 1.24 – 1.10 (1H, m, CH2CH3), 0.90 (3H, t, J 7.0 Hz, 
CH2CH3), 0.86 (3H, d, J 7.0 Hz, CHCH3); δC (100 MHz, CDCl3) 164.1 (C1), 160.6 
(CO2Me), 154.2 (CO2tBu), 142.8 (oxazole C-H), 132.1 (C2), 79.0 (C(CH3)3), 52.3 
(CHNH), 51.2 (OCH3), 38.5 (CHCH3), 28.7 (C(CH3)3), 24.0 (CH2CH3), 14.3 
(CHCH3),10.4 (CH2CH3); m/z (ESI+) 335.1 ([M+Na] 100%); HR-ESIMS: calculated 
for C15H24N2O5Na: 335.1577, found 335.1572 [M+Na]+. This compound is known, 
but no characterisation data has been reported.33 
(2S, 3S) and (2R, 3S) Oxazole 4.50 
Prepared as for the single diastereoisomer, 4.49, using a diastereomeric mix of 
dipeptide 4.48 (0.39 g, 1.17 mmol), (diethylamino)sulfur trifluoride (0.22 mL, 1.6 
mmol)  and CH2Cl2 (11 mL) to give the oxazoline. The oxazole 4.50 was prepared as 
for the single diastereomer with MnO2 (2.2 g) and dry toluene (10 mL). Additional 
MnO2 (0.85 g) and dry toluene (5 mL) were added after 2 hours at reflux, and the 
reaction mixture was heated to reflux for a further 7 hours. The cooled reaction 
mixture was filtered over celite, and the celite washed with EtOAc (5 x 10 mL). The 
filtrate was concentrated in vacuo and the oxazole, 4.50, obtained by silica 
chromatography (50% EtOAc: pet. ether) as a white solid (3 mg, 0.09 mmol, 1 %; 
72: 28 mix of (2S, 3S) and (2R, 3S) diastereomers by 1H NMR): δH (400 MHz, 
CDCl3) 8.18 (1H, s, (2S, 3S  CC-H; 1H, s, (2R, 3S), CC-H), 5.32 (1H, d, J 9.0 Hz, 
(2S, 3S), NHCH), 5.27 (1H, d, J 9.5 Hz, (2S, 3S), NHCH), 4.95 (1H, dd, J 9.5 Hz, 
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5.0 Hz, (2R, 3S), NHCH), 4.86 (1H, dd, J 9.0 Hz, 6.5 Hz, (2S, 3S), NHCH), 3.91 
(3H, s, (2S, 3S), OCH3; 3H, s, (2R, 3S), OCH3), 2.02 – 1.88 (1H, m, (2S, 3S), 
CHCH3; 1H, m, (2R, 3S), CHCH3), 1.50 – 1.39 (10H, m, (2S, 3S), CH2CH3, 
C(CH3)3; 10H, m, (2R, 3S), CH2CH3, C(CH3)3), 1.23 – 1.10 (1H, d, J 7.0 Hz, (2S, 
3S), CH2CH3; 1H, d, J 7.0 Hz, (2R, 3S), CH2CH3), 0.96 - 0.83 (6H, m, (2S, 3S), 
CHCH3, CH2CH3; 6H, m, (2R, 3S), CHCH3, CH2CH3); δC (100 MHz, CDCl3) 165.2 
((2S, 3S), C1; (2R, 3S), C1), 161.6 ((2S, 3S), CO2Me; (2R, 3S), CO2Me), 155.3 ((2S, 
3S), CO2tBu; (2R, 3S), CO2tBu), 143.8 ((2S, 3S), CC-H; (2R, 3S), CC-H), 133.2 ((2S, 
3S), C2; (2R, 3S), C2), 80.1 ((2S, 3S), C(CH3)3; (2R, 3S), C(CH3)3), 53.4, 52.7 ((2S, 
3S), CHNH; (2R, 3S), CHNH), 51.6 ((2S, 3S), OCH3; (2R, 3S), OCH3), 39.5, 39.3 
((2S, 3S), CHCH3; (2R, 3S), CHCH3), 28.3 ((2S, 3S), C(CH3)3; (2R, 3S), C(CH3)3), 
25.9, 25.1 ((2S, 3S), CH2CH3); (2R, 3S), CH2CH3), 15.2, 14.5 (2S, 3S), CHCH3; (2R, 
3S), CHCH3), 11.6, 11.4 ((2S, 3S), CH2CH3; (2R, 3S), CH2CH3); m/z (ESI+) 335.1 
([M+Na] 100%); HR-ESIMS: calculated for C15H24N2O5Na: 335.1577, found 
335.1582 [M+Na]+. 
Preparation of activated MnO2 (Method 2): 
Prepared according to the method set out by Fatiadi.34 A solution of KMnO4 (26.3 g, 
167 mmol) in water (500 mL) was added slowly to a solution of manganese sulfate 
monohydrate (42.3 g, 250 mmol) in water (720 mL) at 60 ˚C in a 2L beaker. The 
solution was stirred at 60 °C for 1 hour. After cooling to room temperature, the 
suspension was filtered. The filtercake was washed with water (~2L) until the pH of 
the aqueous washes was neutral. The filtercake was dried under vacuum over silica 
for to give a dense black solid (86.1 g), to give the unactivated MnO2 with ~68% 
associated water. This was activated immediately before use according to the method 
of Goldman.35 
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Tripeptide Oxazole 4.51 
Oxazole methyl ester 4.10 (3.05 g, 8.96 mmol) was dissolved in a solution of 
methanolic hydrochloric acid (4 M, 21.5 mL) and stirred at room temperature for 18 
hours. The reaction mixture was concentrated in vacuo to give the crude deprotected 
amine as the hydrochloride salt, which was used without further purification 
assuming quantitative yield.  
A solution of Boc-Val-OH (2.83 g, 13.4 mmol) and HOBt (88 %, 0.32g, 2.06 mmol) 
in EtOH (50 mL) were stirred at room temperature for 15 minutes. To this was added 
a solution of the crude amine (8.96 mmol) in EtOH (40 mL) and the reaction mixture 
was cooled to 0-5 °C. N-Methylmorpholine (4.7 mL, 43.0 mmol) was added and the 
reaction was stirred at 0-5 °C for 15 minutes. EDCI (3.08 g, 16.1 mmol) was added, 
and the reaction mixture allowed to reach room temperature overnight. The reaction 
mixture was acidified with pH 2 buffer, filtered, and the filtrate was concentrated in 
vacuo. The residue was partitioned between pH 2 buffer (50 mL) and EtOAc (100 
mL) and the phases were separated. The organic phase was washed with pH 2 buffer 
(25 mL), water (25 mL), saturated aqueous NaHCO3 solution (25 mL) and saturated 
aqueous NaCl solution (25 mL), dried over Na2SO4 and concentrated in vacuo. The 
pure tripeptide, 4.51, was obtained by silica chromatography (EtOAc) as a bright 
white crystalline solid (2.05 g, 5.13 mmol, 57 %; also performed with 1.68 g, 88 %); 
m.p. 99 – 100 ˚C; 25][ Dα  -47.3 (c = 0.52, CHCl3); υ max/cm-1 (neat) 3326 (NH), 3306 
(OH), 1721 (ester C=O), 1687 (amide C=O), 1519 (NH);1H NMR (400 MHz, 
CDCl3) 7.50 (1H, d, J 8.0 Hz, N7-H), 5.43 (1H, d, J 8.5 Hz, N4-H), 5.22 (1H, dt, J 
8.0, 4.0 Hz, C8-H), 4.23 - 4.16 (1H, m, CH2OH), 4.02 – 3.96 (2H, m, C5-H, 
CH2OH), 3.95 – 3.86 (1H, m, CH2OH), 3.80 (3H, s, OCH3), 2.51 (3H, s, oxazole 
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CH3), 2.11 - 2.00 (1H, m, CHCH3), 1.35 (9H, s, C(CH3)3), 0.90 (3H, d, J 7.0 Hz, 
CH(CH3)2), 0.86 (3H, d, J 6.5 Hz, CH(CH3)2); δC (175 MHz, CDCl3) 172.1 (C6), 
162.4 (C12), 159.8 (C9), 156.9 (C30), 156.2 (CO2tBu), 127.3 (C11), 80.2 (C(CH3)3), 
63.1 (C29-H2), 60.2 (C5-H), 52.0 (OCH3), 49.3 (C8-H), 30.8 (C26-H), 28.3 
(C(CH3)3), 19.2 (C28-H3), 17.8 (C28-H3), 12.0 (C30-CH3); m/z (ESI+) 422.1 
([M+Na] 100%); HR-ESIMS: calculated for C18H30N3O7: 400.2078, found 400.2087 
[M+H]+. 
Bisoxazole 4.35 
(Diethylamino)sulfur trifluoride (1.22 mL, 9.24 mmol) was added dropwise to a 
solution of the tripeptide 4.51 (2.05 g, 5.13 mmol) in dry CH2Cl2 (55 mL) at – 78 °C 
under a nitrogen atmosphere. The recation mixture was stirred at -78 °C for 2 hours, 
then at room temperature for 30 minutes. The reaction was quenched with saturated 
aqueous NaHCO3 solution (55 mL) and stirred for 15 minutes. The phases were 
separated and the organic phase was further extracted with CH2Cl2 (2 x 20 ml). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. The 
crude oxazoline was used immediately without further purification 
A suspension of MnO2 (prepared by the method of Fatiadi,34 17.8 g, 103 mmol) in 
toluene (100 mL) was heated to reflux with azeotropic water removal using Dean-
Stark apparatus until no more water could be removed. A solution of the oxazoline 
(5.13 mmol) in toluene (10 mL) was added and the reaction heated to reflux with 
azeotrpic water removal for 6 hours. After cooling to room temperature, an acidic 
solution of sodium sulphite (1.5 g Na2SO3/1 g MnO2 in 5 volumes of water, acidified 
to pH 5 with concentrated H2SO4) was added to the reaction mixture and the pH of 
the aqueous phase was adjusted to 5 and stirred until dissolution of the suspension. 
The phases were separated and the aqueous phase was acidified to pH 2 and 
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extracted with EtOAc (3 x 50 mL). The combined organic phases were washed with 
water (100 mL), saturated aqueous NaHCO3 solution (100 mL), and saturated 
aqueous NaCl solution (100 mL), dried over Na2SO4 and concentrated in vacuo. The 
bisoxazole 4.35 was obtained by silica chromatography (50 % EtOAc: pet. ether) as 
a bright white solid (0.53 g, 1.40 mmol, 27% over 2 steps); All characterisation data 
was identical to that obtained for the previous method.  
Tetrazole Carboxylic Acid 4.52 
LiOH (0.08 g, 3.49 mmol) was added to a stirred suspension of methyl ester 4.35 
(0.19 g, 0.35 mmol) in MeOH (15 mL), THF (15 mL) and water (2.7 mL). After 18 
hours at room temperature, THF (5 mL), MeOH (5 mL) and CH2Cl2 (3 mL) were 
added to the suspension, and the mixture stirred for a further 8 hours, until complete 
by TLC (EtOAc). The mixture was acidified with pH 2 buffer, and the organics 
removed in vacuo. The mixture was extracted with CH2Cl2 (5 x 3 mL), and the 
combined organics were dried over Na2SO4 and concentrated in vacuo to give the 
acid 4.52 as a bright white solid (0.17 g, 0.32 mmol, 92%); m.p. 208 - 210 °C;  24][ Dα  
-53.8 (c = 0.25, MeOH); υ
 max/cm-1 (neat) 3332 (NH), 3120 (OH), 1685 (acid C=O), 
1620 (amide C=O), 1518 (NH); δH (600 MHz, CDCl3) 8.23 (1H, s, C29-H), 8.11 
(1H, s, C32-H), 5.86 (1H, br.s, minor rotamer N4-H), 5.40 (1H, d, J 9.5 Hz, major 
rotamer N4-H), 4.86 (1H, dd, J 9.0, 6.5 Hz, major rotamer C5-H), 4.70 (1H, br. s., 
minor rotamer C5-H), 2.88 (3H, s, C30-CH3), 2.77 (3H, s, C33-CH3), 2.35 - 2.18 
(1H, m, C26-H), 1.54 - 1.37 (9H, m, C(CH3)3), 0.98 (3H, d, J 7.0 Hz, C26(CH3)2), 
0.95 (3H, d, J 7.0 Hz, C26(CH3)2); δC (150 MHz, CDCl3) 165.7 (C6), 165.2 (CO2H), 
162.2 (C12), 157.3 (C33), 155.4, 155.3 (CO2tBu, C15), 153.3 (C30), 143.4 (C14), 
140.23 (C29-H), 130.8 (C11), 129.9 (C8), 128.2 (C17), 120.8 (C32-H), 80.1 
(C(CH3)3), 54.4 (C5-H), 33.0 (C26), 28.3 (C(CH3)3), 18.8, 18.1 (C26(CH3)2), 12.3, 
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12.2 (C30-CH3, C33-CH3); m/z (ESI-) 528.0 ([M-H] 100%); HR-ESIMS: calculated 
for C24H27N5O7SNa: 552.1523, found 552.1540 [M+Na]+.           
Hexapeptide 4.53                                                                                                                                    
HOBt (88 %, 5 mg, 0.032 mmol) was added to a solution of carboxylic acid 4.52 (86 
mg, 0.16 mmol) in EtOH (2 mL), and the reaction mixture was stirred for 15 minutes 
at room temperature. To this was added a solution of L-isoleucine methyl ester 
hydrochloride (70 mg, 0.40 mmol) in EtOH (2 mL) and the mixture was cooled to 0-
5 °C. N-Methyl morpholine (0.11 mL, 1.05 mmol) was added and the mixture was 
stirred at 0-5 °C for 15 minutes. EDCI (46 mg, 0.24 mmol) was added and the 
reaction mixture allowed to reach room temperature overnight. The resulting dense 
white suspension was acidified with pH 2 buffer, and extracted with EtOAc (5 x 5 
mL). The combined organics were washed with saturated aqueous NaCl solution (5 
mL), dried over Na2SO4 and concentrated in vacuo to give the crude hexapeptide. 
Hexapeptide 4.53 was obtained by silica chromatography (2% MeOH: CH2Cl2) as a 
pale yellow crystalline solid (89 mg, 0.136 mmol, 84 %); m.p. 127 - 129 ˚C; 24][ Dα  -
18.4 (c = 0.51, CHCl3); υ max/cm-1 (neat) 3305 (NH), 1742 (ester C=O), 1680, 1630 
(amide C=O), 1510 (NH); δH (500 MHz, CDCl3) 8.23 (1H, s, C29-H), 8.00 (1H, s, 
C32-H), 7.51 (1H, d, J 9.0 Hz, N19-H), 5.33 (1H, d, J 10 Hz, N4-H), 4.87 (1H, dd, J 
9.0, 7.0 Hz, C5-H), 4.75 (1H, dd, J 9.0, 5.5 Hz, C20-H), 3.78 (3H, s, OCH3), 2.91 
(3H, s, C30-CH3), 2.75 (3H, s, C33-CH3), 2.26 (1H, s, C35-H), 2.02 (1H, br. s., C26-
H), 1.61-.1.56 (1H, m, C37-H)1.46 (9H, s, C(CH3)3), 1.34 - 1.25 (1H, m, C37-H), 
1.03 - 0.95 (9H, m, C26(CH3)2, C36-H3, C38-H3); δC (125 MHz, CDCl3) 172.3 
(C21), 165.6 (C6), 162.3 (C12), 161.6 (C18), 154.3 (C15), 153.6 (C33), 153.3 (C9), 
148.2 (C30), 143.8 (C14), 139.0 (C29-H), 130.8 (C11), 130.0, 129.9 (C8, C17), 
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120.1 (C32-H), 80.1 (C(CH3)3), 56.2 (C20), 54.4 (C5), 52.1 (OCH3), 38.0 (C35), 
33.1 (C26), 28.3 (C(CH3)3), 25.3 (C37), 18.8, 18.1 (C26(CH3)2), 15.6 (C36), 12.2, 
11.9, 11.5 (C30-CH3, C33-CH3, C38). Missing one quaternary carbon; m/z (ESI+) 
679.1 ([M+Na] 100%); HR-ESIMS: calculated for C31H40N6O8SNa: 679.2521, found 
679.2522 [M+Na]+.           
Hexapeptide hydrochloride 4.54 
A solution of the Boc-protected hexapeptide 4.53 (89 mg, 0.14 mmol) in methanolic 
hydrochloride (2M, 2.1 mL) was stirred at room temperature for 2 hours. The 
mixture was concentrated in vacuo to give the deprotected amine hydrochloride salt 
4.54 as an amorphous cream solid (80 mg, 0.14 mmol, 99 %); 28][ Dα  +3.50 (c = 
0.495, MeOH); υ
 max/cm-1 (neat) 2966 (NH), 1738 (ester C=O), 1663, 1627 (amide 
C=O), 1512 (NH); δH (700 MHz, MeOD) 8.73 (1H, s, C29-H), 8.27 (1H, s, C32-H), 
4.56 - 4.61 (2H, m, C5-H, C20-H), 3.80 - 3.76 (3H, m, OCH3), 2.89 - 2.86 (3H, m, 
C30-CH3), 2.67 (3H, s, C33-CH3), 2.45 (1H, oct. J 6.5 Hz, C26-H), 2.07 – 2.00 (1H, 
m, C35-H), 1.58 (1H, dqd, J 14.5, 7.5, 4.8 Hz, C37-H), 1.37 - 1.30 (1H, m, C37-H), 
1.16 (3H, d, J 6.5 Hz, C26-CH3), 1.05 (3H, d, J 6.5 Hz, C26-CH3), 1.00 (3H, d, J 6.5 
Hz, C36-H3), 0.98 (3H, t, J 7.5 Hz, C38-H3); δC (175 MHz, MeOD) 172.0 (C21), 
162.0, 161.9 (C6, C12), 160.7 (C18), 154.7, 154.1, 153.1 (C15, C33, C9), 148.6 
(C30), 143.8 (C14), 140.8 (C29-H), 130.4, 130.0, 129.9 (C8, C17, C11), 120.9 (C32-
H), 56.4 (C20), 53.9 (C5), 51.2 (OCH3), 37.3 (C35), 33.1 (C26), 25.3 (C37), 17.4, 
16.7 (C26(CH3)2), 14.6 (C36), 10.5, 10.4, 10.3 (C30-CH3, C33-CH3, C38); m/z 
(ESI+) 579.1 ([M+Na] 100%); HR-ESIMS: calculated for C26H33N6O6S: 557.2177, 
found 557.2189 [M-Cl]+. 
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(S)-2-Hydroxy-3-methylbutanoic acid 4.55                                                                                                                             
Prepared according to the method of Bauer et al.36 A solution of L-valine (1.0 g, 8.54 
mmol) in dilute aqueous sulphuric acid (0.5M, 34 mL, 17.0 mmol) was cooled to 0 
°C. A solution of sodium nitrate (3.53 g, 51.2 mmol) in water (11.5 mL) was added 
dropwise, and the reaction mixture was stirred at 0-5 °C for a further 30 minutes and 
at room temperature overnight. The reaction mixture was extracted with Et2O (5 x 10 
mL). The combined organic extracts were washed with saturated aqueous NaCl 
solution (20 mL), dried over Na2SO4 and concentrated in vacuo to give yellow 
crystals. These were recrystallised from pet. ether to give hydroxyacid 4.55 as bright 
white crystals (0.31 g, 2.62 mmol, 31 %); m.p. 65 - 66 °C (lit.37 65 - 66 °C); 26][ Dα  
+14.0 (c = 1.01, CHCl3) (lit.36 20][ Dα +17.3 (c = 1.06, CHCl3); υ max/cm-1 (neat) 3414 
(OH), 1703 (acid C=O); δH (400 MHz, CDCl3) 6.05 (1H, br.s, CO2H), 4.16 (1H, d, J 
3.5 Hz, CHOH), 2.17 (1H, septd, J 6.5, 3.5 Hz, CH(CH3)2), 1.07 (3H, d, J 6.5 Hz, 
CH(CH3)2), 0.93 (3H, d, J 7.0 Hz, CH(CH3)2); δC (100 MHz, CDCl3) 179.4 (CO2H), 
74.8 (CHOH), 32.0 (CH(CH3)2), 18.8 (CH(CH3)2), 15.9 (CH(CH3)2); m/z (ESI-) 
117.1 ([M-H] 100%); HR-ESIMS: calculated for C5H9O3: 117.0557, found 117.0554 
[M+H]+. The data are consistent with that previously reported.38   
Heptapeptide 4.56 
A solution of the (2S)-2-hydroxy-3-methylbutanoic acid, 4.55, (0.08 g, 0.68 mmol) 
and HOBt (88 %, 0.021 g, 0.14 mmol) in EtOH (3 mL) was stirred at room 
temperature for 15 minutes before being added to a solution of the amine 
hydrochloride salt 4.54 (80 mg, 0.14 mmol) in EtOH (2 mL). The reaction mixture 
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was cooled to 0-5 °C and N-methylmorpholine (0.12 mL, 1.1 mmol) was added. 
After 15 minutes at 0-5 °C, EDCI (0.16 g, 0.68 mmol) was added and the reaction 
mixture allowed to reach room temperature overnight. The mixture was acidified 
with pH 2 buffer and EtOH removed in vacuo. The mixture was extracted with 
EtOAc (4 x 5 mL), and the combined organic extracts were washed with water (5 
mL), saturated aqueous NaHCO3 solution (5 mL), dried over Na2SO4 and 
concentrated in vacuo to give the crude heptapeptide. The alcohol 4.56 was obtained 
by silica chromatography (98:2:0.2 EtOAc:MeOH:AcOH) as an amorphous solid (72 
mg, 0.11 mmol, 81 %); 26][ Dα -50.2 (c = 0.53, CHCl3); υ max/cm-1 (neat) 3432 (NH), 
3265 (OH), 1740 (ester C=O), 1648 (amide C=O), 1507 (NH); δH (500 MHz, 
CDCl3) 8.20 (1H, s, C29-H), 7.97 (1H, s, C32-H), 7.61 (1H, d, J 9.5 Hz, N4-H), 7.49 
(1H, d, J 9.0 Hz, N19-H), 5.22 (1H, dd, J 9.5, 7.0 Hz, C5-H), 4.73 (1H, dd, J 9.0, 5.5 
Hz, C20-H), 4.29 – 4.26 (1H, m, C2-H), 3.77 (3H, s, OCH3), 2.88 (3H, s, C30-CH3), 
2.74 - 2.71 (3H, m, C30-CH3), 2.39 - 2.24 (2H, m, C23-H, C26-H), 2.05 - 1.96 (1H, 
m, 1H, m, C35-H), 1.62 - 1.51 (1H, m, C37-H), 1.34 - 1.23 (1H, m, C37-H), 1.06 - 
0.90 (18H, m, C24-CH3, C25-CH3, C27-CH3, C28-CH3, C36-CH3, C38-CH3); δC 
(125 MHz, CDCl3) 173.4 (C3), 172.2 (C21), 165.6 (C6), 162.1 (C12), 161.6 (C18), 
165.2 (C15), 153.6 (C22), 153.0 (C9), 148.3 (C30), 143.8 (C14), 138.5 (C29-H), 
130.8 (C11), 129.9, 129.8 (C8, C17), 120.2 (C32-H), 76.4 (C2-H), 56.2 (C20), 52.3, 
52.1 (C5, OCH3), 38.0 (C35), 32.9, 31.7 (C23, C26), 25.3 (C37), 19.2, 19.0, 18.5, 
15.6, 15.5 (C24, C25, C27, C28, C36)  12.1, 11.9, 11.5 (C30-CH3, C33-CH3, C38); 
m/z (ESI+) 679.1 ([M+Na] 100%); HR-ESIMS: calculated for C31H40N6O8SNa: 
679.2521, found 679.2528 [M+Na]+. 
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Ketone 4.57 
A solution of alcohol 4.56 (57 mg, 0.087 mmol) in dry CH2Cl2 (3 mL) and dry 
DMSO (0.06 mL) was cooled to 0-5°C under a nitrogen atomosphere. iPr2NEt (0.12 
mL, 0.69 mmol) and SO3.pyr (83 mg, 0.52 mmol) were added sequentially, and the 
reaction stirred at 0-5°C for 3 hours. The mixture was acidified with pH 2 buffer and 
the phases were separated. The aqueous phase was further extracted with CH2Cl2 (3 
x 3 mL), and the combined organic extracts were dried over Na2SO4 and 
concentrated in vacuo to give a yellow gum. This was purified by silica 
chromatography (50% EtOAc: pet. ether) to give ketone 4.57 as a bright white solid 
(37 mg, 0.57 mmol, 65%); m.p. 145-146 °C; 27][ Dα -30.7 (c = 0.52, CHCl3); υ max/cm-
1
 (neat) 3406 (NH), 1739 (ester C=O), 1670 (ketone C=O), 1628 (amide C=O), 1511 
(NH); δH (400 MHz, CDCl3) 8.25 (1H, s, C29-H), 8.00 (1H, s, C32-H), 7.59 (1H, d, 
J 9.5 Hz, N4-H), 7.50 (1H, d, J 9.0 Hz, N19-H), 5.13 (1H, dd, J 9.5, 6.5 Hz, C5-H), 
4.74 (1H, dd, J 9.0, 6.0 Hz, C20-H), 3.75 - 3.82 (3H, m, OCH3), 3.59 (1H, spt, J 7.0 
Hz, C23-H), 2.91 (3H, s, C30-CH3), 2.73 - 2.79 (3H, m, C30-CH3), 2.31 - 2.45 (1H, 
m, C26-H), 1.93 - 2.09 (1H, m, C35-H), 1.51 - 1.63 (1H, m, C37-H), 1.25 - 1.36 
(1H, m, C37-H), 1.18 (3H, d, J 6.5 Hz, C25-H3), 1.15 (3H, d, J 7.0 Hz, C25-H3), 
0.94 - 1.03 (12H, m, C27-H3, C28-H3, C36-H3, C38-H3); δC (125 MHz, CDCl3) 
201.5 (C2), 172.3 (C21), 164.0 (C6), 162.3 (C12), 161.6 (C3), 159.5 (C18), 154.3 
(C15), 153.6 (C33), 153.1 (C9), 148.3 (C30), 143.8 (C14), 138.7 (C29-H), 130.9 
(C11), 130.2 (C8), 130.0 (C17), 120.2 (C32-H), 56.1 (C20-H), 53.0 (C5-H), 52.1 
(CO2CH3), 38.0 (C35-H), 34.3 (C23-H), 32.9 (C26-H), 25.3 (C37-H2), 18.9, 18.2, 
17.8, 17.7 (C24, C25, C27, C28, C36), 12.2, 11.9, 11.5 (C30-CH3, C33-CH3, C38); 
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m/z (ESI+) 677.1 ([M+Na] 100%); HR-ESIMS: calculated for C31H38N6O8SNa: 
677.2364, found 677.2352 [M+Na]+. 
Azolemycin A 4.01 
Hydroxylamine hydrochloride (3.0 mg, 0.04 mmol) and pyridine (3.3 µL, 0.04 
mmol) were added to a stirred solution of ketone 4.57 (9 mg, 0.014 mmol) in MeOH 
(0.6 mL) and CHCl3 (0.6 mL) under a nitrogen atmosphere. After 6 hours at room 
temperature, hydroxylamine hydrochloride (3.0 mg, 0.04 mmol) and pyridine (3.3 
µL, 0.04 mmol) were added and the reaction was stirred at room temperature 
overnight. The reaction mixture was reduced in vacuo and the residue partitioned 
between pH 4 buffer (5 mL) and CH2Cl2, and the phases were separated. The 
aqueous phase was further extracted with CH2Cl2 (3 x 2 mL) and the combined 
organic extracts were dried over Na2SO4 and concentrated in vacuo to give the crude 
oxime. This was purified by silica chromatography (50% EtOAc: pet ether) to give 
azolemycin A, 4.01, as a mix of E/Z stereoisomers (8 mg, 0.012 mmol, 85 %); 25][ Dα
+6.1 (c = 0.17, CHCl3); υ max/cm-1 (neat) 3402 (NH), 3316-3274 (broad, O-H), 1741 
(ester C=O), 1668 (C=N), 1629 (amide C=O), 1513 (NH); δH (700 MHz, CDCl3) 
9.37 (1H, br. s., NOH), 8.26 (1H, m, C29-H), 8.00 (1H, m, C32-H), 7.60 (1H, d, J 
10.0 Hz, N4-H), 7.51 (1H, d, J 9.0 Hz, N19-H), 5.25 (1H, dd, J 10.0, 6.0 Hz, C5-H), 
4.75 (1H, dd, J 9.0, 5.5 Hz, C20-H), 3.78 (3H, s, OCH3), 3.50 (1H, sept, J 7.0 Hz, 
C23-H), 2.90 (3H, s, C30-CH3), 2.75 (3H, s, C33-CH3), 2.36 - 2.30 (1H, m, C26-H), 
2.05 – 1.99 (1H, m, C35-H), 1.57 (1H, dqd, J 15.0, 7.5 Hz, 5.0 Hz, C37-H2), 1.31 
(1H, d, J 7.5 Hz, C25-CH3), 1.30 – 1.23 (4H, m, C25-H3, C37-H2), 1.02 (3H, d, J 7.0 
Hz, C28-CH3), 1.00 (3H, d, J 7.0 Hz, C28-CH3), 0.98 (3H, d, J 7.0 Hz, C36-CH3), 
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0.97 (3H, t, J 7.5 Hz, C38-CH3); Minor stereoisomer peaks at 5.34 (1H, dd, J 9.0, 6.0 
Hz, C5-H), 2.97 - 3.02 (1H, m, C23-H), 2.43 - 2.37 (1H, m, C26-H), 1.19 - 1.17 (3H, 
m, C25-CH3), 1.15 - 1.17 (1H, m, C25-CH3); δC (175 MHz, CDCl3) 172.3 (C21), 
165.6 (C6), 163.8 (C3), 162.3 (C12), 161.6 (C18), 158.8 (C2), 154.3 (C15), 153.7 
(C33), 152.9 (C9), 148.3 (C30), 143.8 (C14), 138.6 (C29-H), 130.9 (C11), 129.9, 
129.8 (C17, C8), 120.2 (C32-H), 56.2 (C20-H), 52.6 (C5-H), 52.1 (CO2CH3), 38.0 
(C35-H), 32.9 (C26-H), 25.8 (C23-H), 25.3 (C37-H2), 18.9, 18.7, 18.5, 18.3, 15.6 
(C24, C25, C27, C28, C36), 12.1, 11.8, 11.5 (C30-CH3, C33-CH3, C38); m/z (ESI-) 
668.2 ([M-H] 100%); HR-ESIMS: calculated for C31H39N7O8SNa: 692.2473, found 
692.2479 [M+Na]+, calculated for C31H38N7O8S: 668.2508, found 668.2470 [M-H]-. 
The data are consistent with the natural product. 
Azolemycin B 4.02 
Methoxyamine hydrochloride (3.8 mg, 0.046 mmol) and pyridine (3.7 µL, 0.046 
mmol) were added to a stirred solution of ketone 4.57 (10 mg, 0.015 mmol) in 
MeOH (0.5 mL) and CHCl3 (0.2 mL) under a nitrogen atmosphere. After 4 hours, 
the reaction mixture was reduced in vacuo and the residue partitioned between pH 4 
buffer (3 mL) and CH2Cl2 (2 mL). The phases were separated and the aqueous phase 
further extracted with CH2Cl2 (3 x 2 mL). The combined organic extracts were dried 
over Na2SO4 and concentrated in vacuo. Azolemycin B, 4.02, was obtained as a mix 
of E/Z stereoisomers by silica chromatography (50% EtOAc: pet. ether) as a white 
solid (9 mg, 0.013 mmol, 87 %); 21][ Dα  +27.6 (c = 0.12, CHCl3); υ max/cm-1 (neat) 
3414 (NH), 1741 (ester C=O), 1672 (C=N), 1630 (amide C=O), 1509 (NH); δH (400 
MHz, CDCl3) 8.24 (1H, s, C29-H), 8.00 (1H, s, C32-H), 7.51 (1H, d, J 9.0 Hz, N19-
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H), 7.36 (1H, d, J 8.5 Hz, N4-H), 5.29 (1H, dd, J 8.5, 6.5 Hz, C5-H), 4.75 (1H, dd, J 
9.0, 5.5 Hz, C20-H), 3.95 (3H, s, NOCH3), 3.78 (3H, s, CO2CH3), 2.98 (1H, sept, J 
7.0 Hz, C23-H), 2.91 (3H, s, C30-CH3), 2.75 (3H, s, C33-CH3), 2.42 - 2.32 (1H, m, 
C26-H), 2.00 – 1.89 (1H, m, C35-H), 1.52 – 1.45 (1H, m, C37-H2), 1.36 - 1.25 (3H, 
m, C37-H2), 1.16 (3H, d, J 7.0 Hz, C25-H3), 1.14 (3H, d, J 7.0 Hz, C25-H3), 1.05 - 
0.94 (12H, m, C36-CH3,C38-CH3, C28-CH3, C28-CH3); Minor stereoisomer peaks 
at 5.18 (1H, dd, J 9.5, 7.0 Hz, C5-H), 4.00 (3H, s, NOCH3), 3.45 - 3.35 (1H, m, C23-
H), 1.23 (3H, d, J 7.0 Hz, C25-CH3), 1.22 (3H, d, J 7.0 Hz, C25-CH3); During the 
time taken to resubmit the compound for further NMR experiments, the sample 
isomerized to give predominately the other stereoisomer. δH (700 MHz, CDCl3) 8.24 
(1H, s, C29-H), 8.00 (1H, s, C32-H), 7.51 (1H, d, J 9.0 Hz, N19-H), 7.27 – 7.27 (1H, 
m, N4-H), 5.18 (1H, dd, J 9.0, 7.0 Hz, C5-H), 4.75 (1H, dd, J 9.0, 5.5 Hz, C20-H), 
4.00 (3H, s, NOCH3), 3.78 (1H, s, CO2CH3), 3.40 (1H, sept, J 7.0 Hz, C23-H), 2.91 
(3H, s, C30-CH3), 2.75 (3H, s, C33-CH3), 2.35 (1H, oct, J 7.0 Hz, C26-H), 2.05 - 
1.99 (1H, m, C35-H), 1.60 - 1.53 (1H, m, C37-H2), 1.33 - 1.26 (1H, m, C37-H2), 
1.23 (3H, d, J 7.0 Hz, C25-H3), 1.22 (3H, d, J 7.0 Hz, C25-H3), 1.03 (3H, d, J 7.0 
Hz, C28-CH3), 1.00 (3H, d, J 6.5 Hz, C28-CH3), 0.97 (3H, t, J 7.5 Hz, C38-H3), 0.96 
(3H, d, J 6.5 Hz, C35-H3); δC (175 MHz, CDCl3) 172.3 (C21), 165.1 (C6), 162.7 
(C3), 162.3 (C12), 161.6 (C18), 157.1 (C2), 154.3 (C15), 153.6 (C33), 153.3 (C9), 
148.3 (C30), 143.8 (C14), 138.6 (C29-H), 130.8 (C11), 130.0, 129.9 (C17, C8), 
120.1 (C32-H), 63.0 (NOCH3), 56.1 (C20-H), 52.6 (C5-H), 52.1 (CO2CH3), 38.0 
(C35-H), 33.0 (C26-H), 25.9 (C23-H), 25.3 (C37-H2), 19.0, 18.6, 18.5, 15.6 (C24, 
C25, C27, C28, C36), 12.2, 11.9, 11.5 (C30-CH3, C33-CH3, C38); m/z (ESI+) 706.2 
([M+H] 100%); HR-ESIMS: calculated for C32H41N7O8SNa: 706.2630, found 
706.2625 [M+Na]+. The data are consistent with that obtained for the natural 
product.  
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Heptapeptide 4.58 
A solution of Boc-Val-OH (79 mg, 0.37 mmol) and HOBt (88 %, 11 mg, 0.08 
mmol) in EtOH (2 mL) was stirred for 5 minutes and added to a solution of amine 
hydrochloride 4.54 (44 mg, 0.075 mmol) in EtOH (1 mL). The solution was cooled 
to 0 ˚C and N-methyl morpholine (0.07 mL, 0.60 mmol) added. After 15 minutes, 
EDCI (86 mg, 0.45 mmol) was added and the reaction mixture was stirred to room 
temperature overnight. pH 2 buffer (3 mL) was added and the EtOH removed in 
vacuo. The mixture was extracted with EtOAc (4 x 5 mL), and the combined organic 
solvents were dried over Na2SO4 and concentrated in vacuo.  The residue was 
purified by silica chromatography (EtOAc) to give a white solid. Trituration of this 
with Et2O (3 x 5 mL) gave heptapeptide 4.58 as a bright white crystalline solid (34 
mg, 0.045 mmol, 60 %); m.p. 201 – 202 ˚C; 28][ Dα  -24.5 (c = 0.70, CHCl3); υ max/cm-
1
 (neat) 3333, 3257 (NH), 1734 (ester C=O), 1686, 1653 (amide C=O), 1516 (NH); 
δH (700 MHz, CDCl3) 8.23 (1H, s, C29-H), 8.00 (1H, s, C32-H), 7.51 (1H, d, J 9.0 
Hz, N19-H), 6.69 (1H, d, J 8.5 Hz, N4-H), 5.19 (1H, dd, J 9.0, 6.5 Hz, C5-H), 5.03 
(1H, d, J 8.0 Hz, N1-H), 4.74 (1H, dd, J 9.0, 5.5 Hz, C20-H) 3.93 (1H, dd, J 8.5, 6.5 
Hz, C2-H), 3.77 (3H, s, OCH3), 2.91 (3H, s, C30-CH3), 2.75 (3H, s, C33-CH3), 2.32 
(1H, oct, J 6.5 Hz, C26-H), 2.21 - 2.13 (1H, m, C23-H), 2.09 - 1.94 (1H, m, C35-H), 
1.60 - 1.54 (1H, m, C37-H2), 1.45 (9H, s, C(CH3)3), 1.33 - 1.26 (1H, m, C37-H2), 
1.05 - 0.91 (18H, m, 2 x C25-H3, 2 x C27-H3, C36-H3, C38-H3); δC (175 MHz, 
CDCl3) 172.3 (C21), 171.6 (C3), 164.8 (C6), 162.3 (C12), 161.6 (C18), 155.9 
(CO2tBu), 154.3 (C15), 153.6 (C33), 153.2 (C9), 148.2 (C30), 143.8 (C14), 138.6 
(C29-H), 130.8 (C11), 130.1, 129.5 (C8, C17), 120.1 (C32-H), 80.1 (C(CH3)3), 60.3 
(C2), 56.1 (C20), 52.8 (C5), 52.1 (OCH3), 38.1 (C35), 32.8 (C26), 30.4 (C23), 28.3 
(C(CH3)3), 19.4, 18.8, 18.2, 17.9, 15.6 (2 x C24-H3, 2 x C27-H3, C36-H3), 12.2, 11.9, 
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(C30-CH3, C33-CH3), 11.5 (C38-H3); m/z (ESI+) 778.3 ([M+Na] 100%); HR-
ESIMS: calculated for C36H49N7O9SNa: 778.3205, found 778.3191 [M+Na]+. 
Tetraoxazole Methyl Ester 4.59 
A solution of pentapeptide alcohol 4.30 (0.10 g, 0.19 mmol) in dry CH2Cl2 (20 mL) 
was cooled to -78 ˚C under nitrogen. (Diethylamino)sulfur trifluoride (0.05 mL, 0.35 
mmol) was added and the reaction mixture was stirred at -78 ˚C for 2 hours, then at 
room temperature for 30 minutes. The reaction was quenched with saturated aqueous 
NaHCO3 solution (10 mL) and was stirred for a further 15 minutes. The phases were 
separated and the aqueous phase was further extracted with CH2Cl2 (2 x 10 mL). The 
combined organic extracts were dried over Na2SO4 and concentrated in vacuo to give 
the crude oxazoline as a bright yellow oil (0.10 g), which was used immediately 
without further purification.  
A solution of the oxazoline (0.10g, 0.19 mmol) in CCl4 (0.5 mL), MeCN (0.7 mL) 
and pyridine (0.7 mL) was cooled to 0 ˚C under nitrogen. 1, 8-
Diazabicyclo[5.4.0]undec-7-ene  (0.12 mL, 0.81 mmol) was added and the reaction 
mixture was allowed to reach room temperature over 72 hours. The reaction mixture 
was quenched with pH 2 buffer (5 mL) and extracted with CH2Cl2 (3 x 5 mL). The 
combined organic extracts were dried over Na2SO4 and concentrated in vacuo to give 
the crude oxazole. Purification by silica chromatography (5 % MeOH: CH2Cl2) gave 
the oxazole 4.59 as a sticky colourless oil (90 mg, 0.17 mmol, 89 %); 25][ Dα -38.3 (c 
= 0.87, CHCl3); υ max/cm-1 (neat) 3330 (NH), 1712 (ester C=O), 1682 (amide C=O), 
1523 (NH); δH (400 MHz, CDCl3) 8.39 (1H, s, C32-H), 8.28 (1H, s, C29-H), 5.32 
(1H, d, J 9.0 Hz, N4-H), 4.84 (1H, dd, J 9.0, 6.0 Hz, C5-H), 3.94 (3H, s, OCH3), 
2.83 (3H, s, C30-CH3), 2.72 (3H, s, C30-CH3), 2.29 - 2.18 (1H, m, C36-H), 1.44 
(9H, s, C(CH3)3), 1.02 - 0.91 (6H, m, 2 x C27-H3); δC (100 MHz, CDCl3) 165.5 (C6), 
287 
 
162.5 (C18), 156.7, 156.6 (C12, C33), 166.4, 154.0, 152.9, 151.3 (CO2tBu, C9, C15, 
C30), 138.8, 138.6 (C29-H, C32-H), 131.0 (C8), 129.8 (C14), 128.4 (C17), 125.7 
(C11), 80.1 (C(CH3)3), 54.3 (C5-H), 52.1 (OCH3), 33.0 (C26-H), 28.3 (C(CH3)3), 
18.7, 18.0 (2 x C27-H3), 12.1, 11.9 (C30-CH3, C33-CH3); m/z (ESI+) 550.1 ([M+Na] 
100%); HR-ESIMS: calculated for C25H29N5O8Na: 550.1908, found 550.1909 
[M+Na]+. 
Tetraoxazole Carboxylic Acid 4.60 
A solution of LiOH (0.04 g, 1.71 mmol) in water (1.3 mL) was added to a solution of 
tetraoxazole methyl ester 4.59 (90 mg, 0.17 mmol) in THF (7.5 mL), CH2Cl2, (1.0 
mL) and MeOH (7.5 mL). After 6 hours at room temperature, the reaction mixture 
was acidified with pH 2 buffer and the organic solvents removed in vacuo. EtOAc 
(10 mL) was added and the phases were separated. The aqueous phase was further 
extracted with EtOAc (3 x 5 mL) and the combined organic extracts were dried over 
Na2SO4 and concentrated in vacuo to give acid 4.60 as a sticky colourless oil (60 mg, 
0.11 mmol, 67 %); 23][ Dα -15.9 (c = 0.15, CHCl3); υ max/cm-1 (neat) 3338 (NH), 3317 
(O-H), 1701 (ester C=O), 1655 (amide C=O), 1524 (NH); δH (400 MHz, CDCl3) 
8.40 (1H, s, C32-H), 8.30 (1H, s, C29-H), 5.39 (1H, d, J 9.5 Hz, N4-H), 4.86 (1H, 
dd, J 9.0, 6.0 Hz, C5-H), 2.84 (3H, s, C30-CH3), 2.76 (3H, s, C33-CH3), 2.29 - 2.19 
(1H, m, C26-H), 1.49 - 1.44 (9H, m, C(CH3)3), 0.99 - 0.93 ppm (6H, m, 2 x C27-
CH3); δC (100 MHz, CDCl3) 164.6 (C6), 164.1 (CO2H), 156.5 (C33), 155.8 (C12), 
154.4, 152.9, 152.0, 150.4 (C9, C11, C15, C30), 137.8, 137.8 (C29-H, C32-H), 
129.8 (C14), 128.7 (C8), 127.1 (C17), 124.6 (C11), 79.1 (C(CH3)3), 53.3 (C5-H), 
32.0 (C26-H), 27.3 (C(CH3)3), 17.7, 17.0 (2 x C27-CH3), 11.2, 10.9 (C30-CH3, C33-
CH3); m/z (ESI+) 536.1 ([M+Na] 100%); HR-ESIMS: calculated for C24H27N5O8Na: 
536.1752, found 536.1751 [M+Na]+. 
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Tetraoxazole Hexapeptide 4.61 
A solution of tetraoxazole carboxylic acid 4.60 (59 mg, 0.11 mmol) and HOBt (88 
%, 4 mg, 0.02 mmol) in EtOH (3 mL) was stirred at room temperature for 15 
minutes. L-Isoleucine methyl ester hydrochloride (52 mg, 0.29 mmol) was added and 
the solution was cooled to 0 ˚C. N-Methyl morpholine (0.08 mL, 0.75 mmol) was 
added followed, after 15 minutes, by EDCI (33 mg, 0.17 mmol), and the mixture was 
allowed to reach room temperature overnight. pH 2 buffer (5 mL) was added and 
mixture was extracted with EtOAc (5 x 5 mL). The combined organic extracts were 
washed with saturated aqueous NaHCO3 solution (5 mL), water (5 mL) and brine (5 
mL), dried over Na2SO4 and concentrated in vacuo. Purification by silica 
chromatography (2% MeOH: CH2Cl2) gave the hexapeptide as a clear pale yellow 
oil (38 mg, 0.06 mmol, 54 %); 28][ Dα -18.2 (c = 0.56, CHCl3);  υ max/cm-1 (neat) 3346 
(NH), 3317 (O-H), 1739 (ester C=O), 1667 (amide C=O), 1511 (NH); δH (600 MHz, 
CDCl3) 8.30, 8.29 (1H, s, C29-H; 1H, s, C32-H), 7.47 (1H, d, J 9.0 Hz, N19-H), 5.32 
(1H, d, J 9.0 Hz, N4-H), 4.85 (1H, dd, J 9.0, 6.0 Hz, C5-H), 4.73 (1H, dd, J 9.0, 5.3 
Hz, C20-H), 3.77 (3H, s, OCH3), 2.86 (3H, s, C30-CH3), 2.72 (3H, s, C33-CH3), 
2.28 - 2.21 (1H, m, C26-H), 2.04 - 1.96 (1H, m, C35-H), 1.55 (1H, dqd, J 13.0, 8.0, 
4.5 Hz, C37-H2), 1.45 (9H, s, C(CH3)3), 1.33 - 1.25 (1H, m, C37-H2), 1.02 - 0.93 
(12H, m, 2 x C27-H3, C36-H3, C38-H3); δC (150 MHz, CDCl3) 172.2 (C21), 165.5 
(C6), 161.4 (C18), 156.9 (C12), 155.4 (CO2tBu), 154.0, 153.7 (C9, C30), 151.9, 
151.4 (C15, C33), 138.8, 138.3 (C29-H, C32-H), 131.1, 129.9, 129.7 (C8, C14, 
C17), 125.7 (C11), 80.1 (C(CH3)3), 56.1 (C20-H), 54.3 (C5-H), 52.1 (OCH3), 38.0 
(C35-H), 33.0 (C26-H), 28.3 (C(CH3)3), 25.3 (C37-H2), 18.7, 18.0 (2 x C27-H3), 
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15.6 (C36-H3), 12.0, 11.8 (C30-CH3, C33-CH3), 11.5 (C38-H3); m/z (ESI+) 663.2 
([M+Na] 100%); HR-ESIMS: calculated for C31H44N7O9: 658.3195, found 658.3196 
[M+NH4]+. 
Tetraoxazole Alcohol 4.63 
Tetraoxazole 4.61 (38 mg, 0.06 mmol) was dissolved in a solution of acetyl chloride 
(0.12 mL, 1.8 mmol) and MeOH (0.8 mL), and the reaction mixture stirred at room 
temperature for 2 hours. The reaction mixture was concentrated in vacuo to give the 
deprotected amine as the hydrochloride salt, 4.62. m/z (ESI+) 563.1 ([M+Na] 100%); 
HR-ESIMS: calculated for C26H32N6O7Na: 563.2225, found 563.2237 [M+Na]+. 
A solution of the alcohol 4.55 (14 mg, 0.12 mmol) and HOBt (88 %, 3 mg, 0.02 
mmol) in EtOH (3 mL) was stirred at room temperature for 10 minutes and added to 
the deprotected amine, 4.62 (0.06 mmol). The mixture was cooled to 0 ˚C, and N-
methyl morpholine (0.04 mL, 0.38 mmol) was added. After 15 minutes, EDCI (30 
mg, 0.14 mmol) was added and the reaction mixture was stirred for 18 hours. pH 2 
buffer (3 mL) and EtOAc (3 mL) were added and the phases were separated. The 
aquoues phase was further extracted with EtOAc (3 x 3 mL), and the combined 
organic extracts were washed with brine (3 mL) and dried over Na2SO4. The alcohol 
4.63 was obtained by silica chromatography (2 % MeOH: EtOAc) as a clear oil (24 
mg, 0.037 mmol, 62 %); 28][ Dα -39.4 (c = 0.34, CHCl3); υ max/cm-1 (neat) 3408 (NH), 
2966 (O-H), 1740 (ester C=O), 1665 (amide C=O), 1515 (NH); δΗ (700 MHz, 
CDCl3) 8.30 (1H, s, C32-H), 8.27 (1H, s, C29-H), 7.48 (1H, d, J 9.0 Hz, N19-H), 
7.37 (1H, d, J 9.0 Hz, N4-H), 5.21 (1H, dd, J 9.0, 6.0 Hz, C5-H), 4.73 (1H, dd, J 9.0, 
5.5 Hz, C20-H), 4.10 - 4.15 (1H, m, C2-H), 3.77 (3H, s, OCH3), 3.30 (1H, br. s., 
OH), 2.85 (3H, s, C30-CH3), 2.72 (3H, s, C33-CH3), 2.34 (1H, oct, J 7.0 Hz, C26-
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H), 2.28 - 2.21 (1H, m, C23-H), 2.03 – 1.97 (1H, m, C35-H), 1.59 - 1.53 (1H, m, 
C37-H2), 1.33 - 1.27 (1H, m, C37-H2), 1.07 – 0.90 (18H, m, 2 x C24-H3, 2 x C27-H3, 
C36-H3, C38-H3); δC (150 MHz, CDCl3) 173.5 (C3), 172.2 (C21), 165.3 (C6), 161.4 
(C18), 156.8 (C12), 153.9, 153.7 (C15, C33), 151.8, 151.4 (C9, C30), 138.9 (C29-
H), 138.4 (C32-H), 131.1 (C14), 130.0, 129.7 (C8, C17), 125.6 (C11), 76.5 (C2-H), 
56.2 (C20-H), 52.3, 52.1 (C5-H, OCH3), 37.9 (C35-H), 32.6 (C26-H), 31.7 (C23-H), 
25.3 (C37-H2), 19.2, 18.7, 18.2, 15.9, 15.6 (2 x C27-H3, 2 x C24-H3, C36-H3), 12.0, 
11.8 (C30-CH3, C33-CH3), 11.5 (C38-H3); m/z (ESI+) 663.2 ([M+Na] 100%); HR-
ESIMS: calculated for C31H40N6O9Na: 663.2749, found 663.2754 [M+Na]+. 
Tetraoxazole Ketone 4.64 
A solution of alcohol 4.63 (24 mg, 0.037 mmol) in dry CH2Cl2 (1.5 mL) and dry 
DMSO (0.03 mL, 0.37 mmol) was stirred at 0 ˚C under N2. Diisopropylethylamine 
(0.05 mL, 0.30 mmol) was added, followed by SO3. pyridine complex (35 mg, 0.22 
mmol) and the reaction mixture was held at 0 ˚C for 6 hours. The reaction mixture 
was quenched with pH 2 buffer and the phases were separated. The aqueous phase 
was further extracted with CH2Cl2 (5 x 3 mL) and the combined organic extracts 
were dried over Na2SO4 and concentrated in vacuo. Ketone 4.64 was obtained by 
silica chromatography as a clear, colourless oil (17 mg, 0.027 mmol, 72 %); 25][ Dα -
28.0 (c = 0.87, CHCl3); υ max/cm-1 (neat) 3401 (NH), 1740 (ester C=O), 1675 (ketone 
C=O), 1662 (amide C=O), 1513 (NH); δH (400 MHz, CDCl3) 8.30 (1H, s, C29-H), 
8.29 (1H, s, (1H, s, C32-H), 7.57 (1H, d, J 9.0 Hz, N4-H), 7.46 (1H, d, J 9.0 Hz, 
N19-H), 5.11 (1H, dd, J 9.5, 7.0 Hz, C5-H), 4.72 (1H, dd, J 9.0, 5.5 Hz, C20-H), 
3.79  (3H, s, OCH3), 3.58 (1H, spt, J 7.0 Hz, C23-H), 2.85 (3H, s, C30-CH3), 2.74 - 
2.70 (3H, m, C33-CH3), 2.35 (1H, oct, J 7.0 Hz, C26-H), 2.06 - 1.94 (1H, m, C35-
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H), 1.62 - 1.49 (1H, m, C37-H2), 1.34 - 1.22 (1H, m, C37-H2), 1.17 (3H, d, J 6.5 Hz, 
C24-H3), 1.14 (6 H, d, J 7.0 Hz, C24-H3), 1.02 - 0.93 (12H, m, 2 x C27-H3, C36-H3, 
C38-H3); δC (100 MHz, CDCl3) 201.5 (C2), 172.2 (CO2Me), 163.9 (C6), 161.4 
(C18), 159.5 (C3), 156.9 (C12), 153.7, 151.9, 151.5 (C9, C15, C30, C33), 139.0 
(C32-H), 138.3 (C29-H), 131.1, 130.1, 129.9 (C8, C14, C17), 125.7 (C11), 56.2, 
(C20-H), 53.0 (C5-H), 52.1 (OCH3), 38.0 (C35-H), 34.3 (C23-H), 32.8 (C26-H), 
25.3 (C37-H2), 18.2, 17.7, 17.6, 15.6 (2 x C27-H3, 2 x C24-H3, C36-H3), 12.0, 11.8 
(C30-CH3, C33-CH3), 11.5 (C38-H3); m/z (ESI+) 661.1 ([M+Na] 100%); HR-
ESIMS: calculated for C31H38N6O9Na: 661.2592, found 661.2606 [M+Na]+. 
Tetraoxazole Analogue of Azolemycin A 4.65 
Pyridine (13 µL, 0.017 mmol) and hydroxylamine hydrochloride (12 mg, 0.017 
mmol) were added to a solution of the ketone 4.64 (17 mg, 0.027 mmol) in MeOH 
(0.6 mL) and CHCl3 (0.6 mL). The reaction mixture was stirred under nitrogen for 18 
hours, and then concentrated in vacuo. The residue was partitioned between CH2Cl2 
(5 mL) and pH 4 buffer (5 mL). The phases were separated and the aqueous phase 
was further extracted with CH2Cl2 (3 x 2 mL). The combined organic extracts were 
dried over sodium sulfate and concentrated in vacuo. The tetraoxazole analogue of 
azolemycin A, 4.65, was obtained by silica chromatography (50 % EtOAc: pet. 
ether) as a clear colourless oil (6 mg, 0.009 mmol, 33 %); 28][ Dα +1.6 (c = 0.19, 
CHCl3); υ max/cm-1 (neat) 3394 (NH), 3304 (OH), 1740 (ester C=O), 1665 (C=N), 
1513 (NH); δH (700MHz, CDCl3) 8.31 (1H, s, C29-H), 8.30 (1H, s, C32-H), 7.51 
(1H, d, J 8.4 Hz, N4-H), 7.48 (1H, d, J 9.2 Hz, N19-H), 5.32 (1H, dd, J 8.8, 6.2 Hz, 
C5-H), 4.74 (1H, dd, J 9.0, 5.5 Hz, C20-H), 3.77 (1H, s, OCH3), 3.01 (1H, sept, J 6.9 
Hz, C23-H), 2.86 (1H, s, C30-CH3), 2.73 (1H, s, C33-CH3), 2.38 (1H, oct, J 6.2 Hz, 
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C26-H), 2.05 - 1.98 (1H, m, C35-H), 1.60 - 1.52 (1H, m, C37-H2), 1.35 - 1.21 (1H, 
m, C37-H2), 1.17 (3H, d, J 6.6 Hz, C24-H3), 1.15 (3H, d, J 7.0 Hz, C24-H3), 1.03 – 
0.99 (9H, m, 2 x C27-H3, C33-H3), 0.97 (3H, t, J 7.3 Hz, C38-H3); Minor 
stereoisomer peaks at 5.20 (1H, dd, J 9.2, 6.6 Hz, C5-H), 3.51 - 3.46 (1H, m, C23-
H), 2.34 – 2.29 (1H, m, C26-H); δC (175MHz, CDCl3) 172.2 (C21), 164.6 (C6), 
161.8 (C18), 161.5 (C3), 157.6 (C2), 156.9 (C9), 153.8, 153.7 (C12, C33), 151.9, 
151.5 (C15, C30), 139.0 (C29-H), 138.3 (C32-H), 131.1 (C17), 129.9, 129.8 (C8, 
C14), 125.7 (C11), 56.1 (C20-H), 52.9 (C5-H), 52.1 (OCH3), 38.0 (C35-H), 32.8 
(C26-H), 30.9 (C23-H), 25.3 (C37-H2), 20.0, 19.8 (2 x C24-H3), 18.9, 18.4 (2 x C27-
H3), 15.6 (C36-H3), 12.0, 11.8 (C30-CH3, C33-CH3), 11.5 (C38-H3); m/z (ESI+) 
675.9 ([M+Na] 100%); HR-ESIMS: calculated for C31H39N7O9Na: 676.2701, found 
767.2697 [M+Na]+. 
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CHAPTER 5: CONCLUSIONS AND FUTURE WORK 
 
5.1 CTLPS AND THIOACIDS 
While the synthesis of the ten CTLPs was successfully completed (Chapter 2), 
neither the linear (Scheme 2), or the block peptide syntheses (Scheme 5) were 
particularly efficient. As this project continued, we became more aware of the 
limitations of conventional peptide coupling reagents, with the removal of by-
products, solubility issues and side-reactions being a constant theme. In addition we 
were becoming increasingly concerned with identifying and quantifying 
epimerization during these reactions.  These CTLPs are currently awaiting biological 
testing, but in the event that any proved to be promising new somatotaxins a more 
robust synthesis would be required. 
While we hoped that thioacids would provide a route for this, the increased levels of 
epimerization during the formation of the thioester precursors compared to the direct 
synthesis of the model peptides meant this route was not viable (Chapter 3). In 
addition, the preparation of the thioesters and subsequent amide bond formation was 
still reliant on standard peptide coupling reagents. While Albericio et al. have 
described direct block peptide formation from related thioester compounds,1 the 
thioesters are still prepared using the methods described by Crich et al.2, 3 
Interestingly, Crich does not report any significant epimerization of the C-terminal 
amino-acids during formation of the thioester, release of the thioacid or subsequent 
amide-bond formation. Albericio noted ~5% racemisation during the formation of 
the peptide Boc-Ala-Ala-Gly-Leu-Try-SC6H4-NO2, but reported no or very low 
epimerization for other thioester peptides. However, as epimerization was identified 
by the measurement of diastereomers in compounds following purification by 
preparation reverse-phase HPLC, rather than the crude reaction mixture, it is difficult 
to say how accurate these are, especially as the diastereomeric ratios are not 
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measured by comparison with a previously prepared, diastereomerically pure 
standard. 
While it is possible that the isoleucine-containing thioesters prepared in Chapter 3 
are not a realistic model for the more natural linear and cyclic peptides synthesized 
by both Crich and Albericio, the fact that preparing the model peptides using 
standard PyBOP coupling conditions (Scheme 21) required fewer steps and gave 
significantly lower levels of epimerization than the equivalent thioester route makes 
it difficult to consider peptide couplings using thioesters as a viable alternative. 
 
5.2 ENZYMES IN PEPTIDE COUPLING 
There is still a need for a general, cheap and epimerisation-free method of peptide 
bond formation, which we do not believe will be met by this thioester route. The vast 
array of onium and related coupling agents available to the chemist today suggests 
that the ‘traditional’ activating agents are also not the answer,4 as no one reagent 
performs well in every situation,5, 6 and often new peptide coupling agents are 
limited in scope to the substrates listed in the initial publication.7 
Enzymes, principally proteases, acylases, amidases, lipases and subtilisin,6, 8 have 
been used for peptide synthesis since 1938,9 and have many apparent advantages 
over synthetic peptide coupling agents, namely proceeding with no racemization, 
mild conditions, and high levels of regio- and stereoselectivity.10 However, reactions 
involving enzymes have often been limited by substrates, often only tolerating L-
amino-acids and their derivatives, and there is a risk of secondary hydrolysis of the 
growing peptide chain. Promisingly, for the enzyme subtilisin, the substrate 
limitation has been remedied by the use of organic solvents and extended reaction 
time, allowing some incorporation of D-amino-acids.11-13 In addition, a number of 
acyl-donors have been developed to be specifically recognized by the enzyme, with 
de Beer et al. describing easily accessible C-terminal esters that gave high levels of 
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amide-bond formation without racemization using Alcalase, a commercial form of 
subtilisin A.14 Crucially, these did not require the use of coupling agents to 
synthesise, and were easy to obtain in a chemically and stereochemically pure form. 
Notably, the guanidophenyl, carboxamidomethyl and trifluroenthyl esters could be 
themselves prepared using enzymatic catalysis, ensuring no epimerization during the 
acylation.15 Where aryl amines were used, simple acids or methyl or benzyl esters 
could be used for the synthesis of arylamides, providing access to di- and 
tripeptides.16 
The use of enzymatic block peptide synthesis is of great interest to us, and it could 
potentially provide a route to new peptidyl CTLPs with comparative ease. 
 
5.3 ISOLEUCINE 
The use of isoleucine-containing molecules as markers to quantify epimerization in 
both peptide bond formation, and during other reactions, has been of considerable 
use throughout the total synthesis of azolemycin A (Chapter 4), where a C-terminal 
valine residue was exposed to relatively harsh conditions during the synthesis of the 
oxazoles and thiazoles. Using isoleucine-containing derivatives as model compounds 
allowed us to be reasonably confident in retaining the stereointegrity of the valine 
throughout the synthesis. In addition, the use of isoleucine containing molecules 
allowed us to accurately predict the relative stereochemistry of the isoleucine residue 
in azeolymycin A. We hope that the trends shown in Chapter 3 (Tables 2 – 4) will 
allow for a general method of identifying the relative stereochemistry of isoleucine 
residues within natural products. 
Further 13C NMR studies in different solvents would provide additional support to 
the assignments made by 1H NMR spectra, especially in compounds where the peaks 
corresponding to the isoleucine α-CH are obscured.  
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Ideally, we would like to expand this work to encorporate the less common D-
isoleucine and L-allo-isoleucine, and thus be able to produce model compounds with 
all four stereoisomers of isoleucine. This would give us the opportunity to validate 
the stereochemical assignment for more peptide-like molecules, such as the natural 
product YM-316291 (Figure 46). By synthesizing a model peptide, including an L-
valine residue and all four stereoisomers of isoleucine it should be possible identify 
the correct amino-acid stereochemistry by comparison with the 1H NMR of the 
isolated natural product.  
The less common L-allo-isoleucine and D-isoleucine are relatively expensive 
commercially, but we hope to obtain them by use of enzymatic resolution as 
described by Greenstein et al.17 
 
5.4 PREPARATION OF UNACTIVATED OXAZOLES 
The principle obstacle in the synthesis of azolemycin A was the oxidation of the 
unactivated oxazolines to oxazoles (Scheme 42, Scheme 44). Ultimately, this was 
achieved using freshly prepared MnO2 with the best yields observed in the synthesis 
of 4.09. Though the yields were low, it is likely they could be improved by 
optimization of the work-up. This provides a valuable route to isolated, non-
conjugated oxazoles.  Both azolemycins A and B are currently awaiting biological 
testing, and the convergent nature of the final iteration of the total synthesis 
described in Chapter 4 would allow for a range of analogues to be prepared if 
required.  
The comparison between the 1H and 13C NMR spectra of azolemycin A 4.01, and the 
tetra-oxazole analogue, 4.65, highlighted some significant differences between the 
peaks for protons and carbons associated with, and adjacent to, azole C (Figures 56 
and 57). It would be useful to compare this data with that of similar mixed azoles 
(e.g. YM-316291 and IB-01211, Figure 46) and also synthesise a number of model 
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compounds containing a mixture of oxazoles and thiazoles to see if it is possible to 
pinpoint the relative position of a thiazole within a group of oxazoles. It would have 
been much more difficult to assign the structure of azolemycin A, and work out the 
position of the thiazole, if it contained only serine-derived oxazoles, as the methyl 
groups on the B and D oxazoles provided useful markers for elucidation of the 
HMBC NMR, and hence assignment of the quarternary carbons.  
Another tool that could be applied to the structural assignment of novel mixed azole 
natural products is atomic-resolution scanning probe microscopy. This has already 
been used successfully to validate the structure of a natural product, previously 
misassigned by NMR spectroscopy.18 Because of the ability of this technique to 
image molecules at an atomic level, comparison of atomic force microscopy (AFM) 
images of azolemycin A, 4.01, and the tetra-oxazole equivalent, 4.65, would allow us 
to confirm it there is any visible difference between a thiazole and an oxazole at this 
level. This data, when used in conjuction with more traditional techniques such as 
NMR and mass-spectrometry, could then assist in the initial structural elucidation of 
new linked polyazole molecules. 
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